<tstset trglang="any" setid="test" srclang="any">
<doc sysid="Edinburgh" docid="doc">
<seg id="1">"this document is a summary of the European Public Inquiry report (EPAR), in which explains how the Committee for Humanarzs (CHMP) has been judged to identify recommendations concerning the application of the drug."</seg>
<seg id="2">"if you need further information about your illness or their treatment, please read the packages (also part of the EPAR) or contact your doctor or a pharmacist."</seg>
<seg id="3">"if you wish to receive further information regarding the recommendations of CHMP, please read the scientific discussion (also part of the EPAR)."</seg>
<seg id="4">"it is available as 5 mg, 10 mg, 15 mg and 30 mg tablets, than 10 mg, 15 mg and 30 mg backlash (tablets that apply in the mouth (1 mg / ml) and as an injection solution (7.5 mg / ml)."</seg>
<seg id="5">"B. wirres thinking and speaking, hallucinations (hearing, or vision of things that are not exist), distrust and madness; • Bipolar disorder, a mental disorder, in which the patients" armed episodes (period periods) alternately with periods of normalized mood. "</seg>
<seg id="6">"bilify is used for the treatment of moderate to heavy manic episodes, and prevention of manic episodes in patients who raised in the past to the drug."</seg>
<seg id="7">Injection solution is used for quick control of increased unrest or behavioural disorders if the oral intake of the drug is not possible.</seg>
<seg id="8">"in both diseases, the solution for taking or the melzenge in patients can be applied to which the bat of tablets are prepared."</seg>
<seg id="9">"patients who are taking other medicines at the same time, which are manufactured just like bilify, the dosage should be adapted by bilify."</seg>
<seg id="10">"this affects the signal transmission between brain cells through" neurotransmitter, "i.e. chemical substances, which enable the communication of nerve cells."</seg>
<seg id="11">Aripizole mainly acts as a "partial agist" for the receptors for the neurotransmitters dopamine and 5-hydroxytryptamine (also called serotonin).</seg>
<seg id="12">"this means that Aripidazole such as 5-hydroxytryptamine and dopamine, but in lower dimensions than the neurotransmitters acts to enable the receptors."</seg>
<seg id="13">"da Dopamine and 5-hydroxytryptamine play a role in schizophrenia and bipolar disorder, which can normalize Aripidazole to normalize the activity of the brain, causing psychotic or manic symptoms and can prevent their re-occurring."</seg>
<seg id="14">"the effectiveness of bilify, the re-act of symptoms, was investigated in three studies about up to one year."</seg>
<seg id="15">The effectiveness of injection solution was compared in two studies on 805 patients with schizophrenia or similar disorders that compared to increased unrest over a period of two hours with a placebo.</seg>
<seg id="16">"in another study, Abilify has been stabilized about twelve weeks to 347 patients with Haloperidol, in another study the effectiveness of bilify and placebo that have been stabilized to 160 patients in which the manic symptoms have already been stabilized with bilify."</seg>
<seg id="17">The effectiveness of bilify injection solution has been compared to a study on 301 patients with bipolar disorder that compared to increased unrest that compared to Lorazepam (a different antipsychotic) and placebo over a period of two hours.</seg>
<seg id="18">"in all studies the change in symptoms of patients were assessed based on a standard scale for bipolar disorder, or the number of patients involved in the treatment."</seg>
<seg id="19">"the company also conducted studies through to examine how the body deducting the melting tablets, and the solution for taking resorbiert (up)."</seg>
<seg id="20">"in the two studies with the injection solution shown patients, the Abilify in doses of 5,25 mg, 75 mg or 15 mg received, a significantly stronger decrease in symptoms increased unrest than the patients who received a placebo."</seg>
<seg id="21">"in the application for the treatment of bipolar disorder, Abilify has been more effective than placebo in four of the five short-term studies than placebo."</seg>
<seg id="22">Abilify prevented more effective than to 74 weeks more effective than placebo the re-occur Manisoden in previously treated patients and when it was additionally administered to an existing treatment.</seg>
<seg id="23">Bilify injections in 10- or 15-mg doses decreased also more effective than placebo the symptoms increased unrest and were similar to Lorazepam.</seg>
<seg id="24">"the most common side effects of bilify (observed at 1 to 10 of 100 patients) are extracted (loss), fatigue, blurry (boldness), fatigue, nausea (constipation), fatigue and exhaustion, ruin (increased saliva), fatigue and exhaustion, restlessness, insomnia (sleeping disorders) and anxiety."</seg>
<seg id="25">"the Committee on Humanarzs (CHMP) led to the conclusion that the benefits of bilify in treating schizophrenia and the prevention of a new manic episode in patients, the mostly manic episodes, and in which the manic episodes came to the treatment with Aripidazole, facing the risks."</seg>
<seg id="26">"in addition, the committee to the result came that the benefits of injection solution in patients with schizophrenia or in patients with schizophrenia or in patients with schizophrenia or in patients with manic episodes of bipolarisation, if a oral therapy is not suitable to prevail over the risks."</seg>
<seg id="27">June 2004 condemned the European Commission to the company Otsuka Pharmaceutical Europe Ltd. approve of the transportation of Abilify in the entire European Union.</seg>
<seg id="28">ABILIFY is for the treatment of moderate to heavy manic episodes of the Bipolar disorder and for the prevention of a new manic episode in patients who had mostly manic episodes and their manic episodes to treatment with Aripiedzol (see Section 5.1).</seg>
<seg id="29">The recommended dose for ABILIFY amounts to 10 or 15 mg / day at an average dose of 15 mg / day regardless of meals.</seg>
<seg id="30">"increased effectiveness in doses over a daily dose of 15 mg was not proven, although individual patients can benefit from a higher dose."</seg>
<seg id="31">The recommended dose for ABILIFY is 15 mg once daily, regardless of meals as monotherapy or combination therapy (see Section 5.1). "</seg>
<seg id="32">The efficacy of ABILIFY in the treatment of schizophrenia and Bipolar disorder in patients &gt; 65 years has not been proven.</seg>
<seg id="33">"with regard to the greater sensitivity of these patient group, a lower initialosis should be considered when clinical factors justify this (see Section 4.4)."</seg>
<seg id="34">"if the CYP3A4 inductor is set out from the combination therapy, the Aripidazole dosage should be reduced to recommended dose (see Section 4.5)."</seg>
<seg id="35">The appearance of suickening behavior belongs to psychotic diseases and affective disorders and has been reported in some cases after the beginning or after changing an anti-psychotic therapy (see Section 4.8).</seg>
<seg id="36">The results of an epidemiological study showed that it was in patients with bipolar disorder any increased addiction risk associated with Aripionzene in comparison to other antipsychotic medicines.</seg>
<seg id="37">"Aripidazole should be used with caution in patients with known cardiovascular disease (Myocardiness or ischaesthood, superstical disorders, hygiene, hypovoluminous, treatment with blood pressure-bearing drugs) or hypertension (including acute and malignant form)."</seg>
<seg id="38">"3 Spätdyskinesien: in clinical trials, which a year or less denced, there were occasional reports on during treatment with Aripirezole Dyskinesia."</seg>
<seg id="39">"if at one with ABILIFY, patients treated signs and symptoms of a puzzdyskinesia should be considered to reduce the dose or break the treatment."</seg>
<seg id="40">"if a patient signs and symptoms developed on a mns, or unclear high fever without an additional clinical manifestation of mns, all anti-psychotic, including ABILIFY."</seg>
<seg id="41">"therefore, Aripidazole should be applied in patients with crampoo cases in the Anamnese or in the states that are applied with varicular cases in connection with caution."</seg>
<seg id="42">"56 - 99 years) with observing patients with psychosis which were associated with Alzheimer's disease, had treated patients who were treated with Aripizole, a increased Sterberisiko compared to the placebo."</seg>
<seg id="43">"however, there was in one of these studies, a trial with fixed dosage, a significant relationship between the dosage and the appeal for unwanted derovascular events treated with Aripionzene (patients)."</seg>
<seg id="44">"hyperglycaemia, in some cases extremely and associated with Ketoazionale or hyperosmolarem coma or death, was reported in patients who were treated with atypical antipsychotic agents, including ABILIFY."</seg>
<seg id="45">There are no precise risk calculations for hyperglycaemia related unwanted events with ABILIFY and other atypical anti-psychotic substances treated patients who allow direct comparisons.</seg>
<seg id="46">Polydipsie, Polyurie, Polyphagie and weakness) are observed and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly in terms of deterioration of glucose levels. "</seg>
<seg id="47">"a weight gain is generally seen in schizophrenia patients and patients with bipolar impacts, the use of anti-psychics, in which weight gain is known as tributaries, or an unhealthy lifestyle and could lead to serious complications."</seg>
<seg id="48">"due to the primary effect of Aripidazole on the central system, caution is advisable when Aripizole is taken in combination with alcohol or other central medicines with itself over-permanent side effects such as Secoding (see Section 4.8)."</seg>
<seg id="49">"the H2-Antagonist Famotidin, a stomach acid blocker, reduces the reset rate of Aripidazole, but this effect is not relevant as clinically."</seg>
<seg id="50">In a clinical trial with healthy promoters increased a high-effective CYP2D6-inhibitor (Chinidin) the AUC of Aripizole to 107% while the Cmax remained unchanged.</seg>
<seg id="51">"it is expected that other high-effective inhibitors from CYP2D6, such as Fluoxetine and paroxetine, similar effects have and therefore should be similar dose reductions."</seg>
<seg id="52">At CYP2D6 'poor' (= "poor") Metabolisians can result in common application with high-effective inhibitors of CYP3A4 in higher Plasma benzene in comparison to CYP2D6 extenze metabolic disorders.</seg>
<seg id="53">"if you consider the joint gift of Ketoconazol or other high-effective CYP3A4-inhibitors with ABILIFY, the potential benefits should prevail over the patients."</seg>
<seg id="54">"other high-effective inhibitors from CYP3A4, such as Itraconazol and HIV proteaseinhibitors, are likely to have similar effects and therefore should be similar dosage reductions."</seg>
<seg id="55">"after drafting the CYP2D6- or 3A4 inhibitors, the dosage was raised by ABILIFY on the dose-height before the beginning of the accompanying therapy."</seg>
<seg id="56">Diltiazem or Escitalopram) or CYP2D6 together with ABILIFY administered can be calculated with a moderate increase in Aripianos.</seg>
<seg id="57">In clinical trials indicated doses of 10-30 mg Aripizole per day does not have significant effect on the Metabolism of the substrate of CYP2D6 (Dextromethmorphinan-Ratio), 2C9 (warfarin), 2C9 (Omeprazol) and 3A4 (Dextromethmorphing). "</seg>
<seg id="58">Patients should be advised to notify your doctor if they are pregnant or plan a pregnancy during treatment with Aripidazole.</seg>
<seg id="59">"due to the insufficient data base for the safety of humans and due to the concerns of the animal studies, this medicine should not be used in pregnancy, unless the potential benefits justifies clearly the potential risk of the fetus."</seg>
<seg id="60">"however, in other antipsychotic medicines, patients should be warned of dangerous machines, including power vehicles, until they are sure that Aripizole has no negative influence on it."</seg>
<seg id="61">The following side effects occurred more frequently (&gt; &gt; 1 / 100) on as under placebo or were classified as possible medical-side effects (*):</seg>
<seg id="62">"the frequency of the below side effects is defined by the following criteria: frequent (&gt; 1 / 100, &lt; 1 / 10); occasionally (&gt; 1 / 1,000, &lt; 1 / 100)."</seg>
<seg id="63">"schizophrenia - in a controlled long-term study of 52 weeks entered in patients who were treated with Aripionism, a total of reduced incidence (25.8%) of EPS including Parkinsonism, Akatheist, Dystonie and Dyskinesia compared to patients who were treated with Haloperidol (57.2%)."</seg>
<seg id="64">In a placebo-controlled long term study for 26 weeks the incidence of EPS 19% amounted to patients under Aripionzene treatment and 13.1% in patients under placebo.</seg>
<seg id="65">"in another controlled long term study about 26 weeks, the incidence of EPS 14,8% was treated with patients who were treated with Aripizole and 15.1% in patients under Olanniin therapy."</seg>
<seg id="66">Manic episodes in Bipolar I disorder - In a controlled study about 12 weeks was the incidence of EPS 23.5% in patients under Aripionzol- treatment and 53.3% in patients under Haloperidol treatment.</seg>
<seg id="67">"in another study about 12 weeks, the incidence of EPS 26,6% amounted to patients under Aripionzene treatment and 17.6% for those under lithium treatment."</seg>
<seg id="68">In the long-term performance phase over 26 weeks in a placebo-controlled study the incidence of EPS 18.2% for patients under Aripionzol- treatment and 15.7% for placebo patients.</seg>
<seg id="69">A comparison between the patient groups under Aripizole and placebo on which potentially clinically significant changes in routinely controlled laboratory parameters occurred revealed not medically significant differences.</seg>
<seg id="70">"the CPK (creatine products of the CPK (creatine products), generally temporarily and asymptomatic, have been observed in 3.5% of patients treated with Aripionzol, compared to 2.0% of patients treated with placebo."</seg>
<seg id="71">"the side-effects that can occur in connection with an anti-psychotic therapy, and about their appearance also in the treatment with Aripizole syndrome, the malignne neuroleptic syndrome and campfanatics, undesirable events and increased mortality in older dementia patients, hyperglycaemia and diabetes mellitus (see Section 4.4)."</seg>
<seg id="72">Clinical trials and since market launch have been accidental or intentional overdoings with Aripionzene alone on adult patients with estimated cans of up to 1260 mg and without deaths.</seg>
<seg id="73">"although there is no information about the efficacy of a heralalysis in treating an overdose with Aripionzene; however, it is unlikely that Hematalysis is used for the treatment of an overdose of use, since Aripidazole has a high plastic fuel delivery."</seg>
<seg id="74">It is thought that the effectiveness of Aripizole in schizophrenia and Bipolar-I disturbances about the combination of a partial agonist effect on Dopamine D2- and Serotonin 5HT1a- receptors and an antagonistic effect on serotonin 5HT2a receptors is conveyed.</seg>
<seg id="75">"Aripiedzol showed a high affinity to Dopamine D2- and D3 receptor and the serotonin 5HT1a and 5HT2a receptor, as well as an excessive affinity to the Dopamine D4-, to alpha-1 inepinephrine and the histamine-H1receptor."</seg>
<seg id="76">"at gift of Aripidazole in doses from 0.5 to 30 mg once daily over 2 weeks to healthy probanden tomography a dosisdependency reduction in the bond of 11C-Racloprid, an D2 / D3 receptor Liganden, on Nucleus caudatus and on the coup."</seg>
<seg id="77">In three placebo-controlled short-time studies (4 to 6 weeks) in 1.228 schizophrbenzene in comparison to placebo a statistically significant stronger improvement of psychological symptoms.</seg>
<seg id="78">"in a Haloperidol-controlled study conducted in week 52 of the proportion of the Responder patients, which include an appeal to the academic medicine, in both groups similar (Aripionzol 77% and Haloperidol 73%)."</seg>
<seg id="79">"current values from the measals, which were defined as secondary studies, including PANSS and the Montgomery-Asberg- anti-operation scale, showed a significant stronger improvement than in bracket dol."</seg>
<seg id="80">In a placebo-controlled study over 26 weeks on stabilized patients with chronic schizophrenia showed itself a significant higher reduction of downrate that was at 34% in the Aripizole group and at 57% below placebo.</seg>
<seg id="81">"in a Olanniin-controlled, multinational Double-blind study conducted in schizophrenia over 26 weeks, the 314 patients entered into a weight gain increase of at least 7% compared to the output value (i.e. an increase of at least 5,6 kg at an average weight of approx. 6 kg)."</seg>
<seg id="82">In two placebo-controlled monotherapy studies with flexible dosage for 3 weeks with patients with a manic or mixed episode of the Bipolar-I disorder showed Aripionzene an opposite placebo superior effectiveness in reducing Manic symptoms over 3 weeks.</seg>
<seg id="83">In a placebo controlled Monotherapy study over 3 weeks with fixed dose of patients with a manic or mixed episode of the Bipolar-I disorder showed Aripiedzol versus placebo not superior effectiveness.</seg>
<seg id="84">"in two placebo- and active-controlled Monotherapy trials over 12 weeks in patients with an imical or mixed episode of a Bipolar-I disorder, with or without psychotic characteristics, which was comparable to placebo efficacy in week 3 and an encouragement, which was comparable to that of lithium or Haloperidol in week 12."</seg>
<seg id="85">"Aripidazole also pointed to 12 a comparable share in patients with the symptomatic remission of the Manie, such as lithium or Haloperidol."</seg>
<seg id="86">"in a placebo controlled study of 6 weeks with patients with a manic or mixed episode of a Bipolar disorder, with or without psychotic characteristics that partly over 2 weeks do not appear on Lithium or Valproat-Monotherapy upon therapeutical symptoms, compared to monotherapy with lithium or Valproat."</seg>
<seg id="87">"10 In a placebo-controlled study conducted over 26 weeks, followed by a long-time extension phase over 74 weeks in manic phase before Randomization had achieved a remission to placebo superior in terms of prevention of a bipolar return, mostly in the prevention of a return in the Manie."</seg>
<seg id="88">"based on in vitro-studies, the enzymes CYP3A4 and CYP2D6 is responsible for the elongation and hydroxyging of Aripidazole, the N-Dealkyeption is catalyzed by CYP3A4."</seg>
<seg id="89">The middle elib period is at approximate 75 hours for Aripionzene in extensive Metabolisians on CYP2D6 and at approximate 146 hours at 'poor' (= 'poor') Metabolisierers via CYP2D6.</seg>
<seg id="90">"at Aripiedzene, there are no differences in the pharmakokinetics between male and female healthy promoters, as well as a pharaokinetic investigation of schizophrenia patient had no gender-dependent effects."</seg>
<seg id="91">A non-specific analysis of the Pharmacokinetics yielded no indication of clinically significant differences with regard to ethnic origin or the effect of smoking on the pharmacokinetics of Aripizole.</seg>
<seg id="92">The pharmacokinetic properties of Aripidazole and Dehdehydrole were similar in patients with severe kidney insufficiency in comparison to young healthy volunteers.</seg>
<seg id="93">"a single-dose study with professional liver cirrhosis of liver cirrhosis (Child-Pugh Class A, B and C) showed no significant effect regarding the impairment of the liver circling of Aripidazole and Dehdehydration of the class C, which is not sufficient to draw conclusions on their metabolic capacity."</seg>
<seg id="94">"based on conventional studies for safety spharmacology, toxicity in repetitive gift, reproduction, genotoxicity and the canogenic potential let the preclinical data have no special dangers for humans."</seg>
<seg id="95">"toxicologically significant effects were observed only in doses or expositions that significantly exceeded the maximum dosage or exposure to humans, so they have limited for the clinical use only limited or no meaning."</seg>
<seg id="96">The effects circulates a dosisdependency-toxicity in rats after 104 weeks at 20 to 60 mg / kg / day (equivalent to 3 mg / kg / kg / day (equivalent to 10 mg / kg / day (USC) at the recommended Maximum Steady-State-exposure (AUC) at the recommended Maximum Steady-State-exposure (AUC) at the recommended Maximaldose in humans).</seg>
<seg id="97">"in addition, a cholelithiasis has been found as a result of the suscephalation of sulphate-conjugates from Aripionzene (AUC) at the recommended clinical dose or the 16- up to 81times the recommended maximaldose when people based on mg / m2)."</seg>
<seg id="98">"however, in the human galle with the highest recommended daily dose of 30 mg found at the sulphate conjugate of hydroxy- Aripizole not more than 6% of the concentrations found in the study over 39 weeks in the Galle by monkeys, and are far below the border values (6%) of in vitro solubility."</seg>
<seg id="99">"in rabbits these effects were said to dosing, which led to Expositions of 3- and 11times of the middle Steady-State AUC in the recommended clinical Maximaldose, observed."</seg>
<seg id="100">"perforated blister packs for transmission of items made of aluminium in folding boxes with 14 x 1, 28 x 1, 49 x 1, 56 x 1, 98 x 1 tablets."</seg>
<seg id="101">"15 Spätdyskinesien: in clinical trials, which a year or less denced, there were occasional reports on during treatment with Aripirezole Dyskinesia."</seg>
<seg id="102">It is thought that the effectiveness of Aripizole in schizophrenia and Bipolar-I disturbances about the combination of a partial agonist effect on Dopamine D2- and Serotonin 5HT1a- receptors and an antagonistic effect on serotonin 5HT2a receptors is conveyed.</seg>
<seg id="103">"22 In a placebo-controlled study conducted over 26 weeks, followed by a long-time extension phase over 74 weeks in manic phase before Randomization had achieved a remission to placebo superior in terms of prevention of a bipolar return, mostly in the prevention of a return in the Manie."</seg>
<seg id="104">"27 Spätdyskinesien: in clinical trials, which a year or less denced, there were occasional reports on during treatment with Aripirezole Dyskinesia."</seg>
<seg id="105">It is thought that the effectiveness of Aripizole in schizophrenia and Bipolar-I disturbances about the combination of a partial agonist effect on Dopamine D2- and Serotonin 5HT1a- receptors and an antagonistic effect on serotonin 5HT2a receptors is conveyed.</seg>
<seg id="106">"34 At a placebo-controlled study over 26 weeks, followed by a long-time extension phase over 74 weeks in manic phase before Randomization had achieved a remission to placebo superior in terms of prevention of a bipolar return, mostly in the prevention of a return in the Manie."</seg>
<seg id="107">"39 Spätdyskinesien: in clinical trials, which a year or less denced, there were occasional reports on during treatment with Aripirezole Dyskinesia."</seg>
<seg id="108">It is thought that the effectiveness of Aripizole in schizophrenia and Bipolar-I disturbances about the combination of a partial agonist effect on Dopamine D2- and Serotonin 5HT1a- receptors and an antagonistic effect on serotonin 5HT2a receptors is conveyed.</seg>
<seg id="109">"46 In a placebo-controlled study over 26 weeks, followed by a long-time extension phase over 74 weeks in manic phase before Randomization had achieved a remission to placebo superior in terms of prevention of a bipolar return, mostly in the prevention of a return in the Manie."</seg>
<seg id="110">The recommended dose for Aripizole is 10 or 15 mg / day at a paydose of 15 mg / day regardless of meals.</seg>
<seg id="111">Patients who have difficulties in the slate of ABILIFY tablets can take the snap-tabletop alternatively to ABILIFY tablets (see Section 5.2).</seg>
<seg id="112">The appearance of suickening behavior belongs to psychotic diseases and affective disturbances were reported in some cases after the beginning or after changing an anti-psychotic therapy (see Section 4.8).</seg>
<seg id="113">"Spätdyskinesien: in clinical trials, which a year or less denced, there were occasional reports on during treatment with Aripirezole Dyskinesia."</seg>
<seg id="114">"clinical manifestations of a mns are high fever, muscle rigidity, changeable consciousness and signs autonomic instability (irregular pulse or blood pressure, tachycarts, sweating and cardiac arrhythmia)."</seg>
<seg id="115">"a weight gain is generally seen in schizophrenia patients and patients with bipolar impacts, the use of anti-psychics, in which weight gain is known or unhealthy lifestyle and could lead to serious complications."</seg>
<seg id="116">Patients should be advised to notify your doctor if they are pregnant or pregnant during treatment with Aripionzene</seg>
<seg id="117">The following side effects occurred more frequently (&gt; &gt; 1 / 100) on as under placebo or were classified as possible medically relevant side effects of the drug (*):</seg>
<seg id="118">In two placebo-controlled monotherapy studies with flexible dosage for 3 weeks with patients with a manic or mixed episode of the Bipolar-I disorder showed Aripionzene an opposite placebo superior effectiveness in reducing Manic symptoms over 3 weeks.</seg>
<seg id="119">"58 In a placebo controlled study of 6 weeks with patients with a manic or mixed episode of a Bipolar disorder, with or without psychotic characteristics that partly over 2 weeks do not appear on Lithium or Valproat-Monotherapy upon therapeutical symptoms, compared to monotherapy with lithium or Valproat."</seg>
<seg id="120">"in a placebo-controlled study over 26 weeks, followed by a long-time extension phase over 74 weeks in manic phase, which had achieved a remission to placebo in terms of preventing an bipolar disorder, predominantly in the prevention of a bipolar disorder in the mania."</seg>
<seg id="121">"in rabbits, these effects were following doses, which were on positions of 3- and 11times of the middle Steady-State AUC at the recommended clinical trials."</seg>
<seg id="122">Patients who have difficulties in the slate of ABILIFY tablets can take the snap-tabletop alternatively to ABILIFY tablets (see Section 5.2).</seg>
<seg id="123">"Spätdyskinesien: in clinical trials, which a year or less denced, there were occasional reports on during treatment with Aripirezole Dyskinesia."</seg>
<seg id="124">"71 In a placebo-controlled study conducted over 6 weeks with patients with a manic or mixed episode of a Bipolar disorder, with or without psychotic characteristics, that partly over 2 weeks do not appear on Lithium or Valproat-Monotherapy with therapeutical symptoms, compared to monotherapy with lithium or Valproat."</seg>
<seg id="125">Patients who have difficulties in the slate of ABILIFY tablets can take the snap-tabletop alternatively to ABILIFY tablets (see Section 5.2).</seg>
<seg id="126">"Spätdyskinesien: in clinical trials, which a year or less denced, there were occasional reports on during treatment with Aripirezole Dyskinesia."</seg>
<seg id="127">84 In a placebo controlled study of 6 weeks with patients with a manic or mixed episode of a Bipolar disorder, with or without psychotic characteristics that partly over 2 weeks do not appear on Lithium or Valproat-Monotherapy upon therapeutical symptoms in comparison to monotherapy with lithium or Valproat. "</seg>
<seg id="128">200 mg fructose je ml 400 mg Sucrose je ml 1.8 mg methyl-4-hydroxybenzoat (E218) each ml 0.2 mg propyl-4-hydroxybenzoat (E216) each ml.</seg>
<seg id="129">The recommended dose for ABILIFY is 15 mg once daily, regardless of meals as monotherapy or combination therapy (see Section 5.1). "</seg>
<seg id="130">"in the prevention of refresh episodes of patients, which have already received Aripizole, the therapy should be continued with the same dose."</seg>
<seg id="131">"Spätdyskinesien: in clinical trials, which a year or less denced, there were occasional reports on during treatment with Aripirezole Dyskinesia."</seg>
<seg id="132">"hyperglycaemia, in some cases extremely and associated with Ketoazionale or hyperosmolarem coma or death, was reported in patients who were treated with atypical antipsychotic agents, including ABILIFY."</seg>
<seg id="133">There are no precise risk calculations for hyperglycaemia related unwanted events with ABILIFY and other atypical anti-psychotic substances treated patients who allow direct comparisons.</seg>
<seg id="134">92 In a clinical trial with healthy promoters increased a high-effective CYP2D6-inhibitor (Chinidin) the AUC of Aripizole to 107% while the Cmax remained unchanged.</seg>
<seg id="135">Diltiazem or Escitalopram) or CYP2D6 together with ABILIFY administered can be calculated with a moderate increase in Aripianos.</seg>
<seg id="136">Manic episodes in Bipolar I disorder - In a controlled study about 12 weeks was the incidence of EPS 23.5% in patients under Aripiprazol-</seg>
<seg id="137">It is thought that the effectiveness of Aripizole in schizophrenia and Bipolar-I disturbances about the combination of a partial agonist effect on Dopamine D2- and Serotonin 5HT1a- receptors and an antagonistic effect on serotonin 5HT2a receptors is conveyed.</seg>
<seg id="138">"in a Olanniin-controlled, multinational Double-blind study conducted in schizophrenia over 26 weeks, the 314 patients entered into a weight gain increase of at least 7% compared to the output value (i.e. an increase of at least 5,6 kg at an average weight of approx. 6 kg)."</seg>
<seg id="139">97 In a placebo-controlled monotherapy study over 3 weeks with fixed episode of the Bipolar-I disorder showed Aripiedzol versus placebo not superior effectiveness.</seg>
<seg id="140">"in a relative bionic addition study, in which the pharmacokinetics of 30 mg Aripizole has been compared with healthy probanden, the relationship was between the geometric Cmax. intermediate value of the solution and the value of tablets at 122% (N = 30)."</seg>
<seg id="141">99 Accepted a cholelithiasis as a result of the suscephalation of sulphate-conjugate in the Galle by monkeys after repetitive orical gift from 25 to 125 mg / kg / day (the 1- up to 3times of the recommended Maximaldose of people based on mg / m2).</seg>
<seg id="142">"in rabbits these effects were said to dosing, which led to Expositions of 3- and 11times of the middle Steady-State AUC in the recommended clinical Maximaldose, observed."</seg>
<seg id="143">ABILIFY injection solution is used for quick control of Agitenderness and behavioural disorders in patients with schizophrenia or in patients with manic episodes of the Bipolar-I disorder if a oral therapy is not recommendable.</seg>
<seg id="144">"once it is clinically appropriate, treatment with Aripipzene injection solution will be terminated and started with the oral application of Aripidazole."</seg>
<seg id="145">To increase the resorption and minimise the variability will be an injection in the M. deltoideus or deep within the gluteus-Maximus muscle under relying by adipous regions.</seg>
<seg id="146">A lower dose of 85 mg (0.3 ml) can depend on the individual clinical status by taking into account the drug or acute therapy into account (see Section 4.5).</seg>
<seg id="147">"in case a further oral treatment with Aripidazole indices is, see the summary of the features of the drug with ABILIFY tablets, ABILIFY tablets, ABILIFY solution for taking."</seg>
<seg id="148">There are no investigations on the effectiveness of Aripizole injection solution in patients with the acting and behavioural disorders that have been different from schizophrenia and manic episodes of the Bipolar-I disorder.</seg>
<seg id="149">"if a parental therapy with benzodiazepines in addition to the Aripianos injection solution is considered necessary, patients should be observed with regard to extreme Seencoding or a blood pressure if (see Section 4.5)."</seg>
<seg id="150">Studies on the safety and effectiveness of Aripionzene injection solution are available for patients with alcohol or drugs poisoning (by distorted or illegal drugs).</seg>
<seg id="151">"Aripidazole should be used with caution in patients with known cardiovascular disease (Myocardiness or ischaesthood, superstical disorders, hygiene, hypovoluminous, treatment with blood pressure-bearing drugs) or hypertension (including acute and malignant form)."</seg>
<seg id="152">"Spätdyskinesien: in clinical trials, which a year or less denced, there were occasional reports on during treatment with Aripirezole Dyskinesia."</seg>
<seg id="153">"clinical manifestations of a mns are high fever, muscle rigidity, alternating consciousness and signs autonomous instability (irregular pulse or blood pressure, tachycarts, sweating and cardiac arrhythmia)."</seg>
<seg id="154">Polydipsie, Polyurie, Polyphagie and weakness) are observed and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly in terms of deterioration of glucose levels. "</seg>
<seg id="155">"a weight gain is generally observed in schizophrenia patients and patients with bipolar impacts, the use of anti-psychics, in which weight gain is known or unhealthy lifestyle and could lead to serious complications."</seg>
<seg id="156">"however, the intensity of the Sedation was greater compared to the number of Aripidazole, in a study, in the healthy probanden Aripidazole (15 mg dosage) and the same at the same time Lorazepam (2 mg dose) intramuscular."</seg>
<seg id="157">"105 The H2-Antagonist Famotidin, a stomach acid blocker, reduces the reset rate of Aripidazole, but this effect is not relevant as clinically."</seg>
<seg id="158">At CYP2D6 'poor' (= "poor") Metabolisians can result in comparison to CYP2D6 extensive Metabolisians the joint application with high-effective inhibitors of CYP3A4 in higher plastic concentration of Aripionzene.</seg>
<seg id="159">"other high-effective inhibitors from CYP3A4, such as Itraconazol and HIV- Proteaseinhibitors, are likely to have similar effects and therefore should be similar dosage reductions."</seg>
<seg id="160">"after drafting the CYP2D6- or 3A4 inhibitors, the dosage was raised by ABILIFY on the dose-height before the beginning of the accompanying therapy."</seg>
<seg id="161">106 Lorazepam (2 mg dose) intramuscular life was the intensity of the Sedation greater compared with that after all of the gift of Aripidazole.</seg>
<seg id="162">The following side effects occurred in clinical trials with Aripiborole injection solution more frequent (&gt; &gt; 1 / 100) than below placebo or were classified as possible medical-relevant side effects (see Section 5.1):</seg>
<seg id="163">"the frequency of the below side effects is defined by the following criteria: frequently (&gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; 1,000, &lt; 1 / 100)."</seg>
<seg id="164">107 The following side effects occurred more frequently on (&gt; &gt; 1 / 100) than below placebo or were classified in clinical trials with oral cozole as possible medically relevant side effects (see Section 5.1):</seg>
<seg id="165">In a placebo-controlled long term study over 26 weeks the incidence of EPS 19% amounted to patients under Aripionzol- treatment and 13.1% in patients under placebo.</seg>
<seg id="166">"in another study about 12 weeks, the incidence of EPS 26,6% amounted to patients under Aripionzol- treatment and 17.6% for those under lithium treatment."</seg>
<seg id="167">In the long-term performance phase over 26 weeks in a placebo-controlled study the incidence of EPS 18.2% for patients under Aripionzene treatment and 15.7% for placebo patients.</seg>
<seg id="168">A comparison between the patient groups under Aripizole and placebo on which potentially clinically significant changes in routinely controlled laboratory parameters occurred revealed not medically significant differences.</seg>
<seg id="169">"the CPK (Creatinphosphokinase), generally temporarily and asymptomatic, have been observed in 3.5% of patients treated with Aripionzol, compared to 2.0% of patients treated with placebo."</seg>
<seg id="170">"the side-effects that can occur in connection with an anti-psychotic therapy, and about their appearance also in the treatment with Aripizole syndrome, the malignne neuroleptic syndrome and campfanatics, undesirable events and increased mortality in older dementia patients, hyperglycaemia and diabetes mellitus (see Section 4.4)."</seg>
<seg id="171">110 and behavioural disturbances were the Aripionzene injection solution with statistically significant major improvements of Agiity / verse disorders compared to placebo and was similar to Haloperidol.</seg>
<seg id="172">In a placebo-controlled short-time study (24 h) with 291 patient with bipolar disorder and the sanity and behavioural disorders associated with a statistically significant improvement in symptoms related to placebo and similar to the Lorazepam- reference.</seg>
<seg id="173">"the observed mean lowered from the raw value on the PANSS Excitement Component score at the primary 2-hour endpoint was 5,8 for placebo, 9,6 for Lorazepam and 8,7 for Aripidazole."</seg>
<seg id="174">"in analyses of subgroups in patients with mixed episodes or patients with severe acting control, a similar effectiveness in relation to the total population has been observed, but a statistical Signifikanz could be determined due to decreased patient number."</seg>
<seg id="175">In three placebo-controlled short-time studies (4 to 6 weeks) in 1.228 schizophrase (oral) compared to placebo a statistically significant stronger improvement of psychological symptoms.</seg>
<seg id="176">"in a Haloperidol-controlled study conducted in week 52 of the proportion of the Responder patients, which include an appeal to the academic medicine, in both groups similar (Aripionzol 77% (oral) and Haloperidol 73%)."</seg>
<seg id="177">"current values from the measals, which were defined as secondary studies, including PANSS and the Montgomery-Asberg-depressants scale, showed a significant stronger improvement than in Haloperidol."</seg>
<seg id="178">In a placebo-controlled study over 26 weeks on stabilized patients with chronic schizophrenia showed itself a significant higher reduction of downrate that was at 34% in the Aripizopzol- (oral) group and at 57% below placebo.</seg>
<seg id="179">"in a Olanniin-controlled, multinational Double-blind study conducted in schizophrenia over 26 weeks, the 314 patients agreed to obtain less patients a weight gain of at least 7% compared to the output value (i.e. an increase of at least 5,6 kg at an average weight of approx. 6 kg)."</seg>
<seg id="180">111 In a placebo-controlled study conducted over 6 weeks with patients with a manic or mixed episode of a Bipolar disorder or Valproat-Monotherapy in therapeutic Serum mirror, yielded the accompanying therapy with Aripionzene (compared to monotherapy with lithium or Valproat). "</seg>
<seg id="181">"in a placebo-controlled study conducted over 26 weeks, by a 74-week academic study, a remission has achieved a remission to placebo over placebo superior in terms of preventing an bipolar return, predominantly in the prevention of an accident in the Manie."</seg>
<seg id="182">The Aripidazole AUC is in the first 2 hours of intra-muscular injtion 90% greater the AUC by gift of the same dose as a tablet; the systemic exposure was similar between the two formulations.</seg>
<seg id="183">In 2 studies with healthy volunteers were the average time until reaching the maximum plasmasegels at 1 to 3 hours.</seg>
<seg id="184">The gift of Aripidazole injection solution was tolerated by rats and monkeys and resulted in no direct toxicity of a target organs in a systemic exposure (AUC) in 15- and 5-times over the maximum humane exposure of 30 mg intramuscular situation.</seg>
<seg id="185">"in studies for reproduction trinity after intravenous application, no security-relevant concerns after maternal exposure, which was 15- (rats) and 29-times (rabbits) above the maximum humane exposure of 30 mg."</seg>
<seg id="186">"based on conventional studies with Aripidazole (oral) for safety spharmacology, toxicity in repetitive gift, reproduction, genotoxicity and the canogenic potential let the preclinical data have no special dangers for humans."</seg>
<seg id="187">"toxicologically significant effects were observed only in doses or expositions that significantly exceeded the maximum dosage or exposure to humans, so they are limited for clinical use only limited or no meaning."</seg>
<seg id="188">The effects circulates a dosisdependency-toxicity in rats after 104 weeks at 20 to 60 mg / kg / day (equivalent to 3 mg / kg / day (equivalent to 10 mg / kg / day (the 10-fold) in the mid-state-state-exposure (AUC) at the recommended Maximum-state-exposure (AUC) at the recommended Maximaldose in humans).</seg>
<seg id="189">"in addition, a cholelithiasis has been found as a result of exhilation of sulphate-conjugates from Aripionzene in Galle by monkey-state-exposure (AUC) at the recommended clinical dose or the 16- to 81-times of the recommended maximaldose when people based on mg / m2)."</seg>
<seg id="190">"in rabbits these effects were said to dosing, which led to Expositions of the 3- and 11-times of the middle-state AUC in the recommended clinical Maximaldose, observed."</seg>
<seg id="191">"regulatory filing system must ensure that before and while the product is marketed, the Pharmacovigilance system, as described in the version 1.0 of module 1.8.1. of the authorisation application is, furnished and functional."</seg>
<seg id="192">"according to" CHMP Guideline on Risk Management Systems for Medicinal products for human use "," the updated risk management plan must be submitted at the same time with the next period odic Safety Update Report (PSUR). "</seg>
<seg id="193">"furthermore, a updated risk management plan must be submitted when new information is to be disclosed, the current security data, denomakovigilance plan or measures to risk minimization may be achieved, at request of the EMEA."</seg>
<seg id="194">14 x 1 tablets 28 x 1 tablets 49 x 1 tablets 56 x 1 tablets 98 x 1 tablets</seg>
<seg id="195">EU / 1 / 04 / 276 / 001 14 x 1 tablets EU / 1 / 04 / 276 / 003 49 x 1 tablets EU / 1 / 04 / 276 / 004 56 x 1 tablets EU / 1 / 04 / 276 / 005 98 x 1 tablets</seg>
<seg id="196">EU / 1 / 04 / 276 / 006 14 x 1 tablets EU / 1 / 04 / 276 / 008 49 x 1 tablets EU / 1 / 04 / 276 / 010 98 x 1 tablets</seg>
<seg id="197">EU / 1 / 04 / 276 / 011 14 x 1 tablets EU / 1 / 04 / 276 / 013 49 x 1 tablets EU / 1 / 04 / 276 / 015 56 x 1 tablets EU / 1 / 04 / 276 / 015 98 x 1 tablets</seg>
<seg id="198">EU / 1 / 04 / 276 / 016 14 x 1 tablets EU / 1 / 04 / 276 / 018 49 x 1 tablets EU / 1 / 04 / 276 / 020 56 x 1 tablets EU / 1 / 04 / 276 / 020 98 x 1 tablets</seg>
<seg id="199">"if one of the above-side effects you have considerably affected or you notice unwanted effects which are not specified in this usage information, please inform your doctor or a pharmacist."</seg>
<seg id="200">"it is used to treat adults who suffer from disease, which is marked by symptoms such as hearing, vision or fidentials of things that are not present, distrust, insing, discontinuous language, wirres behavior and flattering mood."</seg>
<seg id="201">"ABILIFY is applied in adults to treat an area with excessive upfeeling, feeling excessive energy, much less sleep than usual, very fast-speaking with rapidly changing ideas and sometimes strong irritability."</seg>
<seg id="202">"high blood sugar or cases of diabetes (sugar disease) in the family of decay suffer unarbitrary, irregular muscle movements, particularly in the face of cardiac or vascular disease in the family, stroke or temporary maneuver in the brain, stroke or temporary maneuvers in the brain (transitory Attacke / TIA), abnormal blood pressure."</seg>
<seg id="203">"if you suffer as an older patient (loss of memory or other mental abilities), you should or a pegers / a kindred of your doctor will inform you if you ever had a stroke or temporary maneuvercirculation of the brain."</seg>
<seg id="204">"immediately inform your doctor if you are connected to muscle rigidity or rigidity, sweating, changing state of mind, or very fast or irregulating heartbeat."</seg>
<seg id="205">Children and young people ABILIFY is not applicable in children and young people as it has not been studied in patients under the age of 18.</seg>
<seg id="206">Taking care of ABILIFY with other medicines please inform your doctor or pharmacist if you are taking other medicines / apply or have recently taken / applied, even if it is not prescription drugs. "</seg>
<seg id="207">Medicines for the treatment of cardiac arrhythmia or herbal medicines used to treat depression and anxiety. medicines used to treat depression and anxiety disorders are used to treat HIV infection anti-infection drugs which are applied to the treatment of epilepsy</seg>
<seg id="208">"pregnancy and breastfeeding you should not take ABILIFY, if you are pregnant, unless you have discussed this with your doctor."</seg>
<seg id="209">"transport and the provision of machines you should not drive car and operate no tools or machines, until you know how ABILIFY works with you."</seg>
<seg id="210">Please take this medicine only after consultation with your doctor if you know is that you suffer from a intolerance towards certain sugars.</seg>
<seg id="211">Please talk to your doctor or a pharmacist if you have the impression that the effect of ABILIFY is too strong or too weak.</seg>
<seg id="212">"even if you feel better, change or set the daily dose of ABILIFY not to ask without your doctor before."</seg>
<seg id="213">If you have taken a bigger quantity of ABILIFY when you should note that you have recommended more ABILIFY tablets than recommended by your doctor (or if someone else has taken some of your ABILIFY tablets) please contact your doctor.</seg>
<seg id="214">"if you have forgotten the intake of ABILIFY If you have forgotten a dose, take the forgotten dose as soon as you think, however, take the double dosage in one day."</seg>
<seg id="215">"frequent side effects (with more than 1 of 100, less than 1 of 10 treated) uncontrollable feeder, headaches, fatigue, nausea, sleepiness, anxiety problems, anxiety and blurred vision."</seg>
<seg id="216">"occasional side effects (with more than 1 of 1,000, less than 1 of 100 treated) Some people can feel shook, especially if they are standing out of a single or sitting position, or they can determine an accelerated pulse."</seg>
<seg id="217">"please inform your doctor or a pharmacist, if any of the listed side effects you have considerably affected or you notice unwanted side effects which are not listed in this usage information."</seg>
<seg id="218">Like ABILIFY looks and content of the package ABILIFY 5 mg tablets are rectangular and blue with formance of A-007 and 5 on one page.</seg>
<seg id="219">"immediately inform your doctor if you are connected to muscle rigidity or rigidity, sweating, changing state of mind, or very fast or irregulating heartbeat."</seg>
<seg id="220">"even if you feel better, change or set the daily dose of ABILIFY not to ask without your doctor before."</seg>
<seg id="221">As ABILIFY looks and content of the package ABILIFY 10 mg tablets are rectangular and rosafar with embossing from A-008 and 10 on one page.</seg>
<seg id="222">"immediately inform your doctor if you are connected to muscle rigidity or rigidity, sweating, changing state of mind, or very fast or irregulating heartbeat."</seg>
<seg id="223">"even if you feel better, change or set the daily dose of ABILIFY not to ask without your doctor before."</seg>
<seg id="224">"as ABILIFY looks and content of the package ABILIFY 15 mg tablets are round and yellow, with embossing from A-009 and 15 on one page."</seg>
<seg id="225">"immediately inform your doctor if you are connected to muscle rigidity or rigidity, sweating, changing state of mind, or very fast or irregulating heartbeat."</seg>
<seg id="226">"even if you feel better, change or set the daily dose of ABILIFY not to ask without your doctor before."</seg>
<seg id="227">As ABILIFY looks and content of the package ABILIFY 30 mg tablets are round and rosafarben with embossing from A-011 and 30 on one page.</seg>
<seg id="228">"171 If you suffer as an older patient (loss of memory or other mental abilities), you should or a pegers / a kindred of your doctor will inform you if you ever had a stroke or temporary maneuvercirculation of the brain."</seg>
<seg id="229">"immediately inform your doctor if you are connected to muscle rigidity or rigidity, sweating, changing state of mind, or very fast or irregulating heartbeat."</seg>
<seg id="230">"important information about certain other components of ABILIFY patients who should not take phenylalanine, should be aware that ABILIFY Schmelzenge aspartame is included as a source of phenylalanine."</seg>
<seg id="231">"take out immediately after the opening of the blister packs the tablet with dry hands, and put the melzenge on the whole into the tongue."</seg>
<seg id="232">"even if you feel better, change or set the daily dose of ABILIFY not to ask without your doctor before."</seg>
<seg id="233">If you have taken a bigger quantity of ABILIFY when you should note that you have been advised more ABILIFY swemelzenge than recommended by your doctor (or if someone else has taken some of your ABILIFY swemelzenge) please contact your doctor.</seg>
<seg id="234">"calcium tricasilicat, Croscarmor sodium, silicum dioxide, microcrystine Cellulose, aspartame, Acesulfam-Kalium, Vanillin and Ethyl vanilla (contains vanilla in and Ethyl vanillin), wine acid, magnesium, iron (III) - OXID (E172)."</seg>
<seg id="235">"as ABILIFY looks and content of the pack The ABILIFY 10 mg swamp-coated tablets are round and rosafarben, with stamping of" A "over" 640 "on one side and" 10 "on the other."</seg>
<seg id="236">"177 If you suffer as an older patient (loss of memory or other mental abilities), you should or a pegers / a kindred of your doctor will inform you if you ever had a stroke or temporary maneuvercirculation of the brain."</seg>
<seg id="237">"immediately inform your doctor if you are connected to muscle rigidity or rigidity, sweating, changing state of mind, or very fast or irregulating heartbeat."</seg>
<seg id="238">"Calciumtrimetasilicat, Croscarmor-sodium, sical acid-Kalium, vanesulfam-Kalium, Vanillumium, iron (III) - hydroxid-OXID x H2O (E172)."</seg>
<seg id="239">"as ABILIFY looks and content of the pack The ABILIFY 15 mg swamp-coated tablets are round and yellow, with prevalence of" A "over" 641 "on one side and" 15 "on the other."</seg>
<seg id="240">"183 If you suffer as an older patient (loss of memory or other mental abilities), you should or a pegers / a kindred of your doctor will inform you if you ever had a stroke or temporary maneuvercirculation of the brain."</seg>
<seg id="241">"immediately inform your doctor if you are connected to muscle rigidity or rigidity, sweating, changing state of mind, or very fast or irregulating heartbeat."</seg>
<seg id="242">"as ABILIFY looks and content of the pack The ABILIFY 30 mg of melzenge are round and rosafarben, with grazing of" A "over" 643 "on one side and" 30 "on the other."</seg>
<seg id="243">"immediately inform your doctor if you are connected to muscle rigidity or rigidity, sweating, changing state of mind, or very fast or irregulating heartbeat."</seg>
<seg id="244">"transport and the provision of machines you should not drive car and operate no tools or machines, until you know how ABILIFY works with you."</seg>
<seg id="245">190 key information about certain other components of ABILIFY Eder ml ABILIFY solution for taking contains 200 mg of fructose and 400 mg Sucrose.</seg>
<seg id="246">"if your doctor has informed you that you suffer from a intolerance towards certain sugar, please contact your doctor before taking this medicine."</seg>
<seg id="247">"the dose of ABILIFY solution to take into one must be measured with the grounding measurement or the sworn 2 ml trophopette, which are included in the package."</seg>
<seg id="248">Please talk to your doctor or a pharmacist if you have the impression that the effect of ABILIFY is too strong or too weak.</seg>
<seg id="249">If you have taken a bigger quantity of ABILIFY when you should note that you have taken more ABILIFY solution to take longer than by your doctor (or if someone has taken differently ABILIFY solution to take) please contact your doctor.</seg>
<seg id="250">"Dinatrium etat, fructose, glycerol, lacyl-4- hydroxybenzoat (E218), Natriumhydroxybenzoat (E216), Natriumhydroxybenzoat (E216), Natriumhydroxid, soucrose, rounded water and natural citrus cream with other natural flavours."</seg>
<seg id="251">"as ABILIFY looks and content of the package ABILIFY 1 mg / ml solution for taking is a clear, colored fluid in bottles with a child-safe polypropylene foam and 50 ml, 150 ml or 480 ml"</seg>
<seg id="252">"ABILIFY injection solution is used for the rapid treatment of increased unrest and disdoubtful behaviour that are marked by symptoms such as: the hearing, seeing or Fühlen of things that are not present, distrust, insing language, wirres behavior and flattering mood."</seg>
<seg id="253">"people with this disease can also be depressed to feel guilty, anxious or tense. exaggerated energy to have much less sleep than usual, very fast speaking with changing ideas and sometimes strong irritability."</seg>
<seg id="254">"immediately inform your doctor if you are connected to muscle rigidity or rigidity, sweating, changing state of mind, or very fast or irregulating heartbeat."</seg>
<seg id="255">"with application of ABILIFY with other medicines please inform your doctor or pharmacist, if you are taking other medicines / apply or have recently taken / applied, even if it is not prescription drugs."</seg>
<seg id="256">Medicines for the treatment of cardiac arrhythmia or herbal medicines used to treat depression and anxiety. medicines used to treat depression and anxiety diseases are applied to the treatment of HIV infection anti-infection drugs which are applied to the treatment of epilepsy.</seg>
<seg id="257">"196 pregnancy and breastfeeding you should not apply ABILIFY, if you are pregnant, unless you have discussed it with your doctor."</seg>
<seg id="258">Transport and use of machines you should not drive car and use no tools or machines when you have heard after the application of ABILIFY injection solution.</seg>
<seg id="259">"if you have concerns, that you receive more ABILIFY injection solution than you think, please talk to your doctor or pegers about it."</seg>
<seg id="260">"frequent side effects (with more than 1 of 100, less than 1 of 10 treated) by ABILIFY injection solution are fatigue, snail, headache, nausea and vomiting."</seg>
<seg id="261">"occasional side effects (with more than 1 of 1,000, less than 1 of 100 treated) Some people can feel a changed blood pressure, particularly when setting up or sitting, or a quick puls, have a dry feeling inside the mouth or feel debeaten."</seg>
<seg id="262">"frequent side effects (with more than 1 of 100, less than 1 of 10 treated) uncontrollable feeder, headaches, fatigue, nausea, sleepiness, anxiety problems, anxiety and blurred vision."</seg>
<seg id="263">"if you need further information about your illness or their treatment, please read the packages (also part of the EPAR) or contact your doctor or a pharmacist."</seg>
<seg id="264">Abraxane should only be used under the supervision of a qualified Oncologist on the use of Zytostatika (abbreviation of cells) specified departments.</seg>
<seg id="265">"patients in which certain side effects occur to the blood or the nervous system, the dose can be reduced or interrupted the treatment."</seg>
<seg id="266">"(44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail @ emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu http: / / www.emea.europa.eu / or distribution of this document is</seg>
<seg id="267">"the effectiveness of Abraxane was investigated in a major study, on the 460 women with metastatic breast cancer, of which approximately three quarters had to be obtained in the anthracycline."</seg>
<seg id="268">The effect of Abraxane (in all parts or as monotherapy) was compared with the medication used by a conventional paclitaxel drug (given in combination with other medicines to reduce the side effects).</seg>
<seg id="269">"overall, in the principal Study 72 (31%) of 229 with Abraxane patients treated to the treatment, compared to 37 (16%) of the 225 patients, the conventional paclitaxel drug."</seg>
<seg id="270">"however, one regards only the patients who were treated for the first time for metastatic breast cancer, there were no difference between medicines such as time until the deterioration of disease and survival."</seg>
<seg id="271">"contrary to patients, who previously received other treatments of their metastatic breast cancer in terms of these indicators that are more effective than conventional paclitaxel drug."</seg>
<seg id="272">It must also be used in patients who are silent or before the treatment of low neutrophils in the blood.</seg>
<seg id="273">"the Committee on Humanarzs (CHMP) presented that Abraxane suggests more effective than conventional paclitaxel drug, and that it must not be given in contrast to other Paclitaxel drugs to reduce side effects."</seg>
<seg id="274">January 2008 the European Commission shared the artist Bioscience Limited as approve permission for the transport of Abraxane in the entire European Union.</seg>
<seg id="275">Abraxane-Monotherapy is indices for the treatment of metastatic Mammakarcinoma in patients with which the first-line treatment for metastatic disease is missing and for which a standard anthracycline therapy is not shown (see also section 4.4).</seg>
<seg id="276">In patients with severe neutropenny (neutrophortic) &lt; 0,50 x 109 / l over a period of a week or longer) or severe sensoric Neuropathy during the abrasive therapy should be reduced the dose into the subsequent series on 220 mg / m2.</seg>
<seg id="277">"with sensory Neuropathy Grad 3 is the treatment to break down, until an improvement to level 1 or 2 is reached, and in all subsequent cycles the dose must be reduced."</seg>
<seg id="278">There is currently no adequate data for the recommendation of dosage adjustment in patients with mild to moderate impairment of the liver function (see section 4.4. and 5.2).</seg>
<seg id="279">"there were no studies conducted with patients with handicapped kidney function and there is currently no adequate data on recommendation of dosage adjustment to patients with impairment from kidney function (see Section 5.2)."</seg>
<seg id="280">Abraxane is not recommended for use in children under 18 years due to insufficient data on infinity and effectiveness.</seg>
<seg id="281">Abraxane is an Albumin-blown nanoparticles by Paclitaxel that could have considerably other pharmacological characteristics as other formulations of paclitaxel (see Section 5.1 and 5.2).</seg>
<seg id="282">"if an allergic reaction occurs, the drug should be applied immediately and treated with a symptomatic treatment, and the patient may not be treated again with paclitaxel."</seg>
<seg id="283">"in patients should not be initiated later, until the neutrophage number can be turned back to &gt; 1.5 x 109 / l and the thyrofoam number is back to &gt; 100 x 109 / l."</seg>
<seg id="284">Patients with severe liver dysfunctions (bilirubin &gt; 5 x ULN or ASL / ALT &gt; 10 x ULN) should not be treated with Abraxane.</seg>
<seg id="285">"although a clear with abrasion in connection to the cardiotoxicity in the indicative patient is not uncommon, especially in patients with past anthracycline-treatment or underlying cardiac disease or a degenerative cardiac disease."</seg>
<seg id="286">"if in case of patients after the gift of Abraxane nausea, vomiting and diarrhea, these can be treated with the usual antiemetics and conformative means."</seg>
<seg id="287">"Abraxane should not be applied in pregnant or with women of childbearing age, which are not used effectively, except for the treatment of the mother with Paclitaxel is unavoidable."</seg>
<seg id="288">Women of childbearing age should apply during and up to 1 month after the treatment with Abraxane a reliable refinement method.</seg>
<seg id="289">Male patients who will be treated with Abraxane will be advised during and up to six months after treatment a child.</seg>
<seg id="290">Male patients should be advised in front of the treatment of a sperm count because of the therapy with Abraxane the possibility of irreversible infertility.</seg>
<seg id="291">Abrasive can cause side effects such as fatigue (very frequently) and dizziness (frequently) which can impact on the volatility and ability to serve machinery.</seg>
<seg id="292">"below are the most common and most important incidents of side effects listed in 229 patients with metastatic Mammakarcinom, which were treated in pivotal clinical phase III study once every three weeks with 260 mg / m2."</seg>
<seg id="293">Neutropenny was the most noticeable important hematological toxicity (at 79% of patients) and was quick reversible and dosisdependent; LeuCopenie was reported at 71% of patients.</seg>
<seg id="294">Anemia (HB &lt; 10 g / dl) was observed at 46% of patients with abrasive patients and was severe in three cases (HB &lt; 8 g / dl).</seg>
<seg id="295">"in table 1 are the side effects listed, which occurred in conjunction with the Gift of Abraxane as monotherapy at every dose and indications in studies (N = 789)."</seg>
<seg id="296">"very common (&gt; &gt; &gt; / 10, &lt; 1 / 10); occasionally (&gt; &gt; 1 / 1,000, &lt; 1 / 100); rarely (&gt; &gt; &gt; 1,000, &lt; 1 / 1,000); very rare (&lt; 1 / 10,000)."</seg>
<seg id="297">"occasionally: increased blood pressure, weight gain, increased lactose-hydrogenase in the blood, increased blood sugar in the blood, increased blood sugar, increased phosphor in the blood, reduced potassium in the blood of heart disease:"</seg>
<seg id="298">"dysphagie, blacks, dry mouth, painless flesh, loose chair, anti-sophism, pain in the mouth, orale pain, rectal bleeding diseases of the kidneys and urinary tract:"</seg>
<seg id="299">"pain in the breast wall, weakness of the musculature, Genickpain, pain spasms, pain in the skeletal muscles, flanks, discomfort in the limbs, muscle weaks Very often:"</seg>
<seg id="300">Ruin 1 The frequency of hypersensitivity interactions is calculated based on a defined in connection in a population of 789 patients</seg>
<seg id="301">"as these events have been reported on a voluntary basis during clinical practice, no estimates of actual incidence are possible and it was not a causal connection with these events."</seg>
<seg id="302">"Paclitaxel is an antimikrotubules, which promotes the cladding of microtubules from the Tubular indimite, and stabilized the microtubules by inhibitors of their deportation."</seg>
<seg id="303">"this stabilization leads to a inhibition of the normal dynamic reorganization of the mikrotubulular network, which is essential for the vital interphase and the cootic cell functions."</seg>
<seg id="304">It is known that Albumphs has been conveyed into the Transcytosis of Plasmakomponents in the endothelper studies and has been proven in the frame of paclitaxel by endothelper cells.</seg>
<seg id="305">It is assumed that this improved transendotheliale transport is conveyed by the gp-60-Albuminreceptor is conveyed and due to the albuminator Proteins SPARC (compiled protein acidic rich in cysteine) a Paclitaxel accumulation in the field of tumors.</seg>
<seg id="306">The application of Abraxane for metastatic Mammakarcinoma is treated by 106 patients in two single-part ouflaged studies and 454 patients who were treated in a randomised phase-III-comparative study.</seg>
<seg id="307">"in a study 43 patients treated with metastatic Mammakarzinom, which was given in the form of an infusion over 30 minutes with a dose of 175 mg / m2."</seg>
<seg id="308">"in the second study, a dose of 300 mg / m2 as infusion was used over 30 minutes to 63 patients with metastatic Mammakarcinoma."</seg>
<seg id="309">This multi-centric study was conducted in patients with metastatic Mammakarcinoma performed every 3 weeks a monotherapy with Paclitaxel 175 mg / m2 as 3-hour infusion with premedication for contraception of an allergic reaction (N = 225) or in the form of Abraxane 260 mg / m2 as 30-minute infusion (N = 229).</seg>
<seg id="310">"during the recording in the study 64% of patients had a total general condition (ECOG 1 or 2), 79% had visceral Metastases and 76% had more than 3 metastars."</seg>
<seg id="311">"14% of patients previously had no chemotherapy, 27% had only a adjuvant chemotherapy, 40% only because of Metastasification and 19% because of Metastasification and adjuvant treatment."</seg>
<seg id="312">9 The results for the general response rate and time until progression of disease as well as progression-free survival and survival for patients who receive &gt; First-Line therapy are shown below.</seg>
<seg id="313">"neurotoxicity compared to paclitaxel was evaluated by improving a degree of patients suffering, at a time during therapy a peripheral Neuropathy Grad 3 times."</seg>
<seg id="314">The natural course of periphery Neuropathy to sound on baseline due to cumulative toxicity of Abraxane according to &gt; 6 treatment curve was not evaluated and is still unknown.</seg>
<seg id="315">The pharmacokinetics of the total-paclitaxel after 30- and 180-minute infusions of Abraxane with a dose of 80 to 375 mg / m2 was established in clinical studies.</seg>
<seg id="316">"the drug exposure (AUC) increased steadily from 2653 to 16736 ng.h / ml, analogue to a dose of 80 to 300 mg / m2."</seg>
<seg id="317">10 After intravenous gift from Abraxane to patients with metastatic Mammakarcinoma in the recommended clinical dose of 260 mg / m2 took the Paclitaxel-Plasmakonzentration in multilateral manner.</seg>
<seg id="318">The average distribution volume was 632 l / m2; high distribution volume points to a far-reaching extravascular distribution and / or soft delivery of Paclitaxel.</seg>
<seg id="319">In a study with advanced solid tumours the pharmacokinetic properties were compared to intravenous 30-minute infusion of 260 mg / m2.</seg>
<seg id="320">"the Clearance of Paclitaxel was higher (43%) than after an solvent-based Paclitaxel injection, and even the volume of distribution was higher (53%)."</seg>
<seg id="321">Published in the published literature about in-vitro-studies of human liver microsome and tissue layers will be reported that paclitaxel is primarily associated to 6α-hydroxypaclitaxel and 6α-3 "-p-Dihydroxypaclitaxel) metabolized.</seg>
<seg id="322">"after a 30-minute infusion of 260 mg / m2, xane in patients with metastatic Mammakarcinom amounted to the average total dosage with less than 1% of the Metabolites 6α-hydroxypaclitaxel and 3" -p-Hydroxyypaclitaxel, which indicates a far-ranging non-renal clearance. "</seg>
<seg id="323">"however, more than 75 patients aged over 75 years are only available for only 3 patients in this age group at the pharmakokinetic analysis."</seg>
<seg id="324">"the chemical and physical stability was established at 2 ° C - 8 ° C in the original box, and in front of light light over 8 hours."</seg>
<seg id="325">Paclitaxel is a cytotoxic anogenic drugs and as well as other potentially toxic substances should be used when dealing with abrasive drugs.</seg>
<seg id="326">Using a sterile syringe are slowly over a period of at least 1 minute 20 ml a 9 mg / ml (0.9%) soriumchloride infusion in a abrasion bottle.</seg>
<seg id="327">"according to complete addition, the solution should rest a bottle case at least 5 minutes to ensure a good gasketing of the material."</seg>
<seg id="328">"then the tear-bottle should be slowly and carefully peeled and / or inverted, until a complete reset-board of the pulse is done."</seg>
<seg id="329">"if canceled or scinkers are visible, the flow-bottle must again be gently inverted to achieve a complete reset-board."</seg>
<seg id="330">"this will be calculated for the patient all the exact total dose of the 5-mg / ml-Suspension, and the appropriate amount of reconstitutionated xane into an empty, sterile PVC- or non-PVC infusion."</seg>
<seg id="331">"pharmacovigilance system The holder of permission for the transport must ensure that the pharmacovigilance system, as described in version 2.0 and presented in module 1.8.1. of the authorisation application, is set up and works before and while the drug is placed in the traffic."</seg>
<seg id="332">"risk management plan from the holder of permission for the transport system is required to perform in version 4 of the risk management plan (RMP) and in module 1.8.2nd of the authorisation application, as well as all subsequent updates of the RMP, which are agreed with the CHMP."</seg>
<seg id="333">"according to CHMP directive on risk management systems for use in the application, it shall be submitted to date at the same time with the next period odic Safety Update Report (PSUR)."</seg>
<seg id="334">"in addition, an upset room is subject to submit • If new information could enter into the current security specification, the pharmacovigilance plan or risk minimization activities - inside 60 days after reaching an important milestone (Pharmacovigilance or risk minimization) • On request of EMEA</seg>
<seg id="335">"8 hours in the refrigerator in the bottle case, if it is stored in a cardboard box to protect the contents from light."</seg>
<seg id="336">"Abraxane is used for the treatment of Mammakarzinome when other therapies were tried, but not successful, and if you are not successful for anthracycline-contained therapies."</seg>
<seg id="337">Abraxane must not be applied: • If you are hypersensitive (allergic) against paclitaxel or one of the other components of Abraxane • If you are breastfeeding • if your white blood cells are lower (output levels for neutrophy number of &lt; 1.5 x 109 / l - your doctor will inform you about it)</seg>
<seg id="338">"special caution in the application of Abraxane is required: • If you have a correct kidney function, if you have a changeable feeling, tingling, prickingly sense, touchness or muscle tissue, if you suffer from severe liver problems, if you have heart problems."</seg>
<seg id="339">"in use of Abraxane with other medicines please inform the doctor if you apply other medicines or have recently applied, even if this may not be prescription drugs, since this may cause a interaction with abrasive drugs."</seg>
<seg id="340">Women of childbearing age should apply during and up to 1 month after the treatment with Abraxane a reliable refinement method.</seg>
<seg id="341">"in addition, they should be advised in front of the treatment of a sperm count, because of the abrasive treatment there is the possibility of permanent infertility."</seg>
<seg id="342">"traffic-resistance and serve of machinery, xane can cause side effects such as fatigue (very frequently) and severity-feeling (often), which can impact on the volatility, and ability to serve machinery."</seg>
<seg id="343">"if you have also received other medicines within the framework of your treatment, you should consult with regard to driving or serve machines from your doctor."</seg>
<seg id="344">"22 • Effect on the peripheral nerves (pain and numbness) • pain in one or more joints • pain in the muscles • nausea, diarrhea • Cancel and tiredness</seg>
<seg id="345">"the frequent side effects (with at least 1 of 100 patients reported) are: • rash, potable skin, nail pain, bonding disorders, bonding disorders, or mabs, sore throat, sore mouth or sore, sore mouth or sore tongue, mouth soor • dormitories."</seg>
<seg id="346">"the rare side effects (with at least 1 of 10,000 patients) are: • pulmonial infection • Hautraction on another substance after radiotherapy, blood clot"</seg>
<seg id="347">"please inform your doctor or a pharmacist, if any of the listed side effects you have considerably affected or you notice unwanted side effects which are not listed in this usage information."</seg>
<seg id="348">"if they are not used immediately, it can be stored in the bottle of up to 8 hours in the refrigerator (2 ° C - 8 ° C) if it is stored in a cardboard box to protect the contents from light."</seg>
<seg id="349">Any corpouch contains 100 mg paclitaxel. • After the reconstitution contains each ml of the Suspension 5 mg paclitaxel. • The other part is the album solution from the people (contains Natrium, Natriumcaprylat) and N Acetyltryptophan (Ph.Eur.)) "</seg>
<seg id="350">Precautions and application paclitaxel is a cytotoxic anogenic drugs and as well as other potentially toxic substances should be used when dealing with abrasive drugs.</seg>
<seg id="351">Using a sterile syringe should slowly be injected over a period of 1 minute 20 ml a 9 mg / ml (0.9%) soriumchloride infusion in a abrasion bottle.</seg>
<seg id="352">"after that, the flow of bottle for at least 2 minutes slowly and wristwatch and / or inverse, until a complete reset-board of the pulse is done."</seg>
<seg id="353">"for the patient, the exact total dosage volume of 5 mg / ml Suspension calculate and the appropriate amount of reconstitutionally abrasion into an empty, sterile PVC-infusion type IV inject."</seg>
<seg id="354">"Parenteral medicines should be subjected to the application of a visual inspection for possible particles and discolorations, whenever the solution or the containers can allow this."</seg>
<seg id="355">"stability Ungeopened flow-washed with Abraxane are raised up to the date specified on the package, if the flow bottle is stored in a cardboard box to protect the contents from light."</seg>
<seg id="356">"stability of the reconstitutive Suspension in the bottle case After the first reconstitution, the Suspension should immediately be filled into an infusion bag."</seg>
<seg id="357">Member states need to ensure that the holder of permission for the transport market would be supplied before the launch of the medical personnel in dialysis centres and retail outlets with the following information and materials:</seg>
<seg id="358">• Schoeller brownings • summary of the characteristics of the drug by means of expert information), labeling and Packages. • With clear representation of the products of the product accidental cooling for the transport by the patient. "</seg>
<seg id="359">"this means that abseamed of a biological medicine is similar, which is already approved in the European Union (EU) and is called the same substance (also" "reference frequency." ")."</seg>
<seg id="360">"it is used in patients with normal blood values that could occur in connection with a blood transfusion complications, if prior to the procedure is not possible and where a blood loss of 900 to 1 800 ml is expected."</seg>
<seg id="361">Treatment with Abseamed must be initiated under the supervision of a doctor who has experience in the treatment of patients with diseases which is shown for the drug.</seg>
<seg id="362">"in patients with kidney problems and in patients who want to make a self-blood-donation, Abseamed is injected into a vene."</seg>
<seg id="363">Injection can also be made by the patient or his supervisor unless they have received an appropriate guide.</seg>
<seg id="364">"in patients with chronic kidney insufficiency or in patients having received a chemotherapy, the hemostglobets always should lie in the recommended area (between 10 and 12 grams per Deciliter in adults or between 9,5 and 11 g / dl in children)."</seg>
<seg id="365">"the iron values of all patients are to control in front of the treatment, to ensure that no iron deficiency can be administered, and iron supplements should be administered throughout the treatment."</seg>
<seg id="366">"in patients who receive any chemotherapy, or with patients with kidney disease can be caused an anemia caused by a erythropoietinmangel or thereby, that the body is not adequate for the body thropoietin."</seg>
<seg id="367">Erythropoietin is also applied to operations to increase the number of red blood cells and thus to minate the consequences of a blood loss.</seg>
<seg id="368">It is produced by a cell that a gene (DNA) has been brought into the formation of epoetin alfa.</seg>
<seg id="369">Abseamed has been compared with appointments as an injection in a Vene in the framework of a major study of 479 patients suffering from renal problems caused by kidney disease.</seg>
<seg id="370">All patients participating in this study was projected at least eight weeks Eprex / Erypo in a Vene before they were either amed to Abseamed or continue to Eprex / Erypo.</seg>
<seg id="371">The main indeer for the effectiveness was the change in the hematgloomy set between the beginning of the study and the judging period in the weeks 25 to 29.</seg>
<seg id="372">"in addition, the company also laid out the results of a study in which the effects of pronx / Erypo has been studied with those of Eprex / Erypo in 114 cancer patients."</seg>
<seg id="373">"in the study with patients suffering caused by renal problems caused by renal problems, the hematgloomy values were provided in the same measure as in those patients who continue to be Eprex / Erypo."</seg>
<seg id="374">"in comparison to this showed the patients who continue to have Eprex / Erypo, a rise of 0,063 g / dl of the output of 12,0 g / dl."</seg>
<seg id="375">"the most common side effect of Abseamed is a rise in blood pressure, which can occasionally lead to symptoms of a encephalopathy (brain problems) such as sudden, staining headaches and confusions can lead."</seg>
<seg id="376">"Abseamed may not be applied in patients, which may be hypersensitive (allergic) against epoetin alfa or one of the other components."</seg>
<seg id="377">"abseamed as injecting under the skin is not recommended for the treatment of kidney problems, as further studies are required to make sure this is caused by no allergic reactions."</seg>
<seg id="378">"the Committee on Humanarzs (CHMP) led to the conclusion that for Abseamed according to the provisions of the European Union, the drug has been a comparable quality, security and efficacy profile such as Eprex / Erypo."</seg>
<seg id="379">"the company, the Abseamed has been provided for medical practitioners in all Member States informational information, including information on the security of the drug."</seg>
<seg id="380">August 2007 the European Commission shared the Company Medice Drug Pütter GmbH & Co KG for acquiring a retirement in the entire European Union.</seg>
<seg id="381">"treatment of anemia and reduction of transfusion consumes in adults with solid tumours, maligsaw lymphocytic or multiplem myeloma, which is given to chemotherapy (for example, cardiovascular status, pre-existing anemia at the beginning of chemotherapy)."</seg>
<seg id="382">"the treatment should only be performed in patients with moderate anemia (hemoglobin [HB] 10 - 13 g / dl [6,2 - 8,1 mmol / l], no iron deficiency. (4 or more units blood on women; 5 or more units blood in men)."</seg>
<seg id="383">"for the reduction of stranger, Abseamed can be applied to a large elekic orthopedic intervention in adults without a iron organ, where a high risk of transfusion is expected to be expected."</seg>
<seg id="384">HB 10-13 g / dl) and an expected blood loss of 900-1800 ml can be applied not to participate in an autonomous bloodshot program.</seg>
<seg id="385">The hemoglobin target-targets is between 10 and 12 g / dl (6.2 - 7,5 mmol / l) except for pediatric patients with which the hemostasis system between 9,5 and 11 g / dl (5.5 - 6.8 mmol / l) should be.</seg>
<seg id="386">"depending on age, gender and overall disease changes may vary depending on age, gender and overall disease burden; therefore, the assessment of the individual clinical trials and disease condition is required by the doctor."</seg>
<seg id="387">A rise in Hämop bins to be more than 2 g / dl (1.25 mmol / l) over a period of four weeks should be avoided.</seg>
<seg id="388">"due to the variability of patients you can occasionally be observed in a patient individual hemorrhoid, or under the hemorrhobin- target concentration."</seg>
<seg id="389">"in view of these hemglogloomy variability, the hemostasis has been trying to achieve the hemoglobin target-target groups of 10 g / dl (6.2 mmol / l) up to 12 g / dl (7,5 mmol / l)."</seg>
<seg id="390">If the hemostasis is worth more than 2 g / dl (1.25 mmol / l) per month or when the permanent hemorrhoid 12 g / dl (7,5 mmol / l) exceeds the epoetin-alfa dose to reduce 25%.</seg>
<seg id="391">Patients should be engulously monitored to ensure that epoetin alfa is required in the lowest dose which is required for controlling the anemia and anemia symptoms.</seg>
<seg id="392">The present clinical results suggest that patients with an initial amount of HB-value (&lt; 6 g / dl or &lt; 3,75 mmol / l) may require higher profits than patients in which the initial anemia is less heavy (HB &gt; 8 g / dl or &gt; 5 mmol / l).</seg>
<seg id="393">"the present clinical results suggest that patients with an initial amount of HB-value (&lt; 6,8 g / dl or &lt; 4,25 mmol / l) may require higher profits than patients in which the initial anemia is less heavily shaped (HB &gt; 6,8 g / dl or &gt; 4,25 mmol / l)."</seg>
<seg id="394">"initial dose 50 - / kg three times a week by means of intravenous application, if necessary with a dosage auction of 25} / kg (three times per week), until the desired destination is achieved (this should be done in steps of at least 4 weeks)."</seg>
<seg id="395">"assumptive symptoms and responds may vary depending on age, gender and overall disease burden; therefore, the assessment of the individual clinical trials and disease condition is required by the doctor."</seg>
<seg id="396">"in view of these hemglogloomy variability, the hemostasis has been trying to achieve the hemoglobin target-target groups of 10 g / dl (6.2 mmol / l) up to 12 g / dl (7,5 mmol / l)."</seg>
<seg id="397">Patients should be engulously monitored to ensure that epoetin alfa is required in the lowest dose which is required for controlling the analogy symptoms.</seg>
<seg id="398">"if after 4 treatment weeks of the Hämogloomy, it is worth at least 1 g / dl (apmmol / l) or the Retikulocytes compared to the output value, the dose of 150 is i.e. / kg three times per week or 450 lbs / kg will be kept once a week."</seg>
<seg id="399">"if the Hämoglobinanrose &lt; 1 g / dl (&lt; Nummmol / l) and the Retikulozytennumber &lt; 40,000 cells / µl opposite the curly value, the dose should be raised to 300 copies / kg three times a week."</seg>
<seg id="400">"if after further 4 treatment weeks with 300 copies / kg three times a week of Hämop binge for &gt; &gt; 1 g / dl (&gt; _ 64mmol / l) or the Retikulozytention, should retain the dose of 300 copies / kg three times a week."</seg>
<seg id="401">"in contrast, the hemorrhoid is worth around &lt; 1 g / dl (&lt; Nummmol / l) or the Retikulocytes compared to the output, is an appeal to the epoetin-alfa therapy improbably and the treatment should be cancelled."</seg>
<seg id="402">Patients with mild anemia (hematokrit 33 - 39%) in which the precautionary deposits are required in a dose of 600. / kg of body weight twice weekly for 3 weeks before operating procedure.</seg>
<seg id="403">"with the iron substitution, the iron substitution should be made available as early as possible - for example a few weeks before the beginning of the autecologists blood circulation program - so that before starting the seamed therapy large iron reserves are available."</seg>
<seg id="404">"the recommended dosage is 600 - / kg epoetin alfa, which should once weekly over three weeks (day 21, 14 and 7) before operating procedure and on the day of the surgery (day 0)."</seg>
<seg id="405">"in this context, epoetin alfa characterizes 300 copies / kg every 10 consecutive days before, on the day of the surgery, and 4 days immediately afterwards."</seg>
<seg id="406">"alternatively, the injecting is given at the end of the dialysis on the hose of a flistelnav, followed by 10 ml of isotonical cookery solution to insure the hose and ensure sufficient injection of the drug."</seg>
<seg id="407">Patients suffering from treatment with any erythropoetin at a erythroblast openie (Pure Red Cell Aplasia, PRCA) should not receive a seamed or another Erythropoetin (see Section 4.4 - Erythroblastopenie). "</seg>
<seg id="408">"heart attack or stroke within one month before the treatment, instabile Angina pectoral, increased risk for deep venous Thrombosis (e.g. anamnesty known venous Throism)."</seg>
<seg id="409">"in patients who are envisaged for a major electorthodontic procedure, the application of epoetin alfa to participate in the following advantages, vascular disease disease or zerrovascular disease; in patients with recently recurring coronary heart disease or zerrovascular event."</seg>
<seg id="410">Erythroblastopenie (PRCA) Very rare has been reported on the appearance of an anti-mediated PRCA to for years of treatment with subcutaneous Erythropoetin.</seg>
<seg id="411">"in case of patients with sudden alcohol loss, defined as a reduction of hemorrhoid (1 - 2 g / dl per month) with increased need for non-profit (iron, foldable, infection or inflammation, blood loss and hemorolysis)."</seg>
<seg id="412">"if the Retikulocytes value, taking into account the anemia (i.e. the Retikulozyten" Index "), which is lower (&lt; 20,000 / mm3 or &lt; 0.5%), the thyrocypoetin-antibodies and an examination of bone marrow are intended to diagnose the diagnosis of a PRCA."</seg>
<seg id="413">The data on immunogenicity in subcutaneous applications of abseamed in patients with a risk for an anti-induced PRCA (patients with renal anemia) are not adequate.</seg>
<seg id="414">8 For patients with chronic kidney insufficiency should not be exceeded at the maintenance therapy that will not be overstepped down in section 4.2 Lahaz-border of the hermoglobin targets.</seg>
<seg id="415">In clinical trials a raised mortality risk and risks for serious cardiovascular events were observed if Erythropoese-stimulating active ingredients (ESA) have been given by a heads of over 12 g / dl (7.5 mmol / l).</seg>
<seg id="416">Controlled clinical trials have no significant benefit that is attributable to the gift of epos when the hemostasis concentration has increased over the control of anti-blood symptoms and the avoidance of blood transmergers.</seg>
<seg id="417">The Hämoglobinanincreased should be approximately 1 g / dl (apmmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of an increase in hypertension.</seg>
<seg id="418">In patients with chronic kidney insufficiency and clinically evidently coronary heart disease or shrine insufficiency should not be overstepped down in section 4.2 recommended upper limit of the hermoglobin targets.</seg>
<seg id="419">"after the present knowledge of this knowledge by the treatment of anemia with epoetin alfa in adults with kidney insufficiency, which are not yet dialyzed, the progression of kidney insufficiency is not accelerated."</seg>
<seg id="420">In tumour patients under chemotherapy should be considered for the evaluation of the treatment of epoetin alfa a 2 - 3-week delay between epoetin-alfa-gift and the erythropoetin response (patients who need to be transacted).</seg>
<seg id="421">If the HB increase is larger than 2 g / dl (1,25 mmol / l) per month or a HB-value of 13 g / dl (see Section 4.2 treatment of patients with chemotherapyconditional anemia - dosage adjustment with the aim of keeping the heads up between 10 g / dl and 12 g / dl).</seg>
<seg id="422">The decision to use recombinant Erythropoetine should be based on a benefit risk considering the participation of the respective patient which should also consider the specific clinical context.</seg>
<seg id="423">"in patients who are intended for a larger electro-orthopedic procedure, if possible, before the beginning of the epoetin-alfa therapy, the cause of anemia is examined and treated accordingly."</seg>
<seg id="424">Patients who undergo up a major electorthodontic procedure should have an appropriate thyrombd prophylaxis because they have an increased risk for throatrophic and vascular diseases, particularly with an underlying cardiovascular disease. "</seg>
<seg id="425">"in addition, it can not be excluded that for treatment with epoetin alfa to patients with an output shredresgloomy value of &gt; 13 g / dl an increased risk for postoperative ophical / vascular events can exist."</seg>
<seg id="426">"in several controlled studies, epoeins has not been proven to improve the overall survival with symptomatic anemia, or diminished the risk of tumor creep."</seg>
<seg id="427">"4 months in patients with metastatic breast cancer, which was given to chemotherapy if a heads-global target-series of 12 - 14 g / dl (7,5 - 8,7 mmol / l) was pursued."</seg>
<seg id="428">"epoetin alfa is applied together with Ciclosporin, should be controlled the blood level of Ciclosporin and the Ciclosporindosis to the increasing Hämatokrit."</seg>
<seg id="429">From in-vitro-investigations into tumours do not arise any evidence of a interaction between epoetin alfa and G-CSF or GM-CSF regarding hematological differentiation or proliferation.</seg>
<seg id="430">"about thrombotanical, vascular events such as myocardium, cervirombosis, arterial thrombosis, arterial thyrombosis and 11 bloodthirst in artificial kidneys, as well as patients under epoetin alfa."</seg>
<seg id="431">The most common side-effect during treatment with epoetin alfa is a dosisdependent increase in blood pressure or the deterioration of an existing hypertension.</seg>
<seg id="432">An increased incidence of thrombal events (see Section 4.4 and Section 4.8 - General) was observed in patients under the treatment of erythropoetine.</seg>
<seg id="433">Regardless of the erythropoetin treatment it can occur in surgical patients with cardiovascular disease and vascular complications.</seg>
<seg id="434">"the GM-based epoetin alfa is glycol, and with respect to the amino acids and carbohydrates are identical with the endogenous Erythropoetin, which was isolated from the urine of local patients."</seg>
<seg id="435">It could be demonstrated using cultures of human bone marches that epoetin alfa specifically stimulated the erythropoese and the leukopoese is not affected.</seg>
<seg id="436">389 patients with hemogblastosis (221 multiple Myelome, 144 Non-Hodgkin- Lymph) and 332 patients with solid tumors (172 Mammakartery, 64 bronchialkarzinome, 22 bronchialkarzinome, 21 gastrospinal Carcinoma and 30 more). "</seg>
<seg id="437">1895 patients with solid tumors (683 Mammakarzinome, 260 bronchialkarzinome, 174 gynecological tumors, 300 gastrounale Tumors and 478 other) and 802 patients with hemblastoma. "</seg>
<seg id="438">Survival and tumors were examined in five major controlled studies with a total of 2833 patients; four of these studies were doublinded placebocontrolled studies and</seg>
<seg id="439">In the open study there was no difference in the overall survival between the humanitarian humanic erythropoetin treated patients and the patient's patients.</seg>
<seg id="440">"in these studies, the patient treated with recombinant Erythropoetin treated patients with anemia due to various frequent Malignome consistent, statistically significant higher mortality than in controls."</seg>
<seg id="441">The overall survival in the studies could not be explained by differences in the incidence of thymbosis and related complications with recurring erythropoetin treated patients and at control.</seg>
<seg id="442">There is an increased risk for throembocharmed events in tumours that are treated with recombinant erythropoetin with a negative impact on the overall survival cannot be ruled out.</seg>
<seg id="443">"it is not clear how far this results are dealt with on the use of recombinant erythropoetin in tumour patients with the aim of achieving a hemorrhoid less than 13 g / dl, since too few patients were included with this characteristic."</seg>
<seg id="444">"epoetin-alfa provisions according to repetitive intravenous application showed a half-value of about 4 hours in healthy volunteers, and a somewhat prolonged half-life of approximately 5 hours in patients with kidney insufficiency."</seg>
<seg id="445">"after subcutan injection, the serum mirror of epoetin alfa are much lower than the serum mirror, which can be reached after intravenous injection."</seg>
<seg id="446">"there are no grief: the serum mirror remain the same, regardless of whether they are determined 24 hours after the first gift, or 24 hours after the final gift."</seg>
<seg id="447">(bone markfibrosis is a known compensatory of chronic kidney insufficiency in humans and could be attributed to a secondary hyperparathyresteroids or unfamiliar factors.</seg>
<seg id="448">"in a study at Hematalysis patients who were treated three years with epoetin alfa, the incidence of bone markers were treated with dialysis patients who were not treated with epoetin alfa."</seg>
<seg id="449">14 In animal experimental studies with annuously the 20times the one recommended for the application at humans recommended Wochendosis led epoetin alfa to diminishing federate body weight to a delay in the Ossification and a rise in fine mortality.</seg>
<seg id="450">These reports are based on vitro findings with cells from humanic tumor samples that are for the clinical situation but of unsafer Signifikanz.</seg>
<seg id="451">"within the framework of the patient-patient application, the patient can store the patient for a maximum of 3 days outside the coolness and not over 25 ° C."</seg>
<seg id="452">"the syringes are equipped with Graduation rings and the volume is displayed by a sticky label, so if necessary, the dimension of partial volumes is possible."</seg>
<seg id="453">The treatment with Abseamed must be initiated under the supervision of doctors who have experience in the treatment of patients with the above indications.</seg>
<seg id="454">"21 The recommended dosage is 600 - / kg epoetin alfa, which should once weekly over three weeks (day 21, 14 and 7) before operating procedure and on the day of the surgery (day 0)."</seg>
<seg id="455">23 In patients with chronic kidney insufficiency should not be exceeded at the maintenance therapy the upper limit of the hermoglobin target-target cannot be exceeded.</seg>
<seg id="456">The Hämoglobinanincreased should be approximately 1 g / dl (apmmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of an increase in hypertension.</seg>
<seg id="457">"about thrombotanical, vascular events such as myocardium, cervirombosis, arterial thrombosis, arterial thyrombosis and 26 bloodthirties in artificial kidneys, as well as patients under epoetin alfa."</seg>
<seg id="458">An increased incidence of thrombal events (see Section 4.4 and Section 4.8 - General) was observed in patients under the treatment of erythropoetine.</seg>
<seg id="459">389 patients with hemogblastosis (221 multiple Myelome, 144 Non-Hodgkin- Lymph) and 332 patients with solid tumors (172 Mammakartery, 64 bronchialkarzinome, 22 bronchialkarzinome, 21 gastrospinal Carcinoma and 30 more). "</seg>
<seg id="460">"29 In animal experimental studies with annuously the 20times the one recommended for the application at humans recommended Wochendosis led epoetin alfa to diminish federate body weight, to a delay in the Ossification and a rise in fine mortality."</seg>
<seg id="461">"within the framework of the patient-patient application, the patient can store the patient for a maximum of 3 days outside the coolness and not over 25 ° C."</seg>
<seg id="462">"36 The recommended dosage is 600 - / kg epoetin alfa, which is once weekly over three weeks (day 21, 14 and 7) before operating procedure and on the day of the surgery (day 0)."</seg>
<seg id="463">38 For patients with chronic kidney insufficiency should not be exceeded at the maintenance therapy the upper limit of the hermoglobin target-target cannot be exceeded.</seg>
<seg id="464">The Hämoglobinanincreased should be approximately 1 g / dl (apmmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of an increase in hypertension.</seg>
<seg id="465">"about thrombotanical, vascular events such as myocardium, cervirombosis, arterial thrombosis, arterial thyrombosis and 41 blood clot in artificial kidneys, as well as patients under epoetin alfa, reported as well as patients under epoetin alfa."</seg>
<seg id="466">An increased incidence of thrombal events (see Section 4.4 and Section 4.8 - General) was observed in patients under the treatment of erythropoetine.</seg>
<seg id="467">389 patients with hemogblastosis (221 multiple Myelome, 144 Non-Hodgkin- Lymph) and 332 patients with solid tumors (172 Mammakartery, 64 bronchialkarzinome, 22 bronchialkarzinome, 21 gastrospinal Carcinoma and 30 more). "</seg>
<seg id="468">44 In animal experimental studies with annuously the 20times the one recommended for the application at humans recommended Wochendosis led epoetin alfa to diminishing federate body weight to a delay in the Ossification and a rise in fine mortality.</seg>
<seg id="469">"within the framework of the patient-patient application, the patient can store the patient for a maximum of 3 days outside the coolness and not over 25 ° C."</seg>
<seg id="470">"51 The recommended dosage is 600 - / kg epoetin alfa, which should once weekly over three weeks (day 21, 14 and 7) before operating procedure and on the day of the surgery (day 0)."</seg>
<seg id="471">53 For patients with chronic kidney insufficiency should not be exceeded at the maintenance therapy that will not be overstepped down in section 4.2 Lahaz-border of the hermoglobin targets.</seg>
<seg id="472">The Hämoglobinanincreased should be approximately 1 g / dl (apmmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of an increase in hypertension.</seg>
<seg id="473">"about thrombotanical, vascular events such as myocardium, cervirombosis, arterial thrombosis, arterial thyrombosis and 56 blood clot in artificial kidneys, as well as patients under epoetin alfa, reported as well as patients under epoetin alfa."</seg>
<seg id="474">An increased incidence of thrombal events (see Section 4.4 and Section 4.8 - General) was observed in patients under the treatment of erythropoetine.</seg>
<seg id="475">389 patients with hemogblastosis (221 multiple Myelome, 144 Non-Hodgkin- Lymph) and 332 patients with solid tumors (172 Mammakartery, 64 bronchialkarzinome, 22 bronchialkarzinome, 21 gastrospinal Carcinoma and 30 more). "</seg>
<seg id="476">"59 In animal experimental studies with approximate the 20times the one recommended for the application at humans, Wochendosis led epoetin alfa to diminish federate body weight, to a delay in the Ossification and a rise in fine mortality."</seg>
<seg id="477">"within the framework of the patient-patient application, the patient can store the patient for a maximum of 3 days outside the coolness and not over 25 ° C."</seg>
<seg id="478">"66 The recommended dosage is 600 - / kg epoetin alfa, which should once weekly over three weeks (day 21, 14 and 7) before operating procedure and on the day of the surgery (day 0)."</seg>
<seg id="479">68 In patients with chronic kidney insufficiency should not be exceeded at the maintenance therapy that will not be overstepped down in section 4.2 Lahaz-border of the hermoglobin targets.</seg>
<seg id="480">The Hämoglobinanincreased should be approximately 1 g / dl (apmmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of an increase in hypertension.</seg>
<seg id="481">"about thrombotanical, vascular events such as myocardium, cervirombosis, arterial thrombosis, arterial thyrombosis and 71 blood clot in artificial kidneys, as well as patients under epoetin alfa."</seg>
<seg id="482">An increased incidence of thrombal events (see Section 4.4 and Section 4.8 - General) was observed in patients under the treatment of erythropoetine.</seg>
<seg id="483">389 patients with hemogblastosis (221 multiple Myelome, 144 Non-Hodgkin- Lymph) and 332 patients with solid tumors (172 Mammakartery, 64 bronchialkarzinome, 22 bronchialkarzinome, 21 gastrospinal Carcinoma and 30 more). "</seg>
<seg id="484">"74 In animal experimental studies with approximate the 20times the one recommended for the application at humans recommended Wochendosis led epoetin alfa to diminish federate body weight, to a delay in the Ossification and a rise in fine mortality."</seg>
<seg id="485">"within the framework of the patient-patient application, the patient can store the patient for a maximum of 3 days outside the coolness and not over 25 ° C."</seg>
<seg id="486">"81 The recommended dosage is 600 - / kg epoetin alfa, which should once weekly over three weeks (day 21, 14 and 7) before operating procedure and on the day of the surgery (day 0)."</seg>
<seg id="487">"83 At patients with chronic kidney insufficiency should not be exceeded at the maintenance therapy, which will not be overstepped down in section 4.2 Lahaz-border of the hermoglobin targets."</seg>
<seg id="488">The Hämoglobinanincreased should be approximately 1 g / dl (apmmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of an increase in hypertension.</seg>
<seg id="489">"about thrombotanical, vascular events such as myocardium, cervirombosis, arterial thrombosis, arterial thrombosis, arterial thyrombosis and 86 bloodthirst in artificial kidneys, as well as patients under epoetin alfa."</seg>
<seg id="490">An increased incidence of thrombal events (see Section 4.4 and Section 4.8 - General) was observed in patients under the treatment of erythropoetine.</seg>
<seg id="491">389 patients with hemogblastosis (221 multiple Myelome, 144 Non-Hodgkin- Lymph) and 332 patients with solid tumors (172 Mammakartery, 64 bronchialkarzinome, 22 bronchialkarzinome, 21 gastrospinal Carcinoma and 30 more). "</seg>
<seg id="492">"89 In animal experimental studies with approximate the 20times the one recommended for the application at humans recommended Wochendosis led epoetin alfa to diminish federate body weight, to a delay in the Ossification and a rise in fine mortality."</seg>
<seg id="493">"within the framework of the patient-patient application, the patient can store the patient for a maximum of 3 days outside the coolness and not over 25 ° C."</seg>
<seg id="494">"96 The recommended dosage is 600 - / kg epoetin alfa, which is once weekly over three weeks (day 21, 14 and 7) before operating procedure and on the day of the surgery (day 0)."</seg>
<seg id="495">98 When patients with chronic kidney insufficiency should not be exceeded at the maintenance therapy the upper limit of the hermoglobin target-target cannot be exceeded.</seg>
<seg id="496">The Hämoglobinanincreased should be approximately 1 g / dl (apmmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of an increase in hypertension.</seg>
<seg id="497">"about thrombotanical, vascular events such as myocardium, cervirombosis, arterial thrombosis, arterial thyrombosis and 101 blood clot in artificial kidneys, as well as patients under epoetin alfa, reported as well as patients under epoetin alfa."</seg>
<seg id="498">An increased incidence of thrombal events (see Section 4.4 and Section 4.8 - General) was observed in patients under the treatment of erythropoetine.</seg>
<seg id="499">389 patients with hemogblastosis (221 multiple Myelome, 144 Non-Hodgkin- Lymph) and 332 patients with solid tumors (172 Mammakartery, 64 bronchialkarzinome, 22 bronchialkarzinome, 21 gastrospinal Carcinoma and 30 more). "</seg>
<seg id="500">104 In animal experimental studies with annuously the 20times the one recommended for the application at humans recommended Wochendosis led epoetin alfa to diminishing federate body weight to a delay in the Ossification and a rise in fine mortality.</seg>
<seg id="501">"within the framework of the patient-patient application, the patient can store the patient for a maximum of 3 days outside the coolness and not over 25 ° C."</seg>
<seg id="502">"recommended Dosage amounts to 600 i.e. / kg epoetin alfa, which should once weekly over three weeks (day 21, 14 and 7) before operating procedure and on the day of the surgery (day 0)."</seg>
<seg id="503">113 With patients with chronic kidney insufficiency should not be exceeded at the maintenance therapy that will not be overstepped down in section 4.2 Lahaz-border of the hermoglobin targets.</seg>
<seg id="504">The Hämoglobinanincreased should be approximately 1 g / dl (apmmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of an increase in hypertension.</seg>
<seg id="505">"about thrombotanical, vascular events such as myocardium, cervirombosis, arterial Thrombosis, arterial thyrombosis and 116 blood clot in artificial kidneys, such as patients under epoetin alfa, reported as well as patients under epoetin alfa."</seg>
<seg id="506">An increased incidence of thrombal events (see Section 4.4 and Section 4.8 - General) was observed in patients under the treatment of erythropoetine.</seg>
<seg id="507">389 patients with hemogblastosis (221 multiple Myelome, 144 Non-Hodgkin- Lymph) and 332 patients with solid tumors (172 Mammakartery, 64 bronchialkarzinome, 22 bronchialkarzinome, 21 gastrospinal Carcinoma and 30 more). "</seg>
<seg id="508">119 In animal experimental studies with annuously the 20times the one recommended for the application at humans recommended Wochendosis led epoetin alfa to diminishing federate body weight to a delay in the Ossification and a rise in fine mortality.</seg>
<seg id="509">"within the framework of the patient-patient application, the patient can store the patient for a maximum of 3 days outside the coolness and not over 25 ° C."</seg>
<seg id="510">"recommended Dosage amounts to 600 i.e. / kg epoetin alfa, which should once weekly over three weeks (day 21, 14 and 7) before operating procedure and on the day of the surgery (day 0)."</seg>
<seg id="511">"128 For patients with chronic kidney insufficiency should not be exceeded at the maintenance therapy, which will not be overstepped down in section 4.2 Lahaz-border of the hermoglobin targets."</seg>
<seg id="512">The Hämoglobinanincreased should be approximately 1 g / dl (apmmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of an increase in hypertension.</seg>
<seg id="513">"about thrombotanical, vascular events such as myocardium, cervirombosis, arterial thrombosis, arterial thrombosis, arterial thyrombosis and 131 blood clot in artificial kidneys, as well as patients under epoetin alfa."</seg>
<seg id="514">An increased incidence of thrombal events (see Section 4.4 and Section 4.8 - General) was observed in patients under the treatment of erythropoetine.</seg>
<seg id="515">389 patients with hemogblastosis (221 multiple Myelome, 144 Non-Hodgkin- Lymph) and 332 patients with solid tumors (172 Mammakartery, 64 bronchialkarzinome, 22 bronchialkarzinome, 21 gastrospinal Carcinoma and 30 more). "</seg>
<seg id="516">134 In animal experimental studies with annuously the 20times the one recommended for the application at humans recommended Wochendosis led epoetin alfa to diminishing federate body weight to a delay in the Ossification and a rise in fine mortality.</seg>
<seg id="517">"within the framework of the patient-patient application, the patient can store the patient for a maximum of 3 days outside the coolness and not over 25 ° C."</seg>
<seg id="518">"141 The recommended dosage is 600 - / kg epoetin alfa, which is once weekly over three weeks (day 21, 14 and 7) before operating procedure and on the day of the surgery (day 0)."</seg>
<seg id="519">"143 At patients with chronic kidney insufficiency should not be exceeded at the maintenance therapy, which will not be overstepped down in section 4.2 Lahaz-border of the hermoglobin targets."</seg>
<seg id="520">The Hämoglobinanincreased should be approximately 1 g / dl (apmmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of an increase in hypertension.</seg>
<seg id="521">"about thrombotanical, vascular events such as myocardium, cervirombosis, arterial thrombosis, arterial thyrombosis and 146 blood clears in artificial kidneys, as well as patients under epoetin alfa."</seg>
<seg id="522">An increased incidence of thrombal events (see Section 4.4 and Section 4.8 - General) was observed in patients under the treatment of erythropoetine.</seg>
<seg id="523">389 patients with hemogblastosis (221 multiple Myelome, 144 Non-Hodgkin- Lymph) and 332 patients with solid tumors (172 Mammakartery, 64 bronchialkarzinome, 22 bronchialkarzinome, 21 gastrospinal Carcinoma and 30 more). "</seg>
<seg id="524">149 In animal experimental studies with annuously the 20times the one recommended for the application at humans recommended Wochendosis led epoetin alfa to diminishing federate body weight to a delay in the Ossification and a rise in fine mortality.</seg>
<seg id="525">"within the framework of the patient-patient application, the patient can store the patient for a maximum of 3 days outside the coolness and not over 25 ° C."</seg>
<seg id="526">"the holder of permission for the transport agreement has before the launch and agreement with the competent authorities of member states to supply medical personnel in dialysis centres and retail outlets • summary of the characteristics of the product by means of appropriate cooling agents for the transport by the patient."</seg>
<seg id="527">"the holder of permission for the transport system has to ensure that in version 3.0 described and installed in module 1.8.1. of the authorisation application, the pharmacovigilance system has been set up and functional before the drug is applied to the traffic and as long as it is applied to traffic."</seg>
<seg id="528">"the holder of permission for the transport system is obliged to implement the studies and additional measures to the Pharmacovigilance, as defined in Version 5 of the application of the Risk Management Plan (RMP), and in accordance with each subsequent update of the Risk Management Plan."</seg>
<seg id="529">"in accordance with the" CHMP Guideline on Risk Management Systems for the "" CHMP Guideline on Risk Management Systems for human use "" at the same time with the next updated report on the inconceivable of the drug (periodic Safety Update Report, PSUR). "</seg>
<seg id="530">"in addition, an upset room should be submitted: • when receiving new information, the impact on current security specifications (safety specification), the pharmacovigilance plan or risk minimization may be milestones in 60 days after reaching an important (the pharmacovigilance or risk reduction)."</seg>
<seg id="531">"• In a month before your treatment have suffered a heart attack or stroke, if you suffer from instabiler Angina Pectoral (for the first time collagen or increased breast cancer), if you have occurred in the veins (deep Venous thrombosis), if you have occurred earlier than such a bloodshed."</seg>
<seg id="532">"they suffer from severe blood circulation of the heart (coronary heart disease), the arteries of legs or arms (peripheral arterial disease) or the brain (cerebrovascular disease), you have recently had a heart attack or stroke."</seg>
<seg id="533">"during treatment with Abseamed, it can occur within the standard range to a slight dosing-dependent increase in bloodstream number, which is another treatment once more."</seg>
<seg id="534">Your doctor will perform regular bleaching in order to check out the number of platelets during the first 8 weeks of treatment.</seg>
<seg id="535">"iron deficiency, resolution of the red blood cells (hemolysis), blood loss, vitamin C or follow-manned, should be considered and treated before the treatment with Abseamed."</seg>
<seg id="536">Very rarely has been reported on the appearance of an anti-mediated Erythroblastopenie to monate- up to years of treatment with subcutaneous (under the skin sociably) Erythropoetin.</seg>
<seg id="537">"if you suffer from Erythroblastopenie, it will break your therapy with Abseamed and determine how your anemia is best handled."</seg>
<seg id="538">"therefore, Abseamed has to be given by injtion into a Vene (intravenously) if you are treated because of an anemia due to renal disease."</seg>
<seg id="539">A high degree of hemorrhoid worth the risk of problems with the heart or blood vessels and the mortality could be increased.</seg>
<seg id="540">"with increased or increasing potassium, your doctor can consider a break in the treatment with seamed amed, until the potassium levels again lie in the standard range."</seg>
<seg id="541">"if you are suffering from chronic kidney or clinically-obvious coronary heart disease, your doctor will make sure your hemorrhoid will not exceed a certain value."</seg>
<seg id="542">"after the time of present knowledge by the treatment of bloody crimes with adults with chronic kidney disease (kidney insufficiency), which are not yet dialysis, the progression of kidney insufficiency is not accelerated."</seg>
<seg id="543">A 2 - 3-week delay between epoetin-alfa-gift and the desired effect should be considered for the assessment of the effectiveness of seamed amed.</seg>
<seg id="544">200 Your doctor will regularly determine your values of the red blood-colored (hemoglobin) and adjust your abseamed dosage accordingly to keep the risk of a bleeding (throb event) as low as possible.</seg>
<seg id="545">"this risk should have weighed very carefully against the benefits from the treatment with epoetin alfa, e.g. if you are a hesitant risk for throworbotine vascular events, e.g. if you are already narrowing (like a deep venous vascular events) (e.g. a deep Venous thrombosis or pneumonia)."</seg>
<seg id="546">"in case you are cancer patients, consider that abseamed can affect a growth factor for blood protection and under certain circumstances the tumor can impact negative."</seg>
<seg id="547">"if you create a larger orthopedic surgery, prior to the start of treatment with Abseamed the cause of your anaemia is examined and treated accordingly."</seg>
<seg id="548">"if your values of the red blood-coloured (hemoglobin) are too high, you should not receive Abseamed risk for blood-resistance after surgery."</seg>
<seg id="549">"please inform your doctor or a pharmacist, if you are taking other medicines / use or have recently taken / applied, even if it is not prescription drugs."</seg>
<seg id="550">"if you take Ciclosporin (means to suppression of immune system) during your therapy with Abseamed, your doctor will apply certain blood tests to measure the bleeding mirror of Ciclosporin."</seg>
<seg id="551">Laboratory examinations have no interaction between epoetin alfa and G-CSF or GM-CSF (G-CSF and GM-CSF are means of building the immune system, for example with cancer or HIV). "</seg>
<seg id="552">"depending on how your blood poverty (anemia) speaks to treatment, the dose can be adjusted for about every four weeks until your condition is under control."</seg>
<seg id="553">"your doctor will arrange regular exercise tests in order to verify your success's success, and ensure that the drug works correctly and your hemorrhoid worth a certain value."</seg>
<seg id="554">"once you are well adjusted, you will receive regular doses of Abseamed between 25 and 50. / kg twice weekly, divided into two equally big injections."</seg>
<seg id="555">"your doctor will arrange regular exercise tests in order to verify your success's success, and ensure that your hemorrhoid worth a certain value."</seg>
<seg id="556">"depending on how the anemia is on treatment, the dose can be adjusted for about every four weeks until the condition is under control."</seg>
<seg id="557">"to ensure this and ensure that the hemorrhoid is not exceeds a certain value, the treatment doctor will perform regular bleaching."</seg>
<seg id="558">"if it is necessary to shorten the treatment days before surgery, a dose of 300 may be / kg on 10 consecutive days before surgery, on the day of the surgery and another 4 days after the surgery."</seg>
<seg id="559">"however, you can if your doctor keeps this for appropriate, even learning how you bubbles yourself among the skin."</seg>
<seg id="560">"heart, heart bleeding, brain blood, cerebral vascular disorders, arterial thyrombosis, arterial thyrombosis, vascular thyroid, vascular thyroid, vascular thyroid, vascular thyroid, vascular thyroid, vascular thyroid and blood treatment were reported in patients under erythropoetin treatment."</seg>
<seg id="561">"eyelid and the lips (Quincke-Ödem) and shocked allergic reactions with symptoms such as tingling, redness, ittery, heat and accelerated pulse were reported in rare cases."</seg>
<seg id="562">Erythroblastopenie means that no more sufficient red blood cells can be formed in the bone mark (see section "special caution when applying Abseamed is required).</seg>
<seg id="563">After repeated blood-end it can be - independently of the treatment with seamed - to a blood ropuling (throvascular events).</seg>
<seg id="564">Treatment with Abseamed can enter with an increased risk for blood circulation after surgery (postoperative vascular events) when your output shredresgloomy is worth too high</seg>
<seg id="565">"please inform your doctor or a pharmacist, if any of the listed side effects you have considerably affected or if you notice unwanted side effects, which are not listed in this usage information."</seg>
<seg id="566">"if a syringe from the fridge was taken and room temperature has reached (up to 25 ° C), it must be used either within 3 days or be rejected."</seg>
<seg id="567">Aclasta is used for the treatment of the following diseases: • osteoporosis (a disease which makes bones brittle) both for women after menopause and in men.</seg>
<seg id="568">"it is used in patients with high fractional risk (bone breakthroughs), including patients who have recently suffered a sedmatizing as when you fall down; • Morbus Paget of the femur, a disease that changes the normal course of bone growth."</seg>
<seg id="569">"in addition, patients with Morbus Paget must take at least 500 mg of calcium twice daily for at least 10 days after treatment; patients with hip refracture should be obtained before the first infusion a great dose of vitamin D (50 000 to 125 000 IE) oral or by injecting into a muscle."</seg>
<seg id="570">"administration of acetaminopol or isprofen (means against inflammation) shortly after the use of Aclasta can be reduced in the three days following the infusion, such as fever, muscle aches, gripping pain and headaches."</seg>
<seg id="571">"for the treatment of the Morbus Paget, Aclasta can only be prescribed by doctors who have experience in the treatment of this ailment."</seg>
<seg id="572">"as the active ingredient in Aclasta-same is like in zometa, a part of the data material for Zometa was attracted to the evaluation of Aclasta."</seg>
<seg id="573">"during the first study almost 8 000 older women were involved with osteoporosis, and it was investigated the number of spine and hip fractures over a period of three years."</seg>
<seg id="574">"the second study conducted 2 127 men and women with osteoporosis over 50 years, which had recently suffered a girdle. it was investigated the number of fractures over a period of up to five years."</seg>
<seg id="575">"at Morbus Paget, Aclasta was tested in two studies in a total of 357 patients and compared with Risedronat (another Bisphosphonate)."</seg>
<seg id="576">Main indeer for the effectiveness was whether the content of the alkaline phosphatase in Serum (an enzyme that is extracted) in the blood again or at least 75% compared to the starting point.</seg>
<seg id="577">In the study with older women the risk of cyclamen had been reduced to patients under Aclasta (without other osteoporosemedikamente) over a period of three years compared to the patients under placebo around 70%.</seg>
<seg id="578">Compared to all patients under Aclasta (with or without other osteoporosemeditions) with those under placebo was reduced the risk of hip fractures by 41%.</seg>
<seg id="579">In the study with men and women with hip refracture 9% of patients with Aclasta had a Frakupuncture (92 of 1 065) compared to 13% of patients under placebo (139 of 1 062).</seg>
<seg id="580">Most of the side-side effects of Aclasta occur within the first three days after the infusion and are less common in repeated infusions.</seg>
<seg id="581">Aclasta may not be used in patients that may be hypersensitive (allergic) against zoledronic acid or other bisphosphonate or any other components.</seg>
<seg id="582">"as with all bisphosphonate, patients are subject to patients with Aclasta to the risk of kidney disease, reactions to the infusion set and Osteonekrose (dying of bone tissue) in the jaw."</seg>
<seg id="583">"the manufacturer of Aclasta provides enlightening material for doctors ready to prescribing the Aclasta for the treatment of osteoporosis as well as the material for patients, in which the side effects of the drug is explained and pointed out when they should consult the doctor."</seg>
<seg id="584">April 2005 the European Commission shared the company Novartis Europharm Limited permission for the transport of Aclasta in the entire European Union.</seg>
<seg id="585">"conditions ODER restrictions regarding the safe AND effective application of the pharmaceutical drug, DIE DURCH DIE Member ZU, SIND • Conditions of ODER restrictions regarding safe AND effective application of THE ARGE, THE DURCH DIE Member ZU, SIND"</seg>
<seg id="586">"treatment of osteoporosis in postmenopausal women and in men with an increased risk of fractures, including patients with a recently expelled low-traumatization."</seg>
<seg id="587">Patient informational package should be provided and the following core message include: • The Packageing • contraindication in pregnancy and at breastfeeding women • Required Physical activity, the non-smoking and a healthy diet • important signs and symptoms for serious side effects • Wann on medical or occupational assistance. "</seg>
<seg id="588">"treatment of osteoporosis • with postmenopausal women • in men with an increased risk of fractures, including patients with a recently expelled low-traumatization."</seg>
<seg id="589">For the treatment of postmenopausal osteoporosis and osteoporosis in men becomes a intravenous infusion of 5 mg Aclasta once annually.</seg>
<seg id="590">"in patients with low-traumatic hip, the administration of infusion of Aclasta is recommended (see Section 5.1)."</seg>
<seg id="591">"for the treatment of the Morbus Paget, Aclasta can only be prescribed by doctors who have experience in the treatment of the Morbus Paget."</seg>
<seg id="592">"after the treatment of the Morbus Paget with Aclasta, a long retool period was observed in patients that have addressed the therapy (see Section 5.1)."</seg>
<seg id="593">"in addition, it is very advisable to ensure an adequate intake of calcium found twice a day at least 500 mg of elementary calcium, for at least 10 days after the gift of Aclasta (see Section 4.4)."</seg>
<seg id="594">"in patients with a recently expelled low-traumatise, a initialdose of 50,000 to 125.000 is of oral or intra-ular vitamin D recommended before the first Aclasta infusion."</seg>
<seg id="595">"frequency of symptoms, which occur within the first three days after the administration of Aclasta, can be reduced by gift from acetaminopol or Ibuprofen just after applying Aclasta."</seg>
<seg id="596">Patients with kidney-functioning (see Section 4.4) In patients with a Creatinin Clearance &lt; 35 ml / min Aclasta is not recommended as limited clinical experience for this patient impact.</seg>
<seg id="597">Older patients (&gt; 65 years) A tin adjustment is not necessary since the Bioveravailability, Distribution and Elimination in older patients is similar to younger patients. "</seg>
<seg id="598">"children and young people of Aclasta is not recommended for use in children and young people under 18 years, because data is missing and effectiveness."</seg>
<seg id="599">Aclasta is insufficiency in patients with severe kidney insufficiency (Creatinin Clearance &lt; 35 ml / min) is not recommended as for these patient population has limited clinical experience.</seg>
<seg id="600">An existing hypokalzemia is before the treatment of therapy with Aclasta via adequate intake of calcium and vitamin D (see Section 4.3).</seg>
<seg id="601">"because of the quick setup of the effect of Zoledronic acid in the bone structure, a temporary, withsymptomatic Hypokalzemia is able to develop their maximum usually within the first 10 days after the infusion of Aclasta occurs (see Section 4.8)."</seg>
<seg id="602">"in addition, it is very advisable to ensure an adequate intake of calcium found twice a day at least 500 mg of elementary calcium, for at least 10 days after the gift of Aclasta (see Section 4.2)."</seg>
<seg id="603">"cancer prevention, chemotherapy, treatment with cortico-steroids, poor oral hygiene should be weighed in front of an application of bisphosphonate dental treatment treatment."</seg>
<seg id="604">"for patients who need dental grips, no data are available, whether the interruption of treatment with bisphosphonate reduces the risk of Osteonecrosen in the jaw area."</seg>
<seg id="605">The clinical assessment by the care doctor should be the basis for the treatment plan of each patient and are based on an individual benefit risk assessment.</seg>
<seg id="606">"frequency of symptoms, which occur within the first three days after administration of Aclasta, can be reduced by gift from acetaminopol or Ibuprofen just after applying Aclasta (see Section 4.2)."</seg>
<seg id="607">"incidence of considered a serious side-effect in cases of atrial fibrillation was increased by patients, the Aclasta received, increased (1.3%) (51 of 3,862) compared to patients that were placebo (0,6%) (22 of 3,852)."</seg>
<seg id="608">In the osteoporosis studies (PFT, HORIZON - Recurrent Fracture Trial [RFT]) was the overall prevalence of atrial fibrillation between Aclasta (2.7%) and placebo (2,1%). "</seg>
<seg id="609">"very frequent (&gt; &gt; &gt; &gt; &gt; &gt; &gt; / 10, &lt; 1 / 10), occasional (&gt; &gt; / 1,000, &lt; 1 / 100), rare (&gt; &gt; / 1,000, &lt; 1 / 1,000) unwanted mental effects are listed in table 1."</seg>
<seg id="610">Kidney-functioning zoledronic acid was associated with kidney-dysfunctions (i.e. an increase in serum-Creatinins) and in rare cases as acute kidney failure.</seg>
<seg id="611">The change in Kreatinin Clearance (annually before administration) and the appearance of kidney failure and a restricted kidney function were comparable in a clinical trial with osteoporosis over three years compared between the Aclasta- and placebo group.</seg>
<seg id="612">A temporary increase in serum creatinins within 10 days of gift was observed at 1.8 percent of patients compared to 0.8% of patients treated with placebo patients.</seg>
<seg id="613">"based on the evaluation of laboratory findings, the temporary asymptomatic calcium values came below 2% of patients treated with Aclasta in a major clinical trial, compared to 21% of the patients treated with Aclasta in the Morbus-Paget studies."</seg>
<seg id="614">"all patients received additional sufficient amounts of vitamin D and calcium in the study for postmenopausal osteoporosis, in the study for avoiding clinical fractures and in the Morbus-Paget studies (see Section 4.2)."</seg>
<seg id="615">"in the study for the prevention of clinical fractures, the vitamin D mirror was not tested routinely, but most patients received an initialdose vitamin D before the administration of Aclasta (see Section 4.2)."</seg>
<seg id="616">"local reactions After the administration of Zoledronic acid in a major clinical trial was reported on local reactions to infusion, such as redness, swelling and / or pain (0.7%)."</seg>
<seg id="617">"osteonecrosen in the temporal area of ningly, above all in cancer patients, about Osteonecrosen (primarily in the maxar area) reports with bisphosphonate, including zoledronic acid."</seg>
<seg id="618">"many of these patients had signs of local infections including osteomyelitis, and the majority of reports refers to cancer patients according to tooth extraction or other reproductive effects."</seg>
<seg id="619">7 study with 7.736 patients joined Osteonekrose in an orthodonate area with an Aclasta and on one with placebo patients treated.</seg>
<seg id="620">"in the event of an overdose which leads to a clinically relevant Hypokalzemia, can be achieved by gift of oral calcium and / or a intravenous infusion of calcium gluconat."</seg>
<seg id="621">Clinical effectiveness in the treatment of postmenopausal osteoporosis (PFT) The effectiveness and safety of Aclasta 5 mg once a year for 3 consecutive years (7.736 women aged 65 and 89 years) with either a bone female or a BMD-T-Score for the thigh as ≤ -2.5 with or without signs of an existing spinal cycle.</seg>
<seg id="622">Effects on morphometrical vertebfractal Aclasta lowered significantly over a period of three years and already after a year the frequency of one or more new spinal postings (see table 2).</seg>
<seg id="623">Aclasta treatment-treated patients aged 75 years and older had compared to 60% reduced risk for spinal patients compared to placebo patients (p &lt; 0.0001).</seg>
<seg id="624">"effects on the fractures of Aclasta pointed a straight-lasting effect over three years, which resulted in one by 41% (95% CI, 17% to 58%) reduced risk to hip fractures."</seg>
<seg id="625">"effect on bone density (BMD) Aclasta rose the bone of bone hydrofluoric acid, hips and the distal radius compared to the placebo treatment significantly compared to all seasons (6, 12, 24 and 36 months)."</seg>
<seg id="626">"9 At the bone density of the steering buzz around 6,7%, the whole hip by 6.0%, the thigh as by 5,1% and the distal radius by 3.2%."</seg>
<seg id="627">Bone histology At 152 postmenopausal osteoporot patients treated with Aclasta (N = 82) or placebo (N = 70) were taken one year after the third annual dose of bonbiopsies from the pelvic camera.</seg>
<seg id="628">A micro-tomography (µCT) analysis showed up to placebo treated patients compared to placebo an increase in the truncated bone volumens and the preservation of the trailers of bone architecture.</seg>
<seg id="629">Bone markers The bones-specific alkaline phosphatase (BSAP), the N-terminale Propeptid of the type-C-Telopeptid (b-CTX) in Serum were determined in sub-groups of 517 to 1.246 patients in periodic intervals during the period of study. "</seg>
<seg id="630">The treatment with an annual 5-mg-dose of Aclasta reduced by 30% compared to the output value and was held at 28% below the output value up to 36 months.</seg>
<seg id="631">P1NP significantly reduced by 61% below the output value after 12 months and was held at 52% below the output value up to 36 months.</seg>
<seg id="632">B-CTX was significantly reduced by 61% below the output level after 12 months and was held at 55% below the output value up to 36 months.</seg>
<seg id="633">"the vitamin D mirror have not been measured by routinely, but majority of patients received an initial ssdose vitamin D (50,000 up to 125.000) (or intra-muscular) 2 weeks before the infusion."</seg>
<seg id="634">The total amount was at 10% (101 patients) in the group treated with Aclasta-treated group compared to 13% (141 patients) in the placebo group.</seg>
<seg id="635">Effect on bone mineral density (BMD) In HORIZON-RFT-study increased the Aclasta treatment compared to placebo treatment the BMD in total and thigh as at all times.</seg>
<seg id="636">The Aclasta treatment led over 24 months in comparison to placebo treatment to an increase in the BMD by 5.5% at the total amount of 4.3% at the thigh.</seg>
<seg id="637">Clinical effectiveness in men in the HORIZON-RFT study were randomized and in 185 patients the BMD was assessed after 24 months.</seg>
<seg id="638">The study was not designed to show a reduction in clinical fractures in men; the frequency of clinical fractures was 7.5% with Aclasta-treated men compared to 8.9% on placebo.</seg>
<seg id="639">In another study in men (study CZOL446M2308) was the once annual administration of Aclasta compared to once weekly change from Alendrongat on a percentage change from the BMD after 24 months compared to the output value.</seg>
<seg id="640">Clinical effectiveness of the treatment at Morbus Paget of the Knower Aclasta was investigated in patients aged 30 years ago (mean servum mirror of alkaline phosphatase in accordance with the 2.6times up to 3.2 million) specific upper level of inclusion in the study).</seg>
<seg id="641">11 The effectiveness of infusion of 5 mg Zoledronic acid compared to taking 30 mg of Risedronage once a day during 2 months was proved in two sixty studies.</seg>
<seg id="642">In the combined results after 6 months a similar decrease of pain kickness and pain-control was observed in comparison to the raw value for Aclasta and Risedronat.</seg>
<seg id="643">Patients who were classified in the end of the sixteen major study as Responder (compared to the therapy) could be taken into an observance phase.</seg>
<seg id="644">"from the 143 with Aclasta and the 107 with Risedronage, patients treated at the follow-up study, compared to 71 that were treated with Aclasta, compared to 71 of the postoperative phase of 18 months after the application."</seg>
<seg id="645">"a multi-time and multiple 5 and 15 minutes lasting infusions of 2, 4, 8 and 16 mg Zoledronic acid in 64 patients, following pharmacokinetic data, which proved to be dosed independent."</seg>
<seg id="646">"after that, the plasmasonry took fast on &lt; 10% of the maximum-value after 4 h and &lt; 1% after 24 h, followed by a long-lasting phase very low concentration, no more than 0.1% of the maximum value."</seg>
<seg id="647">"raving biphasical disappearance from the big cycle with half-times t ½ α, followed ½ hours, followed by a long Eliminationary phase with a temporal Elimination period t ½ g 146 hours."</seg>
<seg id="648">"the early interlocking phases (α and β, with the above-mentioned ½ -values), presumably the rapid resorption in the bones and excretion over the kidneys."</seg>
<seg id="649">"in the first 24 hours 39 ± 16% of administered dose in urine, while the rest is mainly tied to bone tissue."</seg>
<seg id="650">"overall body Clearance is independent of the dose, 5,04 ± 2.5 l / h and remains unaffected by gender, age, race or body weight."</seg>
<seg id="651">An extension of the infusion period from 5 to 15 minutes led to the decrease of the Zoledronym for 30% at the end of the infusion, but had no effect on the surface at the curve (Plasmakonzentration against Time). "</seg>
<seg id="652">A diminished clearance by Cytochrom-P450-Enzymphenic acid is unlikely in humans and because they are not metabolized or not a direct and / or irreversible, carbon-dependent Inhibitor of the P450- "</seg>
<seg id="653">Special patient groups (see section 4.2) The renal Clearance of the Zoledronic acid corted with the Creatinin Clearance; namely 75 ± 33% of the Creatinin Clearance; and was under 64 subexamined patients in average 84 ± 29 ml / min (range 22 to 143 ml / min).</seg>
<seg id="654">It follows that an easy (Clcr = 50- 80 ml / min) and an excessive kidney-function down to a creatinin Clearance up to 35 ml / min no dosage adjustment of the Zoledronic acid.</seg>
<seg id="655">"as for heavy kidney failure (Creatinin- Clearance &lt; 30 ml / min) only limited data, are not possible for this population."</seg>
<seg id="656">Acute toxicity The highest non-efficient single dose was with mice 10 mg / kg body weight and with rats 0.2 mg / kg body weight.</seg>
<seg id="657">"in case studies in dogs were individuals of 1,0 mg / kg (based on AUC the 6multiple of the recommended human therapeutic exposure), administered over a period of 15 minutes, good and without a renal bezzlement."</seg>
<seg id="658">"subchronic and chronic toxicity In studies with intravenous application, the renal tolerability of Zoledronic acid was administered by 6-minute infusion in 3-day intervals, resulting in intervals of 2- 3 weeks (a cumulative dosage, which corresponds to 7times of the human therapeutic exposure to the AUC, corresponds to the AUC, equivalent to the AUC, corresponds to."</seg>
<seg id="659">"in long-term studies with repeated application in cumulated outpositions, which exceeded the maximum of the intended human exposure, toxicological effects occurred at other organs, including the gastrounaltrakt and the liver, as well as to the intravenous injection office."</seg>
<seg id="660">The most common finding of studies with repeated application was an multiplied Spongiosa in the metaphyse of the long bones in the growth phase with almost all doses, a finding that reflects the pharmacological, antiresorptive effect of the substance. "</seg>
<seg id="661">"in rats, one also observed a teratogenicity in doses from 0.7 mg / kg than outward and inner (visceral) abnormalities and such a skeleton."</seg>
<seg id="662">In rabbits have no teratogenic effects or embryo-fetal effects observed although the maternal toxicity compared with 0.1 mg / kg as a result of a lower Serum calcium levels.</seg>
<seg id="663">"if the drug is not used immediately, the user is responsible for storage period and the conditions in front of the application; normally 24 h at 2 ° C to 8 ° C."</seg>
<seg id="664">"Aclasta is used as a package containing a bottle of a packet or as a bundling consisting of 5 packs, which each have a bottle."</seg>
<seg id="665">"treatment of osteoporosis in postmenopausal women and in men with an increased risk of fractures, including patients with a recently expelled low-traumatization."</seg>
<seg id="666">Patient informational package should be provided and the following core message include: • The Packageing • contraindication of calcium and vitamin D, appropriate physical activity, the non-smoking and a healthy diet 17 • Wichal signs and symptoms for serious side effects • Wann on medical or occupational assistance. "</seg>
<seg id="667">"July 2007, completed on 29 September 2006, in the module 1.8.1 of the authorisation of the Pharmacovigilance system in force and works before and while the product is marketed."</seg>
<seg id="668">Risco-Management-Plan The holder of permission for the transport is required to carry out the studies and additional activities to the pharmaceutical vigilance plan of the approved version 004 of the risk management plan (RMP) in Modul 1.8.2 of the authorisation application and all subsequent versions of the RMP approved by CHMP.</seg>
<seg id="669">"according to CHMP Directive on risk management systems for human medicine, the revised Room should be submitted together with the next" periodic Safety Update Report (PSUR). "</seg>
<seg id="670">A reworking party should be filed • If new information could be disclosed to affect the current statements on security that could affect the pharmakovigilance Plan or activities to minimize the risk. • Innate 60 days when an important milestone (for the pharmacovigilance or risk minimization) has been achieved. • On request of the EMEA.</seg>
<seg id="671">"Zoledronic acid is a representative of a subclass, called Bisphosphonate, and is used for the treatment of osteoporosis in postmenopausal women, the osteoporosis in men and the Morbus Paget of the femur."</seg>
<seg id="672">"decreasing blood levels of sex hormones, especially oestrogen made from androgens, play a role in the rather gradual loss of bone mass that is observed in men."</seg>
<seg id="673">"at the Morbus Paget is carried out at bone structure to quickly, and new bone material is built unarranged, which makes bone mineral weaker than normal."</seg>
<seg id="674">"Aclasta acts, once again normalized the bone structure, thereby ensuring a normal bone-formation and thus gives the bones again strength."</seg>
<seg id="675">"if you are in dental treatment or need a dental surgery, inform your doctor that you will be treated with Aclasta."</seg>
<seg id="676">"with application of Aclasta using other medicines please inform your doctor, pharmacists or nursing staff, if you are taking other medicines / or have recently taken / applied, even if it is not prescription drugs."</seg>
<seg id="677">"for your doctor it is especially important to know if you are taking medicines, of which they are ashamed of the kidneys."</seg>
<seg id="678">"when using Aclasta together with food and drinks, you are worried that according to the instructions of your doctor can take enough fluid before and after treatment with Aclasta."</seg>
<seg id="679">Osteoporosis The usual dosage is 5 mg once per year that is administered by your doctor or nursing staff as an infusion in a Vene.</seg>
<seg id="680">"if you have recently broken the hip, is recommended to make appointments of Aclasta two or more weeks after the operating supply of the girdle."</seg>
<seg id="681">"Morbus Paget The usual dosage is 5 mg, which is administered by your doctor or nursing staff as an infusion in a Vene."</seg>
<seg id="682">"as Aclasta has a long time, you may require a further dose first after one year or longer."</seg>
<seg id="683">It is important to follow these instructions exactly so that the calcium mirror in your blood is not too low in time after infusion.</seg>
<seg id="684">"at Morbus Paget, Aclasta can last longer than a year, and your doctor will inform you if you need a renewed treatment."</seg>
<seg id="685">"if the administration of Aclasta has been missed, you will get in touch with your doctor or hospital in order to arrange a new date."</seg>
<seg id="686">"before completion of the therapy with Aclasta If you are considering the termination of treatment with Aclasta sockets, please take your next doctor first doctor and discuss it with your doctor."</seg>
<seg id="687">Side effects associated with the first infusion appear very frequently on (for more than 30% of patients) are after the subsequent infusions but less frequent.</seg>
<seg id="688">"fever and shoots, muscle or joint pain and headache, occur within the first three days after the administration of Aclasta."</seg>
<seg id="689">"currently it is unclear whether Aclasta can cause this irregular heartbeats, but you should report it to your doctor if you notice such symptoms after you have Aclasta."</seg>
<seg id="690">"physical indications due to low calcium-concentration in blood, such as muscle cramps or kribbelndes or numbbes feeling, especially in the area around the mouth."</seg>
<seg id="691">"flu, sleeplessness, fatigue, tying, weatherless, baldness, cremess, mischieviness, mischieviness, crease, creeping skin, creeping skin, frequented urinate, creeping urinate, temporary increase of serum-creatinins, tissue swelling and thirst."</seg>
<seg id="692">Persistent pain and / or not healing wounds in the mouth or by the jaws were reported above all in patients who were treated with bisphosphonate because of other diseases.</seg>
<seg id="693">"allergic reactions, including rare cases of respiratory problems, nuts and angioedema (such as swelling at the face, the tongue or in the throat), was reported."</seg>
<seg id="694">"please inform your doctor, druggist or nursing staff, if any of the listed side effects you have considerably affected or you notice unwanted side effects which are not listed in this usage information."</seg>
<seg id="695">"if the drug is not used immediately, the user is responsible for storage and conditions until the application; normally 24 h at 2 ° C up to 8 ° C."</seg>
<seg id="696">"in patients with one recently expelled low-traumatization is recommended, the infusion of Aclasta two or more weeks after the operational care of the fracture."</seg>
<seg id="697">"before and after administration of Aclasta, patients need to be sufficiently supplied with fluid; this is especially important in patients who receive a diuretic therapy."</seg>
<seg id="698">"because of the quick setup of the effect of Zoledronic acid in the bone structure, a temporary, sometimes symptomatic, develop Hypokalzemia, whose maximum usually occurs within the first 10 days after the infusion of Aclasta."</seg>
<seg id="699">"in addition, it is very advisable to ensure patients with Morbus Paget an adequate intake of calcium, in accordance with at least twice a day 500 mg of elementary calcium, for at least 10 days after the gift of Aclasta."</seg>
<seg id="700">"in patients with a recently expelled low-traumatic hip, an initial dose of 50,000 to 125.000 is of oral or intramuscular vitamin D before the infusion of Aclasta recommended."</seg>
<seg id="701">"if you need further information about your illness or their treatment, please read the packages (also part of the EPAR) or contact your doctor or a pharmacist."</seg>
<seg id="702">"ACOMPLIA is additionally applied to a diet and exercise for the treatment of adult patients, • to aid in obesity (disease) index (BMI) of 30 kg / m ² or above or • that are overweight (BMI of 27 kg / m ² or above) and in addition one or more I"</seg>
<seg id="703">"furthermore, four studies conducted over 7 000 patients in which ACOMPLIA was used in comparison to a placebo as supportive means for setting the smoking."</seg>
<seg id="704">"the studies on the adjustment of the smoking, showed no uniform results, so that the effect of ACOMPLIA was difficult to assess this application."</seg>
<seg id="705">"which risk is associated with ACOMPLIA, which were observed during the studies (observed in more than 1 of 10 patients), nausea (nausea) and infections of the upper respiratory e. ng The complete listing of the related side effects reported in connection with ACOMPLIA, the effects of the package included."</seg>
<seg id="706">"it must also be used in patients who suffer from an existing severe depression or treated with anti depressants, as it may increase the risk of depression, and among other things in a small minority of patients sufficiency."</seg>
<seg id="707">Caution is offered with drugs use of ACOMPLIA with medicinal products such as Ketoconazol or Itraconazol (a means for applying at HIV- Infection), Telithromycin or Clarithromycin (antibiotics). "</seg>
<seg id="708">The Committee on Humanarzs (CHMP) led to the conclusion that the effectiveness of ACOMPLIA with regard to weight reduction in patients with obesity or overweight</seg>
<seg id="709">Medicines applied in patients who need it from health and not for cosmetic reasons (by providing enlightenarians for patients and doctors) and around Arz</seg>
<seg id="710">It Additional to diet and exercise for the treatment of obesity (BMI &gt; 30 kg / m ²) or obese patients (BMI &gt; 27 kg / m ²) that have one or more risk factors such as type-2 diabetes or dyslipidemia (see Section 5.1).</seg>
<seg id="711">ACOMPLIA is not recommended for use in children and young people under the age of 18.</seg>
<seg id="712">"La depressive disorders or moods with depressed symptoms were made up to 10%, sufficiency in up to 1% of patients who received Rimonabant (see Section 4.8)."</seg>
<seg id="713">"the risk and depressive disorders may not be used for Rimonabant, unless the benefit of the treatment in the individual case exceed the risk (see Section 4.3 and 4.8)."</seg>
<seg id="714">"he Also in patients, which - in addition to aid to obesity, no discernable risks may occur, depressed reactions occur."</seg>
<seg id="715">Dependents or other nearby persons are to indicate that it is necessary to monitor the re-act of such symptoms and obtain immediate advice if these symptoms rise. ln</seg>
<seg id="716">• Elaging patients The effectiveness and invariability of Rimonabant in the treatment of patients over 75 years were not sufficiently demonstrated.</seg>
<seg id="717">Patients with a cardiovascular event (Myocardinal or stroke etc.) less than 6 months ago were completed by studies with Rimonabant. ln</seg>
<seg id="718">"Rifampicin, Phenytoin, Phenobarbital, carbamazepin, Johannisag) is not examined, is believed that the simultaneous gift of potent CYP3A4 inductors has been the plasma centration of Rimonabant."</seg>
<seg id="719">"SSE has investigated important patients as well as in patients with a obesity, and in addition to 3800 patients in other indications."</seg>
<seg id="720">The following table (table 1) shows the unwanted effects of placeable effects in placebocontrolled studies in patients who were treated for weight reduction and because of accompanying metabolic diseases.</seg>
<seg id="721">If the incidence are statistically significant higher than the corresponding placeborate (for unwanted effects &gt; 1%) or when they were clinically relevant (for unwanted effects &lt; 1%). ng In the evaluation of side effects are laid down the following skins:</seg>
<seg id="722">"very common (&gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt;, &lt; 0.1%); very t lä"</seg>
<seg id="723">"in a familiarity study, in which a limited number of people were administered by up to 300 mg, only light symptoms have been observed."</seg>
<seg id="724">Patients had a BMI &gt; 30 kg / m ² or BMI &gt; 27 kg / m ² and one at the same time existing hypertension and / or Dyslipidemia.</seg>
<seg id="725">"N weight reduction after a year amounted to ACOMPLIA, 20 mg 6,5 kg, relative to 1.6 kg for the placebo group (difference -4.6 kg of CI95% -5,3; -4,4, p &lt; 0,001)."</seg>
<seg id="726">"patients who have been treated with ACOMPLIA, 20 mg, and 1.2 kg in the placebo group (difference -3,8 kg; CI95% -4,4, -3,3; p &lt; 0,001)."</seg>
<seg id="727">After 2 years the difference in total weight reduction between ACOMPLIA and placebo -4.4 kg (CI95% -5.0.0%; -3,4 to p &lt; 0.001).</seg>
<seg id="728">9 weight reduction and other risk factors in studies in patients without diabetes in which a mixed population of patients with</seg>
<seg id="729">Of Rimonabant 20 mg was seen an average waste of triglyceride by 6.6% (output value triglyceride implants mmol / l) compared to a rise of 5.5%</seg>
<seg id="730">In a second study in patients with obesity and so far untreated type-2- Diabetes (Serenade) was the absolute change in the HbA1c-value (with a starting value of 7.3% for both groups) after 6 months -0,8 for Rimonabant 20 mg and -0.3 under placebo</seg>
<seg id="731">The percentage of patients who reached a HbA1c- value of &lt; 7% was 51% in the Rimonabant group and 35% in the placebo group.</seg>
<seg id="732">"the difference between medium weight change between 20 mg- and placebo group was at 3,8 kg (CI95% -5,0, -2,6 p &lt; 0,001)."</seg>
<seg id="733">"improvement of the HbA1c value in patients suffering from Rimonabant 20 mg, were about 50% by direct effects of Rimonabant and about 50% by reducing weight-reduction. n."</seg>
<seg id="734">2 hours reached the steady state plasmasonry were reached after 13 days (Cmax = 196 ± 28.1 ng / ml; Ctrough = 91.6 ± 14.1 ng / ml; AUC0-24 = 2960 ± 268 ng.h / ml).</seg>
<seg id="735">"nourishment of food: he promoters, which received Rimonabant either in the food-state or after a fat-rich meal, in case of food supply a round 67% increased Cmax or by 48% increased ng AUC."</seg>
<seg id="736">Patients with black skin colour can count up to 31% lower jmax and one by 43% lower AUC as patients of other ethnic populations.</seg>
<seg id="737">N populationspharmactic analyses (age range 18- 81 years) is estimated that a 75- year-old patient is estimated 21% higher Cmax and one by 27% higher AUC as a 40-year-old</seg>
<seg id="738">"5.3's clinical data on safety he had unwanted effects that were not observed in clinical trials, but ng in animals according to exposure in human therapeutic field have been evaluated as possibly relevant for the clinical use:"</seg>
<seg id="739">"in some cases, however, not in all cases the beginning of the convulsions appear to be connected with procedural stress on how to deal with the animals."</seg>
<seg id="740">"has been given Rimonabant over a longer period before the pairing (9 weeks), which gives a recovery from the initials of Rimonabant, so no unwanted effects on the fertilisation or cymbings were observed."</seg>
<seg id="741">The influence of Rimonabant on the prehistoric and post-natural development was investigated at the rat in doses of up to 10 mg / kg / day.</seg>
<seg id="742">In a study of rats for preparedness and postnatal development a exposure to Rimonabant in utero and by means of lactation are no changes in learning or on memory.</seg>
<seg id="743">Detailed information on this medicine is available on the website of the European Drug Agency (EMEA) http: / / www.emea.europa.eu / availbar. itte n eim Arz</seg>
<seg id="744">"La On the packing state of the medication by means the name and address of the manufacturer, which are responsible for releasing the relevant Charge."</seg>
<seg id="745">"26 heavenating psychiatric events such as depression or moods were reported in patients, the ACOMPLIA, reports (see paragraph."</seg>
<seg id="746">"SSE If you encounter the symptoms of depression, see below) during treatment with ACOMPLIA, please contact your doctor and break the treatment."</seg>
<seg id="747">"sound-feeling, diarrhea, anxiety, itching, excessive sweating, fatigue pains or tapping, descending or tingling) in hands and feet, heat bids, fall, gripping infects, damage, gripping clove."</seg>
<seg id="748">"SSE informs your doctor or chemist, if any of the listed side effects you have considerably affected or you notice unwanted side effects which are not listed in this usage information."</seg>
<seg id="749">"summary of the EPAR for the public This document is a summary of the European Public Inquiry report (EPAR), in which explains how the Committee for Humanarzs (CHMP) has been judged to identify recommendations concerning the application of the drug."</seg>
<seg id="750">Actos is used to treat type-2 diabetes (also known as non-dependent diabetes) in patients (especially overweight patients) in which metformin (a diabetesmedication) is not shown. • It can be applied along with another diabetesmedial medicine (Dualtherapy).</seg>
<seg id="751">"it can also be applied to metals in patients (especially overweight patients), which cannot be satisfactory with metformin alone in the highest possible dose."</seg>
<seg id="752">"in combination with a Sulfonylharnstoff or insulin, the previous dose of the sulphone treatment can be kept, except for patients with hypoglycaemia (low blood sugar); here, the dose of sulphone resin or insulin should be reduced."</seg>
<seg id="753">"this means that the body insulin insulin can be improved in better and the blood sugar levels, thus allowing for type-2 diabetes."</seg>
<seg id="754">"more than 1 400 patients were examined the effectiveness of acetone in tripletherapy; in addition, patients received a combination of metformin with a Sulfonylharnstoff, in addition they got up to 3.5 years either Actos or placebo."</seg>
<seg id="755">"in studies the concentration of a substance in the blood (glycosyliated hemoglobin, HbA1c) is measured, which shows how well the blood sugar is adjusted."</seg>
<seg id="756">"accounts led to a reduction of the HbA1c value, which suggests the blood sugar levels in application of doses of 15 mg, 30 mg and 45 mg."</seg>
<seg id="757">"at the end of the triplea study, the effect of the additional gift from Actos to existing treatment with metformin and a Sulfonylharnstoff in lowering the HbA1c values by 0.8%, while the additional gift of placebo has led to a reduction of 1.7%."</seg>
<seg id="758">"in a small study, in which the combination of acettos and insulin in 289 patients were examined, the patient, the accounts in addition to insulin took, a reduction of the HbA1c values are compared with 0.14% compared to patients who were additionally placebo."</seg>
<seg id="759">"the most common side effects associated with Actos were visual disorders, infections of the upper respiratory tract (decrees), weight gain and hypoesthesia (decreased sensitivity to maturity)."</seg>
<seg id="760">"Actos must be used neither in patients, which may be hypersensitive (allergic) compared to Pioglitazon or one of the other components, still in patients with liver problems, heart insufficiency or diabetic cletoaziector - in the blood)."</seg>
<seg id="761">It has been decided that Actos is to serve as an alternative to the standard treatment with metformin in patients with metformin which metformin is not shown.</seg>
<seg id="762">October 2000 presents the European Commission to the company Takeda Europe R & D Centre Limited permission for the transport of accounts in the entire European Union.</seg>
<seg id="763">"the tablets are white to white, round, domed and wear on one side the marking" "15" "and on the other side the wording" ACTOS. "</seg>
<seg id="764">"Pioglitazon is also shown for the combination of insulin in patients with type 2 diabetes mellitus, their blood sugar with insulin inadequate and in which metals are unsuitable because of contraindications or incompatibility. (see Section 4.4)."</seg>
<seg id="765">"for use of pioglitazon in patients under 18 years of age, no data is available, therefore the application in this age group is not recommended."</seg>
<seg id="766">"in patients suffering through the presence at least one risk factor (e.g. previous heart disease or symptomatic coronary heart disease), the doctor should start treatment with the lowest available dose and increase the dose."</seg>
<seg id="767">"patients should be observed on signs and symptoms of a heart insufficiency, weight gain or oil to be observed, especially those with reduced cardiac reserve."</seg>
<seg id="768">Patients should be observed on signs and symptoms of a heart failure to increase weight gain and oil to be observed when pioglitazon is used in combination with insulin.</seg>
<seg id="769">A cardiovascular Outcome study with Pioglitazon in patients under 75 years of type 2 diabetes mellitus and an existing advanced makrovascular disease has been carried out.</seg>
<seg id="770">"this study showed an increase in reports of heart failure, which resulted in an increase in mortality in the study."</seg>
<seg id="771">In patients with increased output liver enzymes (ALT &gt; 2.5 x upper limit of the standard area) or with other signs of a liver illness may not be used Pioglitazon.</seg>
<seg id="772">"when the ALT-mirror is lifted up to the 3-fold the upper limit of the standard range, the liver enzymes are as soon as possible to control."</seg>
<seg id="773">"if a patient symptoms developed, point out to a hepatic dysfunction, such as unresolved nausea, vomiting, tiredness, appetitions and / or darker Harn, the liver enzymes are to be checked."</seg>
<seg id="774">The decision whether treatment of patients with Pioglitazon should be continued until the pre-operation must be led by the clinical assessment.</seg>
<seg id="775">In clinical trials with Pioglitazon has been proven to be a dosisdependency weight gain in some cases and in some cases with a fluid retention.</seg>
<seg id="776">As a result of a Hämellution entered the therapy with Pioglitazon a lower reduction of the middle heads (relative reduction to 4%) and the hematokrits (relative reduction to 4.8%).</seg>
<seg id="777">Similar changes have been observed in comparative controlled studies with Pioglitazon in patients under metformin (relative reduction of hemorrhop to 3-4%) and insulin (relative reduction of the hemorrhop to 1-2% and the hematokrits by 1-3%).</seg>
<seg id="778">"as a result of increased insulin insensitivity, the Pioglitazon is considered to be oral or triply-combination therapy with insulin, the risk of a dose-dependent hypoglycaemia."</seg>
<seg id="779">"after the launch of the market in the treatment with Thiazolidindions, including Pioglitazon, on a appearance or a deterioration of a diabetic broulum, reported by a reduction of the visual acency."</seg>
<seg id="780">"it is unclear whether between the intake of pioglitazon and the appearance of Makulaögermen should be aware of the possibility of a Makulaöderms, if patients should report about disorders of visual acidity; a suitable ophthalmic examination should be considered."</seg>
<seg id="781">"in a summary analysis of messages unwanted events with regard to bone armament, controlled, double-clinical trials over a period of up to 3.5 years with more than 8,100 patients treated with Pioglitazure."</seg>
<seg id="782">"the investigated Fracupuncture incidence was 1,9 fractures for 100 patients with pioglitazon, treated with pioglitazon treated with women, who were treated with a comparative drugs."</seg>
<seg id="783">"in the pro-active study, a study of 3.5 years for the study of cardiovascular events, frogs in 44 / 870 (5,1%; 1.0 fractures per 100 patient years) of patients who were treated with a comparative drugs."</seg>
<seg id="784">Patients should be aware of the possibility of pregnancy and if a patient wishes a pregnancy or this occurs to the treatment (see Section 4.6).</seg>
<seg id="785">Studies on the investigation of interactions have shown that Pioglitazon are not relevant effects on the pharmacokinetics or pharmaceutical dynamics of Digoxin, warfarin, phenprocoumon and metformin exercises. "</seg>
<seg id="786">"interactions with medicines that are metabolized by these enzymes, e.g. orale contrazeptiva, cyclosporin, calcium-blocker and HMGCoA reduction are not to be expected."</seg>
<seg id="787">The simultaneous application of Pioglitazon with Gemfibrozil (a cytochrom P450 2C8- Inhibitor) resulted in an increase in AUC by Pioglitazon to the 3-fold.</seg>
<seg id="788">The simultaneous application of Pioglitazon with rifampicin (a cytochrom P450 2C8 indutor) resulted in lowering the AUC of Pioglitazon around 54%.</seg>
<seg id="789">This is due to that in treatment with Pioglitazon which decreased in pregnancy and increased insulin resistance of maternity and thus reduces the availability of the metabolic substrates for the fetal growth.</seg>
<seg id="790">"very common &gt; 1 / 10, &lt; 1 / 10, &lt; 1 / 10, &lt; 1 / 100; rarely &gt; 1 / 1000, &lt; 1 / 1000; very rare &lt; 1 / 10000, individual cases: unknown (of these data is not estimable)."</seg>
<seg id="791">These lead to a temporary Change of the Turgor and the Brechungsindeer of Linse as they are also observed in other hypoglycaemic drugs.</seg>
<seg id="792">"in clinical trials with Pioglitazon, ALT connector over the trash of the upper limit of the standard field is often commonly referred to as under placebo but rarer than in comparative groups under metformin or Sulfonylharnstoff."</seg>
<seg id="793">In an Outcome study in patients with an advanced advanced makrovascular disease the frequency of severe heart failure is less than below placebo when pioglitazon bzw.</seg>
<seg id="794">"since market launch has rarely been reported on heart insufficiency under Pioglitazon, however, if Pioglitazon is used in combination with insulin or in patients with cardiovascular sufficiency in the Anamnese."</seg>
<seg id="795">"it was conducted a summary analysis of messages unwanted events with regard to bone armament, controlled, double-clinical trials over a period of up to 3.5 years with more than 8,100 patients treated with pioglitazon, and over 7,400 patients in the groups treated with comparative drugs."</seg>
<seg id="796">"in the over a period of 3.5 years running proactive study, Fractures were treated with 44 / 870 (5.1%) which were treated with pioglitazon, compared with 23 / 905 (2.5%) in patients who were treated with a comparative drugs."</seg>
<seg id="797">"when taking the maximum dose of 120 mg / day over four days, then 180 mg / day over seven days occurred no symptoms."</seg>
<seg id="798">Pioglitazon seems to have an activation of specific nuclear receptors (Peroxisome Proliferation Activated Receptors Activated Receptor-g (PPAR-g)) to an increased insulin insensitivity of liver, fats and skeleton-cells. "</seg>
<seg id="799">It could be shown that Pioglitazon has reduced Glucoseproduction in the liver and increases the peripheral gluctance in case of insulin resistance.</seg>
<seg id="800">A clinical study involving pioglitazon versus Gliclazid as monotherapy was continued over two years to examine the time up to the patient's therapeutic effects (defined as HbA1c &gt; 8.0% after the first 6 treatments).</seg>
<seg id="801">"at the time after two years after the treatment of therapy, a blood sugar control (defined as HbA1c &lt; 8.0%) can be maintained by Pioglitazon at 69% of patients (compared to 50% of patients under Gliclazid)."</seg>
<seg id="802">"in a placebocontrolled study of 12 months, patients whose blood sugar has been discontinued despite three months, to Pioglitazon or placebo randomized."</seg>
<seg id="803">"in patients under pioglitazon, the middle HbA1c has reduced to 0,45%, compared to patients who continue to only have insulin; a reduction of insulin insulin combination with Pioglitazon treated group has been observed."</seg>
<seg id="804">Clinical trials over a year showed a statistically significant decrease of the album in / Kreatinin Quotienes compared to the raw materials.</seg>
<seg id="805">The effect of Pioglitazon (Monotherapy with 45 mg versus placebo) was tested in a small period of 18 weeks submitted to type-2 diabetics.</seg>
<seg id="806">"in most clinical trials, compared to placebo a reduction of total plasma triglycemeride and the free fatty acids and an increase in HDL- cholesterol levels as well as low levels, soundically not significantly elevated LDL- cholesterol levels observed."</seg>
<seg id="807">In clinical trials over a period of up to two years of reduced pioglitazon compared to placebo, metformin or gliclazide the total plunger glycaeride and the free fatty acids and increased the HDL cholesterol levels. "</seg>
<seg id="808">Compared to placebo was found no statistically significant increase of the LDL cholesterol levels which have been observed during metformin and gliclazide decreased value.</seg>
<seg id="809">"in a study about 20 weeks of reduced pioglitazon not only the sober Triglyceride, but improved beyond the triglyceride absorption as well as to the hepatic triglycemeride synthesis."</seg>
<seg id="810">"in the proactive study, a cardiovascular Outcome study, 5238 patients with type 2 diabetes mellitus and pre-advanced makrovascular illness were randomized over a period of up to 3.5 years in addition to existing antidiabetic and cardiovascular therapy either Pioglitazon or placebo."</seg>
<seg id="811">"after oral application Pioglitazon is rapidly resorbi, whereby the top concentration on unchangeable Pioglitazon is usually reached 2 hours after application."</seg>
<seg id="812">"on this basis, the contribution of M-IV becomes effective in the effectiveness of pioglitazon, whereas the relative efficacy of M-II is minimal."</seg>
<seg id="813">"in Interaction studies, Pioglitazon has no relevant effect on the pharmacokinetics or pharmaceutical dynamics of Digoxin, warfarin, phenprocoumon and metformin exercises."</seg>
<seg id="814">The simultaneous application of Pioglitazon with Gemfibrozil (a Cytochrom P450 2C8- Inhibitor) or with Rifampicin (a Cytochrom P450 2C8 indus) or lowers the Plasmakonzentration of Pioglitazon (see Section 4.5).</seg>
<seg id="815">"after oral application of radioactive marked pioglitazon in humans, the marker was mainly found in feces (55%) and to a lesser extent in the Harn (45%)."</seg>
<seg id="816">The average plasma Eliminationary period of unchangeable pioglitazon is at the age of 5-6 hours and that of the entire active Metabolites is 16 - 23 hours.</seg>
<seg id="817">The Plasmakonzentrations of Pioglitazon and its metabolic ites are lower in patients with reduced kidney function lower than with healthy volunteers, with the rationale of the oral Clearance of the mother subtle. "</seg>
<seg id="818">"toxicological studies occurred with mice, rats, dogs and monkey conform after repeated appointments, anemia and reversibly excentric coronary cardioprotary hypertropy."</seg>
<seg id="819">"this is due to that, in treatment with pioglitazon, diminished in the bases of hyperinsulinemia and increased insulin resistance of maternity, thus reducing the availability of the metabolic substrates for the fetal growth."</seg>
<seg id="820">In long-term studies (up to 2 years) were induced by the Ratte increased incidences of hyperplasia (in male and female rats) and tumors (in male rats) of the bladder epithelium.</seg>
<seg id="821">In a zoa-model of the familiarization Polyposis (FAP) the treatment with two other Thiazolidindions led to an increased frequency of colorontology.</seg>
<seg id="822">"the tablets are white to white, round, flat and wear on one side the marking" "30" "and on the other side the wording" ACTOS. "</seg>
<seg id="823">"the investigated Fracupuncture incidence was 1,9 fractures for 100 patients with pioglitazon, treated with pioglitazon treated with women, who were treated with a comparative drugs."</seg>
<seg id="824">"in the pro-active study, a study of 3.5 years for the study of cardiovascular events, frogs in 44 / 870 (5,1%; 1.0 fractures per 100 patient years) of patients who were treated with a comparative drugs."</seg>
<seg id="825">In another study over two years the effects of a combination therapy of metformin was investigated with Pioglitazon or Gliclazid.</seg>
<seg id="826">Clinical trials over 1 year showed a statistically significant decrease of the album in / Kreatinin Quotienes compared to the raw materials.</seg>
<seg id="827">"in a study about 20 weeks of reduced pioglitazon not only the sober Triglyceride, but also improved the postprandial triglyceride levels, this is both an effect on the Tryglycemeride absorption as well as to the hepatic Tryglizerid synthesis."</seg>
<seg id="828">"although the study was missing with regard to its primary end, a combination of the overall mortality, not-deadly mercenisation, leg amputation above the ankle, koronarer Revascularization and Revascularization of the leg arteries, reveal the results that with the intake of pioglitazon no cardiovascular long-term risks are connected."</seg>
<seg id="829">"the tablets are white to white, round, flat and wear on one side the marking" 45 "and on the other side the wording" ACTOS. "</seg>
<seg id="830">"in a summary analysis of messages unwanted events with regard to bone armament, controlled, double-clinical trials over a period of up to 3.5 years with more than 8.100 patients who were treated with Pioglitazon, showed himself an increased incidence of bone armament in women."</seg>
<seg id="831">"in the pro-active study, a study of 3.5 years for the study of cardiovascular events, frogs in 44 / 870 (5,1%; 1.0 fractures per 100 patient years) of patients who were treated with a comparative drugs."</seg>
<seg id="832">"in a study about 20 weeks of reduced pioglitazon not only the sober Triglyceride, but improved beyond the triglyceride absorption as well as to the hepatic triglycemeride synthesis."</seg>
<seg id="833">"on the packing state of the drug, the name and address of the manufacturer, which is responsible for releasing the relevant Charge."</seg>
<seg id="834">"the Pharmaceutical entrepreneurs will submit an additional 6 monatigen Periodic Safety Update Report (PSUR) and then annual PSURs, until a different decision of CHMP."</seg>
<seg id="835">It must be a updated risk management plan according to CHMP-Guideline on Risk Management Systems for Medicinal Products for Human Use.</seg>
<seg id="836">"if you are suffering from type 2 diabetes, accounts support 15 mg tablets take control of your blood sugar levels by introducing a better devaluation of the body insulin."</seg>
<seg id="837">"if you know is known that you are suffering from sugar intake, please contact us prior to taking account accounts in 15mg tablets your doctor."</seg>
<seg id="838">"please inform your doctor or a pharmacist, if you have more medicines or have recently taken, even if it is not prescription drugs."</seg>
<seg id="839">"if you take Actos 15 mg tablets in combination with other medicines to treat diabetes (such as insulin, chloroclamide, glyclazid, Tolbuttond, Toltamide, your doctor will tell you whether you need to reduce the dose of your medicines."</seg>
<seg id="840">"in some patients with long-sept type 2 diabetes mellitus and coronary stroke, who were treated with acetone and insulin, developing a heart-sufficiency."</seg>
<seg id="841">Clinical trials in which Pioglitazon has been compared with other oral Antidiabetic or placebo (effective tablets) showed itself in women (but not in men) that took pioglitazon to a higher number of bone armament.</seg>
<seg id="842">"if you have accidentally taken too many tablets, or if any other or a child has taken your medicine, you must get in touch with a doctor or a pharmacist."</seg>
<seg id="843">"as Actos looks and content of the package Actos 15 mg tablets are white to white, round, curved tablets with the marking" 15 "on one side and the title" ACTOS "on the other side."</seg>
<seg id="844">"if you are suffering from type 2 diabetes, accounts support 30 mg tablets take control of your blood sugar levels by introducing a better devaluation of the body insulin."</seg>
<seg id="845">"if you know is known that you are suffering from sugar intake, please contact us before taking accounts for 30mg tablets your doctor."</seg>
<seg id="846">"if you have an account 30 mg tablets in combination with other medicines to treat diabetes (such as insulin, chloroclamide, glyclazid, Tolbutamide), your doctor will notify you whether you need to reduce the dose of your medicines."</seg>
<seg id="847">"61 Informing your doctor as soon as possible, if you find signs of a heart failure, such as unusual shorthfulness or swift weight gain or local fluctuations (Ödeme)."</seg>
<seg id="848">Clinical trials in which Pioglitazon has been compared with other oral Antidiabetic or placebo (effective tablets) showed itself in women (but not in men) that took pioglitazon to a higher number of bone armament.</seg>
<seg id="849">"as Actos looks and content of the package Actos 30 mg tablets are white to white, round, flat tablets with the marking" 30 "on one side and the title" ACTOS "on the other side."</seg>
<seg id="850">"if you are suffering from type 2 diabetes, accounts support 45 mg tablets take control of your blood sugar levels by introducing a better devaluation of the body insulin."</seg>
<seg id="851">"if you know is known that you are suffering from sugar intake, please contact Actos 45mg tablets to your doctor before taking account."</seg>
<seg id="852">"if you use Actos 45 mg tablets in combination with other medicines to treat diabetes (such as insulin, chloroclamide, glyclazid, Tolbuttond, Toltamide, your doctor will tell you whether you need to reduce the dose of your medicines."</seg>
<seg id="853">"66 With some patients with long-sewn type 2 diabetes mellitus and coronary stroke, who were treated with acetone and insulin, developed a heart-sufficiency."</seg>
<seg id="854">"inform you as soon as possible your doctor if you sign signs of a heart failure, such as unusual shortness or swift weight gain or local fluctuations (Ödeme)."</seg>
<seg id="855">Clinical trials in which Pioglitazon has been compared with other oral Antidiabetic or placebo (effective tablets) showed itself in women (but not in men) that took pioglitazon to a higher number of bone armament.</seg>
<seg id="856">"67 If one of the above-side effects you have considerably affected or you notice unwanted effects which are not specified in this usage information, please inform your doctor or a pharmacist."</seg>
<seg id="857">"as Actos looks and content of the package Actos 45 mg tablets are white to white, round, flat tablets with the marking" 45 "on one side and the title" ACTOS "on the other side."</seg>
<seg id="858">This document is a summary of the European publicity report (EPAR) in which explains how the Committee on Humanarzs (CHMP) is assessed to identify recommendations concerning the application of the drug.</seg>
<seg id="859">"if you need more information about your medical condition or the treatment of your disease, please read the packages (which is also part of the EPAR) or contact a doctor or a pharmacist."</seg>
<seg id="860">"if you wish to receive further information on the basis of recommendations of CHMP, please read the scientific discussion (which is also part of the EPAR)."</seg>
<seg id="861">Actraphana 10: soluble insulin in 10% and isophan insulin insulin 80% Actraphancies 30: soluble insulin 30% and isophan insulin insulin 60% Actraphancies 50: soluble insulin 50% and isophan insulin insulin 50% and isophan-insulin 50%</seg>
<seg id="862">Actraphane is usually applied once or twice a day when a quick initializing effect is desired together with a longer lasting effect.</seg>
<seg id="863">(44-20) 74 18 84 00 fax (44-20) 74 18 86 68 E-mail: mail @ emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int</seg>
<seg id="864">"Actraphanae was tested in a total of 294 patients with type-1 diabetes, where the pancreas is unable to produce insulin, and type-2 diabetes, where the body is not able to use the insulin effectively."</seg>
<seg id="865">"in the study, after 12 weeks the concentration of a substance (glycosyliated hemoglobin (HbA1c) is measured, which shows how well the blood sugar is adjusted."</seg>
<seg id="866">"Actraphanae led to a decrease of the HbA1c Spiegels, which pointed out that blood sugar levels were similar to another human hormone."</seg>
<seg id="867">"Actraphanae should not be applied in patients, which may possibly be hypersensitive (allergic) to humaninsulin (rDNA) or one of the other components."</seg>
<seg id="868">"in addition, the doses of Actraphanmay need to be adapted if it is administered together with a number of other medicines that can affect the blood sugar (the full list is the pack carrier)."</seg>
<seg id="869">The Committee on Humanarzs (CHMP) led to the conclusion that the benefits of acetaphanous in the treatment of diabetes against the risks.</seg>
<seg id="870">October 2002 the European Commission shared the Novo Nordisk A / S for the transport of Actraphanans across the European Union.</seg>
<seg id="871">"mixed insulin products are usually applied once or twice a day, when a quick initializing effect is desired together with a longer lasting effect."</seg>
<seg id="872">Injecting needle must be loaded under the skin at least 6 seconds to ensure that the entire dose was injected.</seg>
<seg id="873">"patients whose blood sugar has improved, for example, by a intensified insulin therapy, the hypoglycaemia will have changed and should be advised accordingly."</seg>
<seg id="874">"any change with regard to strength, brand (manufacturer), insulin type (fast acting, biphasical, long-effective insulin, insulin or insulin analogue) and / or manufacturing method (through recombinant DNA to insulin animal origin) can cause a change in dosage."</seg>
<seg id="875">"if the change to Actraphans is necessary for patients to be a dosage adjustment, it can be necessary for the first dosage or in the first weeks or months after switching."</seg>
<seg id="876">"some patients, in which hypoglycaemic reactions after a change of animal in human insulin occurred, reported that the early warring symptoms of a hypoglycaemia reported less pronounced or different than with their previous insulin."</seg>
<seg id="877">"trips that go over several times, the patient should be pointed out to take the advice of his physician because such trips can lead to that insulin and meals are applied to other times or must be taken."</seg>
<seg id="878">The doctor must therefore account for potential interdependencies in therapy and will always consult his patients according to other medicines.</seg>
<seg id="879">4 Soy hypoglycaemia as well as hyperglycaemia that can occur in a not sufficiently controlled diabetestherapy increase the risk of abnormalities and fertility in utero.</seg>
<seg id="880">Heavy hypoglycemic can lead to awareness and / or cursing and with temporary or permanent disorders of brain function and even death.</seg>
<seg id="881">Diseases of the nervous system nest - peripheral Neuropathy A speedy recovery of blood sugar control can be connected with complaints that are referred to as acute Neuropathy and usually are reversible.</seg>
<seg id="882">"5 A intensification of insulin therapy with a ruptive improvement in bloodstream can, however, be connected with a temporary deterioration of diabetic retinopathy."</seg>
<seg id="883">Diseases of the skin and the shelter - Lipodystrophy In the injections can arise a lipodystrophy if failed to switch the inserting inside the injections.</seg>
<seg id="884">"general diseases and complaints at the administration of the nests - Local Transensitivity to the injections while insulin therapy can occur with local hypersensitivity (redness, swelling, itching, pain, and hematoma at the injections)."</seg>
<seg id="885">"diseases of the immune system temporal - Urtikaria, Exanthem Very rare - anaphylactic reactions of generic soreness, itching, gastrouninal disorders, angioneuronal disorders, low blood pressure and impotence / awareness."</seg>
<seg id="886">However a hypoglycaemia is able to develop rapidly: • Easy hypoglycemic bodies can be treated by gloral bolts of glucose or sugary foods.</seg>
<seg id="887">Diabetic should therefore always be trauma perplexed to have sweets, biscuits or sugar fruit juice from glucagon (0.5 to 1,0 mg) by an intra-muscular or subcutaneous injecting from Glucagon which is given intravenously by the doctor. "</seg>
<seg id="888">"the effect starts within half an hour, the active max is reached within 2 to 8 hours and the entire operation is up to 24 hours."</seg>
<seg id="889">"Resorption The Resorption profile lies in it, that it is the product of a mixture of insulin products with more quickly or consumed resorption."</seg>
<seg id="890">A series of administration (hydrolyse-) places on the Humaninsulin molecule were considered; none of the division made by the splits Metabolites is active.</seg>
<seg id="891">"based on conventional studies for safety spharmacology, toxicity in repetitive gift, genotoxicity, to the carcinogenic potential and for reproduction of toxicity, the preclinical data cannot be distinguished with special dangers for humans."</seg>
<seg id="892">"it is recommended - after the Actraphanwbag was taken from the fridge - the temperature of insulin to room temperature (not over 25 ° C), before it will be resushed according to the manual for the first use."</seg>
<seg id="893">"some patients, in which hypoglycaemic reactions after a change of animal in human insulin occurred, reported that the early warring symptoms of a hypoglycaemia reported less pronounced or different than with their previous insulin."</seg>
<seg id="894">The doctor must therefore account for potential interdependencies in therapy and will always consult his patients according to other medicines.</seg>
<seg id="895">12 Soy hypoglycaemia as well as hyperglycaemia that can occur in a not sufficiently controlled diabetestherapy increase the risk of abnormalities and fertility in utero.</seg>
<seg id="896">13 A Intention of insulin therapy with a ruptive improvement in bloodstream can however be connected with a temporary deterioration of diabetic retinopathy.</seg>
<seg id="897">The terminale semi-life time (t ½) is therefore rather a measure of the restructuring as a measure of the Elimination of insulin from the plasma (insulin has in the bloodstream one t ½ of only a few minutes).</seg>
<seg id="898">"it is recommended - after the Actraphanwbag was taken from the fridge - the temperature of insulin to room temperature (not over 25 ° C), before it will be resushed according to the manual for the first use."</seg>
<seg id="899">"some patients, in which hypoglycaemic reactions after a change of animal in human insulin occurred, reported that the early warring symptoms of a hypoglycaemia reported less pronounced or different than with their previous insulin."</seg>
<seg id="900">20 Soy hypoglycaemia as well as hyperglycaemia that can occur in a not sufficiently controlled diabetestherapy increase the risk of abnormalities and fertility in utero.</seg>
<seg id="901">21 A Intention of insulin therapy with a ruptive improvement in bloodstream can however be connected with a temporary deterioration of diabetic retinopathy.</seg>
<seg id="902">"diseases of the immune system temporal - Urtikaria, Exanthem Very rare - anaphylactic reactions of generic soreness, itching, gastrouninal disorders, angioneuronal disorders, low blood pressure and impotence / awareness."</seg>
<seg id="903">Cartridges may only be used together with products which are compatible with them and ensure a safe and effective function of the cartridge.</seg>
<seg id="904">"it is recommended - after Actraphanous Penfill from the fridge was taken, the temperature of the insulin to room temperature (not over 25 ° C) will rise before it will be resushed according to the manual for the first use."</seg>
<seg id="905">"some patients, in which hypoglycaemic reactions after a change of animal in human insulin occurred, reported that the early warring symptoms of a hypoglycaemia reported less pronounced or different than with their previous insulin."</seg>
<seg id="906">"28 Soy hypoglycaemia as well as hyperglycaemia, which can occur in a not sufficiently controlled diabetestherapy, increase the risk of abnormalities and fertility in utero."</seg>
<seg id="907">29 A Intention of insulin therapy with a ruptive improvement in bloodstream can however be connected with a temporary deterioration of diabetic retinopathy.</seg>
<seg id="908">"some patients, in which hypoglycaemic reactions after a change of animal in human insulin occurred, reported that the early warring symptoms of a hypoglycaemia reported less pronounced or different than with their previous insulin."</seg>
<seg id="909">36 Soy hypoglycaemia as well as hyperglycaemia that can occur in a not sufficiently controlled diabetestherapy increase the risk of abnormalities and fertility in utero.</seg>
<seg id="910">37 A Intention of insulin therapy with a ruptive improvement in bloodstream can however be connected with a temporary deterioration of diabetic retinopathy.</seg>
<seg id="911">44 Soy hypoglycaemia as well as hyperglycaemia that can occur in a not sufficiently controlled diabetestherapy increase the risk of abnormalities and fertility in utero.</seg>
<seg id="912">45 A Intention of insulin therapy with a ruptive improvement in bloodstream can however be connected with a temporary deterioration of diabetic retinopathy.</seg>
<seg id="913">"some patients, in which hypoglycaemic reactions after a change of animal in human insulin occurred, reported that the early warring symptoms of a hypoglycaemia reported less pronounced or different than with their previous insulin."</seg>
<seg id="914">52 Soy hypoglycaemia as well as hyperglycaemia that can occur in a not sufficiently controlled diabetestherapy increase the risk of abnormalities and fertility in utero.</seg>
<seg id="915">53 A Intention of insulin therapy with a ruptive improvement in bloodstream can however be connected with a temporary deterioration of diabetic retinopathy.</seg>
<seg id="916">Injections must be prepared in front of the injtion so that the doser glers goes back to zero and a insulin-guide at the head of the injecting needle appears.</seg>
<seg id="917">"59 patients whose blood sugar has improved, for example, by a intensified insulin therapy, the hypoglycaemia will have changed and should be advised accordingly."</seg>
<seg id="918">"hypoglycaemia as well as hyperglycaemia, which can occur in a not sufficiently controlled diabetestherapy, increase the risk of abnormalities and fertility in utero."</seg>
<seg id="919">"however, a intensification of insulin therapy with an unruptible improvement in bloodstream can however be connected with a temporary deterioration of diabetic retinopathy."</seg>
<seg id="920">"diseases of the immune system temporal - Urtikaria, Exanthem Very rare - anaphylactic reactions of generic soreness, itching, gastrouninal disorders, angioneuronal disorders, low blood pressure and impotence / awareness."</seg>
<seg id="921">These precast should only be used together with products which are compatible with them and ensure a safe and effective functioning of the production.</seg>
<seg id="922">It is recommended - after Actraphans NovoLet out from the fridge - the temperature of insulin to room temperature (not over 25 ° C) can be done before it will be resushed according to the manual for the first use.</seg>
<seg id="923">"67 patients whose blood sugar has improved, for example, by a intensified insulin therapy, the hypoglycaemia will have changed and should be advised accordingly."</seg>
<seg id="924">"75 patients whose blood sugar has improved, for example, by a intensified insulin therapy, the hypoglycaemia will have changed and should be advised accordingly."</seg>
<seg id="925">"83 patients whose blood sugar has improved, for example, by a intensified insulin therapy, the hypoglycaemia will have changed and should be advised accordingly."</seg>
<seg id="926">"91 patients whose blood sugar has improved significantly, for instance, can be altered through a intensified insulin therapy, the hypoglycaemia will have changed and should be advised accordingly."</seg>
<seg id="927">"99 patients whose blood sugar has improved, for example, by a intensified insulin therapy, the hypoglycaemia will have changed and should be advised accordingly."</seg>
<seg id="928">"any change with regard to strength, brand (manufacturer), insulin type (fast acting, biphasical, slow insulin etc.), type of insulin (animal insulin, insulin or insulin analog) and / or manufacturing method (through recombinant DNA to insulin animal origin) can cause a change in dosage."</seg>
<seg id="929">"it is recommended - after Actraphanous Innolet from the fridge was taken from the fridge, the temperature of insulin to room temperature (not over 25 ° C) will rise before it will be resushed according to the manual for the first use."</seg>
<seg id="930">It is recommended - after ActraphanflexPen from the fridge was taken from the fridge - the temperature of insulin to room temperature (not over 25 ° C) will rise before it will be resushed according to the manual for the first use.</seg>
<seg id="931">"on the packing state of the drug, the name and address of the manufacturer, which is responsible for releasing the relevant Charge."</seg>
<seg id="932">Stored in the refrigerator (2 ° C - 8 ° C) Not emfreeze the flow of water in the envelope to protect the content from light after quarry: not in the fridge or over 25 ° C</seg>
<seg id="933">Subcutaneous use of osfill cartridges are intended for application with insulin objects ranging from Novo Nordisk providing guidance by resusurning Packages must be used only by one person</seg>
<seg id="934">Stored in the refrigerator (2 ° C - 8 ° C) Not Enfreezing the cartridge in carton to protect the contents from light to protect: not in the fridge or over 30 ° C</seg>
<seg id="935">Subcutaneous use of osfill cartridges are intended for application with insulin objects ranging from Novo Nordisk providing guidance by resusurning Packages. it can only be used by one person</seg>
<seg id="936">Subcutaneous use of osfill cartridges are intended for application with insulin objects ranging from Novo Nordisk providing guidance by resusurning Packages must be used only by one person</seg>
<seg id="937">Subcutaneous use of osfill cartridges are intended for use with insulin objects ranging from Novo Nordisk providing guidance by resusurning Packages. Actraphans 40 Penfill may only be used by one person</seg>
<seg id="938">Subcutaneous use of osfill cartridges are intended for application with insulin objects ranging from Novo Nordisk providing guidance by resuspening Packages. 50 Penfill may only be used by one person</seg>
<seg id="939">Subcutaneous application of use with Actraphanous 10 NovoLet's provide NovoFine injection molds provided by instructions Actraphan.10 NovoLet's not only be used by one person</seg>
<seg id="940">Stored in the refrigerator (2 ° C - 8 ° C) Not to protect light from the quarry: not in the fridge or over 30 ° C</seg>
<seg id="941">Subcutaneous application of use with Actraphanane 20 NovoLet's provide NovoFine injection molds provided by instructions Actraphane 20 NovoLet's only be used by one person</seg>
<seg id="942">Subcutaneous application of use with Actraphans 30 NovoLet's provide NovoFine injection molds provided by instructions Actraphans 30 NovoLet's only be used by one person</seg>
<seg id="943">Subcutaneous application of use with Actraphanous 40 NovoLet's provide NovoFine injection molds provided by instructions Actraphans 40 NovoLet's only be used by one person</seg>
<seg id="944">Subcutaneous application of use with Actraphana 50 NovoLet's provide NovoFine injection molds provided by instructions Actraphane 50 NovoLet's not only be used by one person</seg>
<seg id="945">Subcutaneous application Zur use with Actraphans 30 Innolet are provided NovoFine S injection molds provided by instructions Actraphans 30 Innouns can only be used by one person</seg>
<seg id="946">"this means that about half an hour after you have applied it, your blood sugar begins to sink and that the effect will last approximately 24 hours."</seg>
<seg id="947">"if you have allergic (hypersensitive) to this insulin product, Metacresol or any of the other components (see Section 7 Further information)."</seg>
<seg id="948">Pay attention to those under 5 world side effects are possible? described symptoms of an allergy. if you feel the first signs of hypoglycaemia (symptoms of a downforce).</seg>
<seg id="949">"if your doctor has a change from a insulin type or brand to another, you may need to be adjusted the dose through your doctor."</seg>
<seg id="950">"► Readers you using the label, whether it is about the correct insulin type, disinfect the rubber compound with a medical Tupid."</seg>
<seg id="951">"if this is not completely wrong, if you get the tear-bottle to your pharmacy, if it was not correctly retained or frozen (see 6 How is Actraphancies) if it is not evenly white and decayed."</seg>
<seg id="952">Use the injection technique that has recommended your doctor or your diabetesberaterin recommended ► Let the injecting needle at least 6 seconds long under your skin to ensure that the whole dose was injected.</seg>
<seg id="953">"the warfs of a subduck can suddenly occur and can be: cold silence, cold-age skin, headaches, dullness, unusual visual impairments, nervousness, nervousness or citations, anxiety, confusion, conceptions."</seg>
<seg id="954">"tell your relatives, friends and close workmates that they bring you in case of a awareness into the stable side situation and immediately leave a doctor."</seg>
<seg id="955">"you may not give you anything to eat or to drink nothing, because you can get rid of it. ► If a heavy duty cycle may not be treated (temporary or lasting) brain damage or even to death, search your doctor."</seg>
<seg id="956">"you can regain the consciousness faster, when the hormone Glucagon is familiar with a person who is familiar with its gift."</seg>
<seg id="957">This can happen: • If you need too much insulin injecting if you eat too little or have a meal • If you have more than otherwise physically tense.</seg>
<seg id="958">"intensified uregestion, thirst, appetitions, nausea or fatigue, fetched skin, mouth-dry and fruity (after acetone) rifender breath."</seg>
<seg id="959">• You have forgotten a insulin objects • repetitive injecting less insulin than you need • an infection or fever • more food than usual • less physical exercise as usual.</seg>
<seg id="960">"if you often give yourself an injection at the same place, this point can shrink the subcereal tissues (Lipatrophy) or increase (Lipohypertrophia)."</seg>
<seg id="961">"if you notice depressions or thickeness of your skin at the injections, tell your doctor or your diabetesberlantern to this, because these reactions can worsen or affect the inclusion of your insulin, if you are injected into such a place."</seg>
<seg id="962">"immediately look at a doctor if the symptoms of an allergy to other parts of the body can spread, or if you suddenly feel uncomfortable and you can suddenly feel uncomfortable and you have the impression that you snail yourself or you have the impression to become conscious."</seg>
<seg id="963">They may have a very rare heavy allergic reaction to Actraphanans or one of its components (a so-called systemic allergic reaction).</seg>
<seg id="964">"if one of the above-side effects you have considerably affected or you notice unwanted effects which are not specified in this usage information, please inform your doctor, your diabetesberlantern or your pharmacist."</seg>
<seg id="965">What Actraphanae 30 contains - The drug is employed by recombinant DNA technology employed in human (30% as soluble insulin and 70% as isophan insulin).</seg>
<seg id="966">"as Actraphanae looks and content of the package The injection, is called murky, white, acqueous Suspension in packs of 1 or 5 mt. with 5 mump removal with 5 mt. from 10 ml to each 10 ml."</seg>
<seg id="967">Use the injection technique that has recommended your doctor or your diabetesberaterin recommended ► Let the injecting needle at least 6 seconds long under your skin to ensure that the whole dose was injected.</seg>
<seg id="968">"it is recommended - after it was taken out of the refrigerator - the temperature of a bottle case to ambient temperatures, before insulin accordance with the manual for the first use is resushed."</seg>
<seg id="969">"as Actraphanae looks and content of the package The injection, is called murky, white, acqueous Suspension in packs of 1 or 5 mt. with 5 mump removal with 5 mt. from 10 ml to each 10 ml."</seg>
<seg id="970">"► Readers you using the label, whether it is about the correct insulin type, please always check the osfill cartridge including the rubber colbens (stopover)."</seg>
<seg id="971">Do not use it if any damage to see or a gap between the rubber colts and the white tape of the label is visible.</seg>
<seg id="972">"for more information can be found on the operating instructions of your insulin management system. ► desinfect the rubber compound, with a medical tampant. ► Benal you always use any injecting a new injection, to avoid an contamination."</seg>
<seg id="973">"► in insulin infusion pumps, if the penfill or the device, which has been abandoned, damaged or disrupted, there is the danger of extinction of insulin, if it has not been stored properly or frozen (see 6 How is Actraphancies);) if it is not evenly white and decayed."</seg>
<seg id="974">"if you need to be treated with Actraphana 10 Penfill and another insulin in osfill cartridges, you should use two insulin objects, each one for each insulin type."</seg>
<seg id="975">"before you use the cartridge into the insulin objects, move them at least 20 times between the positions a and b and down (see illustration), so that the glass ball moved from one end of the cartridge to another."</seg>
<seg id="976">Use the injection technique that has been advised your doctor or your diet systems in order to ensure that the full dosage was injected at least 6 seconds long under your skin to ensure that the full dose is injected to the injecting and to ensure the injaphor without ascending injecting needle.</seg>
<seg id="977">"183 Sign with your relatives, friends and close workmates that they bring you in case of a awareness into the stable side situation and immediately leave a doctor."</seg>
<seg id="978">• You have forgotten a insulin objects • repetitive injecting less insulin than you need • an infection or fever • more food than usual • less physical exercise as usual.</seg>
<seg id="979">"if one of the above-side effects you have considerably affected or you notice unwanted effects which are not specified in this usage information, please inform your doctor, your diabetesberlantern or your pharmacist."</seg>
<seg id="980">"it is recommended - after it was taken from the refrigerator - the temperature of the Penster cartridge to leave room temperature, before insulin accordance with the manual for the first use is resushed."</seg>
<seg id="981">"185 payment the cartridges always in carton, if you do not use it to protect them from light."</seg>
<seg id="982">What Actraphan10 contains - The drug is employed by recombinant DNA technology employed insulin human (10% as soluble insulin and 90% as isophan insulin).</seg>
<seg id="983">"as Actraphanae looks and content of the package The injection, is called murky, white, acqueous Suspension in packs of 1, 5 or 10 cartridges to each 3 ml."</seg>
<seg id="984">"for more information can be found on the operating instructions of your insulin management system. ► desinfect the rubber compound, with a medical tampant. ► Benal you always use any injecting a new injection, to avoid an contamination."</seg>
<seg id="985">"if you need to be treated with Actraphana 20 Penfill and another insulin in osfill cartridges, you should use two insulin objects, each one for each insulin type."</seg>
<seg id="986">"189 Sign your relatives, friends and close workmates, that they bring you in case of a awareness into the stable side situation and immediately leave a doctor."</seg>
<seg id="987">"if one of the above-side effects you have considerably affected or you notice unwanted effects which are not specified in this usage information, please inform your doctor, your diabetesberlantern or your pharmacist."</seg>
<seg id="988">191 assures the cartridges always in carton if you don't use it to protect them from light.</seg>
<seg id="989">What Actraphan20 includes - The drug is employed by recombinant DNA technology employed in human (20% as soluble insulin and 80% as isophan insulin).</seg>
<seg id="990">"as Actraphanae looks and content of the package The injection, is called murky, white, acqueous Suspension in packs of 1, 5 or 10 cartridges to each 3 ml."</seg>
<seg id="991">"for more information can be found on the operating instructions of your insulin management system. ► desinfect the rubber compound, with a medical tampant. ► Benal you always use any injecting a new injection, to avoid an contamination."</seg>
<seg id="992">"if you need to be treated with Actraphana 30 Penfill and another insulin in osfill cartridges, you should use two insulin objects, each one for each insulin type."</seg>
<seg id="993">"195 Sign You have your relatives, friends and close workmates that they bring you in the event of a awareness into the stable side situation and immediately leave a doctor."</seg>
<seg id="994">"if one of the above-side effects you have considerably affected or you notice unwanted effects which are not specified in this usage information, please inform your doctor, your diabetesberlantern or your pharmacist."</seg>
<seg id="995">197 payment the cartridges always in carton if you don't use them to protect them from light.</seg>
<seg id="996">"manufacturer The manufacturer can be identified by the batch name, which is printed on the whip of the carton and on the label, identified:"</seg>
<seg id="997">"if at the second and third place of the Charge's name the Drawer combination W5, S6, P5, K7 or ZF appears, the manufacturer Novo Nordisk A / S, Novo Allé, DK- 2880 Bagsvaerd, Denmark"</seg>
<seg id="998">"if at the second and third place of the Charge's name comes the drawing combination of H7 or T6, the manufacturer Novo Nordisk Production SAS, 45, Avenue d'Orléan, F-28002 Chartres, France."</seg>
<seg id="999">"for more information can be found on the operating instructions of your insul injecting system. ► desinfect the rubber compound, with a medical tampant. ► Bench always for any injecting a new injection, to avoid an contamination."</seg>
<seg id="1000">"if you are treated with Actraphans 40 Penfill and another insulin in osfill cartridges, you should use two insulin objects, each one for each insulin type."</seg>
<seg id="1001">"201 Sign your relatives, friends and close workmates that they bring you in case of a awareness into the stable side situation and immediately leave a doctor."</seg>
<seg id="1002">"if one of the above-side effects you have considerably affected or you notice unwanted effects which are not specified in this usage information, please inform your doctor, your diabetesberlantern or your pharmacist."</seg>
<seg id="1003">203 Remains the cartridges always in carton if you don't use it to protect them from light.</seg>
<seg id="1004">What Actraphan40 contains - The drug is employed by recombinant DNA technology employed insulin human (40% as soluble insulin and 60% as isophan insulin).</seg>
<seg id="1005">"for more information can be found on the operating instructions of your insul injecting system. ► desinfect the rubber compound, with a medical tampant. ► Bench always for any injecting a new injection, to avoid an contamination."</seg>
<seg id="1006">"if you need to be treated with Actraphana 50 Penfill and another insulin in osfill cartridges, you should use two insulin objects, each one for each insulin type."</seg>
<seg id="1007">"before you use the Penate cartridge into the insulin objects, move them at least 20 times between the positions a and b and down (see illustration), so that the glass ball moved from one end of the cartridge to another."</seg>
<seg id="1008">"207 sells your relatives, friends and close workmates that they bring you in case of a awareness into the stable side situation and immediately leave a doctor."</seg>
<seg id="1009">"if one of the above-side effects you have considerably affected or you notice unwanted effects which are not specified in this usage information, please inform your doctor, your diabetesberlantern or your pharmacist."</seg>
<seg id="1010">209 Discover the cartridges always in carton if you don't use them to protect them from light.</seg>
<seg id="1011">What Actraphanae 50 includes - The drug is employed by recombinant DNA technology employed in human (50% as soluble insulin and 50% as isophan insulin).</seg>
<seg id="1012">Oral antidiabetic (for example), monoidal anti-inhibitor (MAO-Hemmer), anangiotensin- Converting-enzymes, anti-acid-steroids, anasympathomimetics, growth hormones, Danazol, Octreotid or Lanreotid. "</seg>
<seg id="1013">► How to test by using the label 'whether it is the right Insul intyp you always use for any injecting a new injecting to avoid an contamination.</seg>
<seg id="1014">"► in insulin infusion pumps ► when the NovoLet dropped, damaged or depressed, there is the danger of extinction of insulin, if it was not correctly retained or frozen (see 6 How is Actraphancies);) if it is not evenly white and decayed."</seg>
<seg id="1015">"the warfs of a subduck can suddenly occur and can be: cold silence, cold-age skin, headaches, dullness, unusual visual impairments, nervousness, nervousness or citations, anxiety, confusion, conceptions."</seg>
<seg id="1016">"214 If one of the above-side effects you have considerably affected or you notice unwanted side effects which are not specified in this usage information, please inform your doctor, your diabetesberlantern or your pharmacist."</seg>
<seg id="1017">"in use of NovoLet's fuss and those who are used shortly, or are used as a substitute, are not in the refrigerator to retain."</seg>
<seg id="1018">"it is recommended that after he was taken from the refrigerator - the temperature of NovoLet's finishing in room temperature before the insulin, in accordance with the operating instructions for the first use will be resushed."</seg>
<seg id="1019">Let the wear cap of your NovoLet production still set if NovoLet's not in use to protect the insulin in front of light.</seg>
<seg id="1020">"as Actraphanae looks and content of the package The injection, is called murky, white, acqueous Suspension in packs of 5 or 10 Complete to each 3 ml."</seg>
<seg id="1021">"prior to each injection, check if any at least 12 units insulin in the cartridge are left, so that an evenly mix is ensured."</seg>
<seg id="1022">Just go to avoid the injection of air and to ensure a correct dosage: • Hold you Actraphanans 10 NovoLet with the injector to the top • Klopate a few times with the finger easily against the cartridge.</seg>
<seg id="1023">"if airbubbles are present, this will keep up in the cartridge • During You Actraphana 10 NovoLet continue to keep up with the injector to the top, turn the button down to the top button (figure D) • Now keep track of the injection-needle a drop in insulin."</seg>
<seg id="1024">• Set the wear board back so on the prefuss that indicates the number 0 to the dosing brand (figure E) • control if the button-knob is pushed into.</seg>
<seg id="1025">"if not, turn the wear cap, up to the knob-button-pressed • Keep up your Actraphanous 10 NovoLet's horizontally."</seg>
<seg id="1026">"if the press knob can not move freely to the outside, insulin from the injecting is pressed • The scale is shown on the map, 2, 4, 6, 8, 10, 12, 14, 16 and 18 units."</seg>
<seg id="1027">"the button-button moves to the outside while you turn the wear cap • The scale under the button-button displays 20, 40 and 60 units."</seg>
<seg id="1028">"check the dose • notice the number on the winding kit directly next to the dosing brand • notice the highest number you have set on the button button, turn the wear cap simply forward or backwards until you have set the right number of units."</seg>
<seg id="1029">"otherwise there will be insulin from the injecting needle, and the dosage given will not be correct • If you have tempted to set a dose of more than 78 units, take the following steps through:"</seg>
<seg id="1030">Then take the wear board and put them back on that the 0 of the dosing brand is opposite.</seg>
<seg id="1031">Be sure to press only during the injtion on the button knob. • Keep the pushbutton after the injecting quite in-pressed until the injection-needle was drawn from the skin.</seg>
<seg id="1032">"if not, turn the wear cap, up to the button knob and then proceed as described in front of the use • Can we listen to the pressing of the press button."</seg>
<seg id="1033">"it may be inaccurate, you can not set a dose which is higher than the number of remaining units sold in the cartridge units • You can use the rest scale scale to be seen as much insulin still exists."</seg>
<seg id="1034">Oral antidiabetic (for example), monoidal anti-inhibitor (MAO-Hemmer), anangiotensin- Converting-enzymes, anti-acid-steroids, anasympathomimetics, growth hormones, Danazol, Octreotid or Lanreotid. "</seg>
<seg id="1035">"224 If any of the above-side effects you have considerably affected or you notice unwanted side effects which are not specified in this usage information, please inform your doctor, your diabetesberlantern or your pharmacist."</seg>
<seg id="1036">"226 For each injection, check if any at least 12 units insulin in the cartridge are left, so that an evenly mix is ensured."</seg>
<seg id="1037">Just go to avoid the injection of air and to ensure a correct dosage: • Hold you Actraphanane 20 NovoLet with the injector to the top • Klopate a few times with the finger easily against the cartridge.</seg>
<seg id="1038">"if airbubbles are present, this will keep up in the cartridge • During you Actraphane 20 NovoLet continue to keep up with the injector to the top, turn the button down into the direction of the arrow button (figure D) • Now you must push the push-button down (figure D) • Now the tip of the injection-needle is a drop in insulin."</seg>
<seg id="1039">"if not, turn the wear cap, up to the knob-button-pressed • Keep up your Actraphanane 20 NovoLet's horizontally."</seg>
<seg id="1040">Oral antidiabetic (for example), monoidal anti-inhibitor (MAO-Hemmer), anangiotensin- Converting-enzymes, anti-acid-steroids, anasympathomimetics, growth hormones, Danazol, Octreotid or Lanreotid. "</seg>
<seg id="1041">"234 If any of the listed side effects you have considerably affected or you notice unwanted effects which are not specified in this usage information, please inform your doctor, your thabetesberlantern or your pharmacist."</seg>
<seg id="1042">"236 In each injection, check if any at least 12 units insulin in the cartridge are left, so that an evenly mix is ensured."</seg>
<seg id="1043">Just go to avoid the injection of air and to ensure a correct dosage: • Hold you Actraphanane 30 NovoLet with the injector to the top • Klopate a few times with the finger easily against the cartridge.</seg>
<seg id="1044">"if airbubbles are present, this will keep up in the cartridge • During you Actraphana 30 NovoLet continue to keep up with the injector to the top, turn the button down into the direction of the pipes (figure D) • Now you must push the button-button down (figure D) • Now the tip of the injection-needle is a drop in insulin."</seg>
<seg id="1045">"if not, turn the wear cap, up to the knob-button-pressed • Keep up your Actraphanane 30 NovoLet me horizontal."</seg>
<seg id="1046">Oral antidiabetic (for example), monoidal anti-inhibitor (MAO-Hemmer), anangiotensin- Converting-enzymes, anti-acid-steroids, anasympathomimetics, growth hormones, Danazol, Octreotid or Lanreotid. "</seg>
<seg id="1047">"244 If any of the above-side effects you have considerably affected or you notice unwanted effects which are not specified in this usage information, please inform your doctor, your diabetesberlantern or your pharmacist."</seg>
<seg id="1048">246 In each injection • please check if any at least 12 units insulin in the cartridge are left to ensure an evenly mix.</seg>
<seg id="1049">Just go to avoid the injection of air and to ensure a correct dosage: • Hold you Actraphanous 40 NovoLet with the injector to the top • Klopate a few times with the finger easily against the cartridge.</seg>
<seg id="1050">"if airbubbles are present, this will keep up in the cartridge • During you Actraphanous 40 NovoLet continue to keep up with the injector to the top, turn the button down into the direction of the arrow button (figure D) • Now you must drop the button in the top of the injection-needle a drop in insulin."</seg>
<seg id="1051">"if not, turn the wear cap, up to the knob-button-pressed • Keep up your Actraphanous 40 NovoLet me horizontal."</seg>
<seg id="1052">Oral antidiabetic (for example), monoidal anti-inhibitor (MAO-Hemmer), anangiotensin- Converting-enzymes, anti-acid-steroids, anasympathomimetics, growth hormones, Danazol, Octreotid or Lanreotid. "</seg>
<seg id="1053">"254 If any of the listed side effects you have considerably affected or you notice unwanted side effects, which are not specified in this usage information, please inform your doctor, your diabetesberlantern or your pharmacist."</seg>
<seg id="1054">"it is recommended that after he was taken from the refrigerator - the temperature of NovoLet's finishing in room temperature before the insulin, in accordance with the operating instructions for the first use will be resushed."</seg>
<seg id="1055">"256 Before each injection, check if any at least 12 units insulin in the cartridge are left, so that an evenly mix is ensured."</seg>
<seg id="1056">Just go to avoid the injection of air and to ensure a correct dosage: • Hold you Actraphanane 50 NovoLet with the injector to the top • Klopate a few times with the finger easily against the cartridge.</seg>
<seg id="1057">"if airbubbles are present, this will keep up in the cartridge • During you Actraphana 50 NovoLet's continue to keep up with the injector to the top, turn the button down into the direction of the arrow."</seg>
<seg id="1058">"if not, turn the wear cap, up to the knob-button-pressed • Keep up your Actraphanous 50 NovoLet me horizontal."</seg>
<seg id="1059">Oral antidiabetic (for example), monoidal anti-inhibitor (MAO-Hemmer), anangiotensin- Converting-enzymes, anti-acid-steroids, anasympathomimetics, growth hormones, Danazol, Octreotid or Lanreotid. "</seg>
<seg id="1060">"► in insulin infusion pumps, when the Innolet dropped, damaged or depressed, there is the danger of extinction of insulin, if it was not correctly retained or frozen (see 6 How is Actraphancies);) if it is not evenly white and decayed."</seg>
<seg id="1061">"the warfs of a subduck can suddenly occur and can be: cold silence, cold-age skin, headaches, dullness, unusual visual impairments, nervousness, nervousness or citations, anxiety, confusion, conceptions."</seg>
<seg id="1062">"264 If one of the above-side effects you have considerably affected or you notice unwanted side effects which are not specified in this usage information, please inform your doctor, your diabetesberlantern or your pharmacist."</seg>
<seg id="1063">"in use-being InnoLet's Complete and those who are used shortly or are used as a substitute, are not to be kept in the refrigerator."</seg>
<seg id="1064">"it is recommended - after being taken from the refrigerator - the temperature of the InnoLet's Complete to ambient to room temperature before insulin accordance with the manual for the first use is resushed."</seg>
<seg id="1065">Let the wear-cap of your InnoLet production still set up if Innolet is not in use to protect the insulin in front of light.</seg>
<seg id="1066">"as Actraphanae looks and content of the package The injection, is called murky, white, acqueous Suspension in packs of 1, 5 or 10 Complete to each 3 ml."</seg>
<seg id="1067">"the movement must be repeated until the liquid white and murky looks like, after the reset, lead the following steps of injection without delay."</seg>
<seg id="1068">• Desdisinfect the rubber compound with a medical Tupid • Bench you always for any injecting a new injection-needle to avoid a contamination from a NovoFine S injecting crane and tightening on Actraphanane 30 InnoLet (Figure 1B) • Pull opening the large external injections and the inner injections.</seg>
<seg id="1069">"• controls always, whether the press knob is completely pushed and the tin-regulator on zero is • Make the number of units that you inject by turning the dose-regulator in clockwise (Figure 2)."</seg>
<seg id="1070">Do not use the Restmengen- scale to measure your insulin dose • you listen to each individually set unit a client noise.</seg>
<seg id="1071">Guide the injection technique that has shown your doctor • Give yourself the dose by pressing the knob (picture 3).</seg>
<seg id="1072">"the dosage ator has to be returned to zero and you listen to the injection, the injecting must not block after injecting for at least 6 seconds while injecting the dosage adjustment to zero if you press the injector to zero if you press the injecting needle according to the injecting."</seg>
<seg id="1073">"medical personnel, family members and other supervisors must follow general precautions to remove and disposal of injecting injections to avoid unintentional styles with the injecting needle."</seg>
<seg id="1074">Oral antidiabetic (for example), monoidal anti-inhibitor (MAO-Hemmer), anangiotensin- Converting-enzymes, anti-acid-steroids, anasympathomimetics, growth hormones, Danazol, Octreotid or Lanreotid. "</seg>
<seg id="1075">"► in insulin infusion pumps, if the Flexpen was dropped, damaged or bruised, there is danger of extinction of insulin, if it was not correctly retained or frozen (see 6 How is Actraphancies);) if it is not evenly white and decayed."</seg>
<seg id="1076">"if you notice depressions or thickeness of your skin at the injections, tell your doctor or your diabetesberlantern to this, because these reactions can worsen or affect the inclusion of your insulin, if you are injected into such a place."</seg>
<seg id="1077">"274 If any of the above-side effects you have considerably affected or you notice unwanted effects which are not specified in this usage information, please inform your doctor, your diabetesberlantern or your pharmacist."</seg>
<seg id="1078">"in use, FlexPen Complete and those who are used shortly or are used as a substitute, are not in the refrigerator to retain."</seg>
<seg id="1079">"it is recommended that after he was taken from the refrigerator - the temperature of FlexPen comes to room temperature, before insulin accordance with the manual for the first use is resushed."</seg>
<seg id="1080">Let the wear-cap of your Flexpen always set up if Flexpen is not in use to protect the insulin in front of light.</seg>
<seg id="1081">"as Actraphanae looks and content of the package The injection, is called murky, white, acqueous Suspension in packs of 1, 5 or 10 Complete to each 3 ml."</seg>
<seg id="1082">"manufacturer The manufacturer can be identified by the batch name, which is printed on the whip of the carton and on the label, identified:"</seg>
<seg id="1083">"275 • Falls on the second and third place of the Charge term W5, S6, P5, K7 or ZF appears, the manufacturer Novo Nordisk, SAS, 45, Avenue d'Orléans, F- 28002 Chartres, France."</seg>
<seg id="1084">"B filling the prey between positions 1 and 2 twenty times and off, so that the glass ball from one end of the cartridge moves to the other."</seg>
<seg id="1085">"move the production of at least 10 times between positions 1 and 2, and from until the liquid has been uniform and decayed."</seg>
<seg id="1086">"• To reduce the risk of accidental veneer, never put the inner envelope again on the injection-needle, after having taken them once."</seg>
<seg id="1087">279 G Hold you the Flexpen with the injector to the top and knock a few times with the finger easily against the cartridge so that existing air bubbles will gather in the cartridge up.</seg>
<seg id="1088">The dose can be corrected either as well as down below by turning the dosage pre-optionally in the appropriate direction until the correct dose compared to mark the ad is displayed.</seg>
<seg id="1089">"this document is a summary of the European Public Inquiry report (EPAR), in which explains how the Committee for Humanarzs (CHMP) has been judged to identify recommendations concerning the application of the drug."</seg>
<seg id="1090">"the quartz effective component in Actrapid, insulin human (rDNA), is produced with the procedure of the so-called" recombinant technology ":"</seg>
<seg id="1091">(44-20) 74 18 84 00 Fax (44-20) 74 18 86 68 E-mail: mail @ emea.europa.eu http: / / www.emea.europa.eu © EMEA 2007 Reproduction and / or distribution of this document is called for non commercial Purposes only provided by the EMEA is How was Actrapid examined?</seg>
<seg id="1092">"Actrapid may not be applied in patients, which may be hypersensitive to insulin human (rDNA) or one of the other components."</seg>
<seg id="1093">"furthermore, the doses of Actrapid may need to be adapted if it is administered together with a number of other medicines that can impact on blood sugar."</seg>
<seg id="1094">October 2002 the European Commission shared the Novo Nordisk A / S for acquiring Actrapid in the entire European Union.</seg>
<seg id="1095">"when two kinds of insulin mixed, the quantity of the fast acting insulin must be raised, then the amount of the long-acting insulin."</seg>
<seg id="1096">"3 If when changing to Actrapid is necessary for patients to be a dosage adjustment, it can be necessary for the first dosage or in the first weeks or months after the conversion."</seg>
<seg id="1097">"trips that go over several times, the patient should be pointed out to take the advice of his physician because such trips can lead to that insulin and meals are applied to other times or must be taken."</seg>
<seg id="1098">"5 General ailments and complaints at the administration of the nests - Local Transensitivity to the injections while insulin therapy can occur local hypersensitivity (redness, swelling, itching, pain, and hematoma at the injections)."</seg>
<seg id="1099">Diabetic should therefore always be trauma perplexed to have sweets, biscuits or sugar fruit juice from glucagon (0.5 to 1,0 mg) by an intra-muscular or subcutaneous injecting from Glucagon which is given intravenously by the doctor. "</seg>
<seg id="1100">A clinical trial in an intensive course for the treatment of hyperglycaemia (blood sugar over 10 mmol / l) with 204 diabetic patients containing a intravenous Actrapid indued Normoglycaemia (blood sugar 4.8% reduction (8% compared to 4.8%).</seg>
<seg id="1101">"the effect starts within half an hour, the active max is reached within 1.5 to 3.5 hours and the entire operation is about 7 to 8 hours."</seg>
<seg id="1102">Children and young people The pharaokinetic profile of Actrapid was studied at a smaller number (n = 18) diabetic children (aged between 6 and 12 years) and adolescent (aged between 13 and 17 years).</seg>
<seg id="1103">"the data is limited, however, the assumption that the pharmacokinetic profile of children and young people are similar to adults."</seg>
<seg id="1104">Infusion systems with Actrapid in concentrations 0.3 L / ml - 1,0 - i.e. / ml insulin human consumption of 0.7% sodium glucose and 10% D- Glucose with 40 mmol / l Calichloride are stable with use of infusion of polypropylene from polypropylene at room temperature 24 hours.</seg>
<seg id="1105">"11 If when changing to Actrapid is necessary for patients to be a dosage adjustment, it can be necessary for the first dosage or in the first weeks or months after the conversion."</seg>
<seg id="1106">"trips that go over several times, the patient should be pointed out to take the advice of his physician because such trips can lead to that insulin and meals are applied to other times or must be taken."</seg>
<seg id="1107">"13 General ailments and complaints at the administration of the nests - Local Tranlative reaction to the injections while insulin therapy can occur with local hypersensitivity (redness, swelling, itching, pain, and hematoma at the injections)."</seg>
<seg id="1108">Diabetic should therefore always be trauma perplexed to have sweets, biscuits or sugar fruit juice from glucagon (0.5 to 1,0 mg) by an intra-muscular or subcutaneous injecting from Glucagon which is given intravenously by the doctor. "</seg>
<seg id="1109">Children and young people The pharaokinetic profile of Actrapid was studied at a smaller number (n = 18) diabetic children (aged between 6 and 12 years) and adolescent (aged between 13 and 17 years).</seg>
<seg id="1110">"the intravenous application of acetone made of predateens or cartridges should be an exception, and only in situations where no diarrhea are available."</seg>
<seg id="1111">"if the change to Actrapid is necessary for patients to be a dosage adjustment, it can be necessary for the first dosage or in the first weeks or months after switching."</seg>
<seg id="1112">21 diseases of the skin and the shelter - Lipodystrophy In the injections can arise a lipodystrophy if failed to switch the inserting inside the injections.</seg>
<seg id="1113">Children and young people The pharaokinetic profile of Actrapid was studied at a smaller number (n = 18) diabetic children (aged between 6 and 12 years) and adolescent (aged between 13 and 17 years).</seg>
<seg id="1114">29 diseases of the skin and the shelter - Lipodystrophy In the injections can arise a lipodystrophy if failed to switch the inserting inside the injections.</seg>
<seg id="1115">"diseases of the immune system temporal - Urtikaria, Exanthem Very rare - anaphylactic reactions of generic soreness, itching, gastrouninal disorders, angioneuronal disorders, low blood pressure and impotence / awareness."</seg>
<seg id="1116">Children and young people The pharaokinetic profile of Actrapid was studied at a smaller number (n = 18) diabetic children (aged between 6 and 12 years) and adolescent (aged between 13 and 17 years).</seg>
<seg id="1117">"diseases of the immune system temporal - Urtikaria, Exanthem Very rare - anaphylactic reactions of generic soreness, itching, gastrouninal disorders, angioneuronal disorders, low blood pressure and impotence / awareness."</seg>
<seg id="1118">38 A clinical trial in an intensive course for the treatment of hyperglycaemia (blood sugar over 10 mmol / l) with 204 diabetics and 1344 non-diabetic patients containing a intravenous Actrapid indued Normoglycaemia (blood sugar 4.8% compared to 4.8%).</seg>
<seg id="1119">"diseases of the immune system temporal - Urtikaria, Exanthem Very rare - anaphylactic reactions of generic soreness, itching, gastrouninal disorders, angioneuronal disorders, low blood pressure and impotence / awareness."</seg>
<seg id="1120">"46 A clinical trial in an intensive course for the treatment of hyperglycaemia (blood sugar over 10 mmol / l) with 204 diabetic patients, which has been subjected to larger surgical interventions (blood sugar 4,4 - 6,1 mmol / l) reduced to 42% reduced (8% compared to 4.8%)."</seg>
<seg id="1121">Store in the refrigerator (2 ° C - 8 ° C) Not Enfrighten the flow of water in the envelope to protect the content from light after quarry: not in the fridge or over 25 ° C</seg>
<seg id="1122">Subcutaneous application Penfill cartridges are intended for use with Novo Nordisk Drives systems provided Packagapid Penfill may only be used by one person</seg>
<seg id="1123">Stored in the refrigerator (2 ° C - 8 ° C) Not Enfreeze The cartridge in carton to protect the contents from light to protect: not in the fridge or over 30 ° C</seg>
<seg id="1124">Subcutaneous application of use with Actrapid NovoLet's NovoFine injection molds provided Packagapid NovoLet's only be used by one person</seg>
<seg id="1125">Stored in the refrigerator (2 ° C - 8 ° C) Not to protect light from the quarry: not in the fridge or over 30 ° C</seg>
<seg id="1126">Subcutaneous application of use with Actrapid InnoLet's NovoFine S injectors provided Packagapid InnoLet's only be used by one person</seg>
<seg id="1127">"this means that about half an hour after you have applied it, your blood sugar begins to sink and that the effect is about 8 hours."</seg>
<seg id="1128">► please check the label 'label' whether it is about the right insulin type. ► desinfect the rubber compound with a medical Tupid.</seg>
<seg id="1129">"if this is not completely wrong, if you get the tear-bottle to your pharmacy, if it was not correctly retained or frozen (see 6 How is Actrapid) if it does not clear the water and colourless."</seg>
<seg id="1130">Use the injection technique that has recommended your doctor or your diabetesberaterin recommended ► Let the injecting needle at least 6 seconds long under your skin to ensure that the whole dose was injected.</seg>
<seg id="1131">"83 tell your relatives, friends and close workmates that they bring you in the event of a awareness into the stable side situation and immediately leave a doctor."</seg>
<seg id="1132">They may have a very rare heavy allergic reaction to Actrapid or one of its components (a so-called systemic allergic reaction).</seg>
<seg id="1133">The injection solution is considered as clear as a clear, colorful solution in packs of 1 or 5 perch bottles to each 10 ml or a bundling with 5 mt. from 10 ml to each 10 ml. "</seg>
<seg id="1134">"89 Sign your relatives, friends and close workmates that they bring you in case of awareness in the stable side situation and immediately give a doctor."</seg>
<seg id="1135">"please check the label, whether it is the correct insulin type, check the cartridge including the rubber colbens (stopover)."</seg>
<seg id="1136">"► in insulin infusion pumps, if the penfill or the device, which has been abandoned, damaged or falsified; there is the danger of extinction of insulin, if it was not correctly retained or frozen (see 6 How is Actrapid to retain?), if it does not clear the water and colourless."</seg>
<seg id="1137">"if you need to be treated with Actrapid Penfill and another insulin in osfill cartridges, you should use two insulin objects, each one for each insulin type."</seg>
<seg id="1138">Use the injection technique that has been advised your doctor or your diet systems in order to ensure that the full dosage was injected at least 6 seconds long under your skin to ensure that the full dose is injected to the injecting and to unlocking the injector without upted injecting needle.</seg>
<seg id="1139">"- If in the second and third place of the Charge's name, the charcombination W5, S6, P5, K7 or ZF appears, the manufacturer Novo Nordisk A / S, Novo Allé, DK-2880 Bagsvaerd, Denmark"</seg>
<seg id="1140">"in case of the second and third place of the Charge term the charcombination of H7 or T6 appears, the manufacturer Novo Nordisk Production SAS, 45, Avenue d" Orléans, F- 28002 Chartres, France. "</seg>
<seg id="1141">Oral antidiabetic (for example), monoidal anti-inhibitor (MAO-Hemmer), anangiotensin- Converting-enzymes, anti-acid-steroids, anasympathomimetics, growth hormones, Danazol, Octreotid or Lanreotid. "</seg>
<seg id="1142">► How to review by using the label 'whether it is about the right insulin type. you always use any injecting a new injecting to avoid an contamination.</seg>
<seg id="1143">"► in insulin infusion pumps ► when the NovoLet dropped, damaged or disrupted; there is the danger of extinction of insulin, if it was not correctly retained or frozen (see 6 How is Actrapid to retain?), if it does not clear the water and colourless."</seg>
<seg id="1144">This can happen: • If you need too much insulin injecting if you want to eat too little or meal a meal • If you are more than otherwise physically tense</seg>
<seg id="1145">"let the wear cap of your NovoLet production still set, if it is not in use to protect him from light."</seg>
<seg id="1146">Take the exhaust pipe from. • Desininfecting the rubber compound of a new injection-needle to avoid a contamination from a NovoFine injection. • Remove the large outer cap of the injecting needle and the inner cap of the injection-needle.</seg>
<seg id="1147">Just go to avoid the injection of air and to ensure a correct dosage: • Hold you Actrapid NovoLet with the injector to the top • Klopate a few times with the finger easily against the cartridge.</seg>
<seg id="1148">"if airbubbles are present, this will keep up in the cartridge if you keep the injecting next to the top, turn the cartridge up in the direction of the arrow (illustration B) • During the injector next to the top, press the button down to the top of the injection-needle a drop in insulin."</seg>
<seg id="1149">• Set the wear board back so on the finished pen that the number 0 is shown in front of the dosing brand (figure D) • control if the press knob is pushed into.</seg>
<seg id="1150">"if the button knob can not move freely, insulin from the injecting is pressed • The scale is shown on the map, 2, 4, 6, 8, 10, 12, 14, 16 and 18 units."</seg>
<seg id="1151">"the button-button moves to the outside while you turn the wear cap • The scale under the pushbutton-button (pushbutton-button) shows 20, 40 and 60 units."</seg>
<seg id="1152">"107 • Record the highest number you can see on the button knocked away • If you have set a false dose, turn the wear cap simply forward or backwards until you have set the right number of units."</seg>
<seg id="1153">"turn it up until the button knob down and you feel a resistance, then take the wear cap and put them back on that the 0 of the dosing brand is opposite."</seg>
<seg id="1154">Be sure to press only during the injections to press knob • Keep the pushbutton after the injecting quite in-pressed until the injecting needle was drawn from the skin.</seg>
<seg id="1155">"it may possibly be inaccurate, you can not set a dose which is higher than the number of remaining units sold in the cartridge units • You can use the Restmengenala to be used as much insulin still remaining, but you cannot use it to stop your dose or select it."</seg>
<seg id="1156">Oral antidiabetic (for example), monoidal anti-inhibitor (MAO-Hemmer), anangiotensin- Converting-enzymes, anti-acid-steroids, anasympathomimetics, growth hormones, Danazol, Octreotid or Lanreotid. "</seg>
<seg id="1157">"► in insulin infusion pumps ► when the Innolet dropped, damaged or disrupted; there is the danger of extinction of insulin, if it was not correctly retained or frozen (see 6 How is Actrapid);) if it does not clear the water and colourless."</seg>
<seg id="1158">Let the wear-cap of your InnoLet production still set up if he is not in use to protect him from light.</seg>
<seg id="1159">• Desdisinfect the rubber compound with a medical Tupid • Bench you always for any injecting a new injecting crane straight and firm on Actrapid InnoLet (Illustration) • Pull the large outer cap of the injection-needle and the inner cap of the injection-needle.</seg>
<seg id="1160">"the dose-regulator turns out to zero and you listen to the injection, the injecting must not block after injecting at least 6 seconds while injecting the dosage adjustment to zero, as the doser glers must push to zero if you press the injector, after each injection."</seg>
<seg id="1161">Oral antidiabetic (for example), monoidal anti-inhibitor (MAO-Hemmer), anangiotensin- Converting-enzymes, anti-acid-steroids, anasympathomimetics, growth hormones, Danazol, Octreotid or Lanreotid. "</seg>
<seg id="1162">121 ► when it has not been stored properly or frozen (see 6 How is Actrapid to retain?) ► if it does not look like water and colourless.</seg>
<seg id="1163">"if one of the above-side effects you have considerably affected or you notice unwanted effects which are not specified in this usage information, please inform your doctor, your diabetesberlantern or your pharmacist."</seg>
<seg id="1164">"let the wear cap of your Flexpen finished, if it is not in use to protect him from light."</seg>
<seg id="1165">F Hold you the Flexpen with the injector to the top and knock a few times with the finger easily against the cartridge so that the existing air bubbles will gather in the cartridge up.</seg>
<seg id="1166">The dose can be corrected either as well as down below by turning the dosage pre-optionally in the appropriate direction until the correct dose compared to the marker of the Dosisence.</seg>
<seg id="1167">"Adenuric is used in patients having previously used signs of crystallaggradation, including arthritis (pain and inflammation in joints) or gases in joints."</seg>
<seg id="1168">"if the urethinner is still over 6 mg per deciliter, the dose can be increased once every day 120 mg every day."</seg>
<seg id="1169">"during the first treatment options, the patients can still occur and is therefore recommended that patients are at least during the first six months of treatment with Adenuric, additional medicines for contraception of gases."</seg>
<seg id="1170">"the drug is not recommended in children and in patients who had an organtransplant, as it was not examined for these groups."</seg>
<seg id="1171">"in the first study, at the 1 072 patients participating, the effectiveness of three different adenuric disparities (once daily 80, 120 and 240 mg) were compared with the one placebo (searchmeditations) and from Allopurinol (another drug for the treatment of hyperurikemia)."</seg>
<seg id="1172">"in the second study, two doses of Adenuric (once daily 80 and 120 mg) were compared to 762 patients each with Allopurinol."</seg>
<seg id="1173">In both studies Allopurinol was applied in a dose of once daily 300 mg; patients with kidney problems received only 100 mg per day.</seg>
<seg id="1174">Main indeer for the effectiveness was the number of patients whose urinary tract in the blood at the last three measurements collected under 6 mg / dl.</seg>
<seg id="1175">"in the first study, 48% (126 of 262) of patients, the adenuric was captured in a dose of once daily 80 mg, and 65% (175 from 269) of patients who took once daily 120 mg, with the last three measurements a urinary tract in the blood of under 6 mg / dl."</seg>
<seg id="1176">"in comparison to this, this was about 22% (60 of 268) of patients with Allopurinol and none of the 134 patients under placebo on the case."</seg>
<seg id="1177">"the most common side effects of adenuric (observed in 1 to 10 of 100 patients) are headaches, diarrhea, nausea (nausea), rash and normal liver enzymes."</seg>
<seg id="1178">"especially in patients with heart bodies, there may also be an increased risk of certain side effects that affect the heart and blood vessels."</seg>
<seg id="1179">"the Committee on Humanarztorial (CHMP) led to the conclusion that Adenuric was more effective in lowering the urinary tract in the blood than Allopurinol, but there could also be a higher risk of side effects associated with the heart and blood vessels."</seg>
<seg id="1180">"the treatment of chronic hyperurikemia in diseases, which have already led to Uratablaggradations (including one of the medical history known or current present gags, and / or a Gichtarsoon)."</seg>
<seg id="1181">If the serum harshssodium after 2-4 weeks still &gt; 6 mg / dl (357 µmol / l) can be considered a dosage increase on ADENURIC 120 mg 1 x daily into consideration.</seg>
<seg id="1182">In patients with severe kidney charges the effectiveness and safety were not fully examined (Creatinin- Clearance &lt; 30 ml / min, see Section 5.2). "</seg>
<seg id="1183">Children and young people there are no experiences with children and young people who are not recommended using Febuxostat in this patient group.</seg>
<seg id="1184">"organtransplants" "As there is no experience with organtransplants, the application of Febuxostal is not recommended in this patient group (see Section 5.1)."</seg>
<seg id="1185">Cardiovascular diseases in patients with metastatic coronary heart disease or decompensated heart disease is not recommended (see Section 4.8).</seg>
<seg id="1186">"as with other hard-saving medicines, it may occur during the treatment commenced to a acute tightening, because by lowering the serum sisodium turespiegels first can be mobilised in the tissues."</seg>
<seg id="1187">"B. in maligning diseases and their treatment, Lesch- Nyhan-syndrome), the absolute concentration of Xanthin in the urine often appears so far, that it comes to a derivative in the urinary tract."</seg>
<seg id="1188">Liver diseases During the clinical trials of phase 3 were observed slight removal of liver transplant in working with Febuxostate patients (3.5%).</seg>
<seg id="1189">It is therefore recommended to perform before starting the Febuxostator and further course depending on clinical trials for a liver tumour (see Section 5.1).</seg>
<seg id="1190">Theophylline Zs was not performed any intereffective studies on Febuxostasis but it is known that the XO inhibitors can lead to a rise of theophylapse. it was also reported for other XO inhibitors.</seg>
<seg id="1191">In Probanden the simultaneous gift of Febuxostat and Naproxen 250 mg 2 x daily with a rise in Febuxostature (Cmax 28%, AUC 41% and t1 / 2 26%). "</seg>
<seg id="1192">In clinical trials the application of nroxen or other NSAR / Cox-2 inhibitors were not related to a clinically significant increase of unwanted events.</seg>
<seg id="1193">Colosin / Indometacin / Hydrochlorthiazid / Warfarin Febuxostat can be used together with colosin or Indometacin with without that a dosage adjustment for Febuxostat or the same at the same time invalid other substance is required.</seg>
<seg id="1194">"in a study with Probanden 120 mg ADENURIC 1 x every day a mean 22% increase in AUC of Desipramine, a CYP2D6 substrate, indicating a possible weak inhibitory effect of Febuxostat on the CYP2D6 enzyme in vivo."</seg>
<seg id="1195">"Antazida It could be shown that the simultaneous intake of an antacid, the magnesium hydroxide and aluminum hydroxide contains about 1 hour) delay and a decrease in the Cmax around 32%, but no significant change in AUC."</seg>
<seg id="1196">Pregnancy data on a very limited number of exponated pregnancies can not be shown on side effects of Febuxos at pregnancy or the health of Fetus / newborns.</seg>
<seg id="1197">"animal experimental studies do not leave a direct or indirect effect on pregnancy, embryonic / fetal development or birth (see Section 5.3)."</seg>
<seg id="1198">Patients should be cautious on the taxes of a vehicle to be careful of machines or in the exercise of dangerous activities until they may be reasonably secure that ADENURIC is not influenced their performance.</seg>
<seg id="1199">A numerically higher incidence of the test reported in cardiovascular disease was observed in the pivotal study group in the pivotal study group (1.9 versus 0.3 events per 100 patient years) and in long-term - extension studies (1.9 versus 0.3 events per 100 patient years) and no causal relationship with Febuxostasis could be found.</seg>
<seg id="1200">The risk factors in these patients were an artericlerotic disease and / or a myocardinal or a decompensated heart failure in the hospital.</seg>
<seg id="1201">"frequent (&gt; &gt; &gt; &gt; &gt; 1 / 100 to &lt; 1 / 10), occasional (&gt; &gt; 1 / 1,000 to &lt; 1 / 1,000) side effects that could occur in the treatment groups with 80 mg / 120 mg Febuxan and the (examiner-evaluation) in connection with the drug and in all Febuxtionate treatment groups, are listed below."</seg>
<seg id="1202">"diarrhea, nausea and vomiting are more common in patients who are treated at the same time with Colonies. * * In clinical trials, there were no serious rash or serious surviving actions."</seg>
<seg id="1203">"7 Offene long-term extension studies in the open longtime extension studies have been treated 906 patients up to 1 year long, 57 patients up to 3 years and 53 patients with Febuxostat 80 mg / 120 mg long."</seg>
<seg id="1204">"during the long-term - extension studies reported in-related events, those were similar to which were reported in the studies of phase 3 (see table 1)."</seg>
<seg id="1205">The following treatment related events were reported in all Febuxostat- treatment groups in total more than once and occurred in patients who received Febuxostat 80 mg / 120 mg in long term renewal studies (up to 4 years with a exposure time of &gt; 1.900 patient years).</seg>
<seg id="1206">The following treatments related events were either reported at the pivotal studies of the Phase 3 for these doses either not at all or with a lower frequency:</seg>
<seg id="1207">"diabetes, hyperlipidemia, sleeplessness, squabs, malignity, skin watchiness, malnourishment, rash, rise of potassium concentration in the blood, decrease in lymphocytes, decrease in the number of white blood cells."</seg>
<seg id="1208">Wirth mechanism of uric acid is the endproduct of Purinmetabolic process and is created within the framework of the Reaction skaskade Hypoxanthin → Xanthin → uric acid.</seg>
<seg id="1209">"Febuxostat is a powerful, non-selective Inhibitor of XO (NP-SIXO) with a Ki-value for the in vitro-shirts, which is below the nanomolar area."</seg>
<seg id="1210">"clinical study results The effectiveness of ADENURIC was conducted in two pivotal studies of phase 3 (APEX study and Fact study such as described below), which were conducted using 1.832 patients with hyperurikemia and gout."</seg>
<seg id="1211">The primary efficacy point was in every study the share of patients with which the last three months given certain Serumharnsäurespiegel &lt; 6.0 mg / dl (357 µmol / l) were.</seg>
<seg id="1212">"placebo (n = 134), ADENURIC 80 mg 1 x daily (n = 269), ADENURIC 240 mg 1 x daily (n = 10) for patients with a serrate of study of &gt; 1.5 mg / dl and ≤ 2,0 mg / dl."</seg>
<seg id="1213">The APEX study showed significant superiority both with ADENURIC 80 mg 1 x daily and with ADENURIC 120 mg 1 x daily compared to the treatment with conventional used cans Allopurinol 300 mg (n = 10) / 100 mg (n = 10).</seg>
<seg id="1214">The Fact study showed significant superiority both in the treatment with ADENURIC 80 mg 1 x daily as well as with ADENURIC 120 mg 1 x daily with conventional used dose Allopurinol 300 mg.</seg>
<seg id="1215">Patients with Serum Creatininvalues &gt; 1.5 and ≤ 2.0 mg / dl) or 300 mg 1 x daily (n = 509) were processed for analysis. * p &lt; 0.001 versus Allopurinol that # p &lt; 0.001 versus 80 mg</seg>
<seg id="1216">The reduction of serpharnsäurespiegels on &lt; 6,0 mg / dl (357 µmol / l) was observed on the doctor visit in week 2 and keep permanently kept throughout the treatment.</seg>
<seg id="1217">509 patients received Allopurinol 300 mg 1 x daily; 10 patients with servomotatininassets &gt; 1.5 and &lt; 2,0 mg / dl received 100 mg 1 x daily.</seg>
<seg id="1218">Primary endpoint in the subgroup of patients with kidney-functions and the APEX study evaluated the effectiveness in 40 patients with kidney function.</seg>
<seg id="1219">With ADENURIC the primary efficacy point of 44% (80 mg 1 x daily), 45% (120 mg 1 x daily) and 60% (240 mg 1 x daily) of patients achieved. "</seg>
<seg id="1220">There were no clinically significant differences with regard to percentage of serotonin retenants in specimens where their kidney function (58% in the group with normal kidney function and 55% in the group with severe kidney disease).</seg>
<seg id="1221">Primary endpoint in the subgroup of patients with serum harsself-concentration &gt; 10 mg / dl Etwa 40% of patients (APEX- and Fact study) had a serum hardening of &gt; &gt; 10 mg / dl.</seg>
<seg id="1222">The data collected in two years collected from the open renewal study of phase 3 showed that the continued reduction of incidence of gases were found on &lt; 6 mg / dl (&lt; 357 µmol / l) a decrease of incidence of gases (d. h. more than 97% of patients required no treatment against a gelling club).</seg>
<seg id="1223">"this was associated with a reduction of gout nozzle size, which at 54% of patients had a complete disappearance of the seal until month 24."</seg>
<seg id="1224">Increased TSH- values (&gt; 5.5 µIE / ml) were observed in patients who received a long-term treatment with Febuxostasis (5.5%) in the open longtime extension studies (see Section 4.4).</seg>
<seg id="1225">In healthy probanden the maximum Plasmakoncentations (Cmax) and the area under the Plasmakoncentric Time-Curve (AUC) from Febuxostat to administration more simple and multiplers doses of 10 mg to 120 mg dosages.</seg>
<seg id="1226">"for doses between 120 mg and 300 mg, it is observed for Febuxostat a rise in AUC, which is greater than the dosages."</seg>
<seg id="1227">"after taking simple or multi-multiple doses of 80 and 120 mg 1 x daily, the Cmax is about 2.8-3.7 µg / ml and 5,0-5,3 µg / ml."</seg>
<seg id="1228">"however, there was no clinically significant change in the percentage decrease of serum harsement concentration, provided that this has been tested (multiple doses of 80 mg)."</seg>
<seg id="1229">Distribution The apparent Steady state distribution (Vpp / F) of Febuxostat is located in the range from 29 to 75 l after ingesting cans of 10-300 mg.</seg>
<seg id="1230">"the plasma consumption of Febuxostat is about 99,2% (primary bond to Albumin) and is accessible via the concentration of concentration, which is achieved with doses of 80 and 120 mg."</seg>
<seg id="1231">"in vitro-studies of human liver-microsomen showed that this oxidative Metabolites were primarily formed by CYP1A1, CYP1A2, CYP2C8 or CYP2C9, and that Febuxostatglucuronid originates mainly through UGT 1A1, 1A8 and 1A9."</seg>
<seg id="1232">"after taking a 80 mg dose of 14C-marked Febuxan, about 49% of the dose in urine was considered unchangeable Febuxos (3%), Acylair stimulates (13%), whose well-known oxidative Metabolites and their conjugate (13%), as well as further unknown Metabolites (3%)."</seg>
<seg id="1233">"in addition to excretion over the urine we found approximately 45% of the dose in chair as unchangeable Febuxos (12%), Acylair stimulates (1%), whose well-known oxidative Metabolites and their conjugate (25%), as well as further unknown Metabolites (7%)."</seg>
<seg id="1234">Special patient groups kidney insufficiency After the intake multiplers doses of 80 mg ADENURIC in patients with mild, moderate or severe kidney insufficiency, the Cmax of Febuxos did not change compared to normal kidney function. "</seg>
<seg id="1235">The mean total-AUC of Febuxostat took about the 1.8-fold from 7,5 μ g ⋅ h / ml in the group with normal kidney function on 13.2 μ g ⋅ h / ml in the group with severe kidney endysfunction.</seg>
<seg id="1236">12 Leberre-dysentanglement After stops multipler cans of 80 mg ADENURIC in patients with mild (Child- Pugh Classification A) or intermediate (Child-Pugh Classification A) or intermediate (Child-Pugh-classification B) is not changing the Cmax and AUC of Febuxostat and its Metabolites not significantly compared to prophylactic function.</seg>
<seg id="1237">Age There were no significant changes in terms of AUC from Febuxostat or its Metabolites following ingesting multiplomas from ADENURIC in older patients compared to younger persons.</seg>
<seg id="1238">"carcinogenesis, mutagenesis, impairment of fertilisation At male rats has been a statistically significant increase in uranium rocks (transitional cell and carcinome) only in connection with Xanthin stones used in the highly regarded group, with approximately the 11-fold of exposure to humans, found."</seg>
<seg id="1239">These findings are seen as a result of a specific Purinmetabolic harmonisation and urine composition and for clinical use as not relevant.</seg>
<seg id="1240">It was established that Febuxostasis in oral doses of up to 48 mg / kg / day no effect on the fertilisation and reproductive capacity of male and female rats.</seg>
<seg id="1241">"at high doses, which were approximately at 4.3 of the human therapeutic exposure, entered maternal toxicity, which went into with a reduction of rising performance and a development delay in the descendants of rats."</seg>
<seg id="1242">"teratological studies in lecturers with exposure, which approximately the 4,3-fold and with trageous rabbits with expositions that are approximately the 13-fold of human therapeutic exposure, takes no teratogenic effects."</seg>
<seg id="1243">Colosin / Indometacin / Hydrochlorthiazid / Warfarin Febuxostat can be used together with colosin or Indometacin with without that a dosage adjustment for Febuxostat or the same at the same time invalid other substance is required.</seg>
<seg id="1244">"diarrhea, nausea and vomiting are more common in patients who are treated at the same time with Colonies. * * In clinical trials, there were no serious rash or serious surviving actions."</seg>
<seg id="1245">"21 Offene long-term extension studies in the open longtime extension studies have been treated 906 patients up to 1 year long, 57 patients up to 3 years and 53 patients with Febuxostat 80 mg / 120 mg long."</seg>
<seg id="1246">The primary efficacy point was in every study the share of patients with which the last three months given certain Serumharnsäurespiegel &lt; 6.0 mg / dl (357 µmol / l) were.</seg>
<seg id="1247">The data collected in two years collected from the open renewal study of phase 3 showed that the continued reduction of incidence of gases were found on &lt; 6 mg / dl (&lt; 357 µmol / l) a decrease of incidence of gases (d. h. more than 97% of patients required no treatment against a gelling club).</seg>
<seg id="1248">"26 as immutable Febuxostasis (3%), Acylair curve of the drug (30%), whose well-known oxidative Metabolites and their conjugates (13%), as well as further unknown Metabolites (3%)."</seg>
<seg id="1249">Liver dysfunctions after taking multipler doses of 80 mg ADENURIC in patients with mild (Child- Pugh Classification A) or intermediate (Child-Pugh Classification A) or indirectly (Child-Pugh-classification B) and its Metabolites did not significantly increase compared to probabilities with normal liver function.</seg>
<seg id="1250">"carcinogenesis, mutagenesis, impairment of fertilisation At male rats has been a statistically significant increase in uranium rocks (transitional cell and carcinome) only in connection with Xanthin stones used in the highly regarded group, with approximately the 11-fold of exposure to humans, found."</seg>
<seg id="1251">"the holder of permission for the transport system has assured that a pharmacopovigilance system described as in version 2.0 module 1.8.1 of the authorisation application is prepared before the drug is placed in the traffic, and as long as the drug is brought to the traffic."</seg>
<seg id="1252">A updated network is present in accordance with CHMP Guideline to risk management systems for human medicines with the next period odic Safety Update Report (PSUR).</seg>
<seg id="1253">"in addition, an update of the RMP requires when new information is available, which have an effect on the safety information, the pharmacovigilance plan or activities to risk minimization (Pharmacovigilance or risk minimization) • on request of the EMEA</seg>
<seg id="1254">"in some people the uric acid in the blood and can achieve concentrations, which are so high that uric acid is insoluble."</seg>
<seg id="1255">"if you keep the uretic-concentration by the 1 x daily intake of ADENURIC, the crystallisation is prevented and achieved in this way with the time a minimization of complaints."</seg>
<seg id="1256">ADENURIC must not be taken - if you are hypersensitive (allergic) against the substance Febuxan or one of the other components of ADENURIC.</seg>
<seg id="1257">"inform your doctor before starting with the intake of this medication, when you have a heart disease or had to suffer or at any other heart problem. • If you are suffering because of a high urinary disease or the Lesch-Nyhan-Syndroms (a rare innate disease that is dealt with too much uric acid in the blood)."</seg>
<seg id="1258">"if you have a stroke of heavy pain, pressure-sensitivity, redness, heat strength and joint swing), wait until the gaskfall before you start treatment with ADENURIC."</seg>
<seg id="1259">"this does not have to be in any way, but could also occur with you, especially during the first treatment weeks or - monate, occur if you are ADENURIC."</seg>
<seg id="1260">Your doctor will be prescribing you in need for other medicines to treat an attack case or to treat the associated symptoms (such as pain and joint swelling).</seg>
<seg id="1261">"please inform your doctor or a pharmacist, if you are taking other medicines / use or have recently taken / applied, even if it is not prescription drugs."</seg>
<seg id="1262">"it is especially important that you can use your doctor or pharmacist, if you are taking medicines / apply necessary measures, as interactions with ADENURIC (for the treatment of cancer) • Azathioprin (for the treatment of asthma) • warfarin (for treatment of asthma) • Warfarin (for treating asthma)"</seg>
<seg id="1263">There were no studies on the effects of ADENURIC on the road safety and ability to serve machinery.</seg>
<seg id="1264">"please take ADENURIC therefore only after consultation with your doctor, if you know is that you suffer from a intolerance towards certain sugars."</seg>
<seg id="1265">"on the back of the blister packs the single weekdays are printed, so you can check if you have taken a tablet every day. • The tablets need to be taken up and can be taken with or without food."</seg>
<seg id="1266">"if you are intentionally taken an overdose, please contact your doctor or the staff of the next hospital hospital."</seg>
<seg id="1267">"if you have forgotten the intake of ADENURIC, you will get it as soon as possible, unless the next intake is just before."</seg>
<seg id="1268">"when you demolish the intake of ADENURIC, your urinary tract can rise again, and your complaints can worsen because new Uratcrystals can form in your joints and kidneys as well as their environment."</seg>
<seg id="1269">"frequent side-side effects (more than 1 of 100 treated, but less than 1 of 10 untreated): • Contract • headaches • rash • nausea</seg>
<seg id="1270">"rare side effects (more than 1 of 10,000 treated, but less than 1 of 1,000 treated): • weakness • Nervousness • Durduke"</seg>
<seg id="1271">"please inform your doctor or a pharmacist, if any of the listed side effects you have considerably affected or you notice unwanted side effects which are not listed in this usage information."</seg>
<seg id="1272">ADENURIC is available in 2 versions with 14 tablets (pack with 28 tablets) or in 6 blister packs of each 14 tablets (package with 84 tablets).</seg>
<seg id="1273">Бълария Adamsen Pharma 24 rue Erlanger F-75781 Paris Cedex 16 France Tél: + 33 - 1 - 44 96 13 13</seg>
<seg id="1274">Danmark, Norge, Suomi / Finland, Sverige, Ísland Institut Färögatan 33 SE - 164 51 Kista Sverige / Rudi / Sími / Sími / Sími / Sími / Sími: + 46 8 588 370 70 "</seg>
<seg id="1275">"ADROVANCE is used for the treatment of osteoporosis (a disorder where the bone coerous) are used in women after menopause, where there is a risk of low vitamin D mirror."</seg>
<seg id="1276">"the patient has to take the tablet with a full glass of water (no mineral water) at least 30 minutes before eating, drinking, or taking other medicines (including antacids, calcium, and vitaminsupplements)."</seg>
<seg id="1277">"to avoid a irritation of the esophagus, the patient may follow up after the first food intake of the day, the earliest 30 minutes after taking the tablet should not lie down."</seg>
<seg id="1278">"as Alendronage and vitamin D3 are already separated from each other in medicinal products, the company placed data from previous studies and the published literature."</seg>
<seg id="1279">The company also led a study with 35 men and 682 postmenopausal women with osteoporosis to prove the effectiveness of ADROVANCE in terms of increasing the vitamin D spy.</seg>
<seg id="1280">"after a 15-week treatment, the proportion of patients with low vitamin D mirror was treated with the patient which were treated with ADROVANCE (11%) than those who recorded only Alendronat (32%)."</seg>
<seg id="1281">"the company also laid out data that in ADROVANCE enthused Alendronat dosage, exactly the dose which is required for preventing a bone loss."</seg>
<seg id="1282">"the most common side effects (observed in 1 to 10 of 100 patients) are headaches, pain of musculoskeletal (muscles, bones or joints) and symptoms of the digestive apparatus (digestive disorders), sorcence (digestive disorders), sorceries (digestive disorders), sorceries (digestive disorders), sorcereal, dysphagie (lymph), onated abdomes (broken stomach) as well as sauerres."</seg>
<seg id="1283">In patients with any hypersensitivity (allergy) against Alendronage, vitamin D3 or one of the other components may not be used as ADROVANCE. "</seg>
<seg id="1284">It must not be applied in diseases of the esophagus; in patients with hypocalcemia (low calcium levels) or in patients who cannot stand alone for at least 30 minutes.</seg>
<seg id="1285">January2007 the European Commission shared by Merck Sharp & Dohme Ltd. approve permission for the transport of ADROVANCE in the entire European Union.</seg>
<seg id="1286">"capsule shaped, white to broken white tablets, marked with the outline of a button on the one side and" 710 "on the other side."</seg>
<seg id="1287">"ADROVANCE is only with water (not with mineral water) at least 30 minutes before the first food, drink or taking part of drugs (including antacids, calcium, and vitamine complementary resources) for the day."</seg>
<seg id="1288">The following references are exactly to follow to reduce the risk of esophageal irritation and associated side effects (see Section 4.4):</seg>
<seg id="1289">"• ADROVANCE should be swallowed after the arrival of the day only with a full glass of water (at least 200 ml), as a risk for oropharyngeal ulcera. • The patients should not take place before the first food intake of the day, the earliest 30 minutes after taking the tablet."</seg>
<seg id="1290">"B. peptic Ultimo, active gastrounale bleeding or surgical interventions in the upper Gastroleinaltract except Pyloroplasty, are given only under special caution (see Section 4.3)."</seg>
<seg id="1291">"eco-sophism, such as Ösophism, ösophageal ultsa and ösophageal erosion, were rare in patients under the ingestion of Alendronat (partly were these severe and required a hospital instruction)."</seg>
<seg id="1292">"the doctor should therefore draw attention to all signs and symptoms that will point out on possible arterophageal reactions, and patients should be pointed out at the appearance of symptoms of irritation, or retrosprimal pain or new or merged pain solves (see Section 4.8)."</seg>
<seg id="1293">"3 The risk of severe punishment side effects appears to be increased in patients who do not take correctly correctly and / or after the occurrence of symptoms that point to an ösophageal irritation."</seg>
<seg id="1294">It is very important that all dosing assignments will be passed on to the patient and be understood by the patient (see Section 4.2).</seg>
<seg id="1295">"during large, clinical trials with Alendronat no increased risk has been determined, rarely (according to launch) gastric and Duodenalulzera, including some severe and with complications, reported (see Section 4.8)."</seg>
<seg id="1296">"Osteonekrose of the Kieffer, usually associated with a tooth extraction and / or a local infection (including Osteomyelitis), was reported in cancer patients, whose therapist stands predominantly intravenously administered Bisphosphonate."</seg>
<seg id="1297">"there are no data available to provide information about whether the sealing of a Bisphosphonattherapy for patients who need a kiefersurgical procedure, which diminished the risk of an osteonecrose of the pending."</seg>
<seg id="1298">The clinical assessment by the care doctor is authoritative of the treatment planning in each patient based on an individual benefit risk assessment.</seg>
<seg id="1299">Patients should be instructed that they should take the cessation of taking a dose of ADROVANCE the tablet next morning after having noticed their omissions.</seg>
<seg id="1300">"you should not take two tablets on the same day, but taking the intake of one tablet per week as originally planned on the weekday."</seg>
<seg id="1301">Other diseases which affect the mineral metabolism (such as vitamin D-lack and hypoparathyresteroids) should be treated before the treatment of therapy with ADROVANCE.</seg>
<seg id="1302">"Alendrones foods and drinks (including mineral water), calcium supplements, antacid and some orale medicines may impair the resorption of alendronat, if they are at the same time."</seg>
<seg id="1303">"therefore, patients after ingestion of Alendronat must wait at least 30 minutes before they take other medicines (see sections 4.2 and 5.2)."</seg>
<seg id="1304">"although specific interactionstudies have not been carried out, Alendronat in clinical trials were taken together with a variety of usually prescribed drugs, without clinically relevant interactions."</seg>
<seg id="1305">ADROVANCE is only intended for use in postmenopausal women and therefore does not apply during pregnancy or impending women.</seg>
<seg id="1306">Animal studies with Alendronat leave no indication of directly damaging effects in terms of pregnancy, the embryonic / fetal or post-natal development. "</seg>
<seg id="1307">Osteonekrose of the jaw was reported in patients under Bisphosphonate; most reports come from cancer patients but was also reported in osteoporosepages.</seg>
<seg id="1308">Still descendant of serum-calcium up to &lt; 8.0 mg / dl (2,0 mmol / l) and the Serum- phosphate up to ≤ 2.0 mg / dl (zone mmol / l) in both treatment groups with similar frequency.</seg>
<seg id="1309">"Alendronat as a result of a oral overdose, Hypocalcemia, hypophosphatemia and side effects in the upper Gastrounaltrakt, like Magenversible, Sodgery, Gastritis or Ulzera."</seg>
<seg id="1310">Colecalciferol (vitamin D3) Vitamin D3 is produced in the skin by UV-light on the conversion of 7-Dehydroje to vitamin D3.</seg>
<seg id="1311">"the main effect of 1,25-Dihydroxyture D3 is the increase in the absence of calcium and phosphate, as well as the regulation of serum calcium, the renal excretion of calcium and phosphate, bone formation and bone resorsion."</seg>
<seg id="1312">"in severe cases, a lack of secondary hyperparathyresteroids, hypophosphatemia, weakness of the proximal muscles and osteomalazie and thus to a further increased risk of falls and bone breakdowns in osteoporot people."</seg>
<seg id="1313">"Bone mineral oil) on spine or hip, the 2.5 standard deviations under the middle value for a normal, young population lies, or regardless of bone density as present pathological fractal."</seg>
<seg id="1314">The patients received ADROVANCE in the lower force (70 mg / 2.800) (n = 350) or FOSAMAX (Alendronat) 70 mg once weekly (n = 332); more vitamin D supplements were prohibited.</seg>
<seg id="1315">After 15-week treatment the middle servings of 25-hydroxyture was significantly higher (26%) in the group under ADROVANCE (70 mg / 2.800)) (56 nmol / l]) than in the group under Alendronat alone (46 nmol / l]).</seg>
<seg id="1316">ADROVANCE (70 mg / 2.800)) reduced to 15 weeks the share of patients with vitamin D-insufficiency (serum value of 25-hydroxyture D &lt; 37,5 nmol / l [&lt; 15 ng / ml]) by 62.5% compared to Alendronat alone (12% vs.</seg>
<seg id="1317">Studies with Alendronat The therapeutic equation of Alendronat once weekly 70 mg (n = 519) and Alendronat 10 mg daily (n = 370) was proved in one-year Multicenter study at postmenopausal women with osteoporosis.</seg>
<seg id="1318">The effects of Alendronat on bone mass and fractinal women were examined in two phase III trials of identical design (n = 944) as well as in the Fracupuncture intervention (FIT: N = 6.459).</seg>
<seg id="1319">In phase III studies the middle sized the BMD with Alendronat 10 mg / day in proportion to placebo after 3 years 8.8% on the spinal column, 5.5% on the femur and 7.3% on the Trochanter. "</seg>
<seg id="1320">"in the group treated with Alendronat, compared to the placebo group a reduction in 48% (Alendronat 3.2% compared to placebo 6.6%) in the proportion of patients, who suffered one or more spinal textures."</seg>
<seg id="1321">"in the two-year extension of these studies, the cradle of the BMD of spine and Trochanter continues to maintain; even the BMD des Femurhalses and the entire body was maintained."</seg>
<seg id="1322">Fit into two plazed trials at which Alendronat daily (5 mg every day for 2 years and then 10 mg daily continue to be taken either over 1 or 2 years):</seg>
<seg id="1323">In this study the daily gift of Alendronat reduced the appearance of at least a new pedacupuncture around 47% (Alendronat 7.3% compared to placebo 15.0%).</seg>
<seg id="1324">Resorption related to a intravenous reference dose was the mean orale Bioveravailability of Alendronat for women ranging% for doses between 5 and 70 mg after the next fasting and two hours before taking a standardised breakfast.</seg>
<seg id="1325">"the bioavailability took place according to some block% and outs% off, when Alendronat one or half an hour before a standardised breakfast was taken."</seg>
<seg id="1326">"in osteoporosis estuary, alendronage was effective if it was taken at least 30 minutes before the first eating or drinking of the day."</seg>
<seg id="1327">"in healthy volunteers, the gift of oral prednison (20 mg three times daily over five days) is not a clinically significant change in the oral bioavailability of Alendronat (increase in funding in the range of 20% to 44%)."</seg>
<seg id="1328">"9 distribution studies in rats have revealed that Alendronage spread to intravenous gift of 1 mg / kg temporarily in soft parts, but then quickly distributed in the bones or by the judgment."</seg>
<seg id="1329">Excretion after intravenous gift of a single dose of 14C-Alendronat were around 50% of radioactive substance within 72 hours with the urine leased and little or no radioactivity was found in the feces.</seg>
<seg id="1330">"after intravenous gift of a single dose of 10 mg, the renal clearance was made of Alendronat 71 ml / min and the systematic clearance is not 200 ml / min."</seg>
<seg id="1331">"Alendronat is not detoxen in rats, not about the suction or basal transport system of the kidneys, and therefore it is not believed that it is affected by humans the excretion of other medicines by these transports systems."</seg>
<seg id="1332">Resorption of healthy adult specimens (women and men) was after the gift of ADROVANCE after next fasting and two hours before taking a meal the middle surface under the Serum concentration time-curve (AUC0-120 h) for vitamin D3 296,4 ng • h / ml (without consideration endogener vitamin D3 mirror).</seg>
<seg id="1333">The average maximum concentration in Serum (Cmax) of vitamin D3 was 5,9 ng / ml and the medianage to reaching the maximum Serumkonzentration (Tmax) 12 hours.</seg>
<seg id="1334">"Biotransformation vitamin D3 is quickly expanded in the liver rapidly to 25-hydroxyture D3 hydroxyture and then in the kidneys to 1.25-Dihydroxyture D3, the bioactive form, metabolized."</seg>
<seg id="1335">"use of radioactive markided vitamin D3 in healthy volunteers was the mean excretion of radioactivity in urine after 48 hours 2,4%, in the feces to 4 days 4,9%."</seg>
<seg id="1336">"characteristics in patients pre-clinical studies have shown that the proportion of Alendronat, which is not relocated in the bones, quickly over the urine."</seg>
<seg id="1337">"although there is no clinical data on it, it is nonetheless reckoned that the renal Elimination of Alendronat as in the animal will also be reduced to patients with reduced kidney function."</seg>
<seg id="1338">Therefore in patients with reduced kidney function can be expected to expect from Alendronat in the bones (see Section 4.2).</seg>
<seg id="1339">"Alendronat non-clinical data on the basis of conventional studies for safety spharmacology, for chronic toxicity, genotoxicity and the canogenic potential do not allow particular dangers to recognise."</seg>
<seg id="1340">"studies on rats showed that the gift of Alendronat are pregnant with the appearance of Dystokie with the appearance of Dystokie with the appearance of Dystokie, attributed to a hypocalcemia."</seg>
<seg id="1341">Micro-crystalline Cellulose (E 460) Lactose Mittelketceride Gelatine Croscimitable silicone hydroxytoluol (Ph.Eur.) (E 321) strength, modified (corn) Alloy natriumsilicat (E 554) "</seg>
<seg id="1342">"Etui with sealed aluminium / aluminium blister packs in cartons to 2 (1 Etui with 2 tablets), 6 (3 Etuis with 4 tablets), 12 (3 otuis with 4 tablets) or 40 (10 Etuis with 4 tablets) tablets."</seg>
<seg id="1343">EU / 1 / 06 / 364 / 001 - 2 tablets EU / 1 / 06 / 364 / 003 - 6 tablets EU / 1 / 06 / 364 / 004 - 12 tablets EU / 1 / 06 / 364 / 005 - 40 tablets</seg>
<seg id="1344">"rectangular-like, white to broken white tablets, marked with the outline of a button on one side and" 270 "on the other side."</seg>
<seg id="1345">13 • The patients should not lie down at least 30 minutes after taking the ADROVANCE. • ADROVANCE should not be taken before bedtime or before the first advent of the day.</seg>
<seg id="1346">"the risk of severe punishment side effects seems to be increased in patients who do not take correctly and / or after the occurrence of symptoms that point to an ösophageal irritation."</seg>
<seg id="1347">"during large, clinical trials with Alendronat no increased risk has been determined, rarely (according to launch) gastric and Duodenalulzera, including some severe and with complications, reported (see Section 4.8)."</seg>
<seg id="1348">18 Colecalciferol (vitamin D3) Vitamin D3 is produced in the skin by UV-light on the conversion of 7-Dehydroje to vitamin D3.</seg>
<seg id="1349">The patients received ADROVANCE in the lower force (70 mg / 2.800) (n = 350) or FOSAMAX (Alendronat) 70 mg once weekly (n = 332); more vitamin D supplements were prohibited.</seg>
<seg id="1350">"vitamin D3 (the quantity of vitamin D3 in the higher dose of ADROVANCE) once weekly, was shown in a 24-week extension study with 619 postmenopausal women with osteoporosis."</seg>
<seg id="1351">After 24-week's treatment the middle servings of 25-hydroxyture was significantly higher in the 5.600-I.E.-Vitamin C (69 nmol / l]) than in the 2.800-I.E.-Vitamin C (64 nmol / l [25.5 ng / ml]).</seg>
<seg id="1352">There was no statistically significant difference between the groups of patients with hypercalciurie at the end of the 24-week extension.</seg>
<seg id="1353">3.1% on the overall guardian in the group of 70 mg once weekly or in the 10 mg every day.</seg>
<seg id="1354">In this study the daily gift of Alendronat reduced the appearance of at least a new pedacupuncture around 47% (Alendronat 7.3% compared to placebo 15.0%).</seg>
<seg id="1355">"the bioavailability took place according to some block% and outs% off, when Alendronat one or half an hour before a standardised breakfast"</seg>
<seg id="1356">Distribution studies to rats have revealed that Alendronage distributed to intravenous gift of 1 mg / kg temporarily in soft parts but then quickly distributed in the bones or by the urine.</seg>
<seg id="1357">Resorption of healthy adult probanden (women and men) was after the gift of ADROVANCE (70 mg / 5,600)) after nightly fasting and two hours before taking a meal the middle surface under the Serum concentration time-curve (AUC0-80 h) for vitamin D3 490,2 ng • h / ml (without consideration endogener vitamin D3 mirror).</seg>
<seg id="1358">The average maximum concentration in Serum (Cmax) of vitamin D3 was 12.2 ng / ml and the medianage to reaching the maximum Serumkonzentration (Tmax) 10,6 hours. "</seg>
<seg id="1359">Smaller volumes are spread in fat and muscle tissues and are stored there as vitamin D3 to later become released in the cycle.</seg>
<seg id="1360">"21 vitamin D3 becomes fast to 25-hydroxyture D3 hydroxyture and then in the kidney zu 1.25-Dihydroxyture D3, the bioactive form, metabolized."</seg>
<seg id="1361">There were no evidence on saturation of the takeover of the feminizing of cumulative intravenous doses up to 35 mg / kg at animals.</seg>
<seg id="1362">"Etui with sealed aluminium / aluminium blister packs in cartons to 2 (1 ebtui with 2 tablets), 4 (1 contui with 4 tablets), 12 (3 otuis with 4 tablets) tablets."</seg>
<seg id="1363">"Pharmakovigilance system The holder of permission for the transport system has assured that a pharmacopovigilance system is described as in version 2 module 1.8.1 of the filing documents, before the drug is available to market, and so long is available as market-marketed medicines will be marketed in the market."</seg>
<seg id="1364">"risk management Plan The holder of permission for the transport is obliged to perform studies and further pharmacovigilance plan, which are described in the risk management plan (RMP) and its corresponding updates in accordance with Version 1 module 1.8.2 of the regulatory authorities."</seg>
<seg id="1365">A updated network is present in accordance with CHMP Guideline to risk management systems for human medicines with the next period odic Saftey Update Report (PSUR).</seg>
<seg id="1366">"in addition, an update of the RMP - when new information can be presented, which have an effect on the safety information, Pharmakovigilance plan or activities to risk minimization - within 60 days after reaching important milestones (pharmacovigilance or risk minimization) - on request of the EMEA</seg>
<seg id="1367">"take a ADROVANCE tablet after getting up and before taking any other medicines, taking the tablet with a full glass of water (not chewn and not lutches)."</seg>
<seg id="1368">Maybe you would like to read this later again. • If you have any further questions please contact your doctor or a pharmacist. • This drug was personally prescribed.</seg>
<seg id="1369">"in menopause the ovaries produce no female hormones, estrogen, more that help to preserve the skeleton of women healthy."</seg>
<seg id="1370">"the fraternity usually arise at the hip, the spine or the wrist, and can not only cause pain, but also considerable problems like booming attitude (" Witwenbuckel ") and a loss of mobility."</seg>
<seg id="1371">"ADROVANCE does not only prevent loss of bone mass, but also helps to diminish the bone loss again and diminish the risk of spinal and hip eruptions."</seg>
<seg id="1372">Constriction of the esophagus or gorge (3) if it is not possible to sit at least 30 minutes to sit or stand (4) if your doctor has noticed that your calcium content is lower in the blood.</seg>
<seg id="1373">"40: if you have problems in hitting, or with digestion, • If your calcium levels are lower in the blood, • If you have a cancer or radiotherapy, • If you are dying (Cortisongrads), • If you do not go routing to your dental treatment."</seg>
<seg id="1374">These complaints can then occur in particular when the patients take the ADROVANCE tablet with a full glass of water and / or expended up from 30 minutes after taking.</seg>
<seg id="1375">"by taking ADROVANCE with other medicines Calciumcomplementary, Antazida and some other medicines can hinder the effectiveness of ADROVANCE during incalculating intake."</seg>
<seg id="1376">"certain medicines or food additives can hinder vitamin D in the body including artificial rock, minerals, Orlistat and the cholesterinsenkenden medicine cholestyramine and colestipol."</seg>
<seg id="1377">"please inform your doctor or a pharmacist, if you are taking other medicines / apply / or have recently taken / applied, even if it is not prescription drug."</seg>
<seg id="1378">Please take this medicine only after consultation with your doctor if you know is that you suffer from a intolerance towards certain sugars.</seg>
<seg id="1379">"please follow the instructions 2), 3), 4) and 5) to facilitate the transportation of the ADROVANCE tablet into the stomach and to diminish possible irritation of the esophagus (Ösophagus - the pipes that connects your mouth with the stomach)."</seg>
<seg id="1380">(2) Take the ADROVANCE tablet after the first listing and prior to taking any other medicines only with a full glass (at least 200 ml) water (not with mineral water). • Not with coffee or tea. • Not with juice or milk.</seg>
<seg id="1381">(3) Lead not to - stay fully erect (in seats, in stand or walking) - at least 30 minutes after taking the tablet. "</seg>
<seg id="1382">"(5) If you encounter difficulties or pain when throwing up, pain behind the thorid, reigning or deteriorating soaking, you will set ADROVANCE and look for your doctor."</seg>
<seg id="1383">"(6) Waiting your ADROVANCE tablet at least 30 minutes before you take your first food, drinks or other medicines such as antacid (magic medicine), calcium or vitaminates on that day."</seg>
<seg id="1384">"should you accidentally taken too many tablets at one time, drink a full glass of milk and contact your doctor."</seg>
<seg id="1385">"if you have failed taking a tablet, take just one tablet the next morning after you noticed your omisance."</seg>
<seg id="1386">"common: • sucking armrests; sorrow of the spears; dextring the spill; sorting, muscle and / or joint pain, • pain, muscle and / or joint pain, • pancreas; digestive; digestive; disstipation; diarrhea, • headaches."</seg>
<seg id="1387">"occasionally: • nausea; vomiting, • irritation and inflammation of the esophagus (Ösophagus - the pipes that connects your mouth with your stomach) or the stomach germ, • rash; Juckreiz; gerent skin."</seg>
<seg id="1388">"after market launch, the following side effects were reported (frequency not known): • (torque, • fatigue, • hair loss, • jaw problems (Osteonekrose) in conjunction with consume wound healing and infections, often after the pulling of teeth, • swelling at hands or legs."</seg>
<seg id="1389">43 puzzles it's helpful when you note which complaints you had when they began and how long they stopped.</seg>
<seg id="1390">"other components are microcrystine Cellulose (E 460), tactose, medium-chain hydrochlorine, sucrose, high disperous silicium dioxide (Ph.Eur.) (E 321), strength, modified (corn), and aluminium-natriumsilicat (E 554)."</seg>
<seg id="1391">The tablets are in Etuis with sealed aluminium / aluminium blister packs in the following packaging sizes: • 2 tablets (1 ebtui with 4 tablets in aluminum blister packs) • 12 tablets (3 Etuis with 4 tablets in aluminum blister packs) • 40 tablets (10 Etuis with 4 tablets in aluminum blister packs) • 40 tablets (10 Etuis with 4 tablets in aluminum blister packs).</seg>
<seg id="1392">"in menopause the ovaries produce no female hormones, estrogen, more that help to preserve the skeleton of women healthy."</seg>
<seg id="1393">"48 If you have allergies, • If you have problems in hitting, or with digestion, • If you have problems, if you have cancer or radiotherapy, • If you have a chemotherapy or radiotherapy, • If you do not proceed routing (Cortisongrads), if you are not routine for dental treatment."</seg>
<seg id="1394">"by taking ADROVANCE with other medicines Calciumcomplementary, Antazida and some other medicines can hinder the effectiveness of ADROVANCE during incalculating intake."</seg>
<seg id="1395">2) Take the ADROVANCE tablet after the first listing and prior to taking any other medicines only with a full glass (at least 200 ml) water (not with mineral water). • Not with coffee or tea. • Not with juice or milk.</seg>
<seg id="1396">3) Leave yourself not - stay fully erect (in seats, in stand or walking) - at least 30 minutes after taking the tablet. "</seg>
<seg id="1397">"5) If you encounter difficulties or soreness to socks, pain behind the thorid, reigning or deteriorating soaking, please use ADROVANCE and look for your doctor."</seg>
<seg id="1398">"6) Waiting your ADROVANCE tablet at least 30 minutes before you take your first food, drinks or other medicines such as antacid (magic medicine), calcium or vitaminates on that day."</seg>
<seg id="1399">"• (filming, • yellow-tails, • tiredness, • hair loss, • jaw problems (Osteonekrose) in conjunction with consume wound healing and infections, often after the pulling of teeth, • swelling at hands or legs."</seg>
<seg id="1400">"tablets are available as rectangular, white to broken white tablets, marked with the outline of a button on one side and" 270 "on the other side."</seg>
<seg id="1401">"Advagraf is administered adult patients, to which a kidney or liver transplants, to prevent a repayment of the transplants of the immune system by the immune system."</seg>
<seg id="1402">"since Tacrolimus and Prograf / Prograft have already been deployed in the EU, the company has presented the results from previously made studies with Prograf / prograft and data from the published literature."</seg>
<seg id="1403">"furthermore, the results of a clinical trial was submitted to 668 patients with kidney transplant, whereby the application of Advagraf is compared with Prograf / Prograft or Ciclosporin."</seg>
<seg id="1404">"the main indicator of the effectiveness was the number of patients, where the transplant after treatment of a year was voted (by for example, how often a renewed organtransplantion or a revival of dialysis was needed)."</seg>
<seg id="1405">"in addition, shorter studies on 119 patients were carried out with kidney transplant and 129 patients with liver transplantation and examines as Advagraf in comparison to Prograf / Prograft from the body."</seg>
<seg id="1406">"tremor (trembling), headaches, nausea / Erbreak, diarrhoea problems, increased blood sugar levels (hypertension), diabetes, multiplier (hypertension) and sleeplessness (insomnie)."</seg>
<seg id="1407">In patients with any hypersensitivity (allergy) against Tacrolimus, macrolid antibiotics (such as erythromycin) or one of the other components may not be used as Advagraf. "</seg>
<seg id="1408">Patients and doctors must be careful when others (especially some herbal) drugs simultaneously be taken simultaneously with Advantraf as the Advagraf-dose or the dose of the same could be adjusted accordingly.</seg>
<seg id="1409">"Hartmut Island, retardiert Gelb-orange Gelatinekappers, printed in red tinent with" 0.5 mg "and on the orange capsule with" "647"; "they contain white powder."</seg>
<seg id="1410">"only doctors who are familiar with immunosuppressive therapy and treatment of transplant patients, should arrange this drug or make changes in immunosuppressive therapy."</seg>
<seg id="1411">"due to clinically relevant differences of the systemic exposure of Tacrolimus, this can lead to a transplantation or to an increased incidence of side effects, including under- or overobstruction of repression."</seg>
<seg id="1412">Patients should always maintain the same Tacrolimus formulation and the corresponding daily dosage; transformation of the wording or regime should only be carried out under the narrow control of one in the transplant medical medicine (see sections 4.4 and 4.8).</seg>
<seg id="1413">"as a result of an conversion to an alternative specification, a therapeutic medication has to be carried out and corresponding dosage adjustment must ensure that the systemic exposure of Tacrolimus remains."</seg>
<seg id="1414">"the dosage of Advagraf should be based primarily on the clinical assessment of repayment and tolerability in the individual case, and on blood-reflection (see below)"</seg>
<seg id="1415">"by conversion from Prograf on Advagraf, the Tacrolimus Talmirror should be controlled before the conversion and over two weeks after switching."</seg>
<seg id="1416">"on day 4, the systemic exposure, measured as a demirror, with both formulations both in kidney and in-tranable patients."</seg>
<seg id="1417">Careful and repeated controls of the Tacrolimus talents are recommended during the first two weeks after a transplant under Advagraf in order to ensure proper substance exposure in the immediate aftertransplantion phase.</seg>
<seg id="1418">"because Tacrolimus is a substance with low clearance, can take a adaptation of the Advagraf-Dosisschemas for several days until the steady State is reached."</seg>
<seg id="1419">"if the condition of the patient is allowed in the first postoperative phase no oral intake of drugs, the Tacrolimus treatment can be initiated (prograf 5 mg / ml of concentration at the production of an infusion solution) with a dose of ca."</seg>
<seg id="1420">The duration of applying Zur suppression of the transplantation must be sustained; consequently, a maximum duration of the oral therapy cannot be specified. "</seg>
<seg id="1421">Dosage recommendations - kidney anatomy of the transplant treatment therapy should begin with 0.20 - 0,30 mg / kg / day as a daily routine in the morning.</seg>
<seg id="1422">"further dosages can be required later, as the pharmacokinetics can change from Tacrolimus in the course of stabilisation of the patient after the transplantation."</seg>
<seg id="1423">Dosage recommendations - liver transplant prophylaxis of the transplant treatment therapy should begin with 0.10 - 0.20 mg / kg / day as a daily routine in the morning.</seg>
<seg id="1424">"dosage recommendations - conversion from Prograf on Advagraf must be asked by progrf on Advent dosage given by prograf capsules on a once daily intake of Advagraf, so this conversion base in relation 1: 1 (mg: mg), related to the entire daily dose."</seg>
<seg id="1425">Kidney and liver transplant surgery after a shift from other immunosuppressants to Advent once daily needs treatment with the case in kidney and liver transplant initiate initialdosis for prophylaxis of the transplant treatment.</seg>
<seg id="1426">"heart transplant for adult patients, who are placed on Advagraf is an orale initialdosis of 0,15 mg / kg / day at once morning."</seg>
<seg id="1427">"other transplanantatant Objects, there are no clinical experience with Advocraf in pneumonia, paneras- and colon transplants patients in a oral initialdosis of 0,2 mg / kg / day and at intestinal transplants in a oral initialdose of 0,3 mg / kg / day."</seg>
<seg id="1428">"dosisadapts in special patient groups patients with reduced liver function, for maintenance of blood vessels in the targeted area can be necessary in patients with severe liver dysfunctions a herbance of the dose."</seg>
<seg id="1429">Patients with reduced kidney function Da renal function has no effect on the pharmacokinetics of Tacrolimus can be assumed that a dosage adjustment is not required.</seg>
<seg id="1430">"due to the Nepalotoxic potentials of Tacrolimus, however, a careful monitoring of kidney function is recommended (including a regular determination of the serotonin levels, a calculation of the Creatininclearance and a monitoring of urinary tract)."</seg>
<seg id="1431">Conversion from Ciclosporin to Advagraf When the conversion from a Ciclosporin- to a Tacrolimus-based therapy is advisable (see sections 4.4 and 4.5).</seg>
<seg id="1432">"recommendations to the Talvine in the full blob The dose should be based primarily on the clinical assessment of extraction and tolerability in the individual case, under the aid of full-blown-Tacrolimus talents."</seg>
<seg id="1433">"it is recommended to perform frequent checks of the Tacrolimus talents, during the first two weeks after a transplant, followed by periodic controls during the maintenance therapy."</seg>
<seg id="1434">"blood thatories of Tacrolimus should also change for conversion from prograf on Advagraf, dosisadaption, changes to the immunosuppressive therapy or on simultaneous use of substances, which could change the Tacrolimus circulation. (see Section 4.5)."</seg>
<seg id="1435">"since Advagraf is a drug with a low clearance, adjustments could need several days until the steady State has entered."</seg>
<seg id="1436">Clinical studies suggest that a successful treatment is possible in most cases when the Talmirror in the blood 20 ng / ml can not exceed.</seg>
<seg id="1437">In clinical practice the talent of Tacrolimus generally lie in the age of liver transplant in the first time after liver transplantations usually in the range of 5 - 20 ng / ml and cheating - and savourable patients at 10 - 20 ng / ml.</seg>
<seg id="1438">"during the subsequent treatment therapy of liver, kidney and heart transplant were generally used blood-concentration in the range of 5 - 15 ng / ml."</seg>
<seg id="1439">"this has led to serious unwanted events, including transplantages or other side effects which can occur in a row of Tacrolimus sub- or overexposure."</seg>
<seg id="1440">Patients should always maintain the same Tacrolimus formulation and the corresponding daily dosage; transformation of the wording or regime should only be carried out under the narrow control of one in the transplant medical medicine (see sections 4.2 and 4.8).</seg>
<seg id="1441">"5 based treatment of adult patients with trailers, which proved to be compared to other immunosuppressants as therapy therapy, there are no clinical data for retaining formulation Advagraf."</seg>
<seg id="1442">"for prophylaxis of the transplantatmetering with adult heart transplant and trailers in child-age, there are still no clinical data for the saving formulation Advagraf."</seg>
<seg id="1443">"because of possible interactions formed in the blood and a weakening of the clinical effect of Tacrolimus, the intake of herbal remedies available (hypericum perforatum), or other plant remedies available during treatment with advocacy (see Section 4.5)."</seg>
<seg id="1444">"in patients with diarrhoea, a particularly careful monitoring of the Tacrolimus concentrations on the blood, since the Tacrolimus blood levels will be subject to significant fluctuations in such circumstances."</seg>
<seg id="1445">"in rare cases, among prograf was one as cardiopathy, Kammer- or uroral hypertropy to be observed, which can therefore occur under Advagraf."</seg>
<seg id="1446">"other factors that increase the risk of such clinical disorders, are an already existing heart disease, a treatment with cortical steroids, hypertension, kidney or liver dysfunctions, infections, fluid exposure and oil."</seg>
<seg id="1447">"as with other immunosuppressants, the effect of sunlight or UV light should be restricted because of the possible risk of malignant skin variation by suitable clothing or using a protection factor by using a high level of protection."</seg>
<seg id="1448">"if patients, the Tacrolimus are taking symptoms for PRES such as headaches, cramps and visual dysfunctions, should a radiological investigation (e.g."</seg>
<seg id="1449">"since Advagraf Places, saving, tactose, is performed in patients with the rare galactose intolerance, tactase-lack or glucose-Malactose-Malevidently special caution."</seg>
<seg id="1450">"simultaneous application of drugs or herbal remedies that are known as Hemmer or inductors of CYP3A4, can affect the metabolism of Tacrolimus and thus reduce the blood levels of Tacrolimus."</seg>
<seg id="1451">"it is therefore advisable to monitor the Tacrolimus blood levels at the same level of substances, which can change the CYP3A metabolism, and adjust the Tacrolimus dose for maintaining gender concentrations accordingly (see sections 4.2 and 4.4)."</seg>
<seg id="1452">A strongly distinctive interaction was generated with antimycotic as Ketoconazol, Fluconazol, Itraconazol and Preiconacol as well as with the Macrolid antibiotic for erythromycin and HIV proteins (z). "</seg>
<seg id="1453">"pharmacokinetics studies, that the increase in the blood levels mainly consists of the increased oral bioavailability of Tacrolimus, caused by the inhibition of gastrolimine contamination."</seg>
<seg id="1454">"high-quality prednisolon or methylprednisolon, as it is used in acute disorders, can increase or reduce the concentration of Tacrolimus in the blood."</seg>
<seg id="1455">Effect of Tacrolimus on the metabolism of other medicines tacrolimus is known as CYP3A4-inhibitors; therefore the simultaneous application of Tacrolimus can be metabolized by CYP3A4 metabolized.</seg>
<seg id="1456">"because Tacrolimus descend the clearance of steroid-contrazeptiva, and thus to increase hormones, is particularly careful in decisions about receptive actions."</seg>
<seg id="1457">The results of animal trials have shown that Tacrolimus potentially reduce the clearance of pentobarbital and phenazon and to extend their half-value.</seg>
<seg id="1458">"the results of a low number of investigations on transplant patients do not provide any evidence that among Tacrolimus, compared to other immunosuppressants, an increased risk of unwanted events with regard to the course and outcome of pregnancy."</seg>
<seg id="1459">"in utero exposure, a monitoring of newborns recommends a damaging effects of Tacrolimus (especially with regard to its effect on the kidneys)."</seg>
<seg id="1460">"it is the risk of an early birth (&lt; week 37) and a hypertension of the newborns (incidence 8 of 111 newborns, i.e.:"</seg>
<seg id="1461">"" "immunosuppressants" "immunosuppressants" "immunosuppressants can often be seen precisely because of the treachment of the patient and the simultaneous treatment with a variety of other medicines."</seg>
<seg id="1462">"below are listed side effects after their incidence in descending order: very common (&gt; &gt; &gt; &gt; / 1,000, &lt; 1 / 10), rarely (&gt; &gt; &gt; / 1,000, &lt; 1 / 1,000), very rare (&lt; 1 / 10,000, not known (frequency based on the available data not transferable)."</seg>
<seg id="1463">"Flemish disorders of the cardiac vessels, tachycardio Kammerarrhythmia and cardiac cardiopathy, mercenary arrhythmic arrhythmics, palmeratio, anodiatio, anomalies in the EKG, abnormative heart and pulse frequency"</seg>
<seg id="1464">"diarrhoea, nausea gastrounal inflammation and perforation, bleeding from the stomach-intestinal tract, stomatitis and abdomes, tistical characters and symptoms, obstipation, flatulence, blackles, signs and symptoms in the stomach-intestinal - area"</seg>
<seg id="1465">"infections and parasitism of other highly effective immunosuppressants is in patients suffering from Tacrolimus, the susceptibility to infections (viral, bacterial, trzoic) frequently increased."</seg>
<seg id="1466">"cases of BK-virus affiliated Nephropathy and JC-Virus-Associate-Associate-associated leucoencephalopathy (PML) were reported in patients under immunosuppressive therapy, including therapy with Advagraf."</seg>
<seg id="1467">It was reported on goofy or malignant Neoplasmen including EBV- association-proliferative disorders and skin tumors associated with the treatment with Tacrolimus.</seg>
<seg id="1468">"due to its high molecular weight, its low water solution and the high bond to Erythrocytes and Plasmaproteine can be assumed that Tacrolimus is not dialytic."</seg>
<seg id="1469">"action mechanism and pharmacological effects on molecular level are likely to be conveyed the effects of Tacrolimus by his bond to a cylindrical protein (FKBP12), which is responsible for the enrichment of the connection in the cell."</seg>
<seg id="1470">This leads to a calciumdependency of Signaltransduction due to the T-cell and thus prevents the transcription of a certain series of lymphokin veins.</seg>
<seg id="1471">Tactics are suppressed by the activation of the T-cells and the proliferation of the T-helm cells (such as Interleukin-2, Interleukin-3 and g -Interferon) as well as the expression of the Interleukin-2 receptors. "</seg>
<seg id="1472">12 years of validation in the first 24 weeks in the Advagraf Group (N = 237) 32.6% and in the Prograf group (N = 234) 29,3%.</seg>
<seg id="1473">"patients" survival rates after 12 months of €89,2% for Prograf and 90,8% for Prograf; in Advagraf-Arm grew 25 (14 women, 11 males) and in Prograf-Arm 24 (5 women, 19 men) deaths. "</seg>
<seg id="1474">"kidney anatomy, The effectiveness and safety of Advagraf and Prograf, was compared in combination with Mycophenolatmofetil (MMF) and coronary steroids, compared with 667 de Novo gallentral antacid."</seg>
<seg id="1475">"patients" survival rates after 12 months of €96.9% for advocacy and 97,5% for Prograf; in Advagraf-Arm came 10 (3 women, 7 men) and in Prograf-Arm 8 (3 women, 5 men) deaths. "</seg>
<seg id="1476">"the effectiveness and safety of prograf, Ciclosporin and Advagraf became, each in combination with Basiliximab-antibodies, MMF and coronary steroids, compared with 638 de Novo kidney failure."</seg>
<seg id="1477">"the incidence of treatment days after 12 months (defined as death, transplantatloss or missing Follow-up- data) was 14.0% in the generator Group (N = 212), 15.1% in the Ciclosporin group (N = 212)."</seg>
<seg id="1478">The treatment of treatment has been 3.2% (Advfinch - Ciclosporin) (95.0%) for Advagraf vs Ciclosporin and -1.9% (prograf-Ciclosporin) (95.0%, 5.5%]) for Prograf vs Ciclosporin. "</seg>
<seg id="1479">"in Advagraf-arm came 3 (men), in the Prograf arm 10 (3 women, 7 men) and in Ciclosporin-arm 6 (3 women, 3 men) deaths."</seg>
<seg id="1480">Published results of the primary immunodle with Tacrolimus in the form of twice a daily sharpenant prograf has developed into a recognized primary immunosuppressive form of pancreatic, lung - and intestinal transplants. "</seg>
<seg id="1481">"175 lesied patients, at 475 patients who had subjected to a panal transplant, and in 630 cases after a intestinal transplant as a primary immunosuppressive form."</seg>
<seg id="1482">"overall, the safety profile of orally Prograf in these published studies have been applied to the observations in the large studies, in which prograf with liver, kidney and heart transplant are used to be the primary immunoidal repression."</seg>
<seg id="1483">"lung transplant in an interim analysis about a recent analysis, multi-centric study with orally prograf was reported on 110 patients that were referred to as part of 1: 1-Randomisation either Tacrolimus or Ciclosporin."</seg>
<seg id="1484">"also a chronic transplants, the bronchiolitis obliterans- syndrome, was able to observe less frequent during the first year after the transplant (2.7% versus 8.57%)."</seg>
<seg id="1485">"survival rates after a year was 80.8% in Tacrolimus- and 83% in the Ciclosporin group (Treede et al., 3rd ICI San Diego, USA, 2004; Abstract 22)."</seg>
<seg id="1486">"with the patients treated with Tacrolimus, patients came in 21.7% of the cases to the emergence of a bronchiolitis obliterans compared to 38,0% under Ciclosporin (p = 0,025)."</seg>
<seg id="1487">"the number of cases where of Ciclosporin to Tacrolimus had to be changed (n = 13), was significantly larger (p = 0.02), called by Tacrolimus on Ciclosporin, (n = 2) (Keenan et al., Ann Thoracic Surg 1995; 60: 580)."</seg>
<seg id="1488">"the number of cases in which there was no acute transplantion, was after 6 months (57,7% versus 45,8%) and after one year (50% versus 33,3%) in the lete planning of the Tacrolimus group bigger (Treede et al., J Heart Lung Transplant 2001; 20: 511)."</seg>
<seg id="1489">In a study the frequency of the emergence of a bronchiolitis obliterans- syndroms in the patients treated with Tacrolimus patients.</seg>
<seg id="1490">"Pancreastrance is a multi-centric trial with orally prograf was subjected to 205 patients who were subjected to a randomized trial of Tacrolimus (n = 103) or Ciclosporin (n = 102).</seg>
<seg id="1491">The orale initialdosis (per protocol) of Tacrolimus amounted to 0.2 mg / kg / day and then became to the achievement of the extended talent of 8 to 15 ng / ml on 5.</seg>
<seg id="1492">"intestinal transplantion The published clinical results of a monocentric trial with orally prograf as primary immunosantations revealed in 155 patients (65 only intestinal, 75 liver and intestine and 25 multivischial transplantations) under Tacrolimus and Prednison a upliftment rate of 75% after 1 year, 5% after 5 years and 42% after 10 years."</seg>
<seg id="1493">Methods for early detection of Epstein-Barr (EBV) - and CMV infections, bone margins, additional gift of the Interleukin-2-Antagrin, lead to Talks between 10 and 15 ng / ml and recently transplants (Abu-Elmagd et al., Ann Surg 2001; 234: 404). "</seg>
<seg id="1494">"factors such as a low hemostasis and low protein concentration, which lead to an increase in the unreported group of Tacrolimus, or having a treatment with cortico-steroids, the strengthening of the metabolic pathogens are to be responsible for the transplant and observed higher clearance."</seg>
<seg id="1495">"this makes it clear that Tacrolimus is almost completely metabolized before excretion, whereby the excretion is mainly carried out over the gin."</seg>
<seg id="1496">"in stable patients working from Prograf (twice daily) in relation 1: 1 (mg: mg) compared to the overall tagesdosis, the systemic exposure of Tacrolimus (AUC0-24) under Advagraf took 10% lower than among prograf."</seg>
<seg id="1497">"it is recommended to perform frequent checks of the Tacrolimus talents, during the first two weeks after a transplant, followed by periodic controls during the maintenance therapy."</seg>
<seg id="1498">"21 Zur treatment of adult patients with trailers, which proved to be compared to other immunosuppressants as therapy therapy, are still no clinical data for retaining formulation Advagraf."</seg>
<seg id="1499">"other factors that increase the risk of such clinical disorders, are an already existing heart disease, a treatment with cortical steroids, hypertension, kidney or liver dysfunctions, infections, fluid exposure and oil."</seg>
<seg id="1500">28 Confirmed steaming was within the first 24 weeks in the Advagraf Group (N = 237) 32.6% and in the Prograf group (N = 234) 29,3%.</seg>
<seg id="1501">"the effectiveness and safety of prograf, Ciclosporin and Advagraf became, each in combination with Basiliximab-antibodies, MMF and coronary steroids, compared with 638 de Novo kidney failure."</seg>
<seg id="1502">"tungsten cemented, retaining gray-orange Gelatinekappers, printed in red tinent on the gray red capsule with" 5 mg "and the oraves capsulated with" "687", "they contain white powder."</seg>
<seg id="1503">"it is recommended to perform frequent checks of the Tacrolimus talents, during the first two weeks after a transplant, followed by periodic controls during the maintenance therapy."</seg>
<seg id="1504">"37 Zur treatment of adult patients with a transplant treatment, which proved to be compared to other immunosuppressants as therapy therapy, are still no clinical data for retaining formulation Advagraf."</seg>
<seg id="1505">"other factors that increase the risk of such clinical disorders, are an already existing heart disease, a treatment with cortical steroids, hypertension, kidney or liver dysfunctions, infections, fluid exposure and oil."</seg>
<seg id="1506">44 as the first 24 weeks in the Advagraf Group (N = 237) 32.6% and in the Prograf group (N = 234) 29,3%.</seg>
<seg id="1507">"the effectiveness and safety of prograf, Ciclosporin and Advagraf became, each in combination with Basiliximab-antibodies, MMF and coronary steroids, compared with 638 de Novo kidney failure."</seg>
<seg id="1508">"in total, 34 patients received from Ciclosporin to Tacrolimus, while only 6 Tacrolimus patients needed a different therapy (Bechstein et al., Transplantation 2004; 77: 1221)."</seg>
<seg id="1509">"intestinal transplantion The published clinical results of a monocentric trial with orally prograf as primary immunosantations revealed in 155 patients (65 only intestinal, 75 liver and intestine and 25 multivischial transplantations) under Tacrolimus and Prednison a upliftment rate of 75% after 1 year, 5% after 5 years and 42% after 10 years."</seg>
<seg id="1510">"this makes it clear that Tacrolimus is almost completely metabolized before excretion, whereby the excretion is mainly carried out over the gin."</seg>
<seg id="1511">"risk management Plan The holder of permission for the transport is obliged to perform in the Pharmacovigilance Plan, as described in Version 3.2 of the risk management plan (RMP) and in module 1.8.2nd of the authorisation application, as well as all other updates of the RMP, which are approved by CHMP."</seg>
<seg id="1512">"according to CHMP guideline to the risk management systems for medicines to use at the human being, the updated file must be submitted at the same time with the next-periodic security report (periodic Safety Update Report, PSUR)."</seg>
<seg id="1513">"perhaps, you will also receive Advagraf in the treatment of a repairing of your liver, kidney or heart transplant or another transplants of your body, or because the immune response of your body could not be controlled by a precedent treatment."</seg>
<seg id="1514">"taking care of Advagraf with other medicines please inform your doctor or pharmacist, if you have some other medicines or have recently taken, even if it is not prescription drugs or cure herbal origin."</seg>
<seg id="1515">"Amilorid, Triamteren or Spironolacton), certain pain killer (so-called nonsteroidal anti-steroidal), anti-agulantiques or medicines for treatment of diabetes mellitus."</seg>
<seg id="1516">Pregnancy and lactation If a pregnancy is planned or already exists, consult before taking all medicines your doctor or pharmacist by advice. "</seg>
<seg id="1517">Transport and use of machines you are not allowed to use the wheel of a vehicle or use tools or machines when you're feeling after ingestion of Advagraf or sleepy or blurry.</seg>
<seg id="1518">"important information about certain other components of Advagraf Please take Advagraf only after consultation with your doctor, if you know is that you suffer from a intolerance towards certain sugars."</seg>
<seg id="1519">"ensure that you always receive the same Tacrolimus medicines, if you redeem your prescription, unless your specialist has explicitly agreed to a change of the Tacrolimus drugs."</seg>
<seg id="1520">"if you get a drug, whose appearance may be modified from the customary or the dosages, please talk as soon as possible with your care physician or pharmacist, so that you can get the right medicine."</seg>
<seg id="1521">"thus, your doctor can determine the correct dose and adjust from time to time, it is necessary to carry out regularly bleaching."</seg>
<seg id="1522">"if you have taken a larger quantity of advocacy than you should, If you accidentally have taken a larger quantity of Advantraf, look immediately to your doctor or the emergency department of the next hospital hospital."</seg>
<seg id="1523">"if you have forgotten the intake of Advent If you forgot to take the capsules, please get this at the same day at the earliest possible time."</seg>
<seg id="1524">If you abort the intake of Advagraf in conclusion of the treatment with Advagraf can increase the risk of a repulsion of your transplant.</seg>
<seg id="1525">"Advagraf 0,5 mg Hartmut Island, retardiert, their pale yellow robes with" 0.5 mg "and their oranges underpart with" "647" "are printed in red and which are filled with white powder."</seg>
<seg id="1526">"Advagraf 1 mg Hartmut Island, retardiert, their white waiter with" "1 mg" "and their oranges underpart with" "677" "are both red and filled with white powder."</seg>
<seg id="1527">"Advagraf 5 mg Hartmut Island, retardiert, their gravelous upper part with" 5 mg "and their oranges underpart with" "687" each red printed, and which are filled with white powder. "</seg>
<seg id="1528">"România Astellas Pharma Internaţ ional Detalii de contact pentru România Ş oseaua Bucureş ti 42-44, Clă dire 1, Parter, 013696-Bucureş ti Tel: + 40 (0) 21 361 0495</seg>
<seg id="1529">Slovenská Republika Astellas Pharma s.r.o., organizač ná zlož ka Galvániho 15 / C SK- 821 04 Bratislava 2 Tel: + 421 2 4444 2157</seg>
<seg id="1530">Advate is used for the treatment and prevention of bleeding in patients with hemophilia A (a due to the lack of factor VIII conditional, innate blood clamping). "</seg>
<seg id="1531">The dosage and frequency of the application shall be applied if Advate is used for the treatment of bleeding or the prevention of bleeding in surgical procedures.</seg>
<seg id="1532">Patients with hemophilia A suffer from a factor VIII lack of which causes blood clotting problems such as blood pressure in joints, muscles or inner organs. "</seg>
<seg id="1533">Octocog alfa is not extracted from human plasma but produced according to a method that is called "recombinant DNA technology."</seg>
<seg id="1534">It is produced by a cell that has been introduced to a gene (DNA) that resulted in the formation of human scent factor VIII.</seg>
<seg id="1535">"advocates is similar to another in the European Union called Recombinate, but it is different, however, does not contain proteins for human or animal origin."</seg>
<seg id="1536">"in three additional studies in patients with severe to moderate hemophilia A, including a study with 53 children under six years, the application of the drug was investigated with prevention of bleeding, as well as in surgical interventions."</seg>
<seg id="1537">In the main study the effectiveness of Advate has been rated for prevention of bleeding in 86% of 510 new blood thseptic with "excellent" or with "good."</seg>
<seg id="1538">"the most common side effects of Advate (observed in 1 to 10 of 100 patients) are dizziness, headaches, pyrexie (fever) and the formation of antibodies to factor VIII."</seg>
<seg id="1539">"Advate must not be applied in patients, which may be hypersensitive (allergic) against the human body factor VIII, mouse or hamster, or one of the other components."</seg>
<seg id="1540">March 2004 condemned the European Commission to Baxter AG approved for the transport of Advate in the entire European Union.</seg>
<seg id="1541">"dosage The dosage and duration of the substitution therapy are based on the heavy-wheel of the factor VIII, according to the place and extent of the patient and the clinical condition of the patient."</seg>
<seg id="1542">In the following hemorrhoids the factor VIII used in the appropriate period is not under the given Plasmaspiegel (in% of the standard or in i.e. / dl).</seg>
<seg id="1543">Injection all 12-24 hours (8-24 hours in patients under 6 years) for 3-4 days or longer repeat until the pain and acute impairment are eliminated.</seg>
<seg id="1544">Injection all 8-24 hours (6-12 hours in patients under 6 years) repeat until the danger for the patient is over.</seg>
<seg id="1545">During the treatment course the control of the injecting dose and incidence of injections are an appropriate determining factor VIII-plasmaspiegel.</seg>
<seg id="1546">Individual patients may differ in their response to factor VIII different in vivo Recovery and have different semi-value times.</seg>
<seg id="1547">3 prophylaxis for a long-term prophylaxis of bleeding in patients with severe hemophilia A are to be doses between 20 and 40} by factor VIII per kg body weight at a distance of 2-3 days.</seg>
<seg id="1548">"if the expected factor VIII would not be reached or if the blood pressure is not controlled with a reasonable dose, a test must be carried out if necessary to prove a Inhibitor."</seg>
<seg id="1549">"in patients with high inconsistencies, it is possible that the factor VIII therapy is not effective so other therapeutic interventions must be weighed up."</seg>
<seg id="1550">"the administration speed is to be directed after the patient, whereby maximum injection rate of 10 ml / min should not be exceeded."</seg>
<seg id="1551">The formation of neutralizing antibodies (inhibitors) against factor VIII is a known complication in the treatment of patients with hemophilia A.</seg>
<seg id="1552">These inhibitors are always opposed the procoagulator activity by factor VIII oriented IgG Immunglobulins which is quantified in Bethesda units (B.E.) per ml plasma via modifying Bethesda Assay quantified.</seg>
<seg id="1553">"the risk to develop inhibitors, correlation with the extent of exposure to the factor VIII, whereby the risk will depend within the first 20 exposition of the largest and of genetic and other factors."</seg>
<seg id="1554">"in pre-treated patients (PTPs) with more than 100 activities and anamnestial-known inhibitoric development was observed, after switching from a recombinant factor VIII product to another, the re-occur of (unititrigen) inhibitors."</seg>
<seg id="1555">"due to the strange appearance of the hemophilia A in women, the application of factor VIII during pregnancy and breastfeeding has no experience."</seg>
<seg id="1556">"in the greatest number of patients suspend ADRs were inhibitors against factor VIII (5 patients) which were all diagnosed in previously untreated patients who have a higher risk to formation of inhibitors, headaches (5 patients), fever and dizziness (each 3 patients)."</seg>
<seg id="1557">"very common (&gt; &gt; &gt; &gt; &gt; &gt; &gt; 1 / 100 to &lt; 1 / 10), occasionally (&gt; &gt; &gt; / 1,000 to &lt; 1 / 1,000), very rare &lt; 1 / 10,000), not known (frequency based on the available data is not transferable)."</seg>
<seg id="1558">A) The percentage of patients was calculated by the sum of the individual patients (234) (229) The unexpected waste of the blood clot factor VIII-Spiegels entered postoperatively (10 - 14 postoperative day) in a patient under continuous ADVATE infusion.</seg>
<seg id="1559">The blood clotting has been maintained throughout the time and both the factor VIII mirror in Plasma and the Clearance Rate showed sufficient values on the 15 postoperative day.</seg>
<seg id="1560">In clinical trials with ADVATE on 145 children and adults 2 with diagnosed heavy up to moderate hemophilia A (FVIII &lt; 2%) and previous exposure to factor VIII- concentrates (&gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; 23 B.E. in the modified Bethesda approach).</seg>
<seg id="1561">In addition to any of the 53 ppediatric patients with an age of under 6 years and diagnosed more severe to moderate Exposophilia A (FVIII &lt; 2%) after previous exposure to factor VIII- concentrates (&gt; &gt; 50 days) a FVIII inhibitor.</seg>
<seg id="1562">"in previously, patients treated in a regular clinical study (5%) with ADVATE untreated patients Inhibitors against factor VIII."</seg>
<seg id="1563">The immune response of patients on traces of contaminated proteins was analyzed by the investigation of antibodies against these proteins, laboratory parameters and well-ed side effects. "</seg>
<seg id="1564">"a patient showed both a statistically significant revolting as well as an ongoing peak of antibodies against anti-Cho cell proteins, otherwise however, no signs or symptoms that occurred on an allergic reaction or hypersensitivity."</seg>
<seg id="1565">"four patients were surveyed over the appearance of Urtikaria, pruritus, rash, and increased number of eosinophiles granulocytes with several repetitive production positions within the framework of the study."</seg>
<seg id="1566">"7 As with other intravenous products, ADVATE was reported on hypersensitivity to the allergic type, including anaphylactic / anaphylactoider reactions (frequency not known)."</seg>
<seg id="1567">The active factor VIII appears as a factor for the active factor IX and accelerates the formation of activating factor X for factor X.</seg>
<seg id="1568">All pharmacokinetics studies with ADVATE were performed in patients with severe or moderate hemophilia A (base value of the factor VIII-activity &lt; 2%).</seg>
<seg id="1569">"the pharmacopoinetic parameters come from a cross-Over-study with ADVATE in 100 previously treated patients, or &gt; 10 years and are listed in the table 3 listed below."</seg>
<seg id="1570">Table 3 summary of the Pharmacokinetic parameters of ADVATE at 100 patients with severe to moderate hemophilia A (factor VIII &lt; 2%) PK-parameters (pharmakokinetics)</seg>
<seg id="1571">"not clinical data, based on the studies of safety spharmacology, bludder, repetitive and local toxicity and genotoxicity, show no special risk to man."</seg>
<seg id="1572">"each individual case consists of a single bottle of powder, a flow-bottle with 5 ml solvents (both glass type I with chlorobutyl-rubber-scraper) and a device for reconstitution (BAXJECT II)."</seg>
<seg id="1573">"if the product is still stored in the refrigerator, both flow-bottles with ADVATE powder and solvents out of the fridge and at room temperature (between 15 and 25 ° C)."</seg>
<seg id="1574">A significant increase in the pulse frequency may be reduced by slowdown or temporary downbreak of injecting usually immediately lowered (see sections 4.4 and 4.8).</seg>
<seg id="1575">14 prophylaxis Zur long-term prophylaxis of bleeding in patients with severe hemophilia A are to be doses between 20 and 40} by factor VIII per kg body weight at a distance of 2-3 days.</seg>
<seg id="1576">"due to the strange appearance of the hemophilia A in women, the application of factor VIII during pregnancy and breastfeeding has no experience."</seg>
<seg id="1577">"3 newborn (at the age of 0-1 month), infant (aged 1 month - 2 years), children (aged 2-12 years), youths (aged 12-16), adults (over 16 years)"</seg>
<seg id="1578">In clinical trials with ADVATE on 145 children and adults 4 with diagnosed heavy up to moderate hemophilia A (FVIII &lt; 2%) and previous exposure to factor VIII- concentrates (&gt; &gt; &gt; &gt; &gt; &gt; &gt; for 26 B.E. in the modified Bethesda approach).</seg>
<seg id="1579">18 As for other intravenous products was reported by ADVATE on hypersensitivity to the allergic type, including anaphylactic / anaphylactoider reactions (frequency not known). "</seg>
<seg id="1580">Table 3 summary of the Pharmacokinetic parameters of ADVATE at 100 patients with severe to moderate hemophilia A (factor VIII &lt; 2%) PK-parameters (pharmakokinetics)</seg>
<seg id="1581">"not clinical data, based on the studies of safety spharmacology, bludder, repetitive and local toxicity and genotoxicity, show no special risk to man."</seg>
<seg id="1582">25 prophylaxis Zur long-term prophylaxis of bleeding in patients with severe hemophilia A are to be doses between 20 and 40} by factor VIII per kg body weight at a distance of 2-3 days.</seg>
<seg id="1583">"5 newborn (at the age of 0-1 month), infant (aged 1 month - 2 years), children (aged 2-12 years), youths (aged 12-16), adults (over 16 years)"</seg>
<seg id="1584">In clinical trials with ADVATE on 145 children and adults 6 with diagnosed heavy up to moderate hemophilia A (FVIII &lt; 2%) and previous exposure to factor VIII- concentrates (&gt; &gt; &gt; &gt; &gt; &gt; &gt; for 26 B.E. in the modified Bethesda approach).</seg>
<seg id="1585">"29 As with other intravenous products was reported by ADVATE on hypersensitivity, including anaphylactic / anaphylactoider reactions (frequency not known)."</seg>
<seg id="1586">"not clinical data, based on the studies of safety spharmacology, bludder, repetitive and local toxicity and genotoxicity, show no special risk to man."</seg>
<seg id="1587">36 prophylaxis Zur long-term prophylaxis of bleeding in patients with severe hemophilia A are to be doses between 20 and 40} by factor VIII per kg body weight at a distance of 2-3 days.</seg>
<seg id="1588">"7 newborn (at the age of 0-1 month), infant (aged 1 month - 2 years), children (aged 2-12 years), youths (aged 12-16), adults (over 16 years)"</seg>
<seg id="1589">In clinical trials with ADVATE on 145 children and adults 8 with diagnosed heavy up to moderate hemophilia A (FVIII &lt; 2%) and previous exposure to factor VIII- concentrates (&gt; &gt; &gt; &gt; &gt; &gt; &gt; for 26 B.E. in the modified Bethesda approach).</seg>
<seg id="1590">"40 How to other intravenous products was reported by ADVATE on hypersensitivity, including anaphylactic / anaphylactoider reactions (frequency not known)."</seg>
<seg id="1591">"not clinical data, based on the studies of safety spharmacology, bludder, repetitive and local toxicity and genotoxicity, show no special risk to man."</seg>
<seg id="1592">47 prophylaxis Zur long-term prophylaxis of bleeding in patients with severe hemophilia A are to be doses between 20 and 40} by factor VIII per kg body weight at a distance of 2-3 days.</seg>
<seg id="1593">"9 newborn (at the age of 0-1 month), infant (aged 1 month - 2 years), children (aged 2-12 years), youths (aged 12-16), adults (over 16 years)"</seg>
<seg id="1594">In clinical trials with ADVATE on 145 children and adults 10 with diagnosed heavy up to moderate hemophilia A (FVIII &lt; 2%) and previous exposure to factor VIII- concentrates (&gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; 24 B.E. in the modified Bethesda approach).</seg>
<seg id="1595">51 As with other intravenous products was reported by ADVATE on hypersensitivity to the allergic type, including anaphylactic / anaphylactoider reactions (frequency not known). "</seg>
<seg id="1596">"not clinical data, based on the studies of safety spharmacology, bludder, repetitive and local toxicity and genotoxicity, show no special risk to man."</seg>
<seg id="1597">58 prophylaxis Fur long-term prophylaxis of bleeding in patients with severe hemophilia A are to be doses between 20 and 40} by factor VIII per kg body weight at a distance of 2-3 days.</seg>
<seg id="1598">"11 newborn (at the age of 0-1 month), infant (aged 1 month - 2 years), children (aged 2-12 years), youths (aged 12-16), adults (over 16 years)"</seg>
<seg id="1599">In clinical trials with ADVATE on 145 children and adults 12 with diagnosed heavy up to moderate hemophilia A (FVIII &lt; 2%) and previous exposure to factor VIII- concentrates (&gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; 23 B.E. in the modified Bethesda approach).</seg>
<seg id="1600">62 As for other intravenous products was reported by ADVATE on hypersensitivity to the allergic type, including anaphylactic / anaphylactoider reactions (frequency not known). "</seg>
<seg id="1601">"not clinical data, based on the studies of safety spharmacology, bludder, repetitive and local toxicity and genotoxicity, show no special risk to man."</seg>
<seg id="1602">"Pharmacovigilance system The filing system must ensure that an Pharmacovigilance system, as described in section 1.1 of the chapter 1.8.1 of the pharmaceutical authorisation, and that this system is located throughout the entire period in which the product remains on the market."</seg>
<seg id="1603">"as defined in the CHMP directive on the risk-management plan for human-drugs, these updates are to be submitted at the same time with the next period odic Safety Update Report (PSUR)."</seg>
<seg id="1604">"• If new information can be found, the influence on valid safety instructions, the pharmacovigilance plan or measures to risk minimization may be made within 60 days of an important event (with regard to the pharmacovigilance or on a measure to risk minimization)"</seg>
<seg id="1605">1 bottle case with ADVATE 500 I.E Octocog alfa, 1 box-bottle of 5 ml steriliated water for injections, 1 BAXJECT II medicine product. "</seg>
<seg id="1606">1 bottle case with ADVATE 1000 I.E Octocog alfa, 1 box-bottle of 5 ml steriliated water for injections, 1 BAXJECT II medicine product "</seg>
<seg id="1607">"special caution when applying ADVATE is required, you should inform your doctor if you have recently been treated with factor VIII products, especially if you have inhibitors."</seg>
<seg id="1608">"these symptoms can represent early signs of an anaphylactic shock, which can also include following symptoms: extreme Schwindle, consciousness levels and extreme respiration."</seg>
<seg id="1609">"when taking other medicines please inform your doctor if you have other medicines or have recently taken, even if it is non-prescription drugs."</seg>
<seg id="1610">Your doctor will charge your dose ADVATE (in international units or i.e.) depending on your physical body and body weight and whether it is used for prevention or treatment of bleeding.</seg>
<seg id="1611">Patients who develop factor VIII-inhibitors If the expected factorial mirror in your Plasma with ADVATE can not be reached or which can not be controlled by factor VIII-</seg>
<seg id="1612">"in conjunction with operations of catheter infections, lower number of red blood cells, swelling of limbs and joints, prolonged blood, after removal of a drainage, decreased factor VIII, and post surgical hematoms."</seg>
<seg id="1613">Rare side effects on the introduction of the drug on the market has been interviewed via heavy and potentially vital reactions (anaphylactic) and other allergic reactions (see above).</seg>
<seg id="1614">"inform your doctor if any of the listed side effects you have considerably impaired, or if you notice unwanted side effects, which are not listed in this package."</seg>
<seg id="1615">Portugal Baxter Médico Farscêutica Lda Sintra Business Park Zona Industrial da Abrunheira, Edifício 10 P-2710-089 Sintra Tel: + 351 21 925 25 00</seg>
<seg id="1616">Notes regarding the production of the solution • Do not use the bracket date for making it possible. • The BAXJECT II does not use when his sterile barrier acts broken down to his packaging or sign of a manipulation of how in the symbol</seg>
<seg id="1617">Important note: • Not administered for yourself before you have received the special training from your doctor or medical practitioner. • Reporting the product on parleteilchen or discolouration.</seg>
<seg id="1618">"the solution should slowly be administered with an entry speed, which is detrimental to the patient and 10 ml per minute should not be administered."</seg>
<seg id="1619">106 in case of blood results should be the factor VIII mirrors within the relevant period of time (in% or in i.e. / ml).</seg>
<seg id="1620">"these symptoms can represent early signs of an anaphylactic shock, which can also include following symptoms: extreme Schwindle, consciousness levels and extreme respiration."</seg>
<seg id="1621">Patients who develop factor VIII-inhibitors If the expected factorial mirror in your Plasma with ADVATE can not be reached or which can not be controlled by factor VIII-</seg>
<seg id="1622">"occasional side effects itching, intensifying sweating, uncommon flavors, migraine, nausea, vomiting, vanity, mischiousness, irritation, irritation, rash, levelling, extreme sweating,"</seg>
<seg id="1623">"116 In the case of blood results, the factor VIII occurred within the relevant period is not given under the indicated plasma value (in% or in i.e. / ml)."</seg>
<seg id="1624">"these symptoms can represent early signs of an anaphylactic shock, which can also include following symptoms: extreme Schwindle, consciousness levels and extreme respiration."</seg>
<seg id="1625">Patients who develop factor VIII-inhibitors If the expected factorial mirror in your Plasma with ADVATE can not be reached or which can not be controlled by factor VIII-</seg>
<seg id="1626">126 In the event of bleachment should be the factor VIII mirror within the relevant period of time (in% or in i.e. / ml).</seg>
<seg id="1627">"these symptoms can represent early signs of an anaphylactic shock, which can also include following symptoms: extreme Schwindle, consciousness levels and extreme respiration."</seg>
<seg id="1628">Patients who develop factor VIII-inhibitors If the expected factorial mirror in your Plasma with ADVATE can not be reached or which can not be controlled by factor VIII-</seg>
<seg id="1629">136 in case of blood results should be the factor VIII mirrors within the relevant period of time (in% or in i.e. / ml).</seg>
<seg id="1630">"these symptoms can represent early signs of an anaphylactic shock, which can also include following symptoms: extreme Schwindle, consciousness levels and extreme respiration."</seg>
<seg id="1631">Patients who develop factor VIII-inhibitors If the expected factorial mirror in your Plasma with ADVATE can not be reached or which can not be controlled by factor VIII-</seg>
<seg id="1632">146 In case of blood results the factor VIII occurred within the relevant period is no less than in% or in (i.e. / ml).</seg>
<seg id="1633">"these symptoms can represent early signs of an anaphylactic shock, which can also include following symptoms: extreme Schwindle, consciousness levels and extreme respiration."</seg>
<seg id="1634">Patients who develop factor VIII-inhibitors If the expected factorial mirror in your Plasma with ADVATE can not be reached or which can not be controlled by factor VIII-</seg>
<seg id="1635">"occasional side effects itching, intensifying sweating, uncommon flavors, migraine, nausea, vomiting, vanity, mischiousness, irritation, irritation, rash, levelling, extreme sweating,"</seg>
<seg id="1636">Rare side effects on the introduction of the drug on the market has been interviewed via heavy and potentially vital reactions (anaphylactic) and other allergic reactions (see above).</seg>
<seg id="1637">156 in case of blood results should be the factor VIII mirrors within the relevant period is not affected by the indicated plasmaths (in% or in i.e. / ml).</seg>
<seg id="1638">"based on the data collected since the initial authorisation data, the CHMP has continued to be rated as positive, but considering that the safety profile has to be closely monitored for the following reasons:"</seg>
<seg id="1639">"therefore, CHMP opinion on the basis of the safety profile of ADVATE, which makes a submission of PSURs every 6 months, agreed that the regulatory approval should apply for a further extensions in 5 years."</seg>
<seg id="1640">December 2008 Gendux Molecular Limited shared the Committee on Humanarzneimedium (CHMP) officially ending the company to approval for the transport of Advent for the treatment of Li-Fraumeni cancer.</seg>
<seg id="1641">"however, the chest, the brain, the bones or the soft parts (tissues that connects other structures in the body, surrounds and relies) of it."</seg>
<seg id="1642">It is a kind of virus that has been altered genetically so that it can bear a gene in the cells of the body.</seg>
<seg id="1643">"in the virus in Advexin is a" "Adenovirus" "that has been changed so that there can be no copies of themselves and thus does not cause any infections in humans."</seg>
<seg id="1644">"Advexin could have been cropped directly into the tumors, and thus enable the cancer cells to form the normal p53 protein."</seg>
<seg id="1645">"the p53 protein, which is made from that not defective in the human body existing p53 gene, is normally called to restore damaged DNA and to kill the cells when the DNA cannot be recovered."</seg>
<seg id="1646">"at Li-Fraumeni cancer, where the p53 gene defective is broken, the p53-protein is not working properly, and the cancer cells may continue to grow and share."</seg>
<seg id="1647">"the company placed data from a study with a patient prior to the Li-Fraumeni cancer in the field of subtree, in the bones and the brain."</seg>
<seg id="1648">"after the CHMP opinion the answers of the company on the questions were checked, there were still some questions unexplained."</seg>
<seg id="1649">"based on the initial documentation submitted documents, the CHMP sent a list of questions that will be sent to the company."</seg>
<seg id="1650">"according to CHMP opinion, it was not sufficiently proven that the injection of Advexin in Li-Fraumeni-tumors will take advantage for the patient."</seg>
<seg id="1651">"the committee also had concerns regarding the processing of the drug with the body, the type of administration and the security of the drug."</seg>
<seg id="1652">"in addition, the company had not proven sufficient that advocates can be established in a reliable way and that it is neither for the environment nor for people who come in close contact with the patient."</seg>
<seg id="1653">"the company did not notice the CHMP not of it, whether the repercussions for patients has currently participating in clinical studies or" Compassionate Use "programmes with Advancement."</seg>
<seg id="1654">Changed active ingredients' signifies that the tablets are so merged that one of the effective components immediately and the other is slowly released over a few hours.</seg>
<seg id="1655">Aerinaze is used for treating the symptoms of seasonal allergic rhinitis (hay fever, caused by an allergy to pollen) in patients with nasal slum swelling (hidden nose). "</seg>
<seg id="1656">"for adults and young adults aged 12, the recommended dose of aerinaze is twice a tablet that should be taken entirely with a glass of water with or without food."</seg>
<seg id="1657">"the duration of the treatment should be as short as possible and ends, as soon as the symptoms, especially the swelling of the nose endometrium (hidden nose)."</seg>
<seg id="1658">"treatment of more than 10 days is not recommended, because the effects of the drug can be saved on the constipation of the nose."</seg>
<seg id="1659">The main effective dimensions were the changes of the severity of the hay ympic symptoms which were reported by the patients before the start of treatment and during the 15-day treatment.</seg>
<seg id="1660">"during the trial the patients carried their symptoms every 12 hours into a journal, and evaluated with a standard scale, as heavy the symptoms in the last 12 hours."</seg>
<seg id="1661">"considering all hay fever symptoms except the constipation of the nose reported the patients, the aerinaze, were compared with a decrease of symptoms by 46,0%, compared to 35,9% in the patients who captured pseudoephedrine alone."</seg>
<seg id="1662">"if only the swelling of the Nasenschlalp was considered, the patients showed the aerinaze an alleviation of symptoms around 37,4% compared to 26.7% in the patient who took desloradin alone."</seg>
<seg id="1663">"the most common side effects of aerinaze (observed in 1 to 10 of 100 patients) are tachycaress (heart ure), mouth-drying, pulling, redness, fatigue, fatigue, insomnia (somnia), somnia (sleeability), somnia and nervousness."</seg>
<seg id="1664">"Aerinaze is allowed to treat patients, which may be hypersensitive (allergic) against desweatadin, Pseudoephedrine or one of the other components, against inepintoxins or Loratadin (another medicine for the treatment of allergies) are not being applied."</seg>
<seg id="1665">Aerinaze must also not be used in patients who suffer from a Engangle glaucoma (hypertension), cardiac or vascular diseases (hypertension), hyperthyroid (hyperfunction of the thyroid) or having a hemorrhoid effect (caused by a hemorrhoid effect) or having a hemorrhoid effect. "</seg>
<seg id="1666">On 30 July 2007 the European Commission adopted the Company SP Europe to approve the promotion of aerinaze throughout the European Union.</seg>
<seg id="1667">"the tablet can be taken with a glass of water, however, is to swallow in the whole (i.e. without them to break, break or chewn)."</seg>
<seg id="1668">Aerinaze should be applied due to the failure of data to infinity and effectiveness (see Section 5.1) not in children under 12 years of age.</seg>
<seg id="1669">The duration of the application is as short as possible to keep and should not be continued after bottling the symptoms.</seg>
<seg id="1670">"it is recommended to limit the use of use on 10 days, as for long-term application the activity of pseudoephedrine can decrease in time."</seg>
<seg id="1671">"after decrease in the swelling of the grinding in the upper respiration, the treatment can be continued when needed with Deseradin as monotherapy."</seg>
<seg id="1672">"as Aerogaze pseudoephedrine includes, the drug is also conformated in patients who are treated with a monoidal oxidase (MAO) or within 2 weeks after the end of such therapy."</seg>
<seg id="1673">"this is due to alphamimetic activity in combination with pseudoephedrine with other vasoconstrigias, Pergolid, Ergotid, Ergothic, Ergothic, Ergothic acid, ephedrephrine, ephedrephrine, Oxymetaboolin, Naphazolin etc.)."</seg>
<seg id="1674">"the safety and effectiveness of this combination therapy were not tested for this patient, and the data are not enough to submit appropriate recommendations to dosage."</seg>
<seg id="1675">The safety and the effectiveness of Aerinaze were not tested in patients with kidney or liver disrupting and the data are not enough to utter corresponding recommendations for dosage.</seg>
<seg id="1676">Patients need to be informed that treatment at the occurrence of a hypertension or tachycarts or of palisations, coronary arrhythmia, nausea or modification of other neurological symptoms (as headaches or reinforcement of headaches) must be removed. "</seg>
<seg id="1677">"in the treatment of the following patient groups, patients with cardiac disease patients should be patient with cardiac disease • patients with a myocardiner in the Anamnese, diabetes mellitus, bladder surgeries or bronchospasmus in the Anamnese."</seg>
<seg id="1678">"Aerinaze is able to prevent at least 48 hours before performing dermatological testing, as antihistaminika can prevent positive reactions on indicators of dooractions or reduce their extent."</seg>
<seg id="1679">"in the context of clinical trials with Deseratadin, where erythromycin or Ketoconazol were additionally administered, however, were not clinically relevant interdependencies or changes in the plasma centration of Deseradin."</seg>
<seg id="1680">"in the results of the psychotor tests, no significant differences could be determined between those with deslorniadin and the patients treated with placebo, regardless of whether deslorests were taken alone or with alcohol."</seg>
<seg id="1681">It has not been identified for the Metabolism of Deseratadin accountable enzyme so that interactions with other medicines could not be ruled out completely.</seg>
<seg id="1682">Deseratadin hemmed in-vivo CYP3A4 not and in-vitro-studies have shown that the drug CYP2D6 does not inhibit and neither a substrate nor an Inhibitor of the P-glycoproteins.</seg>
<seg id="1683">The objections of the use of aerinaze during pregnancy is not guaranteed to gain experience from a large number of affected pregnancies but no increase in frequency of abnormalities compared to incidence of normal population.</seg>
<seg id="1684">"because reproduction studies on animals can not always be transmitted to humans, and due to vaso-strict characteristics of pseudoephedrine should not be applied to aerinaze in pregnancy."</seg>
<seg id="1685">"patients should however be clarified that in very rare cases occur to a lightheadedness, which can lead to impairment of transportation or ability to serve machinery."</seg>
<seg id="1686">"symptoms may vary between a TNS Depression (Seencoding, Apnoe, diminished mental attention, cyanose, coma, heart-cycle collaps) and a ZNS stimulation (sleeplessness, Tremor, convulsions) with possible letals gings."</seg>
<seg id="1687">"headaches, anxiety, scary mould, muscle, and increased muscle tension, euachycarts, convulatory, irritation, irritation, conceal pain, vertigations, tingcloth, tingual pain, tances, and hypertension, or hypotony."</seg>
<seg id="1688">"a TNS stimulation is particularly likely to children, as well as Atropical in-typical symptoms (mouth-dry, pupgravire and - dilatation, hood, hyperthermia and gastrouninal symptoms)."</seg>
<seg id="1689">"these include both the inhibition of provisional cytokinen such as IL-4, IL-6, IL-8 and IL-13 from human corn cells / bophiles as well as the inhibition of the expression of the Adhemsionsmolecules P-Selektin on Endothelper."</seg>
<seg id="1690">"in a single dose study with adults, desweatadin 5 mg has no influence on standard measurement sizes, including strengthening subjective battles or the tasks which are connected with the flies."</seg>
<seg id="1691">In controlled clinical trials at the recommended dosage of 5 mg every day no increased incidence of slums compared to placebo.</seg>
<seg id="1692">"the oral application of pseudoephedrine in the recommended dosage may give further personomimetic effects, such as an increase in blood pressure, a tachycaries or manifestations of a TNS arousal."</seg>
<seg id="1693">"there were 1,248 patients aged between 12 and 78 years with seasonal allergic rhinitis, whereby 414 patients were Aerinaze tablets."</seg>
<seg id="1694">"in both studies the histamine antagonistic effectiveness of Aerinaze tablets, determined by the total cores for the symptom (except nasal slum swelling), significantly higher than among a monotherapy with pseudoephedrine over the 2-week treatment period."</seg>
<seg id="1695">"the effectiveness of aerinaze tablets with regard to the swelling effect, determined by the nose-germ swelling, was significantly higher than among a monotherapy with Deseratadin about the 2-week treatment period."</seg>
<seg id="1696">The effectiveness of Aerinaze tablets showed no significant differences in terms of gender, age or ethnic belonging to patients. "</seg>
<seg id="1697">As part of a single-dose study on the pharmakokinetics of Aerinaze is Deseratadin within 30 minutes after administration in plasma.</seg>
<seg id="1698">"following the peroral application of aerinaze in healthy volunteers over 14 days, the flow-weight of desloradin, 3-hydroxydesloradin and pseudo-ephedradin and pseudo-ephedrine has reached day 10."</seg>
<seg id="1699">"in the framework of a pharaokinetic multi-body study, which has been carried out with the formulation as tablet to healthy adult probanden, was established that four specimens were deswears bad."</seg>
<seg id="1700">A component study indicates that the exposure (Cmax and AUC) of pseudoephedrine after the alleviation of pseudoephedrine after the alleviation of pseudoephedrine in bioaccumulative) was the exposure to gift of a Aerinaze tablet.</seg>
<seg id="1701">"based on the conventional studies for safety spharmacology, for toxicity in repeatedicity and Reproduction filxicity, the preclinical data with Deseradin will not recognise any particular dangers for humans."</seg>
<seg id="1702">"the combination possessed no greater toxicity than their individual components, and the observed effects were generally related to the ingredient pseudoephedrine."</seg>
<seg id="1703">The combination of Loratadin / Pseudoephedrine was the combination of Loratadin / Pseudoephedrine in the oral gift of rats in a dosage of up to 150 mg / kg / day and to rabbits in a dosage of up to 120 mg / kg / day.</seg>
<seg id="1704">March 2007 and in module 1.8.1 of the authorisation application described Pharmacovigilance system and works before and while the product is on the market.</seg>
<seg id="1705">"antihistaminika contribute to the alleviation of allergic symptoms, by preventing histamine, a body-own substance, its effects can unfold."</seg>
<seg id="1706">"Aerinaze tablets relieve symptoms resulting in connection with seasonal allergic rhinitis (hay fever), such as Niesen, current or juckende nose and knitting, or jured eyes with constipation of the nose."</seg>
<seg id="1707">"20 under certain circumstances, you can be particularly sensitive to the Schleimalp abellent medicines pseudoephedrine, which is included in this medicine."</seg>
<seg id="1708">"(randomness), a stenosities of stomach-form (dexteress that leads to a distortion of stomach, of thin stomach or esophagus, bronchospasmen in the sickle (respiratory system), a prostate greatest or problems with the liver, the kidneys or the bladder."</seg>
<seg id="1709">"inform your doctor when using the aerinaze the following symptoms or disorders occur or may be diagnosed: • hypertension, cardiopathy, cardiac arrhythmia, nausea and headaches or reinforcement of existing headaches."</seg>
<seg id="1710">"when taking aerinaze with other medicines please inform your doctor or pharmacist, if you have taken other medicines or have recently taken, even if it is not prescription drugs."</seg>
<seg id="1711">"traffic-resistance and the use of machines in recommended dosage is not to reckon in the recommended dosage is not to be reckon, that Aerinaze leads or down the attention."</seg>
<seg id="1712">If you have taken a larger quantity of aerinaze as you should inform you immediately your doctor or pharmacist if you should have taken a greater amount of aerinaze than you should.</seg>
<seg id="1713">"if you have forgotten the intake of aerinaze If you have forgotten to take a dose of time, take the application as soon as possible and turn the next dose as planned."</seg>
<seg id="1714">"please inform your doctor or a pharmacist, if any of the listed side effects you have considerably affected or you notice unwanted side effects which are not listed in this usage information."</seg>
<seg id="1715">"hunting, plessness with increased physical activity, mouth-dry, swindle, sore throat, disstipation, thirsty, thirst, fatigue, headaches, nervousness, nervousness and lightheadedness."</seg>
<seg id="1716">"cardiac or cardiac arrhythmia, multiplied eyes, creeping eyes, irritation, irritation, irritation, irritation, irritation, irritation, irritation, irritation, irritation, deceived, declessness, anxiety, anxiety and irritability, anxiety, anxiety and irritability."</seg>
<seg id="1717">"after the launch of Deseratadin, very rarely reported about cases of severe allergic reactions (respiratory, whistling breathing, itching and swelling) or rash reported."</seg>
<seg id="1718">"over cases of dull, hunting, stomach pain, nausea, vomziness, declining, somziness, somziness, somziness, somziness, somziness, osteopathy, anxiety with increased physical activity, about cases of a liver disease and about cases of conspicuous liver enzymes was also very rare."</seg>
<seg id="1719">"it is available as 5 mg tablets, 5 mg- Lyphilisat to take (soluble pill), 2.5 mg- and 5 mg zmelzenge (tablets that dissolve in the mouth), 0,5 mg / ml syrup and as 0,5 mg / ml-solution available."</seg>
<seg id="1720">"for children aged one to five years, the dose of 1,25 mg once daily, which is in the form of 2.5 ml syrup bzw."</seg>
<seg id="1721">"for children aged six to eleven years, the dose is 2.5 mg once daily, either in the form of 5 ml syrup bzw."</seg>
<seg id="1722">Aerius has been studied in eight studies with about 4 800 adults and young people with allergic rhinitis (including four studies in seasonal allergic rhinitis and two studies to patients who were also asthma).</seg>
<seg id="1723">"the effectiveness was measured by changing the symptoms (itching, number and size of squares, impairment of sleep and performance in the day) before and after six-week treatment."</seg>
<seg id="1724">"further studies have been submitted to prove that the body is the syrup, the solution to the inserting and the melting tablets in the same way, as the tablets and the application in children is harmless."</seg>
<seg id="1725">"in an allergic rhinitis, when the results of all studies have been taken together, the two-week treatment with 5 mg Aerius to mean average score of 12 to 26%, compared to the reduction of 12 to 26% in patients who received a placebo."</seg>
<seg id="1726">In the two studies at Urtikaria was the decrease of the symptom with Aerius 58 and 67% compared to 40 and 33% compared to placebo patients treated.</seg>
<seg id="1727">"Aerius may not be used in patients who may be hypersensitive (allergic) against Deseratadin, Loratadin or one of the other components."</seg>
<seg id="1728">January 2001 condemned the European Commission to the Company SP Europe a permit for the transport of Aerius in the entire European Union.</seg>
<seg id="1729">"a tablet once daily, with one or without a meal, for alleviation of symptoms with allergic rhinitis (including inter-animal and futile allergic rhinitis) and Urtikaria (see below 5.1)."</seg>
<seg id="1730">There are limited experience from clinical trials for the effectiveness in the application of Deseratadin at young people from 12 to 17 years (see sections 4.8 and 5.1).</seg>
<seg id="1731">"the treatment of the interacting allergic rhinitis (occurrence of symptoms for less than 4 days a week or less than 4 weeks) should be done according to the previous pathway, and can end up after the sound of the symptoms and can be resumed at their re-emergence."</seg>
<seg id="1732">In the Persian rhinitis (occurrence of symptoms in 4 or more days per week and more than 4 weeks) can be recommended to patients during the allergy period.</seg>
<seg id="1733">Clinically relevant interactions have been found within the framework of clinical trials with deslorniadin tablets were not observed in which erythromycin or Ketoconazol were additionally administered (see below 5.1).</seg>
<seg id="1734">"in a clinical-pharmacological study, the intake of Aerius and alcohol were not reinforced by alcohol (see under Section 5.1)."</seg>
<seg id="1735">"patients should however be clarified that in very rare cases to lightheadedness, which can lead to impairment of transportation or ability to serve machinery."</seg>
<seg id="1736">"clinical trials in different indications, including allergic rhinitis and chronically idiopathic Urtikaria, were reported at the recommended dose of 5 mg every day 3% more side effects in patients with Aerius reported as patients who were treated with placebo."</seg>
<seg id="1737">"the most common upward side effects that was reported by the more common than placebo, fatigue (1.2%), mouth-drying (0,8%) and headaches (0.7%)."</seg>
<seg id="1738">"in a clinical trial with 578 patients from 12 to 17 years was the most common side-effects headaches, which were treated at 5.5% of the patients who were treated with desloradin and 6.6% of patients who were treated with placebo."</seg>
<seg id="1739">"in a multi-tosis study, which up to 45 mg of Deseradin (nineteen clinical dose) were administered, were not clinically relevant effects."</seg>
<seg id="1740">This includes both the inhibition of provisional cytokinen such as IL-4, IL-6, IL-8 and IL-13 from human corn cells / bophiles as well as the inhibition of the expression of the Adhemsionsmolecules P-Selektin on Endothelialcells. "</seg>
<seg id="1741">"in the context of a clinical trial with multiple sclerosis, in the Deseratadin in a dosage given up to 20 mg every day over 14 days were administered, no statistically significant or clinically relevant cardiovascular effects were described."</seg>
<seg id="1742">"in a clinical-pharmacological study, in the Deseratadin in a dosage given by 45 mg daily (the neunfold of clinical dose) was administered over ten days, no extension of the QTc interval."</seg>
<seg id="1743">"in a single dosis- study with adults showed desweatadin 5 mg no influence on standard measuring ranges, including strengthening subjective battles or the tasks which are connected with the flies."</seg>
<seg id="1744">"in patients with allergic rhinitis, Aerius was effective in alleviation of symptoms such as Niesen, Nasal secretion and Juckreiz of the nose, itching flow, and redness of eyes as well as Juckreiz on the Gauge."</seg>
<seg id="1745">"in addition to the established classification in saisonal and perennial, allergic rhinitis can also be classified according to the duration of the symptoms, also in intermittent allergic rhinitis and Persian rhinitis."</seg>
<seg id="1746">Interacting allergic rhinitis is defined as the occurrence of symptoms for less than 4 days a week or less than 4 weeks.</seg>
<seg id="1747">Persian rhinitis is defined as the occurrence of symptoms of 4 or more days a week and more than 4 weeks.</seg>
<seg id="1748">"as the basis of the overall cores of the questionnaire to the quality of life in Rhino-cytivitis was shown, diminished Aerius effectively marked by seasonal allergic rhinitis."</seg>
<seg id="1749">"the chronically idiopathic Urtikaria was proxy examined for further forms of the Urtikaria, as the underlying pathology in the different forms is similar and chronic patients can be easily recruited."</seg>
<seg id="1750">"since the impurification of a causal factor in all urticultural illnesses is expected, that Deseratadin is expected in other forms of Urtikaria as well as in other forms of urine therapy; this is confirmed by the recommendations of clinical guidelines."</seg>
<seg id="1751">"in two placebo-controlled studies over 6 weeks in patients with chronic idiopathic priticaria, Aerius was effective in improving Pruritus and the removal of size and number of squares at the end of the first dosage."</seg>
<seg id="1752">"as in other studies with Antihistaminika in chronic idiopathic primoraria, the minority of patients, not on antihistaminika reacted, out of the study."</seg>
<seg id="1753">An improvement of the itch to exceed 50% was observed in 55% of patients compared to 19% of patients compared to 19% of patients treated with placebo patients.</seg>
<seg id="1754">"the treatment with Aerius reduced the disorder of sleep and growth, as measured by a 4-point scale for evaluating these variables."</seg>
<seg id="1755">"in a pharmacokinetics study, where patients were comparable to patients with the general seasonal rhinitis population, has been achieved with 4% of patients a higher concentration of Deseradin."</seg>
<seg id="1756">There are no clue to a clinically relevant grief after once daily use of Deseradin (5- 20 mg) over 14 days before.</seg>
<seg id="1757">"however, for the Metabolism of Deseratadin responsible Enzyte, however, has not been identified yet, so interaction with other medicines will not be ruled out."</seg>
<seg id="1758">Desweatadin hemmed in-vivo not CYP3A4 and in-vitro-studies have shown that the drug CYP2D6 does not inhibit and neither a substrate nor an Inhibitor of the P-glycoproteins.</seg>
<seg id="1759">In a single doso study with Deseratadin in a dosage of 7.5 mg found out meals (fatty-calorie breakfast) not on the availability of Deseradin.</seg>
<seg id="1760">"the pre-clinical trials and Loratadin carried out pre-clinical trials, at a comparable degree of exposure of Deseradin, no qualitative or quantitative differences with regard to the toxicity of Deseradin and of Loratadin."</seg>
<seg id="1761">"based on the conventional studies for safety spharmacology, toxicity in repetitive gift, genotoxicity and the reproduction of clinical data with desloradin do not recognise special dangers for humans."</seg>
<seg id="1762">"colour film (includes Lactose-monohydrates, Hyprof), Titanum, Macrogol 400, Indigocarmin (E 132)), Fargocarmin (E 132)), Carnaubawachs, drilled wax."</seg>
<seg id="1763">Aerius can be taken independently of the meals to alleviate the symptoms with allergic rhinitis (including inter-animal and futile rhinitis) and Urtikaria (see below 5.1).</seg>
<seg id="1764">The prescribing doctor should be aware that most cases of Rhinitis is caused by infection in children under 2 years by infection (see under Section 4.4) and that no data pretends to support the treatment of an infective rhinitis with Aerius.</seg>
<seg id="1765">"in addition to the exclusion of upper respiratory infections or anatomical anomalies should play a role in the diagnosis of Anamnesis, physical investigations and corresponding laboratories."</seg>
<seg id="1766">About 6% of adults and children between 2 and 11 years of metabolic rings are restricted and find out a higher substantive load (see below 5.2).</seg>
<seg id="1767">"the security of Aerius syrup in children between 2 and 11 years, which is restricted to the metabolized, is identical with the children that is normal metabolize."</seg>
<seg id="1768">"this drug contains saccharose and sorbitol; therefore patients should take patients with inherited problems of a fructose intolerance, glucose-absorption, or a Saccharase-Isomaltar- insufficiency of this medicine."</seg>
<seg id="1769">Clinically relevant interactions formed within the framework of clinical trials with Aerius tablets were not observed in which erythromycin or Ketoconazol were additionally administered (see below 5.1).</seg>
<seg id="1770">"in a clinical-pharmacological study, the intake of Aerius tablets and alcohol were not reinforced by alcohol (see under Section 5.1)."</seg>
<seg id="1771">The overall prevalence of side effects in children between 2 and 11 years was similar to the Aerius syrup Group similar to the placebo group.</seg>
<seg id="1772">"clinical trials with adults and young people in different indications, including allergic rhinitis and chronically idiopathic urticaria, were reported in the recommended dose 3% more side effects in patients with Aerius, than in patients who were treated with placebo."</seg>
<seg id="1773">"in a multi-tosis study of adults and young people, who were administered up to 45 mg desloradin (nineteen clinical dose) were administered, were not clinically relevant effects."</seg>
<seg id="1774">"children aged between 1 and 11 years, who came into question for an antihistamine therapy, received a daily Desloradindosis of 1,25 mg (aged between 1 and 5 years) or 2.5 mg (aged between 6 and 11 years)."</seg>
<seg id="1775">"because the course of allergic rhinitis / chronically idiopathic judgaria and the profile of Deseradin are similar in adults and children, the efficacy data of desloradin can be extracted in adults on the children's population."</seg>
<seg id="1776">"in the context of a clinical trial with multi-expertise in adults and young people, in the Deseratadin were used in a dosage of up to 20 mg every day over 14 days, no statistically significant or clinically relevant cardiovascular effects was described."</seg>
<seg id="1777">"in a clinical-pharmacological study in adults and young people, in the Deseratadin were used in a dosage of 45 mg daily (the neunfold of clinical dose) over ten days in adults, no extension of the QTc interval."</seg>
<seg id="1778">"in controlled clinical trials, recommended dosage was determined by 5 mg every day for adults and adolescents no increased incidence of slums compared to placebo."</seg>
<seg id="1779">In a single-day dose of 7.5 mg led Aerius tablets in adults and young people in clinical trials at no impairment of the Psychomotoric.</seg>
<seg id="1780">"in clinical-pharmacological studies in adults it was impaired by the simultaneous intake of alcohol neither to an increase of alcohol induced power impairment, nor to increase the hatch."</seg>
<seg id="1781">"for adult and adolescent patients with allergic rhinitis, Aerius tablets were effective in alleviation of symptoms such as Niesen, Nasal secretion and Juckreiz the nose, itching flow and redness as well as Juckreiz on the Gauge."</seg>
<seg id="1782">"as the basis of the overall cores of the questionnaire to the quality of life on Rhino-netivitis was shown, diminished Aerius tablets effectively produced by seasonal allergic rhinitis."</seg>
<seg id="1783">"in two placebo-controlled studies over 6 weeks in patients with chronic idiopathic priticaria, Aerius was effective in improving Pruritus and the removal of size and number of squares at the end of the first dosage."</seg>
<seg id="1784">"the spread of this limited metaboliant phenotype was comparable to adults (6%) and children between 2 and 11 years (6% adults, 16% children) than in Caucasians (2% adults, 3% children)."</seg>
<seg id="1785">Similar pharmacopoinetic parameters were observed in a pharmacokinetic multi-tosis study with the sirformulation of children between 2 and 11 years with allergic rhinitis that have restricted metabolization.</seg>
<seg id="1786">The loading (AUC) by Deseratadin was after 3 to 6 hours approximately 6times higher and the Cmax about 3 to 4times higher with a temporal half-time period about 120 hours.</seg>
<seg id="1787">There are no clue to a clinically relevant substance grief after once daily use of Deseradin (5- 20 mg) over 14 days in adults and young people.</seg>
<seg id="1788">"12 In different single dose studies showed that AUC- and Cmax values of Deseradin were comparable in paediatric patients with those recommended by adults, who received desloradin-syrup in a dosage of 5 mg."</seg>
<seg id="1789">"however, that's responsible for the Metabolism of Deseratadin responsible Enzyte, however, was not yet identified, so interaction with other medicines could not be ruled out."</seg>
<seg id="1790">"Aerius Sirup is offered in type-III-brown glass bottles with child-safe polypropylene foam with 30, 50, 60, 100, 120, 150, 225 and 300 ml."</seg>
<seg id="1791">"equipped with a rigid, transparent polystyrene gauge, calibrated with 2.5 ml and 5 ml or with an application splash for preparations to take with scaling of 2.5 ml and 5 ml (only for the 150 ml bottle)."</seg>
<seg id="1792">A dose of Aerius Lyphilisat to take once daily in the mouth to alleviate the symptoms with allergic rhinitis (including inter-animal and futile rhinitis) and Urtikaria (see below 5.1).</seg>
<seg id="1793">"immediately before the application, the blister must be carefully opened and the dose of the Lyophiles can be taken from, without having to damage them."</seg>
<seg id="1794">Clinically relevant interactions have been identified as part of clinical trials with Aerius tablets were additionally applied in which erythromycin or Ketoconazol were additionally applied (see below 5.1).</seg>
<seg id="1795">"clinical trials in different indications, including allergic rhinitis and chronic idiopathic Urtikaria, were reported at the recommended dose of 5 mg daily 3% more side effects in patients with Aerius tablets, than in patients who were treated with placebo."</seg>
<seg id="1796">In a multi-tosis study that were used up to 45 mg desloradin (nineteen clinical dose) were not clinically relevant effects.</seg>
<seg id="1797">"in two single dose studies Aerius Lyphilisat was well tolerated; this was documented by clinical laboratory results, medical studies, vital signs and EKG intervals."</seg>
<seg id="1798">"in the context of a clinical trial with multiple sclerosis, in the Deseratadin were used in a dosage of up to 20 mg every day over 14 days, no statistically significant or clinically relevant cardiovascular effects was described."</seg>
<seg id="1799">"in a clinical-pharmacological study, in which Deseratadin was used in a dosage of 45 mg daily (the neunfold of clinical dose) over ten days, no extension of the QTc interval."</seg>
<seg id="1800">In controlled clinical trials at the recommended dosage of 5 mg every day no increased incidence of slums compared to placebo.</seg>
<seg id="1801">"in an 17 single-dose study with adults showed desweatadin 5 mg no influence on standard, measuring sizes, including strengthening subjective battles or the tasks that are connected with the flies."</seg>
<seg id="1802">"in patients with allergic rhinitis, Aerius tablets were effective in alleviation of symptoms such as Niesen, Nasal secretion and Juckreiz of the nose, itching flow, and redness of eyes as well as Juckreiz on the Gauge."</seg>
<seg id="1803">"as the basis of the overall cores of the questionnaire to the quality of life in Rhino-cytivitis was shown, diminished Aerius effectively marked by seasonal allergic rhinitis."</seg>
<seg id="1804">"18 In a Pharmacokinetics study, which were comparable to patients with the general seasonal rhinitis population, with 4% of patients achieved a higher concentration of Deseradin."</seg>
<seg id="1805">"food does not have a significant impact on AUC and Cmax of Aerius Lyophilisat while food Tmax of Deseradin of 2.5 to 4 hours and Tmax of 3-OH-Deseradin of 4 on 6 hours."</seg>
<seg id="1806">Gelatine Mannitol aspartame (E 951) Polacrilin-Kalium dye Opatint Red (contains iron (III) and Hypromo (E 464)) aroma Tutti-Frutti-free citric acid</seg>
<seg id="1807">An Aerius 2.5 mg leg-tablett once daily in the mouth place to alleviate the symptoms with allergic rhinitis (including inter-animal and fuisticians allergic rhinitis) and Urtikaria (see below 5.1).</seg>
<seg id="1808">Two Aerius 2.5 mg screzenge once daily in the mouth to alleviate the symptoms with allergic rhinitis (including inter-animal and fuisticians allergic rhinitis) and Urtikaria (see below 5.1).</seg>
<seg id="1809">There are limited experience from clinical trials to effectiveness in the application of Deseratadin at young people from 12 to 17 years (see sections 4.8 and 5.1)</seg>
<seg id="1810">"immediately before the application, the blister must be carefully opened and the dose of smote-coated tablet can be taken without defects."</seg>
<seg id="1811">The effectiveness and inconceivable of Aerius 2.5 mg of melzenge in the treatment of children under 6 years have not been proven.</seg>
<seg id="1812">The overall prevalence of the side effects between the desloratadine Sirup- and the placebo group was the same and turned not it significantly from the safety-provided safety profile.</seg>
<seg id="1813">In the recommended dose Aerius Schmelus Schmelzenges was found on the Aerius 5 mg of conventional tablets and the Aerius 5 mg Lyophiisat to initiate formulation of Deseradin.</seg>
<seg id="1814">"in the context of a clinical trial with multiplants, in the Deseratadin were used in a dosage of up to 20 mg every day over 14 days, no statistically significant or clinically"</seg>
<seg id="1815">"in a single dose study with adults, desweatadin 5 mg has no influence on standard and measuring sizes, including strengthening subjective battles or the tasks which are connected with the flies."</seg>
<seg id="1816">"the spread of this poor metaboliant phenotype was comparable to an adult (6%) and paediatric patients aged 2 to 11 years (6%), and under black (adults 18%, children 16%), the safety profile of these patients was not deviating from that of the general population."</seg>
<seg id="1817">In single-dose crossover studies by Aerius Stmelzenge with Aerius 5 mg conventional tablets or Aerius 5 mg Lyphilisat to take were the formulations of bioilling.</seg>
<seg id="1818">"Aerius 2.5 mg tablets were not examined in paediatric patients, but in conjunction with the Dosisfinite data for Aerius Schmelzenge the use of 2.5 mg dosage for children aged 6 to 11 years."</seg>
<seg id="1819">"food does not have a significant impact on AUC and Cmax of Aerius Aerius Lyphilisat, while food Tmax of Deseradin of 2.5 to 4 hours and Tmax of 3-OH- Deseratadin of 4 to 6 hours."</seg>
<seg id="1820">"the overall analysis of preclinical and clinical irritation tests for the melting tablett, revealed that this formulation is a probable risk for local irritation in clinical use."</seg>
<seg id="1821">Microcrystine Cellulose pre-mastered strength Carboxymethylmethylmethylmethylmethacrylate Citronensäure hydrogencarbonate Citaol Aspartame (E951) aroma Tutti Frutti</seg>
<seg id="1822">"the Kaltformidable foile consists of Polyvinyl-loride (PVC) for a matter-related polyamide (Opa) film, liable laminated on an aluminium foil, liable laminated on a polyvinylchloride (PVC) film."</seg>
<seg id="1823">An Aerius 5 mg Tmelzenge once daily in the mouth to alleviate the symptoms with allergic rhinitis (including inter-animal and fuisticians allergic rhinitis) and Urtikaria (see below 5.1).</seg>
<seg id="1824">In the recommended dose Aerius 5 mg of melting tablette was found on the Aerius 5 mg of conventional tablets and the Aerius 5 mg Lyphilisat to initiate formulation of Deseradin.</seg>
<seg id="1825">"in the context of a clinical trial with multiple sclerosis, in the Deseratadin were used in a dosage of up to 20 mg every day over 14 days, no statistically significant or clinically relevant cardiovascular effects was described."</seg>
<seg id="1826">"with an 30 single-dose study with adults, desweatadin 5 mg has no influence on standard and measuring sizes, including strengthening subjective battles or the tasks which are connected with the flies."</seg>
<seg id="1827">"in patients with allergic rhinitis, Aerius tablets were effective in alleviation of symptoms such as Niesen, Nasal secretion and Juckreiz of the nose, itching flow, and redness of eyes as well as Juckreiz on the Gauge."</seg>
<seg id="1828">In single-dose crossover studies of Aerius 5 mg zmelzenge with Aerius 5 mg conventional tablets or Aerius 5 mg Lyphilisat to take were the formulations of bioilling.</seg>
<seg id="1829">"the overall analysis of preclinical and clinical irritation tests for the melting tablett, revealed that this formulation is a probable risk for local irritation in clinical use."</seg>
<seg id="1830">"the safety of Desloradin with children aged 2 to 11 years, which is restricted to the metabolized, is identical with the children that is normal metabolize."</seg>
<seg id="1831">"this drug contains sorbitol; therefore patients should take patients with inherited problems of a fructtosad intolerance, glucose-absorption, or a Saccharase-isomaltase-insufficiency of this medicine."</seg>
<seg id="1832">The overall prevalence of side effects in children between 2 and 11 years was similar to the desloradin Group similar to the placebo group.</seg>
<seg id="1833">"for infants between 6 and 23 months were the most common unwanted side effects, reported by the more common than placebo (3.7%), fever (2,3%) and sleeplessness (2.3%)."</seg>
<seg id="1834">"in an additional study, Avastin was observed in an additional dose of 2.5 mg desperate Engadin solution for taking no side effects in patients aged between 6 and 11 years."</seg>
<seg id="1835">In the recommended doses were the Plasmakoncentations of Desloratadin (see below 5.2) in the children's and adult population.</seg>
<seg id="1836">"in controlled clinical trials, recommended dosage was determined by 5 mg every day for adults and adolescents no increased incidence of slums compared to placebo."</seg>
<seg id="1837">"in addition to the established classification in saisonal and perennial, allergic rhinitis can be allergic to the duration of the symptoms alternatively also in intermittent allergic rhinitis and"</seg>
<seg id="1838">"as the basis of the overall cores of the questionnaire to the quality of life on Rhino-netivitis was shown, diminishes Aerius tablets effectively produced by seasonal allergic rhinitis."</seg>
<seg id="1839">"the spread of this limited metaboliant phenotype was comparable to adults (6%) and children between 2 and 11 years (6% adults, 16% children) than in Caucasians (2% adults, 3% children)."</seg>
<seg id="1840">"as Aerius solution for taking the same concentration of Deseradin, no bioaccumulative study was required and it is expected that it corresponds to the syrup and the tablets."</seg>
<seg id="1841">"in different single dose studies proved that AUC- and Cmax values of Deseradin were comparable in paediatric patients with recommended doses, which were desperate Engadin-syrup in a dosage of 5 mg."</seg>
<seg id="1842">"Sorbitol, propylene glycol, Sucralose E 955, Natriumcitrate 2 H2O, natural and artificial flavors (Bubble-gum), water-free citric acid, sodium water."</seg>
<seg id="1843">"Aerius solution for taking is offered with 30, 50, 60, 100, 120, 150, 225 and 300 ml in type III brown glazing with a child-resistant polyethylene fixed-coated application."</seg>
<seg id="1844">All packaging sizes except the 150 ml packet size are offered with a measuring poon with markings for dosing capacity of 2.5 ml and 5 ml.</seg>
<seg id="1845">The 150 ml packet size is a messspoon or a applicator for preparations for recording of 2.5 ml and 5 ml attached.</seg>
<seg id="1846">"subsequently to the extension of the approval, the filing owner will submit a regular updated reports on the inconceivable of a drug with every two years unless it becomes somewhat different from CHMP."</seg>
<seg id="1847">1 film-tablett 3 film-tablett 7 film-tablett 14 film-tablett 20 film-tablett 20 film-tablett 30 movie-coated tablet 100 movie-coated tablet</seg>
<seg id="1848">1 film-tablett 3 film-tablett 7 film-tablett 14 film-tablett 20 film-tablett 20 film-tablett 30 movie-coated tablet 100 movie-coated tablet</seg>
<seg id="1849">Sirup 30 ml with 1 measuring spoon 60 ml with 1 measuring spoon 150 ml with 1 measuring poon 150 ml with 1 measuring tubes for 150 ml with 1 measuring results for ingestion 225 ml with 1 measuring poon 300 ml with 1 measuring poon</seg>
<seg id="1850">30 ml with 1 measuring spoon 60 ml with 1 measuring spoon 150 ml with 1 measuring poon 150 ml with 1 measuring tubes 150 ml with 1 measuring results for ingestion 225 ml with 1 measuring spoon 300 ml with 1 measuring poon</seg>
<seg id="1851">1 dose of Lyphilisat to take 2 cans of lyophiisat for taking 10 cans of lyophiisat to take 30 doses of Lyphilisat to Eintake 30 cans of Lyphilisat to Eintake 30 cans of Lyphilisat to Eintake 50 cans of Lyphilisat to take 100 cans of Lyphilisat to take 100 cans of Lyphilisat to take over 100 cans of Lyphilisat.</seg>
<seg id="1852">5 melting tablett 10 Stmelzenge 10 Stmelzenge 20 Schmelzenge 20 Schmelzenge 60 Schmelzenge (90 melting brackets) for 100 pallet-tablett-tablecfold</seg>
<seg id="1853">Solution for taking 30 ml with 1 measuring spoon 60 ml with 1 measuring poon 150 ml with 1 measuring poon 150 ml with 1 measuring tubes for 150 ml with 1 measuring results for ingestion 225 ml with 1 measuring poon 300 ml with 1 measuring poon</seg>
<seg id="1854">Pregnancy and lactation questions you may ask during pregnancy and lactation before taking all medicines your doctor or pharmacist by advice.</seg>
<seg id="1855">"traffic-resistance and the use of machines in recommended dosage is not to reckon in recommended dosage, is not to be reckoned that asterius leads to lightheadedness or declining the attention."</seg>
<seg id="1856">"if you have told by your doctor you have a intolerance against certain sugar, ask your doctor before you take this medicine."</seg>
<seg id="1857">"regarding treatment of treatment, your doctor will determine the type of allergic rhinitis under which you suffer and will determine how long you should take Aerius."</seg>
<seg id="1858">"if your allergic rhinitis is intermittingly (the symptoms are less than 4 days a week occur or less than 4 weeks, your doctor will recommend you a treatment scheme that depends on your previous disease."</seg>
<seg id="1859">"if your allergic rhinitis is persist (symptoms in 4 or more days per week), your doctor may recommend you a longer lasting treatment."</seg>
<seg id="1860">"if you have forgotten the intake of Aerius If you have forgotten your dose into time, take them as soon as possible and follow the normal treatment plan."</seg>
<seg id="1861">"71 But after the launch of Aerius has been very rare about cases of severe allergic reactions (difficulties when breathing, whistling breathing, itching and swelling) and rash."</seg>
<seg id="1862">"over cases of heart knock, hunting, stomach pain, nausea, vomziness, somziness, declining, ingestation, mutucinations, accidents, anxiety with increased physical activity, liver enzymes and unusual liver-functional activity was also very rare."</seg>
<seg id="1863">"tablet form consists of color-colored film (includes Lactos- monohydrates, titanium dioxide, Macrogol 400, Indigocarmin (E 132)), colored film (contains Hyprostitute, Macrogol 400), Carnaubawax, born wax."</seg>
<seg id="1864">"Aerius 5 mg film-coated tablets are individually in blister packs of 1, 2, 3, 5, 7, 10, 14, 30, 50, 90, 90, 50 or 100 tablets."</seg>
<seg id="1865">"Aerius Sirup is shown for children between 1 and 11 years, young people (12 years and older) and adults, older people."</seg>
<seg id="1866">Important information about certain other components of Aerius you should not take Syerius syrup if you are allergic to the dye 110 square.</seg>
<seg id="1867">"if your doctor has told your doctor you have an intolerance towards some sugars, please contact your doctor before taking this medicine."</seg>
<seg id="1868">"when the syrup is a applicator Sure to take on scaling with scaling, you can use this alternatively to take the appropriate amount of syrup."</seg>
<seg id="1869">"regarding treatment of treatment, your doctor will determine the type of allergic rhinitis under which you suffer and will determine how long you should take Aerius syrup."</seg>
<seg id="1870">"however, with children under 2 years of diarrhoea, fever and insomnia common side effects, while in adults tiredness, mouth-drying and headaches were reported as placebo."</seg>
<seg id="1871">"after the launch of Aerius, very rare on cases of severe allergic reactions (difficulties when breathing, whistling breathing, itching and swelling) and rash reported."</seg>
<seg id="1872">"77 Aerius Sirup is available in bottles with child-safe wear cap with 30, 50, 60, 100, 120, 150, 225 and 300 ml."</seg>
<seg id="1873">"Aerius Lyphilisat to take improves the symptoms with allergic rhinitis (by an allergy-up inflammation of the nose-length, such as hay fever or pet food allergy)."</seg>
<seg id="1874">"when taking Aerius Lyphilisat, taking along with food and drink Aerius Lyphilisat to take and do not need to be taken with water or any other fluid."</seg>
<seg id="1875">"regarding treatment of treatment, your doctor will determine the type of allergic rhinitis under which you suffer and will determine how long you should take Aerius Lyphilisat."</seg>
<seg id="1876">"81 If you have forgotten the intake of Aerius Lyophilisat, If you have forgotten your dose to take in time, take them as soon as possible and follow the normal treatment plan."</seg>
<seg id="1877">"after the launch of Aerius, very rare on cases of severe allergic reactions (difficulties when breathing, whistling breathing, itching and swelling) and rash reported."</seg>
<seg id="1878">"Aerius Lyphilisat to take is individually in blister packs of 1, 2, 3, 5, 7, 10, 14, 15, 20, 30, 30, 50 or 100 cans of the Lyophilus."</seg>
<seg id="1879">"Aerius Schmelzenge improves the symptoms with allergic rhinitis (by an allergy-up inflammation of the nose-length, such as hay fever or pet foods - allergy)."</seg>
<seg id="1880">"when taking Aerius melting tablets, along with food and drink Aerius Schmelzenge does not need to be taken with water or any other fluid."</seg>
<seg id="1881">"regarding treatment of treatment, your doctor will determine the type of allergic rhinitis under which you suffer and will determine how long you should take Aerius melting tablets."</seg>
<seg id="1882">"86 If you have forgotten the intake of Aerius shuttzenge, If you have forgotten your dose into time, take them as soon as possible and follow the normal treatment plan."</seg>
<seg id="1883">"Aerius Schmelzenge is individually wrapped in blister packs of 5, 6, 10, 12, 15, 18, 60, 90, 50, 60, 90 and 100 cans of melting tablett."</seg>
<seg id="1884">"when taking Aerius melting tablets, along with food and drink Aerius Schmelzenge does not need to be taken with water or any other fluid."</seg>
<seg id="1885">"if you have forgotten the intake of Aerius melting tablets, If you have forgotten your dose to take in time, take them as soon as possible and follow the normal treatment plan."</seg>
<seg id="1886">"after the launch of Aerius, very rare on cases of severe allergic reactions (difficulties when breathing, whistling breathing, itching and swelling) and rash reported."</seg>
<seg id="1887">"Aerius solution for inclusion is shown for children between 1 and 11 years, young people (12 years and older) and adults, older people included."</seg>
<seg id="1888">"if the solution for taking a application of application for recording with scaling, you can use this alternatively to take the appropriate amount of solution for taking."</seg>
<seg id="1889">"regarding treatment of treatment, your doctor will determine the type of allergic rhinitis under which you suffer and will determine how long you should take Aerius solution for taking."</seg>
<seg id="1890">"however, with children under 2 years of diarrhea, fever and sleeplessness frequent side effects whilst in adult fatigue, mouth-drying and headaches were reported as placebo."</seg>
<seg id="1891">"97 Aerius solution for taking is available in bottles with child-safe wear cap with 30, 50, 60, 100, 120, 150, 225 and 300 ml."</seg>
<seg id="1892">The 150 ml packet size is a messspoon or an application splash for use with scaling of 2.5 ml- and 5 ml-doses.</seg>
<seg id="1893">June 2008 Novartis Vaccines and Diagnostics S.r.l. the Committee on Humanarzs (CHMP) officially distributed its application for authorisation from Aflunov to the prevention of aviary H5N1 influenza in adults and elderly people.</seg>
<seg id="1894">"Aflunov should be applied in adults and older people for the protection against flu, which is caused by the tribe (type) H5N1 of the influenza-A-virus."</seg>
<seg id="1895">"this is a special kind of vaccine that might cause a trunk of influenza, which could cause a future pandemic."</seg>
<seg id="1896">"a flu-pandemic breaks out when a new trunk of the flu virus emerging, which can easily spread from man to person because people still have no immunity (no protection) against it."</seg>
<seg id="1897">"according to administration of the vaccine the immune system recognises the immune system contained in the vaccine parts of the flu-virus as" "physically" "and forms antibodies against it."</seg>
<seg id="1898">This is the immune system later in the position to form a contact with a flu virus that can form more quickly antibodies.</seg>
<seg id="1899">"subsequently, the membrane keeper of the virus with the" "surface antigens" (proteins on the membrane surface, which recognizes the human body as body-alien), certified and used as a component of the vaccine. "</seg>
<seg id="1900">"a inspection of some of the study centers showed that the study was not conducted according to the" "good clinical practice" "(GCP)."</seg>
<seg id="1901">Thereby the scope of the clinical data base for evaluating the security of the vaccine is not out to fulfill the requirements of the guidelines of the EMEA for Prepandemic vaccines.</seg>
<seg id="1902">"should you take part in a clinical test and need more information about your treatment, please contact your care doctor."</seg>
<seg id="1903">"if you wish to receive further information regarding the recommendations of CHMP, please read the scientific debate (also part of the EPAR)."</seg>
<seg id="1904">"it is used in combination with other antiviral medicines to treat adults and children over four years, which is caused by human immunomweakevirus of type 1 (HIV-1), which caused the acquired immunomynynsyndrome (AIDS)."</seg>
<seg id="1905">"for patients who cannot swallow the capsules, Agenerase stands as a solution for taking, but this cannot be taken together with Ritonavir because the safety of this combination was not examined."</seg>
<seg id="1906">"Agenerative should only be enacted when the doctor has tested, which anti-viral medicines has taken before, and the likelihood has been assessed for the virus on the drug."</seg>
<seg id="1907">The recommended dose for patients over twelve years is 600 mg twice daily that are taken along with twice daily 100 mg of Ritonavir and other antiviral medicines.</seg>
<seg id="1908">"in children between four and twelve years, and in patients with a body weight of less than 50 kg, the recommended dose of Agenerative is governed by the body weight."</seg>
<seg id="1909">"in combination with other antiviral medicines, reduces the HIV quantity in the blood and keeps them at low levels."</seg>
<seg id="1910">"AIDS not cure AIDS, however, can delay the damage of the immune system and thus also delay the development of suffering with AIDS infections and diseases."</seg>
<seg id="1911">"Agenerative drugs has been studied in combination with other antiviral medicines, but without Ritonavir, studied in two main studies with 736 HIV-infected adults, which previously did not have been treated with proteasers."</seg>
<seg id="1912">"this with low dosified Ritonavir reinforced medicinal products has been taken in 206 adults, which had previously taken proteins, with other proteins."</seg>
<seg id="1913">Main indeer for the effectiveness was the proportion of patients with non-evidence concentrations of HIV in the blood (Viruslast) or the change in the viral last after treatment.</seg>
<seg id="1914">"in studies with patients who had previously taken no proteasiness, although after 48 weeks under Agenerative more patients had a Viruslast under 400 copies / ml than below placebo, but Agenerative was less effective than Indinavir."</seg>
<seg id="1915">"in children, Agenerase also decreased the Viruslast, but with the children, who were previously treated with proteasiness, only very few on the treatment."</seg>
<seg id="1916">"in the study with adults, who had been treated earlier with proteasiness, the Vironavir-reinforced medicinal products are as effective as other proteins in the past:"</seg>
<seg id="1917">"in patients with HIV, which was resisted against four other proteins, it came under Agenerative with Ritonavir to a stronger waste of the Viruslast after four weeks than in patients who continue their previous proteins."</seg>
<seg id="1918">"the most common side effects of Agenerative (observed in more than 1 of 10 patients) are headaches, diarrhoea (diarrhoea), nausea (nausea), vomiting, rash and Fatigue (tiredness)."</seg>
<seg id="1919">2 / 3 Agenerase may not be applied in patients that may be hypersensitive (allergic) against amprenavir or one of the other components.</seg>
<seg id="1920">"Agenerative may also not be used in patients, the currant (a herbal supplements for treating depression) or medicines that are being built just like Agenerative or are in high concentrations in the blood health harmful."</seg>
<seg id="1921">"as with other medicines against HIV consists of patients suffering, the risk of a lipodystrophy (changes in the distribution of the body fat), a osteonekrose (distributing of bone tissue) or an immunodious syndroms (symptoms of an infection, which are caused by the emerging immune system)."</seg>
<seg id="1922">The Committee on Humanarzs (CHMP) led to the conclusion that the advantages of Agenerative drugs used in combination with other antiretroviral medicines to treat HIV-1 infected adults and children over four years compared to the risks.</seg>
<seg id="1923">"Agenerative is usually taken together with pharmacokinetic amplifiers, but the Committee established that the benefits of Agenerative in combination with Ritonavir in patients who have previously taken no proteasiness."</seg>
<seg id="1924">"generic conditions was originally approved under" extraordinary circumstances, "because at the time of approval for scientific reasons it was limited only limited information."</seg>
<seg id="1925">October 2000 condemned the European Commission to the Glaxo Group Limited as approve of the transportation of Agenerative in the entire European Union.</seg>
<seg id="1926">"Agenerative drugs is available in combination with other antiretroviral medicines to treat HIV-1- infected, proteins, adults and children from 4 years onwards."</seg>
<seg id="1927">"for usually, Agenerative capsules are to be administered for pharmakokinetic booster by Amprenavir, along with low doses of Ritonavir (see sections 4.2 and 4.5)."</seg>
<seg id="1928">The use of amprenavir should take place in consideration of the individual viral resistance and the pre-treatment of the patient (see Section 5.1).</seg>
<seg id="1929">The bioavailability of amprenavir as a solution to income is 14% lower than from Amprenavir as a capsule; therefore these are Agenerative capsules and solution for taking on a milligram per milligram basis not exchangeable (see Section 5.2).</seg>
<seg id="1930">The recommended dose for Agenerative capsules is 600 mg Amprenavir twice daily along with 100 mg of Ritonavir twice daily in combination with other antiretroviral medicines.</seg>
<seg id="1931">"2 If Agenerative capsules are used without the amplifictive addition of Ritonavir (booster), higher doses must be applied to Agenerative (1200 mg twice daily)."</seg>
<seg id="1932">The recommended dose for Agenerative capsules is 20 mg of amprenavir / kg body weight twice daily in combination with other antiretroviral medicines up to a daily dose of 2400 mg Amprenavir that should not be exceeded (see Section 5.1).</seg>
<seg id="1933">"the pharmacokinetics, effectiveness and safety of Agenerative in combination with low doses of Ritonavir or other proteins, were not examined in children."</seg>
<seg id="1934">"Agenerative is not recommended for use in children under 4 years, due to the failure of data to infinity and effectiveness (see Section 5.2)."</seg>
<seg id="1935">"based on pharmacokinetic data the dose of Agenerative capsules should be reduced to 450 mg twice daily, and in patients with severe liver dysfunctions on 300 mg twice daily."</seg>
<seg id="1936">The simultaneous application is to be performed with caution in patients with mild or moderate liver dysfunction in patients with severe liver interruption they are contrained (see Section 4.3).</seg>
<seg id="1937">Agenerative may not be given simultaneously with pharmaceuticals which have a low therapeutic width and also represent substrate of the Cytochrom P450-Isoenzymes 3A4 (CYP3A4).</seg>
<seg id="1938">Herbal preparations to contain the curd (hypericum perforatum) may not be used due to the risk of reduced plastic concentration and a diminished therapeutic effect of amprenavir during the intake of amprenavir (see Section 4.5).</seg>
<seg id="1939">Patients should be pointed out that Agenerative or any other antiretroviral therapy does not lead to a cure of HIV infection and that they can continue to develop opportunistic infections or other complications of an HIV infection.</seg>
<seg id="1940">The present antiretroviral therapy including the treatment with agenerase does not prevent the risk of transferring HIV to others through sexual contact or contamination with blood.</seg>
<seg id="1941">"usually, Agenerative capsules are to be applied together with low doses of Ritonavir and in combination with other antiretroviral medicines (see Section 4.2)."</seg>
<seg id="1942">Patients suffering from chronic hepatitis B or C and treated with an antiretroviral therapy have a increased risk for severe liver impacts with potentially deadly course.</seg>
<seg id="1943">"for the event of simultaneous antiviral treatment of hepatitis B or C, please read the relevant information of this medicine."</seg>
<seg id="1944">Patients with existing restricted liver function including a chronic-active hepatitis also show an increased frequency of liver dysfunctions under an antiretroviral therapy and should be monitored according to clinical practice.</seg>
<seg id="1945">The simultaneous application of Agenerative or Ritonavir with Fluticason or other gluten-cores that will be confused unless the possible benefits of treatment the risk of systemic corsteroids including Morbus Cushing and Stockression of adrenal-function weighs (see Section 4.5).</seg>
<seg id="1946">"since the metabolism of the HMG CoA reducer Lovastatin and Simvastatin continued to depend on CYP3A4, a simultaneous closure of Agenerative with Lovastatin and Simvastatin due to the increased risk of myopathies including Rhabdomyolysen."</seg>
<seg id="1947">"4 For some medicines that may cause serious or life-threatening unwanted effects, such as Carbamazepin, phenytoin, tricyclic antidepressants and warfarin (under supervision of the International Normalised ratio), methods are available for determining the substance concentration."</seg>
<seg id="1948">"in patients who take these drugs simultaneously, aromatic can be less effective due to decreased plastic level of amprenavir (see Section 4.5)."</seg>
<seg id="1949">"due to the possibility of metabolic interactions with amprenavir, the effectiveness of hormonal contraceptive can be changed, however the information is not sufficient to estimate the type of interactions."</seg>
<seg id="1950">"when methadone is given at the same time with amprenavir, patients should therefore be monitored on oppivets symptoms, particularly if there is also a low doses of Ritonavir."</seg>
<seg id="1951">"due to the possible risk of toxicity, due to the high propylene glycolgehogs of the Agenerative solution to the admission, this subform of children under an age of four years should be exercised and should be applied with caution in certain other patient groups."</seg>
<seg id="1952">"Agenerative should be set on a duration 5, if a rash may be accompanied by systemic or allergic symptoms (see Section 4.8)."</seg>
<seg id="1953">"in patients who received an antiretroviral therapy including proteasants, hyperglycaemia is reported by the appearance of diabetes mellitus, hyperglycaemia or an exasculation of an existing diabetes mellitus."</seg>
<seg id="1954">Many of the patients had other diseases which were necessary for their therapy drugs which are associated with the development of diabetes mellitus or a hyperglycaemia.</seg>
<seg id="1955">"B. higher age, and with pharmaceutical-dependent factors, as a longer continuous antiretroviral treatment and the associated metabolic disorders."</seg>
<seg id="1956">"with hashophiles patients (type A and B), which were treated with proteasers, reports of an increase in bleeding including spontaneous hematutaner hematoms and hematthrows."</seg>
<seg id="1957">In case of HIV infected patients with severe immune defective patients may develop a inflammatory reactions to asymptomatic or residual opportunistic infections that leads to severe clinical conditions or deterioration of symptoms.</seg>
<seg id="1958">"although a multi factorial ministries is accepted (including application of coronary steroids, alcohol consumption, severe immune repression, higher body-Mass-Index), cases of Osteonecrose especially in patients with advanced HIV disease and / or long-term application of antiretroviral hepatitis (ART)."</seg>
<seg id="1959">CYP3A4-substrate with low therapeutic width of Agenerase must not be given simultaneously with pharmaceuticals which represent a low therapeutic width and also represent substrate of the Cytochrom P450-Isoenzymes 3A4 (CYP3A4).</seg>
<seg id="1960">CYP2D6 substrate with low therapeutic width Agenerase with Ritonavir must not be combined with pharmaceuticals which are mainly associated with pharmaceuticals and / or life-threatening effects.</seg>
<seg id="1961">It has been shown that Rifampicin a 82% reduction in AUC by Amprenavir which can lead to a virological failure and lead to a resistance development.</seg>
<seg id="1962">"trying to restrict the lowest plastic level through a dosage increase of other protease inhibitors in combination with Ritonavir, very frequently unwanted effects on the liver observed."</seg>
<seg id="1963">Currant (hypericum perforatum) The serum mirror of amprenavir can be humiliated by the simultaneous usage of herbal preparations with curd (hypericum perforatum).</seg>
<seg id="1964">"when a patient already tremigheds, the amprenavirage is and, if possible, to check the Viruslast and dismiss the curd."</seg>
<seg id="1965">A dosage adjustment for one of the drug is not required when Nelfinavir is administered along with Amprenavir (see also Efavirenz below).</seg>
<seg id="1966">508% increase, for Cmax by contrast to 30% lower if Ritonavir (100 mg twice daily) is administered in combination with Amprenavir capsules (600 mg twice daily). "</seg>
<seg id="1967">"in clinical trials, dosing of 600 mg Amprenavir were used twice daily and konavir 100 mg twice daily that occupy the effectiveness and infinity of this treatment scheme."</seg>
<seg id="1968">52% lower when Amprenavir (750 mg twice daily) in combination with Kaletra (400 mg Lopinavir + 100 mg Ritonavir twice daily) was administered.</seg>
<seg id="1969">"the Cmin values of Amprenavir in Plasma, which were achieved in combination of Amprenavir (600 mg twice daily) with Kaletra (400 mg Loponavir twice daily), are approximately 40 to 50% lower than when Amprenavir (600 mg twice daily) can be administered twice daily in combination with 100 mg of Ritonavir twice a day."</seg>
<seg id="1970">"a dosing intake for the simultaneous administration of Amprenavir and Kaletra can not be given, however, it is recommended to be a contighter monitoring because the effectiveness and inconceivable of this combination is not known."</seg>
<seg id="1971">"there has been no pharmacokinetic study used to use Agenerative in combination with Didanosin, but is recommended due to the randomly component of didanosin recommended that the revenues of Didanosin and Agenerase is at least one hour apart. (see Antazida below)."</seg>
<seg id="1972">Therefore at gift of rfavirence in combination with Amprenavir (600 mg twice daily) and Ritonavir (100 mg twice daily) no tin adjustment is required.</seg>
<seg id="1973">The treatment with emavirence in combination with amprenavir and Saquinavir is not recommended as the exposure of both proteins.</seg>
<seg id="1974">The effect of Nevirapon to other proteins and existing limited data suggest that Nevirapinto the serumkonzentration of Amprenavir may be lowers.</seg>
<seg id="1975">"if these drugs should be used simultaneously, caution is advisable, since Delavirdin because of decreased / possibly subtherapeutic plasma will be less effective."</seg>
<seg id="1976">"if these drugs are applied together, caution is advisable; a thorough clinical and virological surveillance should be made, as an accurate forecast of the combination of the combination of amprenavir and Ritonavir is difficult."</seg>
<seg id="1977">The simultaneous gift of amprenavir and rifabutin led to a rise in Plasmakonzentration (AUC) by Rifabutin to 193% and thus to a rise in with rifabutin associated side effects.</seg>
<seg id="1978">"when it is necessary for clinical reasons, rifabutin together with Agenerative is to be administered, to a reduction in dosage of rifabutin at least half of the recommended dose, although there are no clinical data available."</seg>
<seg id="1979">"pharmacokinetic studies with agenerative in combination with erythromycin were not carried out, however the plasma-level of both medicines could be increased in the case of simultaneous administration."</seg>
<seg id="1980">"the simultaneous application of twice daily 700 mg Fosamprenavir and 100 mg of Cetoconazol once daily led to an increase in the Cmax of Ketoconazol in the plasma for the value, which was observed after 200 mg Ketoconazol once daily without simultaneous application of Fosamprenavir."</seg>
<seg id="1981">"other medicines that are listed below, including substrate, Hemmer or inductors of CYP3A4, can be applied if they are applied together with Agenerative disorders, possibly cause interactions."</seg>
<seg id="1982">"patients should therefore be combined on toxic reactions which are linked to these drugs, if they are applied in combination with generosity."</seg>
<seg id="1983">"based on the data of other proteins, it is advisable that Antazida should not be taken at the same time as angenerative, as it may come to resoratory disorders."</seg>
<seg id="1984">"the simultaneous application of anticonvulsva, which are known as an enzymes (phenytoin, phenobstrual, carbamazepin), with amprenavir can lead to a humiliation of the plasmasonry of amprenavir."</seg>
<seg id="1985">"serum concentrations of calcium binders like Amlodipin, Diltiazem, Felodipin, nidipin, Nizdipin, Nizdipin, Nizdipin, Nizdipin, and Verapamil can be increased by Amprenavir, which may increase the activity and toxicity of these drugs."</seg>
<seg id="1986">"simultaneous intake with Agenerative can increase their plasma concentration and reinforce with PDE5-inhibitors associated with PDE5 inhibitors, including hypotension, visual dysfunctions and priapism (see Section 4.4)."</seg>
<seg id="1987">In a clinical study where Ritonavir 100 mg capsules are given twice daily along with 50 µg Fluticasonpropionate intranasal (4 times daily) over 7 days to probanden (90% intensity) (90% -confidenzinterval 82 to 89%).</seg>
<seg id="1988">"consequently, the simultaneous gift of Agenerative with Ritonavir is not recommended, unless the possible benefits of treatment is the risk of systemic cortical _ steroids (see Section 4.4)."</seg>
<seg id="1989">"with HMG CoA reductase inhibitors such as Lovastatin and Simbiatin, their metabolism is greatly dependent on CYP3A4, are distinctive increases of the plasmasonry at simultaneous administration of Agenerative."</seg>
<seg id="1990">"since Plasmaspivic increase in this HMG CoA reductase inhibitors to Myopathy, including a Rhabdomyolysis, the combined application of this medicine is not recommended with amprenavir."</seg>
<seg id="1991">"it is recommended for a common monitoring of the therapeutic concentrations to stabilize the mirror, since the plasma concentration of cyclosporin, Rapamycin and Tacrolimus can be increased by Amprenavir (see Section 4.4)."</seg>
<seg id="1992">"therefore, Agenerase may not be applied together with oral inperceived hdazolam (see Section 4.3) while respecting simultaneous use of Agenerative Midazolam caution."</seg>
<seg id="1993">"data for simultaneous use of parental Midazolam with other protein levels, indicating a possible increase in the plasmasonry from Midazolam to add 3 to 4 times."</seg>
<seg id="1994">"when methadon is administered along with Amprenavir, patients should therefore be monitored on oppivets symptoms, particularly if there is also a low doses of Ritonavir."</seg>
<seg id="1995">"due to the maximum limited number of historic comparisons, no recommendation may be given, like the Amprenavir- dose to adapt, when Amprenavir is administered at the same time with methadon."</seg>
<seg id="1996">"with simultaneous gift of warfarin or other oral anticoagulants along with Agenerative, an increased control of INR (International Normalised ratio) is recommended because of the possibility of a weakening or reinforcement of the anti-thrower effect (see Section 4.4)."</seg>
<seg id="1997">The effect of an additional administration of Ritonavir on hormonal contraceptive is not foreseeable; therefore alternative methods are recommended for receptions.</seg>
<seg id="1998">A careful monitoring of the therapeutic effects and side effects of tricyclic antidepressants (for example Desipramine and Nortryptilin) is recommended for simultaneous gift of Agenerative or (see Section 4.4).</seg>
<seg id="1999">"during pregnancy, this drug can only be applied for careful unconsidering of the potential usage for the mother compared to the possible risks to fetus."</seg>
<seg id="2000">"in the milk, Amprenavir-related substances have been proven in the milk, it is not known whether Amprenavir are overweight in people into the breast milk."</seg>
<seg id="2001">A reproduction study of pregnant rats which was administered by the entry into the uterus until the end of the lactation period Amprenavir. during the lactation period was a diminished increase in the 12 body weight in the offspring.</seg>
<seg id="2002">The further development of the descendants including fertilisation and reproductive capacity was not affected by the administration of amprenavir.</seg>
<seg id="2003">The thoughtfulness of Agenerative was examined in adults and in children from 4 years onwards in controlled clinical trials in combination with various other antiretroviral medicines.</seg>
<seg id="2004">"most associated with the Agenerative treatment associated side effects were slightly to moderate, entered early on and led rarely to the treatment."</seg>
<seg id="2005">"in many of these events is not clear whether in connection with the intake of Agenerative or another at the same time, whether they are applied to HIV treatment."</seg>
<seg id="2006">"most of the below side effects come from two clinical trials (PROAB3001, PROAB3006), in which with Proteasags did not pre-treated patients 1200 mg Agenerative twice daily."</seg>
<seg id="2007">"events (degrees 2 to 4), which were used by the investigators than in connection with the study medicine, and with more than 1% of the patients were performed, as well as under the treatment of rising laboratory changes (degree 3 to 4) are listed."</seg>
<seg id="2008">"antiretroviral therapy therapy has been associated with a redistribution of the body fat (Lipodystrophy) in HIV-patients, including a loss of peripherous and viscereal fat tissues, hypertropy of the breasts and dorsocervical fats."</seg>
<seg id="2009">"under 113 antiretroally non-treated persons, who had been treated with amprenavir in combination with Lamivudin / Zidovetine over a mean period of 36 weeks, was only observed (laps) (&lt; 1%)."</seg>
<seg id="2010">"in the study PROAB 3006, at 245 NTDs (11%) compared to 27 cases (11%) compared to 27 cases (11%) in combination with various NRTIs over a mean duration of 56 weeks (p &lt; 0,001)."</seg>
<seg id="2011">"rashes were usually slightly pronounced, erythematogenous or makulopapulous nature, with or without itch, and occurred spontaneously during the second week of treatment and disappeared spontaneously within two weeks, without the treatment with amprenavir."</seg>
<seg id="2012">"cases of Osteonekrose were reported especially in patients with generally known risk factors, advanced HIV disease or long-term application of antiretroviral hepatitis therapy (ART)."</seg>
<seg id="2013">In case of HIV infected patients with severe immune disorders can be used at the time of introduction of antiretroviral therapy (ART) a inflammatory reactions to asymptomatic or residual opportunistic infections.</seg>
<seg id="2014">"with PI prevalent patients treated 600 mg Agenerative twice daily along with low dowed Ritonavir (degree 2 to 4) and lab changes (degrees 2 to 4) and CPK values, which received among patients, the augenerase along with low dozed konavir, were very frequently stopped."</seg>
<seg id="2015">"in case of overdose, the patient is able to observe signs of an intoxication (see Section 4.8) if necessary, are necessary supportive policies."</seg>
<seg id="2016">"Amprenavir binds to the active centre of HIV-1 protease, and thereby prevents the procession virgag- und gag-pol- polyproteinformation, with the consequence of an education unripper, non-infectious viral infection."</seg>
<seg id="2017">"the antiviral activity of amprenavir in vitro against HIV-1 IIIB was tested both in akut and chronic lymphoatable cell lines (MT-4, CEM-CCRF, H9) as well as in peripheral hemtic lymphocytes."</seg>
<seg id="2018">The 50% Hemmkonzentration (IC50) of Amprenavir is in the range from 0.012 to 0.08 µM with acute cells and amounts to 0.12 µM in chronic cells.</seg>
<seg id="2019">The connection between the activity of amprenavir against HIV-1 in vitro and the inhibition of HIV-1 replication in humans is not yet defined.</seg>
<seg id="2020">"in the treatment of antiretroally, not previously-treated patients with the currently approved Fosamprenavir / Ritonavir-dosages have been observed - as with other Ritonavir-dosed treatment systems - the mutations described above rarely observed."</seg>
<seg id="2021">"in the sixteen of 434, not pre-treated patients having obtained 700mg Fosamprenavir twice a day in the ESS100732 study, a virological failure came up to 48 per week, whereby the 14 insulates could be investigated."</seg>
<seg id="2022">"a otypical analysis of the insulates of 13 of 14 children, where a virological failure entered within the 59 concluded with proteins that were not pre-treated patients who were similar to those in adults."</seg>
<seg id="2023">"L10F / I / V, V11I, I13V, M36V, M36V, I50V, I50V, I50V, I77V, V82V, V82V, I85V, I85V, I85V, L90V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V."</seg>
<seg id="2024">In the study APV30003 and its extension APV30005 (700 mg Fosamprenavir / 100 mg Ritonavir twice daily: N = 107) to patients with virological verbs over 96 weeks, the following protein-mutations: "</seg>
<seg id="2025">On genotypical resistance-based analyses of genotypic interpretations systems can be applied to an assessment of the activity of amprenavir / Ritonavir or Fosamprenavir / Ritonavir in patients with proteasant-resistors isolates.</seg>
<seg id="2026">"the current (July 2006) ANRS-AC-11-algorithm for Fosamprenavir / Ritonavir, Resistenz, or at least 4 of the following mutations L10F / I, L33F, I84V and L90M, with Ritonavir, and a reduced probability of a virological response (Resistenz)."</seg>
<seg id="2027">"the conclusions with regard to the relevance of certain mutations or mutation patterns can be subject to changes due to additional data, and it is recommended to enable the current interpretations systems to analyze the results of Resistenzest tests."</seg>
<seg id="2028">On pherotypical resistance-based analysis clinically valiant interpretations systems can be applied in connection with the genotypic data to an assessment of activity of amprenavir / Ritonavir or Fosamprenavir / Ritonavir in patients with proteasant-resistors isolates.</seg>
<seg id="2029">Companies that sell diagnostic Resistensiders have developed clinically-phänotypic cut-offs (partitions) for FPV / RTV which can be applied to the interpretation of results of a Resident test.</seg>
<seg id="2030">"each of these four with a reduced sensitivity to Amprenavir associated genetic patterns creates a certain crude resistance to Ritonavir, the sensitivity to Indinavir, Nelfinavir and Saquinavir."</seg>
<seg id="2031">There are currently data on the cross-resistance between Amprenavir and other proteasags for all 4 Fosamprenavir Resistenzpfade either alone or in combination with other mutations.</seg>
<seg id="2032">"on the basis of twenty-five antiretroated patients, those with Amprenavir / Ritonavir (three of 25 isolates), Darunavir / Ritonavir (three of 24 isolates), Inequavir / Ritonavir (three of 24 isolates), strings and Tipranavir (four of 24 isolates) and Tipranavir (four of 24 isolates) and Tipranavir (four of 24 isolates) and tionavir (four of 24 Isolate)."</seg>
<seg id="2033">"conversely, Amprenavir maintains its activity against several other proteins of gender-resistant insulation; obtaining this activity seems to be dependent on the number and from type of resistance mutations in the isolates."</seg>
<seg id="2034">The early breaking-off therapy is recommended to keep the accumulation of a variety of mutations in boundaries which can affect the following treatment.</seg>
<seg id="2035">"the cover of the effectiveness of Agenerative in combination with Ritonavir 100 mg twice daily is based on the study PRO30017, a randomized open study (Viruslast &gt; 1000 copies / ml) either with a PI, mostly with low-coated konavir."</seg>
<seg id="2036">"sixty pounds (n = 163) patients with proven virus sensitivity to Agenerative, at least another PI and at least one NRTI were included in the part study A of PRO30017."</seg>
<seg id="2037">The primary analysis presented the non-harness of APV / Ritonavir as compared to the SoC-PI Group with regard to the SoC-PI Group in regard to the SoC-PI Group in the Plasma (HIV-1 RNA) in Plasma after 16 weeks in a non-smoking area of 0.4log10 copies / ml.</seg>
<seg id="2038">"the cover of the effectiveness of ungeboostained dgenerase is based on two uncontrollable studies with a total of 288 HIV infected children aged 2 to 18, of which 152 were treated with PI."</seg>
<seg id="2039">"in the studies, Agenerative solution to take and capsules in doses of 15 mg / kg three times daily, 20 mg / kg twice daily, 20 mg / kg twice daily, with the majority of patients received 20 mg / kg twice a day."</seg>
<seg id="2040">It was not given any low dosized Ritonavir at the same time; the majority of the patients treated with PI-treated patients had at least one (78%) or two (42%) which were administered along with Agenerative NRLA.</seg>
<seg id="2041">After 48 weeks about 25% of the patients included a plasma HIV-1 RNA concentration &lt; 10,000 copies / ml and 9% &lt; 400 copies / ml in a median increase in the CD4 cell count from 26 cells / mm ³ (n = 74) compared to the starting point.</seg>
<seg id="2042">"19 Basics to this data should be considered during treatment optimisation, with PI forward-treated children of the expected benefit of" "unborn" "generosity into consideration."</seg>
<seg id="2043">"for oral administration, the average duration (tmax) is up to maximum Serum concentration of Amprenavir approximately 1 to 2 hours for the capsule and about 0.5 to 1 hour for solving."</seg>
<seg id="2044">508% increase in contrast to 30% by contrast to 30% if Ritonavir (100 mg twice daily) administered together with Amprenavir (600 mg twice daily).</seg>
<seg id="2045">"the administration of amprenavir with a meal guides up to 25% of the AUC, but has no effect on the concentration of Amprenavir 12 hours after dosage (C12)."</seg>
<seg id="2046">"therefore, the minimum concentration of the Steady State (Cmin, ss) remained unaffected by the food intake, although the simultaneous food intake is the extent and rate of resorption."</seg>
<seg id="2047">The apparent distribution volume is approximately 430 l (6 l / kg at a body weight of 70 kg) and leaves a vast distribution of amprenavir from the blood circulation into the tissue.</seg>
<seg id="2048">"this change leads to a decrease of the total concentration of the substance in plasma, with the quantity of uncommon amprenavir, which represents the active part, probably remains unchanged."</seg>
<seg id="2049">"while absolute concentration of uncommon amprenavir remains constant, the percentage of free active components may vary depending on the overall drug industry in the steady State on the range of Cmax, ss to Cmin."</seg>
<seg id="2050">"therefore, medicines, the CYP3A4 inserts, or inhibits a substrate of CYP3A4, be administered with caution when they are given simultaneously with Agenerative (see sections 4.3, 4.4 and 4.5)."</seg>
<seg id="2051">"the gift of Agenerative capsules, either 20 mg / kg twice or 15 mg / kg three times daily, leads to a similar daily Amprenavir-exposure as in adults with a dosage of 1200 mg twice daily."</seg>
<seg id="2052">"Amprenavir is out of the solution 14% less bible version than out of the capsules; therefore, Agenerative solution and Agenerative capsules are not interchangeable on a milligrammbase."</seg>
<seg id="2053">"also, the renal Clearance of Ritonavir is neglected, therefore the impact of a kidney failure to the Elimination of Amprenavir and Ritonavir."</seg>
<seg id="2054">These therapy schemata lead to Amprenavir-plasmasons comparable to those that are obtained in healthy volunteers after a dose of 1200 mg Amprenavir twice a day without simultaneous closure of Ritonavir.</seg>
<seg id="2055">"in long-term studies for canogeneity with amprenavir on mice and rats stood in male animals benigne hepatic cellular enzyome in doses, the exposure to the 2-times (mice) or 3,8- triple (rat) of exposure to 1200 mg of amprenavir."</seg>
<seg id="2056">The 21 underlying mechanism for the emergence of the hepatic cellulary adenome and Carcinoma still has not been clarified and the relevance of these observed effects for the human being is unclear.</seg>
<seg id="2057">"however, from the present exposure data at the people, both from clinical trials and the therapeutic application, however, take little evidence of the acceptance of a clinical relevance of these findings."</seg>
<seg id="2058">"in a standard battery of In-vivo- and In-vitro-Genotoxicity testing, the bacterial reverse mutation tests (Ames test), mouse-lymphom test, microkernel test in human peripheral lymphocytes included, was amprenavir or genital muxic."</seg>
<seg id="2059">This liver toxicity can be monitored and proven in clinical everyday life by means of AST, ALT and the activity of alkaline phosphatase. "</seg>
<seg id="2060">"in clinical studies, there have been no significant liver toxicity in patients, neither during administration of Agenerative or after the end of the treatment."</seg>
<seg id="2061">"studies for toxicity in juveniles were treated with juveniles at an age of 4 days, demonstrated both in control and with Amprenavir."</seg>
<seg id="2062">"in a systemic plasma Exposure, which was significant below (rabbits) or not significantly higher (rats) than the expected exposure under therapeutic dosage, however, were observed a number of low-level changes including Thymuselongation and low-low skeleton, which point out to a delay."</seg>
<seg id="2063">"24 When Agenerative capsules are used without the amplifictive addition of Ritonavir (booster), higher doses must be applied to Agenerative (1200 mg twice daily)."</seg>
<seg id="2064">The recommended dose for Agenerative capsules is 20 mg of amprenavir / kg body weight twice daily in combination with other antiretroviral medicines up to a daily dose of 2400 mg Amprenavir that should not be exceeded (see Section 5.1).</seg>
<seg id="2065">The simultaneous application is said to be treated with caution in patients with dewaking or mild liver disruption with caution in patients with severe liver interruption. (see Section 4.3).</seg>
<seg id="2066">"26 For some medicines that can cause serious or life-threatening unwanted effects, such as Carbamazepin, phenytoin, tricyclic antidepressants and warfarin (under supervision of the International Normalised ratio), methods are available for determining the substance concentration."</seg>
<seg id="2067">"Agenerative should be set in duration 27 when a rash is accompanied by systemic or allergic symptoms, or the veiled are involved (see Section 4.8)."</seg>
<seg id="2068">"an increased risk for lipodystrophy has been associated with individual factors, such as higher age, and with drug dependent factors such as a longer continuous antiretroviral treatment and the associated metabolic disorders."</seg>
<seg id="2069">It has been shown that Rifampicin a 82% reduction in AUC by Amprenavir which can lead to a virological failure and lead to a resistance development.</seg>
<seg id="2070">508% increase, for Cmax by contrast to 30% lower if Ritonavir (100 mg twice daily) is administered in combination with Amprenavir capsules (600 mg twice daily). "</seg>
<seg id="2071">"the Cmin values of Amprenavir in Plasma, which were achieved in combination of Amprenavir (600 mg twice daily) with Kaletra (400 mg Loponavir twice daily), are approximately 40 to 50% lower than when Amprenavir (600 mg twice daily) can be administered twice daily in combination with 100 mg of Ritonavir twice a day."</seg>
<seg id="2072">"a dosing intake for the simultaneous administration of Amprenavir and Kaletra can not be given, however, it is recommended to be a contighter monitoring because the effectiveness and inconceivable of this combination is not known."</seg>
<seg id="2073">The treatment with emavirence in combination with amprenavir and Saquinavir is not recommended as the exposure of both proteins.</seg>
<seg id="2074">"if these drugs are applied together, caution is advisable; a thorough clinical and virological surveillance should be made, as an accurate forecast of the combination of the combination of amprenavir and Ritonavir is difficult."</seg>
<seg id="2075">"if it is necessary for clinical reasons, rifabutin together with Agenerative causes, becomes a reduction in dosage of rifabutin at least half of the recommended dose 31, although there are no clinical data available."</seg>
<seg id="2076">"serum concentrations of calcium binders like Amlodipin, Diltiazem, Felodipin, nidipin, Nizdipin, Nizdipin, and Verapamil can be increased by Amprenavir, which may increase the activity and toxicity of these drugs."</seg>
<seg id="2077">In a clinical study where Ritonavir 100 mg capsules are given twice daily along with 50 µg Fluticasonpropionate intranasal (4 times daily) over 7 days to probanden (90% intensity) (90% -confidenzinterval 82 to 89%).</seg>
<seg id="2078">"with simultaneous gift of warfarin or other oral anticoagulants along with Agenerative, an increased control of INR (International Normalised ratio) is recommended because of the possibility of a weakening or reinforcement of the anti-thrower effect (see Section 4.4)."</seg>
<seg id="2079">The simultaneous administration of Ortho-Novum 1 / 35 (0.035 mg Ethinylestradiol plus 1,0 mg Norethindron) led to a decrease of AUC and Cmin by Amprenavir by 22% bzw.</seg>
<seg id="2080">"during pregnancy, this drug can only be applied for careful unconsidering of the potential usage for the mother compared to the possible risks to the fetus."</seg>
<seg id="2081">A reproduction study of pregnant rats which was administered by the entry into the uterus until the end of the lactation period Amprenavir. during the lactation period was a diminished increase in body weight in the offspring.</seg>
<seg id="2082">The thoughtfulness of Agenerative was examined in adults and in children from 4 years onwards in controlled clinical trials in combination with various other antiretroviral medicines.</seg>
<seg id="2083">"in case of overdose, the patient is able to observe signs of an intoxication (see Section 4.8) if necessary, are necessary supportive policies."</seg>
<seg id="2084">"the antiviral activity of amprenavir in vitro against HIV-1 IIIB was tested both in akut and chronic lymphoatable cell lines (MT-4, CEM-CCRF, H9) as well as peripheral hemtic lymphocytes."</seg>
<seg id="2085">The 50% Hemmkonzentration (IC50) of Amprenavir is located in the range from 0.012 to 0.08 µM in acute cells and amounts to 2 µM in chronic ininfected cells (1 µM = 0.50 µg / ml).</seg>
<seg id="2086">"conversely, Amprenavir maintains its activity against several other proteins of gender-resistant insulation; obtaining this activity seems to be dependent on the number and from type of resistance mutations in the isolates."</seg>
<seg id="2087">"based on this data should be considered during treatment optimisation, with PI prevalent children of the expected benefit of" "unborn" "generosity into consideration."</seg>
<seg id="2088">"while absolute concentration of uncommon amprenavir remains constant, the percentage of free active components may vary depending on the overall drug industry in the steady State on the range of Cmax, ss to Cmin, ss.."</seg>
<seg id="2089">"therefore, medicines, the CYP3A4 inserts, or inhibits a substrate of CYP3A4, be administered with caution when they are given simultaneously with Agenerative (see sections 4.3, 4.4 and 4.5)."</seg>
<seg id="2090">Also the renal Clearance of Ritonavir is negligible; therefore the impact of an kidney failure is likely to be low on the Elimination of Amprenavir and Ritonavir.</seg>
<seg id="2091">In long-term studies on canogeneity with amprenavir on mice and rats appear in male animals benigne hepatic cellular adenome in dosages (mice) or 3.8- triple (rat) the exposure of 1200 mg Amprenavir.</seg>
<seg id="2092">The underlying mechanism for the emergence of the hepatocular adenome and Carcinoma still has not been clarified and the relevance of these observed effects for the human being is unclear.</seg>
<seg id="2093">"however, from the present exposure data at the people, both from clinical trials and from the therapeutic application, there are little evidence of the acceptance of a clinical relevance of these findings."</seg>
<seg id="2094">"in a standard battery of In-vivo- and In-vitro-Genotoxicity testing, the bacterial reverse mutation tests (Ames test), mouse-lymphom test, microkernel test in human peripheral lymphocytes included, was amprenavir or genital muxic."</seg>
<seg id="2095">"studies for toxicity in juveniles were treated with juveniles at an age of 4 days, demonstrated both in control and with Amprenavir."</seg>
<seg id="2096">These results can be exclude that in bulls the Metabolism does not yet fully mature so that Amprenavir or other critical components of the wording (z).</seg>
<seg id="2097">"Agenerative solution for inclusion is in combination with other antiretroviral medicines to treat HIV-1 infected, proteins, adults and children from 4 years onwards."</seg>
<seg id="2098">"the benefit of using Ritonavir" geboosterter "Agenerative solution to intake was not occupied with the patients treated with PI-treated patients with PI-treated patients."</seg>
<seg id="2099">The bioavailability of amprenavir as a solution to income is 14% lower than from Amprenavir as a capsule; therefore these are Agenerative capsules and solution for taking on a milligram per milligram basis not exchangeable (see Section 5.2).</seg>
<seg id="2100">Patients should as soon as they are able to swallow the capsules with the intake of the solution to take (see Section 4.4).</seg>
<seg id="2101">The recommended dose for a generative solution is 17 mg (1,1 ml) Amprenavir / kg body weight three times daily in combination with other antiretroviral medicines up to a daily dose of 2800 mg Amprenavir that should not be exceeded (see Section 5.1).</seg>
<seg id="2102">"in addition, there must be no tin recommendations for the simultaneous application of Agenerative solution to inserting and low dosified konavir can be avoided these combination with these patient groups."</seg>
<seg id="2103">Although a dosage adjustment for amprenavir is not necessary for amprenavir is an application of Agenerative solution for taking patients with kidney failure. (see Section 4.3).</seg>
<seg id="2104">"due to the potential risk of a toxic reaction as a result of high propylene glycol is Agenerative solution for taking children and children under 4 years, pregnant women with reduced liver function or liver fail and in patients with kidney failure."</seg>
<seg id="2105">The simultaneous administration may lead to a competitive inhibition of the metabolic isation of these medicines and potentially cause serious and / or life-threatening unwanted effects such as cardiac arrhythmia (z).</seg>
<seg id="2106">Patients should be pointed out that Agenerative or any other antiretroviral therapy does not lead to a cure of HIV infection and that they continue to develop opportunistic infections or other complications of an HIV infection.</seg>
<seg id="2107">The present antiretroviral therapy including the treatment with Agenerative is not preventing the risk 47 of an transfer of HIV to others through sexual contact or contamination with blood.</seg>
<seg id="2108">"for some medicines that can cause serious or life-threatening unwanted effects, such as Carbamazepin, phenytoin, tricyclic antidepressants and warfarin (under supervision of the International Normalised ratio), methods are available for determining the substance concentration."</seg>
<seg id="2109">"Agenerative should be set in a duration when a rash may be accompanied by systemic or allergic symptoms, or the veiled are involved (see Section 4.8)."</seg>
<seg id="2110">"an increased risk for lipodystrophy has been associated with individual factors, such as higher age, and with pharmaceutical - 49 depending factors, as a longer continuous antiretroviral treatment and the associated metabolic disorders."</seg>
<seg id="2111">"with hashophiles patients (type A and B), which were treated with proteasers, reports of an increase in bleeding including spontaneous hematutaner hematoms and hematthrows."</seg>
<seg id="2112">It has been shown that Rifampicin a 82% reduction in AUC by Amprenavir which can lead to a virological failure and lead to a resistance development.</seg>
<seg id="2113">508% increase, for Cmax by contrast to 30% lower if Ritonavir (100 mg twice daily) is administered in combination with Amprenavir capsules (600 mg twice daily). "</seg>
<seg id="2114">"simultaneous intake with Agenerative can increase their plasma concentration and lead to PDE5-inhibitors associated with PDE5 inhibitors, including hypotension, visual dysfunctions and priapism (see Section 4.4)."</seg>
<seg id="2115">Based on data on 54 other CYP3A4-inhibitors are expected to be significantly higher plastic concentration by Midazolon.</seg>
<seg id="2116">"the potential risk to man is not known as" "Agenerative solution to ingestion may not be applied due to potential toxic reactions of Fetus to the" "propylene glycol" "(see Section 4.3)."</seg>
<seg id="2117">"in the milk, Amprenavir-related substances have been proven in the milk, it is not known whether Amprenavir are overweight in people into the breast milk."</seg>
<seg id="2118">A reproduction study of pregnant rats which was administered by the entry into the uterus until the end of the lactation period Amprenavir. during the lactation period was a diminished increase in the 55 body weight in the offspring.</seg>
<seg id="2119">The thoughtfulness of Agenerative was examined in adults and in children from 4 years onwards in controlled clinical trials in combination with various other antiretroviral medicines.</seg>
<seg id="2120">"in many of these events is not clear whether in connection with the intake of Agenerative or another at the same time, whether they are applied to HIV treatment."</seg>
<seg id="2121">"in the treatment of antiretroally, not previously-treated patients with the currently approved Fosamprenavir / Ritonavir-dosages have been observed - as with other Ritonavir-dosed treatment systems - the mutations described above rarely observed."</seg>
<seg id="2122">The early breakup of an accidental 60 therapy is recommended to keep the accumulation of a variety of mutations in boundaries which can affect the following treatment.</seg>
<seg id="2123">62 Basiating on this data should be considered during treatment optimisation with PI forward-treated children of the expected benefit of "ungebooed" augenerase into consideration.</seg>
<seg id="2124">The apparent distribution volume is approximately 430 l (6 l / kg at a body weight of 70 kg) and can be extended to a large alphony volecumenical penetration of amprenavir from the blood circulation into the tissue.</seg>
<seg id="2125">The underlying mechanism for the emergence of the hepatic cellulary adenome and Carcinoma still has not been clarified and the relevance of these observed effects for the human being is unclear.</seg>
<seg id="2126">"in a systemic plasma Exposure, which was significant below (rabbits) or not significantly higher (rats) than the expected exposure under therapeutic dosage, however, were observed a number of low-level changes including Thymuselongation and low-low skeleton, which point out to a delay."</seg>
<seg id="2127">Maybe you want to read this later again. − If you have any further questions please contact your doctor or pharmacist. − this medicine was personally prescribed.</seg>
<seg id="2128">"it can harm other people even if they have the same discomfort as you. − When one of the above-side effects you have considerably affected or you notice unwanted side effects, which are not listed in this usage information, please inform your doctor or a pharmacist."</seg>
<seg id="2129">"your doctor will normally assign, Agenerative capsules along with low doses of Ritonavir to increase the effect of Agenerative."</seg>
<seg id="2130">The use of Agenerative will be based on your doctor for you carried out individual viral resistance and your medical treatment.</seg>
<seg id="2131">Inform your doctor if you suffer from any of the above diseases or taking any of the above drugs.</seg>
<seg id="2132">"if your doctor recommended that you have Agenerative capsules along with low doses of Ritonavir to enhance the effect (boosting), make sure you have read the usage information about Ritonavir before the start of treatment."</seg>
<seg id="2133">"likewise, no adequate information is recommended to recommend using Agenerative capsules along with Ritonavir for the efficiency of children aged 4 to 12 years or in general in patients under 50 kg of body weight."</seg>
<seg id="2134">"therefore, it is important that you can read the section" "When taking Agenerative with other medicines, before you start using Agenerative."</seg>
<seg id="2135">"possibly you need additional factor VIII to control the blood circulation. − When patients obtained an antiretroviral hepatitis, a redistribution, collection or loss of body fat can occur."</seg>
<seg id="2136">"if you can cause certain medicines that may lead to serious side effects such as Carbamazepine, phenytoin, Tacamycin, tricyclic antidepressants, tricyclic antidepressants, tricyclic antidepressants, tricyclic antidepressants, tricyclic antidepressants, tricyclic antidepressants, tricyclic antidepressants, tricyclic antidepressants, tricyclic antidepressants, tricyclic antidepressants, tricyclic antidepressants, and warfarin, at the same time as Agenerase, your doctor will perform additional blood tests to minimize possible security problems."</seg>
<seg id="2137">It is recommended that HIV positive women should hold their children under no circumstances to avoid transmission of HIV.</seg>
<seg id="2138">Traffic-resistance and management of machines There have been no studies for the influence of heavy-generality or ability to serve machinery.</seg>
<seg id="2139">Please take this medicine only after consultation with your doctor if you know is that you suffer from a intolerance towards certain sugars.</seg>
<seg id="2140">"Didanosin) is advisable that you are taking this more than an hour before or to Agenerative, otherwise the effects of Agenerative can be diminished."</seg>
<seg id="2141">"dose of Agenerative capsules, 600 mg twice daily along with 100 mg of Ritonavir twice daily in combination with other antiretroviral medicines."</seg>
<seg id="2142">"if your doctor decides that taking Ritonavir is not suitable for you, you will have to take higher doses (1200 mg Amprenavir twice daily)."</seg>
<seg id="2143">"85 Damit Agenerative is a major benefit, it is very important that you have the whole day dose that you have prescribed your doctor."</seg>
<seg id="2144">"if you have taken a larger amount of Agenerative, when you should have taken more than the prescribed dose of Agenerative, you should immediately contact your doctor or a pharmacist contact."</seg>
<seg id="2145">"if you have forgotten the intake of Agenerative, you take it once you think and then continue taking the intake as before."</seg>
<seg id="2146">"in treating an HIV infection, it is not always possible to tell whether ascending side effects caused by disgenerase, by other medicines which are taken simultaneously, or by the HIV disease itself."</seg>
<seg id="2147">"headaches, craving, diarrhea, pathologies, vesiations, blacks or itch, occasionally may be the skin rash and you to break down the intake of this medication by force."</seg>
<seg id="2148">"mood, depression, sleeping disorders, appetisers-loss tingling in the lips and in the mouth, uncontrollable movements, unpleasantinal chairs, rise of certain liver enzymes, the transamic gland, the increase of an enzymes of pancreas called Amylase."</seg>
<seg id="2149">Increased blood levels for sugar or cholesterol (a certain blood fat) increases blood levels of a substance called Bilirubin swelling of the face; the lips and the tongue (angioededv).</seg>
<seg id="2150">"this can include fat loss of legs, arms and face, a fat leasing at the stomach and in other internal organs, breast Enlarging and fats in the neck."</seg>
<seg id="2151">"please inform your doctor or a pharmacist, if any of the listed side effects you have considerably affected or you notice unwanted side effects which are not listed in this usage information."</seg>
<seg id="2152">"therefore, it is important that you can read the section" "When taking Agenerative with other medicines, before you start using Agenerative."</seg>
<seg id="2153">"in some patients who receive an antiretroviral hepatitis, one can develop an osteonecrose (dying of bone tissue due to inadequate blood supply of the femur)."</seg>
<seg id="2154">"Didanosin) is advisable that you are taking this more than an hour before or to Agenerative, otherwise the effects of Agenerative can be diminished."</seg>
<seg id="2155">"94 Damit Agenerative is a major benefit, it is very important that you have the whole day dose that you have prescribed your doctor."</seg>
<seg id="2156">"if you have forgotten the intake of Agenerative, you take it once you think and then continue taking the intake as before."</seg>
<seg id="2157">"headaches, craving, diarrhea, pathologies, vesiations, blacks or itch, occasionally may be the skin rash and you to break down the intake of this medication by force."</seg>
<seg id="2158">"please inform your doctor or a pharmacist, if any of the listed side effects you have considerably affected or you notice unwanted side effects which are not listed in this usage information."</seg>
<seg id="2159">"dose of Agenerative capsules, 600 mg twice daily along with 100 mg of Ritonavir twice daily in combination with other antiretroviral medicines."</seg>
<seg id="2160">"with that Agenerative is a major benefit, it is very important that you have the whole day dose that you have prescribed your doctor."</seg>
<seg id="2161">"if you have taken larger amounts of amogenerative, when you should have taken more than the prescribed dose of Agenerative, you should immediately contact your doctor or a pharmacist contact."</seg>
<seg id="2162">"the benefits associated with Ritonavir" "Agenerative" "Agenerative solution to the ingestion was not covered with the patients being treated with proteasants."</seg>
<seg id="2163">For the application lower doses of Ritonavir (usually applied to the reinforcement of the effect [boosting] of Agenerative capsules) along with Agenerative solution to income can be given no metering recommendations.</seg>
<seg id="2164">Ritonavir solution for taking) or in addition propylene glycol during the intake of Agenerative solution (see also Agenerative solution must not be taken).</seg>
<seg id="2165">"your doctor will possibly keep you on side effects, which are associated with the propylene glyphcontent of the Agenerative solution to inclusion in particular, especially if you have a kidney or liver illness."</seg>
<seg id="2166">"111 If you can cause certain medicines that may lead to serious side effects such as Carbamazepine, phenytoin, Tacamycin, tricyclic antidepressants, tricyclic antidepressants, tricyclic antidepressants, tricyclic antidepressants, tricyclic antidepressants, tricyclic antidepressants, tricyclic antidepressants, tricyclic antidepressants, tricyclic antidepressants, tricyclic antidepressants, tricyclic antidepressants, tricyclic antidepressants, tricyclic antidepressants, tricyclic antidepressants, and warfarin, at the same time as Agenerase, your doctor will perform additional blood tests to minimize possible security problems."</seg>
<seg id="2167">Ritonavir solution for taking) or additional propylene glycol are not taking besides ingenerase (see Agenerative may not be taken).</seg>
<seg id="2168">Important information about certain other components of Agenerative solution for taking into the solution includes propylene glycol that may result in high doses to side effects.</seg>
<seg id="2169">"propylene glycol can cause a number of side effects including crampages, lightheadedness, coronary heart and the reduction of the red blood cells (see also agenerase must not be taken, special caution when taking Agenerative is required precautions)."</seg>
<seg id="2170">"if you have forgotten the intake of Agenerative, you take it once you think and then continue taking the intake as before."</seg>
<seg id="2171">"headaches, craving, diarrhea, pathologies, vesiations, blacks or itch, occasionally may be the skin rash and you to break down the intake of this medication by force."</seg>
<seg id="2172">"this can include fat loss of legs, arms and face, a fat leasing at the stomach and in other internal organs, breast Enlarging and fats in the neck."</seg>
<seg id="2173">"other components are propylene glycol, Macrogol 400 (Polyethylenglycol 400), Tocoferchloride, artificial chewood, sodium flavours, sodium citrate, sodium citrate, sodium citrate, purified water."</seg>
<seg id="2174">"the practicality and the duration of treatment with Aldara depend on the disease of treatment: • At a maximum of 16 weeks in the genital area, Aldara is six times weekly five times weekly during one or two four-week treatment cycles, with four weeks break between the treatment of cycles, three times weekly."</seg>
<seg id="2175">The cream stand in front of the bedtime thin-layered on the affected skin surfaces so that they remain enough for a long time (approximately eight hours) on the skin before they washed away.</seg>
<seg id="2176">In all studies Aldara was compared with a placebo (same cream but without the active ingredient). • Aldara was tested in four main studies on 923 patients with warts in the genital area each 16 weeks.</seg>
<seg id="2177">The main indeer for the effectiveness was the number of patients with full cooling of the treated warts. • Aldara was also examined on 724 patients with small bumps in two studies in which patients were treated for six weeks or placebo or placebo either daily or five times weekly.</seg>
<seg id="2178">The main indeer for the effectiveness was the number of patients with full precipitation of tumors after twelve weeks. • Aldara was also tested in two studies in a total of 505 patients with actinic keratants.</seg>
<seg id="2179">In all studies Aldara was more effective than placebo. • When treatment of warts in the genital area was treated 15% to 52% in the patients treated with placebo patients compared to 80% in comparison to 0% to 3% in the placebo group.</seg>
<seg id="2180">The most common side effects of Aldara (observed in more than 1 of 10 patients) are reactions to the application of cream (pain or itch).</seg>
<seg id="2181">"clinical typical, not hyperkeratotic, not hypertropic keratosen (AKS) on the face or on the scalp at immunology of immunotherapy, if the size or the number of lesions limit the effectiveness and / or the acceptance of a cryotherapy, and other topical treatments can be performed or less appropriate."</seg>
<seg id="2182">"Monday, Wednesday and Friday or Tuesday, Thursday and Saturday) before the refuge take up and 6 to 10 hours long on the skin."</seg>
<seg id="2183">"the treatment with imiquimod cream is so long to continue, until all the swarnings have disappeared in genital or perianal area, or up to a maximum of 16 weeks per treatment period."</seg>
<seg id="2184">A break in the treatment described above should be weighed when intensive local inflammatory reactions occur (see Section 4.4) or if in the treatment field a infection is observed.</seg>
<seg id="2185">"if at follow-up investigation of 4 to 8 weeks after the second treatment period, the patients treated only incomplete, another treatment should be started (see Section 4.4)."</seg>
<seg id="2186">"when a dose was dropped, the patient lifts the cream as soon as he / she noticed this and then continue with the usual therapy plan."</seg>
<seg id="2187">Imiquimod cream is to wear in a thin layer and to rubbing the infected skin area until the Cream is completely deducted.</seg>
<seg id="2188">"in these patients, it should be provided with such treatment between the benefit of a treatment with imiquimod and the risk associated with a possible worsening of their autoimmune disease."</seg>
<seg id="2189">It should take place in these patients with an encoding between the benefits of treatment with imiquimod and the risk associated with a possible organ-replication or graft versus-host- reaction associated risk.</seg>
<seg id="2190">"in other studies, in which no daily dispositions have been carried out, two cases of severe phimosis and a case with one to the circumcision leading strips observed."</seg>
<seg id="2191">During an application of imiquimod cream in higher than the recommended doses there is an increased risk to severe local skin irritation (see section 4.2.) In rare cases have also observed heavy local skin irritation that made a treatment necessary and / or to temporary physical impairment.</seg>
<seg id="2192">"in cases where such reactions occurred at the exit of the urethra, some women had trouble passing urine, which made an emergency catheter and a treatment of the affected area."</seg>
<seg id="2193">"for the application of imiquimod cream immediately following a treatment with other calibrated appliences in genital warnings in genital and perianal area, there are no clinical experience until now."</seg>
<seg id="2194">Limited data suggest a higher rate of events reduction in HIV positive patients; Imiquimod cream in this patient group in regards to the elimination of the Feigwarts however showed a lower efficacy.</seg>
<seg id="2195">"the treatment of the Basque cell with Imiquimod within 1 cm to the eyelids, the nose, the lips, or the hairline has not been studied."</seg>
<seg id="2196">Local seaptions are common but the intensity of these reactions occur in general during therapy or the reactions are going back after the treatment with imiquimod cream.</seg>
<seg id="2197">"if it is necessary due to the discomfort of the patient, or due to the severity of the local skin interactions, a treatment of treatment can be made of several days."</seg>
<seg id="2198">The clinical results of the therapy can be assessed after the regeneration of the treated skin approximately 12 weeks after the end of the treatment.</seg>
<seg id="2199">"there is currently no data on long-term healing rates of over 36 months after the treatment, should be considered to be considered with superficiency bases."</seg>
<seg id="2200">"in patients with recurrent and pre-treated BCCs are not clinical experience, so the application is not recommended in pre-treated tumours."</seg>
<seg id="2201">Data from an open clinical study indicate that in large tumors (&gt; 7.25 cm2) a lower probability of response to the imiquimod therapy.</seg>
<seg id="2202">Imiquimod has not been studied for the treatment of acic keratants in eyelids inside the nose or the ears or on the lipse within the lippot.</seg>
<seg id="2203">It is only very limited data on the application of imiquimod for the treatment of accredited keratants to anatomical points outside of the face and the scalp.</seg>
<seg id="2204">"the available data on the actinent Keratose on the underpoor and hands support the effectiveness in this application case, therefore a such application is not recommended."</seg>
<seg id="2205">"local catching actions often appear on, but these reactions tend to take effect in the course of the therapy of intensity or go back after lowering the therapy with imiquimod cream."</seg>
<seg id="2206">"if the local front parties cause large discomfort or are very strong, the treatment can be exposed for several days."</seg>
<seg id="2207">The data of an open clinical trial goes out that patients with more than 8 AK- lesions showed a less complete healing rate than patients with less than 8 lesions.</seg>
<seg id="2208">"because of the immune-stimulating characteristics should be applied imiquimod creams with caution in patients, which received an immunosuppressive treatment (see 4.4)."</seg>
<seg id="2209">"animal studies no direct or indirect harmful effects on pregnancy, the embryo or the post-natal development (see 5.3)."</seg>
<seg id="2210">"although neither a non-recurring application has been quantifiable, serum mirror (&gt; 5ng / ml) can be given no recommendation to use during breastfeeding period."</seg>
<seg id="2211">The most commonly communicated and as likely or possibly with the application of imiquimod cream in the related side effects in the studies with three times weekly treatment were local reactions in the treatment of the Feigwarts (33.7% of the patients treated with Imiquimod-treated patients).</seg>
<seg id="2212">Among the most commonly reported and as likely or possibly with the application of the imiquimod cream in the related side effects belong to complaints about the application of 28,1%.</seg>
<seg id="2213">The patients treated by 185 with Imiquimod-cream patients treated in a placebo-controlled clinical study conducted by Phase III have been shown below.</seg>
<seg id="2214">The most common one as likely or possibly with the application of the imiquimod cream in the related side effect were in these studies in response to the application of application (22% of the patients treated with Imiquimod-treated patients).</seg>
<seg id="2215">The side-effects that were given by 252 into placebocontrolled clinical trials of phase III with imiquimod-cream treated patients with actinic keratose are listed below.</seg>
<seg id="2216">"this according to test planed evaluation of clinical signs indicates that it came into these placebo-controlled clinical trials, including Erythem (61%), Excoriation / Departure (23%) and Ödem (14%) (see Section 4.4)."</seg>
<seg id="2217">"this according to test planed evaluation of clinical signs shows that in these studies with five times a week-effective treatment with Imiquimod cream, very frequently to severe Erythemes (31%), heavy erosion (13%), and too heavy scoring and sales (19%)."</seg>
<seg id="2218">In clinical studies on the examination of the application of imiquimod for the treatment of accredited Keratose, Alopezie with a frequency of 0.3% (5 / 1214) was found at the treatment of treatment or in the surrounding area. "</seg>
<seg id="2219">"the accidental record of 200 mg of Imiquimod, which corresponds to the content of approximately 16 bags could lead to nausea, vomiting, headaches, myalgias and fever."</seg>
<seg id="2220">The clinically weighty side effect that occurred after several oric cans of &gt; 200 mg consisted in Hypotony that normalized after oral or intravenous fluid transmission.</seg>
<seg id="2221">"in a pharmacokinetic investigation, the topical application of Imiquimod has been proven increasing systemic concentrations of the alphainterferons and other cytokine."</seg>
<seg id="2222">In 3 pivotal phase 3 efficacy studies could be shown that the effectiveness in regards to a complete cooling of the Feigwarts was clearly superior to a placebo treatment after 16 weeks of a placebo treatment.</seg>
<seg id="2223">At 60% of a total of 119 with Imiquimod therapy treatments completely off; this was at 20% of the 105 with placebo therapies in the case (95% CI):</seg>
<seg id="2224">A complete healing could be achieved at 23% of 157 with Imiquimod treated male patients compared to 5% of 161 with placebo treated male patients (95% CI):</seg>
<seg id="2225">The effectiveness of Imiquimod in five malicious use per week over 6 weeks was examined in two double flashes, placebo-controlled clinical trials. "</seg>
<seg id="2226">"the target tumors were histologically proof of single primary supervisory board, with a minimum size of 0.5 cm ² and a maximum diameter of 2 cm."</seg>
<seg id="2227">"the data from an open, uncontrollable long term study after four years of present data show that approximately 79.3% [95% CI (73.7%, 84.9%)] of all treated patients were clinically cured for 48 months."</seg>
<seg id="2228">"the effectiveness of Imiquimod on three times weekly application in one or two treatment periods of 4 weeks, interrupted by a fortnight, treatment-free period, was examined in two double flashes, placebocontrolled clinical trials."</seg>
<seg id="2229">"patients had clinically typical, visible, discrete, non-hyperkeratotic, not hypertrophe AK- Läsions within one-related 25 cm2 big treatment areals on the unhairy scalp or on the face."</seg>
<seg id="2230">The single-year data from two combined monitoring tests show a recurrent rate of 27% (35 / 128 patients).</seg>
<seg id="2231">"the approved indications, acroneous indications, actinent Keratose and superfictive bases are usually not tested in paediatric patients and were therefore not investigated."</seg>
<seg id="2232">Aldara Cream was studied in four randomized and double flaged placebo-controlled studies on children aged 2 to 15 years with Molluscum (imiquimod n = 576, placebo n = 313). "</seg>
<seg id="2233">The effectiveness of imiquimod could not be shown in these studies at the dosages (3x / week for a period of &lt; 16 weeks bzw.</seg>
<seg id="2234">A minimum system intake of the 5% of imiquimod cream by the skin of 58 patients with actinent Keratose was observed during three weeks in three weeks.</seg>
<seg id="2235">"the highest law-concentration in Serum at the end of the week 16 were observed between 9 and 12 hours and betrugen 0.1, 0.2 and 1,6 ng / ml in the application in the face (12.5 mg, 1 bag), on the hands / arms (75 mg, 6 bags)."</seg>
<seg id="2236">The calculated-obvious half-time was about 10times higher than the 2hour half-time after the subcutaneous application in a former study; this indicates an extended Retention of the drug in the skin.</seg>
<seg id="2237">The data for systemic exposure showed that the resorption of imiquimod according to topical application on MC-suffering from patients aged 6 to 12 years was low and comparable to those with healthy adults and adults with acute uroposis or supervisclical cell cell.</seg>
<seg id="2238">"in a four months study on the painting, toxicity in the rat led doses of 0.5 and 2.5 mg / kg KG to significantly lower body weight and increased lacz-weight; an also four months long-guided study of the derpainting application yielded no similar effects on the mouse."</seg>
<seg id="2239">A two-year study on carcinogenicity in mice at dermaler administration in three days a week induced no tumors at the application.</seg>
<seg id="2240">"the corresponding mechanism is not known, but since Imiquimod only has a small systemic absorption from human skin and is not mutable, is a risk to humans due to the systemic exposure as very low."</seg>
<seg id="2241">"the tumors appear in the group of mice, treated with the most effective Cream, used earlier and in larger number than in the control group with little UVR."</seg>
<seg id="2242">"it can harm other people, even if these same symptoms have as you. − When one of the above-side effects you have considerably affected or you notice unwanted side effects, which are not listed in this usage information, please inform your doctor or a pharmacist."</seg>
<seg id="2243">● Feigwarts (Condylomata acuminata) formed on the skin in the area of genitals (Geschlechtsdie) and anus.</seg>
<seg id="2244">"if it remains untreated, it can lead to withdrawals, especially in the face - hence, a early detection and - treatment is important."</seg>
<seg id="2245">Tincents are consuming areas of skin that occur in people during their previous life were exposed to sunlight.</seg>
<seg id="2246">"Aldara should only be applied in flat cactal keratants in the face and on the scalp in patients with a healthy immune system, where your doctor has decided that Aldara is the most appropriate treatment for you."</seg>
<seg id="2247">"Aldara Cream supports your body-own immune system in the production of natural substances, which help your body to fight the superficial cell cell, or to fight for the infection with Feigwarts responsible virus."</seg>
<seg id="2248">"O If you have applied earlier once Aldara cream or other, similar preparations, please inform your doctor if you have problems with your immune system. o Use Aldara cream if you have problems with your immune system. o Use Aldara cream if you need problems with your immune system. o avoid the contact with eye, lips and nasal gland."</seg>
<seg id="2249">In case of failing contact the cream with water distant with water. o wont turn out the cream than your doctor you submit. o Note you don't use any more Cream Cream not with a bandage or pavement ab. o Falls reactions to the treated place that give you strong discomfort, wash the cream with a mild soap and water. "</seg>
<seg id="2250">"once the reactions are shortened, you can process the treatment process. o Informing your doctor if they have no normal blood picture."</seg>
<seg id="2251">"if this daily cleaning is not carried out under the foreskin, can be calculated with increased appearance of pre-skin swelling, fertilizers, the skin or difficulties when retraction the foreskin."</seg>
<seg id="2252">"do Aldara Cream not in the urethra (urethra), in the vagina (Scheide), the Zervix (cervix) or within the anus (After)."</seg>
<seg id="2253">"taking other medications have serious problems with your immune system, you should use this medication for no more than one treatment course."</seg>
<seg id="2254">"if you have intercourse with warnings in the genital area, the treatment with Aldara Cream after sexual intercourse (not previously) perform."</seg>
<seg id="2255">"please inform your doctor or a pharmacist, if you apply other medicines or have recently applied, even if it is not prescription drugs."</seg>
<seg id="2256">"breastfeeding your baby during treatment with Aldara cream, because not known whether Imiquimod into the mother's milk."</seg>
<seg id="2257">"the frequency and duration of the treatment are different for Feigwarts, Basalcell, and accredited Keratose (see specific instructions for each application area)."</seg>
<seg id="2258">"wear a thin layer of Aldara cream on the clean, dry skin place with the seigwarts and expel the cream carefully on the skin, until the cream is completely deducted."</seg>
<seg id="2259">"men with warning warts under the foreskin must pull the foreskin every day and wash the skin area, including wash (see Section 2" What must you consider before applying Aldara Cream? ")."</seg>
<seg id="2260">Please talk to your doctor or pharmacist if you have the impression that the effect of Aldara is too strong or too weak.</seg>
<seg id="2261">6 weeks each week each 5 days a week for a sufficient amount of Aldara cream to cover the affected area and 1 cm to cover this area around.</seg>
<seg id="2262">"very common side effects (with more than 1 of 10 patients expected) Total side effects (with less than 1 of 10 patients expected) Seltene side effects (with less than 1 of 1,000 patients expected) Very rare side effects (with less than 1 of 10,000 patients expected)"</seg>
<seg id="2263">Inform your doctor / your doctor or your pharmacist / your pharmacist instantly if you don't feel comfortable during the application of Aldara cream.</seg>
<seg id="2264">"if your skin reacted too strong on the treatment with Aldara cream, you should not use the cream with water and a mild soap wash, and your doctor or your pharmacist."</seg>
<seg id="2265">A reduced number of blood cells may cause you susceptible to infections; they can cause that with you quickly a bluish fleck or she can give rise up.</seg>
<seg id="2266">"inform your doctor or a pharmacist, if any of the listed side effects you have considerably affected or you notice unwanted side effects which are not listed in this usage information."</seg>
<seg id="2267">"in addition, you can feel Juckreiz (32% of patients), burning (26% of patients) or pain in the areas that you have borne Aldara Cream (8% of patients)."</seg>
<seg id="2268">Usually it is a lighter home interactions within about 2 weeks of aborting the treatment again.</seg>
<seg id="2269">"occasionally, some patients notice changes at the applications( Wundsects, inflammation, swelling, purpostis) or irritability, nausea, dry mouth, grips-like symptoms and tiredness."</seg>
<seg id="2270">"occasionally, some patients suffer changes at the applicationsort (hypertension, inflammation, swelling, swelling, swelling, swelling, swelling, swelling, swelling, swelling, sorrow, pain, weakness or shoots."</seg>
<seg id="2271">Aldurazyme is used for the enzymes therapy in patients with secured diagnosis of a mucopolysaccharides I (MPS I; α-Iduronidase deficiency) to treat the non neurological manifestations of the disease (the symptoms which are not associated with brain or nerves in connection).</seg>
<seg id="2272">"this means that certain substances (glycosaminoglykane, gags) will not be disassembled and thus sells in most organs in the body and those ashamed."</seg>
<seg id="2273">"the following no neurological symptoms of the MPS I can occur: enlarged liver, stiff joints, the movements complicate, decreased lung cancer, cardiac and austerity."</seg>
<seg id="2274">The treatment with Alduracyme should be monitored by a doctor who has experience in treating patients with MPS I or other hereditary diseases.</seg>
<seg id="2275">"the administration of Alduracyme should be carried out in a hospital or clinic with revitating units, and patients may require corresponding medicines to prevent an allergic reaction."</seg>
<seg id="2276">(44-20) 74 18 84 00 Fax (44-20) 74 18 86 68 E-mail: mail @ emea.europa.eu http: / / www.emea.europa.eu © EMEA 2007 Reproduction and / or distribution of this document is the "EMEA is" How does Alduracyms work?</seg>
<seg id="2277">"in the study mainly the security of the drug has been investigated, however, it was also tested its effectiveness (by promoting its effect regarding the reduction of the GAG concentrations in the urine and regarding the size of the liver)."</seg>
<seg id="2278">"in children under five years, Aldurazyme the GAG concentrations in the urine of about 60%, and half of the children treated as a normal great liver at the end of the study."</seg>
<seg id="2279">"the most common side effects of Alduracyme in patients aged over five years (observed in more than 1 of 10 patients) are headaches, nausea, stomach pain (joint pain), arthrush, pain, fever and reactions to the infusion."</seg>
<seg id="2280">"very common side effects in patients under five years are increased blood pressure, reduced oxygen saturation (a scanning size of pulmonary function), tachycardie (accelerated heart rate), fever and shook."</seg>
<seg id="2281">Aldurazyme may be used in patients that may possibly have greatly hypersensitive (allergic) to laronidase or one of the other ingredients (anaphylactic reaction) that is not used.</seg>
<seg id="2282">"the European Drug Agency (EMEA) will receive all new information each year, which may possibly be known to examine and update this summary."</seg>
<seg id="2283">The manufacturer of Aldurazyme is obtained patients who receive Alduracyme regarding the reactions to the infusion and the development of antibodies.</seg>
<seg id="2284">June 2003 the European Commission of Genzyme Europe B.V. shared a permit for the transport of Aldurazyme throughout the European Union.</seg>
<seg id="2285">Laronidase is a recombinant form of human α-L-Iduronidase and is produced using recombinant DNA technology using Cho-mammal-Zellkulturen (Chinese Hamster Ovary, Evenstock of the Chinese Hamsters). "</seg>
<seg id="2286">Aldurazyme is the long-term enzymes in patients with secured diagnosis of a mucopolysacchariot I (MPS I, α-Iduronidase deficiency), in order to treat the non-neurological manifestations of the disease (see Section 5.1). "</seg>
<seg id="2287">The treatment with Alduracyme should be carried out by a doctor that has experience in treating patients with MPS I or other hereditary substance diseases.</seg>
<seg id="2288">The initial infusion rate of 2 E / kg / h can be when the patient is tolerated all 15 minutes in a single step to a maximum dose of 43 E / kg / h.</seg>
<seg id="2289">The safety and effectiveness of Alduracyme in adults over 65 years has not been determined and for these patients no dosing scheme can be recommended.</seg>
<seg id="2290">The safety and effectiveness of Alduracyme in patients with kidney or liver insufficiency was not determined and for these patients no dosing scheme can be recommended.</seg>
<seg id="2291">"with Alduracyme patients may develop infectious reactions, which are defined as any related side-effect that occurs during infusion or until the end of the infusion (see Section 4.8)."</seg>
<seg id="2292">"for this reason, especially these patients should continue to be monitored engulously monitored and the infusion of Alduracyme should only be made available in an appropriate clinical environment, in the reinforcement facilities for medical emergencies immediately."</seg>
<seg id="2293">"due to the clinical phase-3 study, it is expected to form almost all patients IgG antibodies against Laronidase, usually within 3 months from treatment."</seg>
<seg id="2294">Patients to develop antibody or symptoms of infectious diseases must be treated with caution when using Alduracyme (see sections 4.3 and 4.8).</seg>
<seg id="2295">"as little experience regarding the resumption of treatment after a longer break, has to be cautious due to the theoretical risk of an oversensitivity reaction after an interruption of treatment."</seg>
<seg id="2296">60 minutes before the start of infusion using medications (antihistaminika and / or antipyretika) to minimize the potential occurrence-related reactions.</seg>
<seg id="2297">"in the event of a slight or medium-heavy infusion reaction, treatment with antihistaminika and acetaminophen / Ibuprofen will be weighed and / or reducing the infusion rate to the half of the infusion rate, in which the reaction occurred."</seg>
<seg id="2298">"in case of a single, severe infusion-related reaction must be stopped until the symptoms are thrown into decline, treatment with antihistaminika and acetaminophen / Ibuprofen is considering."</seg>
<seg id="2299">Infusion can be resumed with a reduction in infusion rate on 1 / 2 - 1 / 4 of the infusion rate in which the reaction occurred to be resumed.</seg>
<seg id="2300">3 become (Antihistaminika and acetaminidol / Ibuprofen and / or corcosteroids) as well as a reduction in infusion rate on 1 / 2 - 1 / 4 of the infusion rate in which the Expected reaction is occurred.</seg>
<seg id="2301">Aldurazyme should not be applied simultaneously with chloroquin or Procain because a potential risk of interference with intracellular recording of Laronidase.</seg>
<seg id="2302">"animal experimental studies do not leave a direct or indirect effect on pregnancy, the embryonic / fetal development, birth and post-natal development (see Section 5.3)."</seg>
<seg id="2303">"there is no data on newborns which were exposed to Laronidase via the milk of milk, is recommended, while the treatment with Alduracyme is not too silent."</seg>
<seg id="2304">"the side effects in clinical trials were introduced mainly as infusion related reactions, which were observed at 53% of patients in phase 3 study (treatment duration up to 4 years) and 35% of patients in the study with participants under 5 years (treatment duration up to 1 year)."</seg>
<seg id="2305">Unwanted drugs related drugs related to Alduracyms that have been observed during phase 3 study and its extension at a total of 45 patients aged 5 years or older in a treatment of 45 years of age groups: very common (&gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; 0 / 10).</seg>
<seg id="2306">"in some patients with severe MPS-I conditional participation of the upper respiratory tract and lungs in the prehistory occurred in addition severe reaction, including bronchospasm, respiratory and facial treatments (see Section 4.4)."</seg>
<seg id="2307">"children of undesired pharmaceutical impacts related to Alduracyme, who were reported in a Phas- 2-study with a total of 20 patients aged under 5 years, with overwhelmingly severe circulation and treatment of up to 12 months, are listed in the table."</seg>
<seg id="2308">"100 E / kg of intravenous once weekly (recommended dose), 200 e / kg of intravenous once weekly, 200 e / kg of intravenous every 2 weeks or 300 E / kg of intravenous every 2 weeks."</seg>
<seg id="2309">"for most patients it occurred within 3 months after the treatment of the treatment of a serotonin version, whereby the patients aged under the age of 5 occurred within 5 years compared to a serotonin version (average after 26 days compared to 45 days in patients aged 5 and older)."</seg>
<seg id="2310">"by the end of the Phase 3 study (or up to a premature expulsion from the study), at 13 / 45 patients no prescribed silicable antibodies, including 3 patients when it has never been to Serokonversion."</seg>
<seg id="2311">"patients with error by low antibodies to the low level of antibodies in the resin, while in patients with high antibodies to determine a variable reduction of gAG in the harn."</seg>
<seg id="2312">Four patients (three in phase 3 study and one in phase 2 study) showed a marginally up to low neutrality inhibitors effect on enzymatic laronidal activity in vitro which seemed to impair the clinical effectiveness and / or reducing GAG in the harn.</seg>
<seg id="2313">"the presence of antibodies did not seem to stand in connection with the incidence of unwanted drugs, even though the occurrence of undesirable drug interactions typically coincided with the formation of IgG antibodies."</seg>
<seg id="2314">The rationale for the enzymes therapy is in one of the hydrolysis of the acoustic substrate and the prevention of a further accumulation of sufficient recovery of the enzymes.</seg>
<seg id="2315">"after intravenous infusion, laronidase is rapidly removed from the circulation and cells into the lysis, most likely via creosis-6-phosphat- receptors."</seg>
<seg id="2316">"the safety and effectiveness of Alduracyms were examined in a randomized, double flea, placebocontrolled phase-3 study at 45 patients aged 6 to 43 years."</seg>
<seg id="2317">"although patients were recruited patients from the study, the majority of patients were seen from the middle phenotype and only one patient pointed to the heavy phenotype."</seg>
<seg id="2318">Patients were recruited if they had an forcized expiratory volume (FEV) of less than 80% of the expected value and they had to be able to stand 6 minutes and walk 5 meters.</seg>
<seg id="2319">The primary outcomes for the efficacy were the percentage change of the expected FEV and the absolute walking distance in the 6-minute walking test.</seg>
<seg id="2320">All patients were subsequently recruited for an open-label renewal study where they received another 3.5 years (182 weeks) each week 100 E / kg Aldurazyms.</seg>
<seg id="2321">"after 26 weeks of therapy, the patients were treated with Aldurazyme patients compared to the placebo group, an improvement in the lung function and the deability to display in the following table."</seg>
<seg id="2322">"in an open renewal study, an improvement and / or maintaining these effects from up to 208 weeks in the Alduracyme / Alduracyme group and 182 weeks in the placebo / Alduracyme group, as follows from the following table."</seg>
<seg id="2323">The decrease of the expected percentage of the FEV is not significant over this period of clinically and the absolute lung volumina increased further proportional to the height of growing children.</seg>
<seg id="2324">"of the 26 patients with a hepaty, on the treatment achieved by 22 (85%) until the end of the study a normal living room size."</seg>
<seg id="2325">Within the first 4 weeks a clear waste of the GAG mirror in the Harn (µg / mg Kreatinin) was established until the study's degree remained constant.</seg>
<seg id="2326">"regarding the heterogeneous pathology between patients, which has been taken into account for five patients (58%), generally an improvement in 26 patients (58%), no change in 10 patients (22%) and a deterioration in 9 patients (20%)."</seg>
<seg id="2327">It became one-year-year open phase-2 study conducted in which primarily the safety and pharmacokinetics of Alduracyms were examined at 20 patients who were at the time of their admission to the study under 5 years (16 patients with severe discontinued form).</seg>
<seg id="2328">In four patients the dosage was increased due to increased AGAG- mirror in the resin in week 22 in the last 26 weeks to 200 e / kg.</seg>
<seg id="2329">"in the case of several patients a size growth (n = 7) and a weight increase (n = 3) was established after the Z-Score for this age group, the younger patients with the heavy duty cycle (&lt; 2.5 years) and all 4 patients with moderate agrapport, whereas in older patients with severe discontinued form were only limited or no progress in cognitive development."</seg>
<seg id="2330">In a phase-4 study examinations were conducted on pharmacodynamic effects of various alduracyme dosing schemata on the GAG mirror in the resin, the liver volume and the 6-minute walking test. "</seg>
<seg id="2331">"100 E / kg of intravenous once weekly (recommended dose), 200 e / kg of intravenous once weekly, 200 e / kg of intravenous every 2 weeks or 300 E / kg of intravenous every 2 weeks."</seg>
<seg id="2332">"the dosing scheme with 200 e / kg of intravenous every 2 weeks may present in patients, the difficulties with weekly infusions, a reasonable alternative; however, is not proven that the long-term clinical effectiveness of these two dosing schemata is equal."</seg>
<seg id="2333">"the European Medicines Agency (EMEA) will evaluate all new information, which will evaluate each year, and if required, the summary of the characteristics of the drug is being updated."</seg>
<seg id="2334">Pharmacopoinetic profile in patients aged 5 years was similar to older and less affected patients.</seg>
<seg id="2335">"based on the conventional studies for safety spharmacology, toxicity in one-time gift, toxicity in repeated gift and reproduction, the preclinical data cannot be recognized for the human being."</seg>
<seg id="2336">"as no tolerant studies have been carried out, this drug may not be mixed with other medicines except with the below 6.6. above."</seg>
<seg id="2337">"if the ready-to-use preparation is not immediately used, this is no longer than 24 hours at 2 ° C - 8º C, provided the dilution under controlled and validated aseptic conditions."</seg>
<seg id="2338">5 ml of concentarte for producing a solution in flow-bottle (type - I-glass) with stopover (silicone chlorbutyl-rubber) and sealing of aluminium (polypropylene).</seg>
<seg id="2339">10 preparation of the Alduracyme infusion (via aseptic technique) • Je to the body weight of the individual patient first determine the number of dilution throughs.</seg>
<seg id="2340">"the holder of permission for the transport system has completed the following study programme within the given time, whose results form the basis for the annual assessment report to the benefit risk."</seg>
<seg id="2341">"this tab will be treated in long-term safety and efficacy information that have been treated with Alduracyme, as well as data for the natural progression of disease in patients without this treatment."</seg>
<seg id="2342">"for patients who suffer from MPS I, an enzyme called α-L-Iduronidase, the particular substances in the body (glycosaminoglykane), either in a small amount of or this enzyme is missing."</seg>
<seg id="2343">"if you have allergic to an allergic reaction (hypersensitive) compared to one of the components of Alduracyme, or if you have performed a severe allergic reaction to laronidase."</seg>
<seg id="2344">A infusion conditional reaction is any side effect that occurs during infusion or until the end of the infusion (see section 4 "What effects are possible").</seg>
<seg id="2345">"when using Alduracyme with other medicines please inform your doctor if you are taking medicines, the chloroquin or Procain, because a possible risk of a diminished effect of Alduracyme."</seg>
<seg id="2346">"please inform your doctor or a pharmacist, if you have taken other medicines or have recently taken, including not prescription drugs."</seg>
<seg id="2347">References to the handling - dilution and application The concentate for the production of an infusion solution must be diluted in front of the application and is provided to the intravenous application (see information for doctors or medical practitioners).</seg>
<seg id="2348">The initial infusion rate of 2 E / kg / h can be when the patient is compatible with it all 15 minutes gradually increased to a maximum dose of 43 E / kg / h.</seg>
<seg id="2349">"in some patients with severe MPS-I- conditional participation of the upper respiratory tract and lungs in the prehistory, but heavy responses to, including Bronchospasm, respiratory and facial treatments."</seg>
<seg id="2350">"very common (Performance at more than 1 of 10 patients): • headaches • nausea, stomach pain, setback pain, pain, pain, shakes • hypertension • hypertension • hypertension • Durtonie • less oxygen in blood • reaction to the infusion set."</seg>
<seg id="2351">"the European Drug Agency (EMEA) will be made available for any new information, which will evaluate each year, and if required, the packages will be updated."</seg>
<seg id="2352">"if the ready-to-use preparation is not immediately used, this is no longer than 24 hours at 2 ° C - 8º C, provided the dilution under controlled and validated aseptic conditions."</seg>
<seg id="2353">Preparation of the Alduracyme infusion (by means of aseptic technique) • Je to the body weight of the individual patient first the number of diluted mops bags.</seg>
<seg id="2354">"Alimta is applied together with cisplatin (a different drug for cancer) in patients who have not yet been removed against cancer (drugs called cancer), and maligne" (malignant - cancer is likely to spread to other parts of the body). • advanced or metastatic "non-single" lung cancer that is not pregnant at the turntables. "</seg>
<seg id="2355">"Alimta is used in patients who have not previously been dealt with, in combination with cisplatin and in patients who have previously made other chemotherapies previously used as a sole therapy."</seg>
<seg id="2356">"to reduce side effects, patients should take care of patients during treatment with Alimta as well as folate (a vitamin) and injections of vitamin B12."</seg>
<seg id="2357">"if Alimta is administered together with cisplatin, should be given before or after the gift of cisplatin as well as an antiemetikum" (drugs against vomiting) and liquids (to remedy a liquid angel). "</seg>
<seg id="2358">"in patients whose blood picture changes, or where certain other side effects occur, the treatment should be uplifted, set or the dose reduces."</seg>
<seg id="2359">"the active form of pemetremit has slowed down the formation of DNA and RNA, and prevents the cells share."</seg>
<seg id="2360">"the transformation of Pemetrexed into its active form goes easier for cancer cells than in healthy cells, which leads to higher concentration of the active form of the drug and a longer time of treatment in cancer cells."</seg>
<seg id="2361">"for the treatment of maligning Pleiamesothelioms, Alimta was examined in a major study of 456 patients who had never received any chemotherapy against their disease."</seg>
<seg id="2362">"in the treatment of non-nuclear lung cancer the effects of Alimta were treated in a study of 571 patients with local advanced or metastatic disease, which previously had previously been treated with chemotherapy, with the effects of docetaxel (another drugs against cancer)."</seg>
<seg id="2363">"Alimta was also compared with gemcitabine (a further drug with cancer), namely both in combination with cisplatin in a study of 1 725 patients who had previously received no chemotherapy for lung cancer."</seg>
<seg id="2364">"patients treated with Alimta and Cisplatin were covered by an average of 12,1 months, compared to 9,3 months in general administration of cisplatin."</seg>
<seg id="2365">"in patients having previously received an chemotherapy, the average survival rates associated with Alimta 8.3 months, compared with 7.2 months at docetaxel."</seg>
<seg id="2366">"in both studies however, patients were diagnosed in which cancer are not the turntables, in the administration of Alimta for longer transition times than with the comparative medicine."</seg>
<seg id="2367">September 2004 condemned the European Commission to the company Eli Lilly Nederland B.V. providing permission for the transport of Alimta in the entire European Union.</seg>
<seg id="2368">Any flow-bottle has to be calculated with 4.8 ml 0.9% iger-injection solution (9 mg / ml) - which results a solution of 25 mg / ml.</seg>
<seg id="2369">The corresponding volume of the necessary Do- SIS is taken from the bottle case and with 0.7% iger sodium injection solution (9 mg / ml) on 100 ml is further diluted (see Section 6.6).</seg>
<seg id="2370">ALIMTA is shown in combination with cisplatin as first-line treatment of patients with locally advanced or metastatic non-smart bronchialkarzinome (see Section 5.1).</seg>
<seg id="2371">ALIMTA in Monotherapy is shown for the treatment in second-line treatment of patients with lo- Kal advanced or metastatic nonsensical bronchial (see Section 5.1).</seg>
<seg id="2372">The recommended dose of ALIMTA 500 mg / m ² body surface (KOF) administered as intravenous infusion over a period of 10 minutes on the first day each 21-day treatment cycle.</seg>
<seg id="2373">The recommended dose of cisplatin amounts to 75 mg / m ² KOF as infusion over a period of 2 hours about 30 minutes after completion of the Pemetrexed- infusion on the first day each 21-day treatment cycle.</seg>
<seg id="2374">"in case of patients with non-German bronchialkarzinome, the recommended dose of ALIMTA 500 mg / m ² KOF administered as intravenous infusion over a period of 10 minutes on the first day each 21-day treatment-cycle."</seg>
<seg id="2375">"to reduce the frequency and severity of Hauters must be given the day before and on the day of Pemetrexed gift, as well as on the day after the treatment a cortico-steroid."</seg>
<seg id="2376">"during the seven days before the first dose of Pemetremit must be taken at least 5 doses of folate, and the intake must be continued during the whole treatment of therapy and for another 21 days after the last Pemetrexed- dosage."</seg>
<seg id="2377">Patients also must also receive an intra-muscular injections of vitamin B12 (1000 micrograms) in the week before the first Pemetrexed dose as well as after each third assignment.</seg>
<seg id="2378">"in patients who receive Pemetremit, every gift should be created a complete blood-picture, including a differentiation of the leucocytes and a Throism."</seg>
<seg id="2379">The alkaline phosphatase (AP), aspartat-Transaminase (AST or SGOT) and Alanin-Transaminase (ALT or SGPT) should be &lt; 3-fold of the upper limit value. "</seg>
<seg id="2380">At the beginning of a new treatment cycle a tin-examination must take place under Bering the Nadirs of the blood balance or the maximum non-hemical toxicity of the pre- hitting therapy.</seg>
<seg id="2381">"after recovery, patients must be treated according to indications in tables 1, 2 and 3, which are applicable to ALIMTA as monotherapy or in combination with cisplatin."</seg>
<seg id="2382">These criteria correspond to the definition of the National Cancer Institute Common toxicity Criteria (CTC v2.0; NCI 1998) &gt; CTC degree 2 bleeding.</seg>
<seg id="2383">"should patients not develop hematological toxicity &gt; degree 3 (except neurotoxicity), the patient has to be interrupted by ALIMTA until the patient has the value before treatment."</seg>
<seg id="2384">"the treatment with ALIMTA has to be cancelled when patients after 2 dosages, a hematological toxicity or non-hematological toxicity, 3 or 4 occurs or so- fort at the occurrence of degrees 3 or 4 neurotoxicity."</seg>
<seg id="2385">Clinical studies have no indication that in patients aged 65 year- or in comparison to patients aged 65 years of age.</seg>
<seg id="2386">ALIMTA is not recommended for use in children under 18 years due to insufficient data on inconceivable and effectiveness.</seg>
<seg id="2387">Clinical trials were measured in patients with a Creatinin Clearance of &gt; &gt; 45 ml / min no dosage adjustment necessary for all patients recommended dosage adjustment.</seg>
<seg id="2388">Data base in patients with a Creatinin Clearance of under 45 ml / min was not adequate; therefore the application is not recommended (see Section 4.4).</seg>
<seg id="2389">"however, patients were evaluated with a liver-functional intake of &gt; the 1,5-fold of the upper Bilirubin- border-value and / or transamic values of &gt; the 3,0-fold of the upper limit level (in the presence of liver metastatic breast), not specifically in studies."</seg>
<seg id="2390">Patients must be supervised with regard to the Kno- chenmarkers and Pemetremit should not be administered to patients before their absolute Neutrophy number returns a value of &gt; &gt; &gt; 100,000 cells / mm ³ and the thyrofoam number has reached a value of &gt; &gt; 100,000 cells / mm ³.</seg>
<seg id="2391">A tin-reduction for further cycles is based on the Nadir's absolute Neutrophy number and maximally non-hematological toxicity as observed in the previous treatment cycles - (see Section 4.2).</seg>
<seg id="2392">A lower toxicity and a reduction of the degree 3 / 4 hematological and non-matured toxicity such as Neutropenie and infection with degrees 3 / 4 Neutropenie was observed if a pre-treatment with folate and vitamin B12 had taken place.</seg>
<seg id="2393">"therefore, all patients need to be dependent on patients with pemetrexed patients, folate and vitamin B12 as a prophylactic measure for reduction-related toxicity (see Section 4.2)."</seg>
<seg id="2394">Patients with mild to medium kidney insufficiency (Creatinin Clearance 45 to 79 ml / min) must be the simultaneous incongestural antiphlogistika (&gt; 1.3 g daily) for at least 2 days before the therapy, on the day of therapy and minde- TENS 2 days after therapy with pemetrete (see Section 4.5). "</seg>
<seg id="2395">"all patients, intended for treatment with Pemetrexed treatment, the intake of NSAIDs must be avoided for at least 5 days before the therapy, the day of therapy and at least 2 days after therapy with Pemetrexed treatment (see Section 4.5)."</seg>
<seg id="2396">"many patients in which these events occur, had corresponding risk factors for the appearance of renal events, including dehydration, pre-existing hypertension or Diabetes."</seg>
<seg id="2397">"therefore, in patients with clinically significant hydration - accumulation in the transcellular space a drainage of Ergonomic treatment can be weighed before the Pemetrexed treatment."</seg>
<seg id="2398">"5 serious cardiovascular events, including Myocardiners, and cerebrovascular events were reported in clinical trials with Pemetrexed occasionally, if this substance is usually administered in combination with another cytotoxic substance."</seg>
<seg id="2399">"for this reason, the simultaneous application of attenuated limps (except money fever, this vaccine is contrained) not recommended (see Section 4.3 and 4.5)."</seg>
<seg id="2400">"since the possibility of an irreversible sketch of the reproductive capacity is made by Pemetrexed, men should be informed before the treatment of treatment, advice regarding the spermatonation."</seg>
<seg id="2401">In patients with normal kidney function (Creatinin Clearance &gt; 80 ml / min) can lead high doses of non-steroidal anti-acetylic acid in high dosage (&gt; &gt; 1,3 g daily) to a decreased pair of effects associated with the consequence of an increased delay of side effects.</seg>
<seg id="2402">Therefore caution is advisable when in patients with normal kidney function (Creatinin Clearance &gt; 80 ml / min) high doses of NSAIDs or Acictylsalicylic acid in high dosage.</seg>
<seg id="2403">"ibuprofen) or Acetylsalicyl- acid in high dosage for at least 2 days before the treatment, a day of therapy and minde- TENS 2 days after therapy with Pemetrexed treatment (see Section 4.4)."</seg>
<seg id="2404">"since there are no data regarding the transaction potential as NSAIDs with long semi-time needed like piro- xicam or rofecoxib, the simultaneous application with Pemetrexed treatment should be avoided on the day of therapy and at least 2 days after therapy with Pemetre-."</seg>
<seg id="2405">"the great intra-individual variability of the status status during the disease and the possibility of interactions between oral anticoagulant and antineoplastic chemotherapy requires an increased monitoring frequency of INR (International Normalised ratio), when the decision was made to treat the patient with oral anticoagulant."</seg>
<seg id="2406">"there are no data for using Pemetrexed case in case of pregnant women, but as with ande- and antimitolites are expected to be an application in the pregnancy serious faulty effects."</seg>
<seg id="2407">Pemetremit should not be applied during pregnancy except when it is demanding and careful weighing of the farm for the mother and the risk to the fetus (see Section 4.4).</seg>
<seg id="2408">"since the possibility of an irreversible sketch of the reproductive capacity is made by Pemetrexed, men should be informed prior to the treatment of treatment, advice regarding the spermakespiviewarps."</seg>
<seg id="2409">"it is not known whether Pemetrexed into the mother's milk, and unwanted effects on the breastfeeding cannot be excluded."</seg>
<seg id="2410">"the following table shows the frequency and severity unwanted effects which were reported in &gt; 5% of 168 patients with Mesotheliom, as well as 163 patients with Mesotheliom, randomized Cisplatin as monotherapy."</seg>
<seg id="2411">"side effects: very common (&gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; / 1,000 and &lt; 1 / 10), occasionally (&gt; &gt; &gt; / 1,000 and &lt; 1 / 1,000), very rare (&lt; 1 / 10,000), and not known (based on the available data of spontaneity)."</seg>
<seg id="2412">* Recipes on National Cancer Institute CTC Version 2 for any toxicity except the event "Creatinin Clearance" * * * referred to National Cancer Institute CTC (v2.0; NCI 1998) should be reported as a degree 1 or 2.</seg>
<seg id="2413">"for this table, a threshold of 5% has been fixed for the inclusion of all events, where the cheap doctor held a connection with Pemetrexed and cisplatin for possible."</seg>
<seg id="2414">"clinical-related CTC toxicity, which were reported by &lt; 1% (occasionally) of patients were reported randomized Cisplatin and pemetremixed, umfists arrhythmia and motoric neuropathy."</seg>
<seg id="2415">"the following table shows the frequency and severity unwanted effects which were reported at &gt; 5% of 265 patients, the randomized Pemetrexed as monotherapy with gifts of Follow yre and vitamin B12 and 276 patients, the randomized docetaxel as monotherapy erhiel-."</seg>
<seg id="2416">* * related to National Cancer Institute CTC Version 2 for any toxicity. * * related to National Cancer Institute CTC (v2.0; NCI 1998) should be reported as a degree 1 or 2.</seg>
<seg id="2417">"for this table, a threshold of 5% has been fixed for the inclusion of all events, where the medical practitioner held a connection with Pemetrexed for possible."</seg>
<seg id="2418">"clinical-related CTC toxicity, which were reported by &lt; 1% (occasionally) of patients were reported in randomized Pemetrexed, comprising supraventricular arrhythmics."</seg>
<seg id="2419">The clinical-related laboratories 3 and 4 was compared with the combined results of three single Pemetrexed-monothermal estuary (n = 164% compared with 5.5%) and an increase in alanintransaminase (15.2% compared to 1.9%).</seg>
<seg id="2420">These underdifferences are likely to result in differences in patient's population as the Pha- se two studies both chemonaive as well as distinctly pre-treated breast cancer patients with existing liver metastatic breast cancer cells.</seg>
<seg id="2421">"the following table shows the frequency and severity unwanted effects which might be possible at &gt; 5% of 839 Pati- Enten with NSCLC, the randomized Cisplatin and Pemetrexed and 830 patients with NSCLC, the randomized Cisplatin and gemcitabin."</seg>
<seg id="2422">11 * P-values &lt; 0.05 comparison of Pemetrexed / cisplatin and gemcitabine / cisplatin, using the "Fisher Exact test". * * * related to National Cancer Institute CTC (v2.0; NCI 1998) should be reported as a degree 1 or 2.</seg>
<seg id="2423">"for this table, a threshold of 5% has been fixed for this table."</seg>
<seg id="2424">"clinical relevant toxicity, which were reported in &gt; 1% and ≤ 5% (often) of patients were reported, the randomized Cisplatin and pemetrexed received, fibre:"</seg>
<seg id="2425">"clinical relevant toxicity, which were reported by &lt; 1% (occasionally) of patients were recorded, domicised Cisplatin and pemetrexed received:"</seg>
<seg id="2426">"serious cardiovascular and cerebrovascular events, including Myocardinosaurs, Angina pectoral, bruised and transitory attacks, which is usually reported in combination with another cytotoxic active ingredient, occasionally."</seg>
<seg id="2427">"clinical trials were reported in patients with pemetrexed treatment occasionally cases of Coli- tis (including hainale and rectal bleeding, sometimes fatal, clinale Perfo- Ration, Iinale Nekrose and Typhlitis)."</seg>
<seg id="2428">Out of clinical trials were reported in patients with pemetrexed treatment occasionally cases of sometimes fatal interstitial lipneumonitis with respiratory insufficiency insufficiency.</seg>
<seg id="2429">It was reported on cases of acute kidney failure in Pemetrexed Monotherapy or in combination with other chemotherapeutics (see Section 4.4).</seg>
<seg id="2430">"there were cases of radiation pneumpneumonitis in patients reported before, during or after their pasemxed therapy were punished (see Section 4.4)."</seg>
<seg id="2431">ALIMTA (Pemetrexed) is a antineoplastic antifolat which is its effect excreatively implicted metabolic processes used for cell replicencing.</seg>
<seg id="2432">In vitro studies showed that Pemetrexed acts as antifolat with several attacks by using the Thymidylatsynthase (TS) and Glycinamidribonucleotidribonuclease (GARFT) - myltransferase (GARFT) - myltransferase (GARFT) - myltransferase (GARFT) - myltransferase (GARFT) - myltransferase (GARFT) - myltransferase (GARFT) - myltransferase (GARFT) blocked by Thymidin- and Purinnucleotides.</seg>
<seg id="2433">"EMPHACIS, a multi-centric, randomized, simple-blinde phase 3 study by ALIMTA plus cisplatin treated patients with malignant Cheesotheliom patients with ALIMTA and cisplatin patients treated a clinically significant advantage over such patients who have been kept only with cisplatin."</seg>
<seg id="2434">The primary analysis of this study was carried out in the population of all patients that were given in the treatment of treatment (randomized and treated).</seg>
<seg id="2435">A statistically significant improvement in clinically relevant symptoms (pain and Dyspnoe) in connection with the malignant Cheuramesotheliom was shown in case of the lunar cancer inhibitor in the ALIMTA / Cisplatin-arm (212 patients) compared to the sole Cispla- Tin-arm (218 patients).</seg>
<seg id="2436">The differences between the two treatment parameters in the ALIMTA / Cisplatin-arm and a distortion of the lung function during the time in the control arm.</seg>
<seg id="2437">"a multi-centric, randomized, open phase III study with ALIMTA against docetaxel in patient with locally advanced or metastatic NSCLC after previous chemotherapy treated with ALIMTA untreated patients (intent to treat populations = 283) and from 7.9 months to with docetaxel treated patients (ITT n = 288)."</seg>
<seg id="2438">An analysis of influence of the histology on the treatment figure fell to favour of ALIMTA in patients with NSCLC with a predominantly not plattenepithelial histology (n = 172; 95% CI = 1.56; 95% CI = 67-Phillip, p = 0.018). "</seg>
<seg id="2439">Limited data of a separating randomised, controlled phase 3 study show that activity data (survival and progression-free survival) for Pemetrexed between patients with (n = 41) and without (n = 540) pre-treatment by docetaxel. "</seg>
<seg id="2440">The efficacy analysis of the PQ Population are consistent with the analyses of ITT Population and support the non-harness of the ALIMTA Cisplatin combination with the gemcitabin cisplatin combination.</seg>
<seg id="2441">Medium PFS was 4.8 months for the combination of ALIMTA Cisplatin compared to 5.4% for the combination of gemcitabin cisplatin (95% CI = 25.3 - 33.9) for the combination of ALIMTA Cisplatin compared to 28,2% (95% CI = 25.0 - 31.4) for the combination of gemcitabin cisplatin.</seg>
<seg id="2442">"the analysis of influence of the NSCLC histology on survival showed clinically relevant differences according to Histology, see below the table below."</seg>
<seg id="2443">CI = Confidenzinterval; ITT = 4-to-treat; N = Size of the total population a statistically subject for non-signia with a total confidensed interval for HR (= Hazard Ratio) clearly under the non-basement limit of 1.17645 (p &lt; 0.001).</seg>
<seg id="2444">Patients treated with ALIMTA and Cisplatin were treated less Transfusions (16.4% versus 28,9%, p &lt; 0,001) and Thrombozytentransfusions (1.8% versus 4.5%, p = 0,002). "</seg>
<seg id="2445">"moreover, patients required patients - rarely the gift from Erythropoetin (10,4% versus 18.1%, p &lt; 0,001), G-CSF / GM-CSF (3,1% versus 7.3%, p = 0,021)."</seg>
<seg id="2446">Pharmacopoinetic properties of pemetrexed according to gifts as monotherapeutics were examined at 426 cancer patients with various solid tumors in cans of 0.2 to 838 mg / m ² in infusion - over a period of 10 minutes.</seg>
<seg id="2447">Pemetrexed primarily remains unchanged in the urine and 70% to 90% of the administered dose are found unchanged within 24 hours after the application in the urine.</seg>
<seg id="2448">Pemetrexed has a total of 91.8 ml / min and half-time in plasma is 3.5 hours in patients with normal kidney sound (Creatinin Clearance 90 ml / min).</seg>
<seg id="2449">In a study with Beagle-dogs that had received for 9 months of intravenous Bolus injections were observed (Degre- Ration / Nekrose of seminiferen epithelium).</seg>
<seg id="2450">"unless applied largely, the storage times and conditions according to preparation within the responsibility of the user and should not overpass 24 hours at 2 to 8 ° C, unless the preparation / dilution has taken place under controlled and validated aseptic conditions."</seg>
<seg id="2451">"redeem the content of the 100 mg-flow-bottles with 4,2 ml 0.9% for sodium-injection solution (9 mg / ml) without preservatives, this results a solution with a concentration of approximately 25 mg / ml pemetable."</seg>
<seg id="2452">The resulting solution is clear and the coloring ranges from colourless to yellow or green-yellow without which the product quality is affected.</seg>
<seg id="2453">"any flow-bottle has to be calculated with 20 ml 0.9% iger-injection solution (9 mg / ml), which results a solution of 25 mg / ml."</seg>
<seg id="2454">"23 serious cardiovascular events, including Myocardiners, and cerebrovascular events were reported in clinical trials with Pemetrexed occasionally, if this substance is usually administered in combination with another cytotoxic substance."</seg>
<seg id="2455">* Recipes on National Cancer Institute CTC Version 2 for any toxicity except the event "Creatinin Clearance" * * * referred to National Cancer Institute CTC (v2.0; NCI 1998) should be reported as a degree 1 or 2.</seg>
<seg id="2456">"for this table, a threshold of 5% fixed for the inclusion of all events, where the correct doctor had a connection with pemetrexed and cisplatin for possible."</seg>
<seg id="2457">* * related to National Cancer Institute CTC Version 2 for any toxicity. * * related to National Cancer Institute CTC (v2.0; NCI 1998) should be reported as a degree 1 or 2.</seg>
<seg id="2458">29 * P-values &lt; 0.05 comparison of Pemetrexed / cisplatin and gemcitabine / cisplatin, using the "Fisher Exact test". * * * related to National Cancer Institute CTC (v2.0; NCI 1998) should be reported as a degree 1 or 2.</seg>
<seg id="2459">"clinical relevant toxicity, which were reported by &lt; 1% (occasionally) of patients were recorded, domicised Cisplatin and pemetrexed received:"</seg>
<seg id="2460">An analysis of influence of the histology on the treatment figure fell to favour of ALIMTA in patients with NSCLC with a predominantly not plattenuhistology to Gunsten from Doxetaxel (n = 172; 95% CI = 1.56; 95% CI = 67-Phillip, p = 0.018). "</seg>
<seg id="2461">"solve the content of 500 mg / ml bottles with 20 ml 0.9% for sodium resolution (9 mg / ml) without preservatives, this results a solution with a concentration of approximately 25 mg / ml pemetable results."</seg>
<seg id="2462">The resulting solution is clear and the coloring is sufficient from colored to yellow or green-yellow without which the product quality is affected.</seg>
<seg id="2463">"Pharmakovigilance system The holder of permission for the transport has to carry out that the pharmaceutical system is available in module 1.8.1 of the approval for the transport, ready and ready to use when the product is placed in the market and while the product is in the market."</seg>
<seg id="2464">"risk Management Plan The holder of permission for the transport is obligated to include the studies and the additional pharmacvigilance plan, as agreed in the version 1.2 of the Risk Management Plan (RMP), presented in modules 1.8.2nd of permission for the transport and all subsequent updates of the RMP that have been agreed by CHMP."</seg>
<seg id="2465">"according to" CHMP Guideline on Risk Management Systems for Medicinal products for human use "" must be submitted to date with the next "" Periodic Safety Update Report "" (PSUR). "</seg>
<seg id="2466">"in addition, an updatalized RMP will have to be submitted • If new information can be presented, which could have an effect on current security specifications, the pharmacovigilance Plan or risk minimization activities - On request by the EMEA."</seg>
<seg id="2467">ALIMTA 100 mg powder for producing a concentration of infusion - ALIMTA 500 mg powder for producing a concentration of infusion for infusion</seg>
<seg id="2468">"ALIMTA is used in patients who have no previous chemotherapy, used to investigate the malignant Pleiamesothelioms (malignant illness of the Rippenfells) in combination with cisplatin, another medicine for the treatment of cancer."</seg>
<seg id="2469">"if you have suffered a kidney or an earlier one, please discuss this with your doctor or medical pharmacy because you may not receive ALIMTA."</seg>
<seg id="2470">"with you prior to each infusion are carried out before each infusion, it is checked whether your renal and liver function is sufficient and whether you have enough blood cells to 49 MTA."</seg>
<seg id="2471">"your doctor may change the dose or break the treatment, unless it requires your general condition and if your blood levels are too low."</seg>
<seg id="2472">"if you also received cisplatin, your doctor will ensure that your body contains sufficient water and you need the necessary medicines to avoid the break before and after the cisplatin gift."</seg>
<seg id="2473">"if you are a fluid collection around the lungs, your doctor may decide to eliminate this fluid before you get ALIMTA."</seg>
<seg id="2474">"if you would like to have a child in the treatment, or during the first 6 months after the treatment, please talk to your doctor or a pharmacist."</seg>
<seg id="2475">"interactions with other medicines please tell your doctor if you are drugs against pain or inflammation (Corporatungen), such as such drugs, the" nonsteroidal anti-inflammatory drugs "(NSAIDs), including medicines that are not prescription (such as Ibuprofen)."</seg>
<seg id="2476">"depending on the planned daunting of your ALIMTA infusion and / or the extent of your kidney function, your doctor will tell you what other medicines you can take, and when."</seg>
<seg id="2477">"please inform your doctor or a pharmacist, if you have taken other medicines or have recently taken, even if it's not prescription drugs."</seg>
<seg id="2478">A nursing pharmacy that nursing staff or a doctor will mix the ALIMTA powder with sterile 0.7% iger soriumchloride-injection solution (9 mg / ml) before it is applied with you.</seg>
<seg id="2479">"your doctor will wrestling you cortison tablets (according to 4 mg Dexametha- son two times daily), which you have to take on the day before, during and on the day after the use of ALIMTA."</seg>
<seg id="2480">Your doctor will take your folic acid (a vitamin) for taking or multivitamins that contain folate acid (350 to 1000 micrograms) that you have to take during the use of ALIMTA a single day.</seg>
<seg id="2481">A week before the use of ALIMTA and about every 9 weeks (according to 3 cycles of treatment with ALIMTA) you will also receive an injection of Vi- tamin B12 (1000 micrograms).</seg>
<seg id="2482">"in this pre-use information, a side effect is described as" very frequently, "this means that it was reported by at least 1 of 10 patients."</seg>
<seg id="2483">"if a side effect is described as" "frequently", "this means that it was reported by at least 1 of 100 patients but reported less than 1 of 10 patients."</seg>
<seg id="2484">"if a side effect is described as" occasionally, "this indicates that it was described by at least 1 of 1,000 but less than 1 of 100 patients, this means that it was reported by at least 1 of 10,000 but less than 1 of 1,000 patients."</seg>
<seg id="2485">"fever or infection (common): if you have a body temperature of 38 ° C or above, sweating or any other sign of infection (because you possibly have less white blood cells than normal what is very common)."</seg>
<seg id="2486">"if you feel tired or weak, quickly in respiratory or blass (because you may then have less hemostals normally, which is very common)."</seg>
<seg id="2487">"if you find a bluish of the gum, the nose or the mouth, or another blood, which is not to stagnation, or a reddish or rosafar urine or uns- expected Blutergades (because you may then have less blood plagued than normal, which is very common)."</seg>
<seg id="2488">"occasionally (occurs at least 1 of 1,000 patients), but less than 1 of 100 patients) increased Pulsrate Colitis (inflammation of the internal cover of the patient) interstitial Pneumatic tis (expelling of water into the body tissues that leads to swelling)."</seg>
<seg id="2489">"rarely (occurs in more than 1 of 10,000 patients), but less than 1 of 1,000 patients)" Radiation Recall "(a rash similar to a heavy sunburn), appearance on the skin, which was previously exposed (several days to years) of a radiation therapy."</seg>
<seg id="2490">"occasionally he came to patients, the ALIMTA, usually in combination with other cancers, received a stroke or stroke with light damage."</seg>
<seg id="2491">"in patients who have also received a radiation-treatment before, during or after their ALIMTA treatment, one through radiation caused inflammation of the lung cancer (narrowing of the lung cancer related to the radiation-treatment in connection)."</seg>
<seg id="2492">"52 Informing your doctor or a pharmacist, if any of the listed side effects you uplifting, or if you notice unwanted side effects which are not listed in this package."</seg>
<seg id="2493">"provided as prescribed, the chemical and physical stability of the diluted and infusion solution in storage in the refrigerator, or at 25 ° C have been proven for a period of 24 hours."</seg>
<seg id="2494">Tél / Tel: + 32- (0) 2 548 84 84 Бълария стлино! + 359 2 491 41 40 č ESá Republika Eli Lilly č R, s.r.o. "</seg>
<seg id="2495">Tel: + 420 234 664 111 Danmark Eli Lilly Danmark A / S TLF: + 45 45 26 6100 Germany Lilly Deutschland GmbH Tel. + 49- (0) 6172 273 722 Eesti Eli Lilly Holly Holly</seg>
<seg id="2496">Tel: + 34-91-623-1732 France Lilly France SAS Tél: + 33- (0) 1 55 49 34 34 Ireland Eli Lilly and Company (Ireland) 1 661 4377 Ísland Icepharma HF.</seg>
<seg id="2497">Tel: + 39- 055 42571 Proof Phadisco Ltd. 7: + 357 22 715000 Latvija Eli Lilly Holly Holly Holdings Limited atstovybė Tel. + 370 (5) 2649600</seg>
<seg id="2498">Tel: + 48 (0) 22 440 33 00 Portugal Lilly Portugal - Producars Farmacêuticos, Lda Tel: + 351-21-4126600 România Eli Lilly România S.R.L. "</seg>
<seg id="2499">Tel: + 421 220 663 111 Suomi / Finland Oy Eli Lilly Sweden AB Phone: + 46- (0) 8 7378800 United Kingdom Eli Lilly and Company Limited Phone: + 44- (0) 1256 315999</seg>
<seg id="2500">Resolve the content of the 100 mg-flow bottles with 4.7 ml 0.9% for sodium-injection solution (9 mg / ml) without preservatives which results in a solution with a concent- rationation of about 25 mg / ml pemetable.</seg>
<seg id="2501">Release the content of 500 mg / ml bottles with 20 ml 0.9% for sodium-injection solution (9 mg / ml) without preservatives which results in a solution with a concent- rationation of about 25 mg / ml pemetable.</seg>
<seg id="2502">The resulting solution is clear and the coloring ranges from colourless to yellow or green-yellow without the proving quality is affected.</seg>
<seg id="2503">"it is applied in overweight adults with a body mass set (Body Mass Index - BMI) of &gt; &gt; 28 kg per square meter in conjunction with a calorie-calorie diet."</seg>
<seg id="2504">Patients who do Ali take no weight loss after 12 weeks should contact their doctor or a pharmacist.</seg>
<seg id="2505">"if these enzymes are inhibited, they can not dismantle some fats in the food, thereby causing a quarter of the residual fats unleashed the intestine."</seg>
<seg id="2506">In a third study Alli was compared with 391 overweight patients with a BMI between 25 and 28 kg / m2 with placebo.</seg>
<seg id="2507">"in the two studies in patients with a BMI of &gt; 28 kg / m2 patients had received patients who recorded their average weight loss of 4,8 kg, compared to 2,3 kg when taking placebo."</seg>
<seg id="2508">In the study with Alli in patients with BMI between 25 and 28 kg / m2 could not be observed for the patient-relevant weight loss.</seg>
<seg id="2509">"the most common side effects of Alli (observed in more than 1 of 10 patients) are often staging spots at after, fledged (Winde) with Stuhlabia, Stuhldst, fetal / hovering chair, abortion öll Secrets (decay), Flatulence (Winds) and soft chairs."</seg>
<seg id="2510">It must not be applied in patients being treated with Ciclosporin (to prevent the organ of treatment for transplant patients) or with medicines such as warfarin to prevent bleeding islands.</seg>
<seg id="2511">"it must also be used in case of patients suffering from a long-term Malabsorbing ficiency Syndrome (in which not enough nutrients from the digestive tract) or to cholestase (a liver disease) suffer, and in pregnant or nursing mothers."</seg>
<seg id="2512">July 2007 the European Commission shared the Glaxo Group Limited as approve permission for the transport of Orlistat GSK in the entire European Union.</seg>
<seg id="2513">Alli is used to weight reduction in adults with overweight (Body-Mass-Index-Index BMI &gt; 28 kg / m2) and should be applied in combination with a slightly hypocalorical diet.</seg>
<seg id="2514">"alli must not be used by children and young people under 18, because not enough data on effectiveness and safety."</seg>
<seg id="2515">"however, Orlistat however only minimal resorbiert is only minimal and in patients with reduced liver and / or kidney function, no adjustment of the dosage is necessary."</seg>
<seg id="2516">• hypersensitivity to the active ingredient or other components • simultaneous treatment with Ciclosporin (see Section 4.6) • Chronicle (see Section 4.6) • Period treatment with warfarin or other oral anticoagulants (see sections 4.5 and 4.8)</seg>
<seg id="2517">The likelihood of the awakening gastrounal symptoms (see Section 4.8) can increase if alli made together with a fat meal or fetters diet.</seg>
<seg id="2518">"since the weight-reduction in diabetes can be carried out with improved metabolic control, patients should consult a medication against diabetes, before beginning a therapy with alli made a doctor or a pharmacist, because the dosage of the antidiabetic may be adjusted."</seg>
<seg id="2519">"patients, the alli as well as drugs against hypertension or increased cholesterol levels should consult their physician or pharmacists, whether the dosage must be adjusted."</seg>
<seg id="2520">"it is recommended to meet additional fluctuating measures, in order to bow the possible contraception of the oral contraception (see Section 4.5)."</seg>
<seg id="2521">"in a study on interdependences of drugs as well as in several cases with simultaneous use of Orlistat and Ciclosporin, a waste of Ciclosporin was observed."</seg>
<seg id="2522">"in the application of warfarin or other oral anticoagulant in combination with Orlistat, the Quick values could be influenced (internationally normated ratio, INR) (see Section 4.8)."</seg>
<seg id="2523">"most patients who were treated in clinical trials up to 4 full years with Orlistat, the concentrations of vitamins A, D, E and K and the beta carotins are in the standard."</seg>
<seg id="2524">"however, the patient should be advised to take a complementary multivitamin supplement to ensure sufficient vitamine intake (see Section 4.4)."</seg>
<seg id="2525">"after the gift of a one-Maldosis Amiodaron was observed with a limited number of healthy volunteers, which at the same time Orlistat received, a low value of the Amiodaron Plasmakonzentration."</seg>
<seg id="2526">"animal experimental studies did not show any direct or indirect harmful effects on pregnancy, embryonic / fetal development, birth or post-natal development (see Section 5.3)."</seg>
<seg id="2527">"the side effects of Orlistat are mainly gastrouninal nature and depend on the pharmacological effects of the medication by means, since absorption of biases is prevented."</seg>
<seg id="2528">The gastrouninal side effects have been established from clinical trials with Orlistat 60 mg for a period of 18 months to 2 years and were generally easy and temporary.</seg>
<seg id="2529">"the differences are defined as follows: very common (&gt; &gt; &gt; &gt; &gt; / 10, &lt; 1 / 10), occasionally (&gt; &gt; &gt; / 1,000, &lt; 1 / 1,000) and very rare (&lt; 1 / 10,000), not known (frequency based on the available data not transferable)."</seg>
<seg id="2530">"the frequency of the familiar side effects that have been established after the launch of Orlistat, is not known as these events were voluntarily reported from a population of uncertain magnitude."</seg>
<seg id="2531">† It is plausible that treatment with alli made with regard to possible or actual gastrouninal side effects can lead.</seg>
<seg id="2532">Individual doses of 800 mg Orlistat and multi-capacity of up to 400 mg three times a day were administered over a period of 15 days to normal and overweight specimens that occurred over a period of 15 days without a significant clinical findings.</seg>
<seg id="2533">"in the majority of the cases reported by Orlistat-overdose, either side effects or similar effects were reported in the recommended dose of Orlistat."</seg>
<seg id="2534">"based on investigations on humans and animals can be attributed from a quick replication of any systemic effects, which are due to the lipasing properties of Orlistat."</seg>
<seg id="2535">The therapeutic effect sets in the lumens of the stomach and the upper dune-living coatings in the active serene rest of the gastral and panatic lipasen.</seg>
<seg id="2536">"clinical trials has been derived that 60 mg Orlistat, three times daily, absorption of approximately 25% of the food is blocked."</seg>
<seg id="2537">"two double flea, randomized, placebocontrolled studies in adults with a BMI &gt; 28 kg / m2 occupy the effectiveness of 60 mg Orlistat, which was taken three times daily in combination with a hypokaline, fetal nutrition."</seg>
<seg id="2538">"the primary parameters, the change of body weight compared to the output value (at the time of Randomisation), has been assessed as follows: as a change in the body weight in the study shift (table 1) and as percentage of those who have lost over 10% of their output weight (table 2)."</seg>
<seg id="2539">"although in both studies the weight reduction has been observed over 12 months, the greatest weightloss in the first six months has been observed."</seg>
<seg id="2540">The average change in the overall cholesterin was with Orlistat 60 mg -2.8% (output worth 5,20 mmol / l) and with placebo + 2.9% (output worth 5.5 mmol / l).</seg>
<seg id="2541">The average change of the LDL cholesterol amounted to Orlistat 60 mg -3.5% (curly value drimmol / l) and with placebo + 3.6% (output worth 3.41 mmol / l).</seg>
<seg id="2542">"in the waist, the average change -4.5 cm with Orlistat 60 mg (output value 103,7 cm) and with placebo -3,6 cm (output worth 103,5 cm)."</seg>
<seg id="2543">Plasticoncentations of not metabolified Orlistat were 8 hours following the orals of 360 mg Orlistat does not measurable (&lt; 5 ng / ml).</seg>
<seg id="2544">7 In general could not be used for therapeutic dosages in Plasma only sporadic and in extremely low concentrations (&lt; 10 ng / ml or 0.02 µmol) and without signs of gulation.</seg>
<seg id="2545">"in a study with adipous patients, which was administered minimal systemically resorated dose, namely M1 (in position 4 hydrolysified Lactonring) and M3 (M1 after splitting the N-formyl ring), and M3 (M1 after lowering the N-formyl ring group), identified to the approximate 42% of the overall plasmakoncentation."</seg>
<seg id="2546">"based on conventional studies on safety spharmacology, toxicity in repetitive gabe, genotoxicity, canogenous potential and reproduction, the preclinical data cannot be a special threat to man."</seg>
<seg id="2547">"pharmacovigilance system The holder of permission for the transport must ensure that the Pharmacovigilance system, described in accordance with version 1.8.1. of the authorisation application, is applied and works before and while the product is available on the market."</seg>
<seg id="2548">"risk management planning The holder of permission for the transport system is obliged to carry out the studies and additional pharmaceuticals plan (RMP) from October 2008 in accordance with module 1.8.2nd of the authorisation application, as well as all other updates of the RMPs, which are agreed with the Committee on Humanarzs (CHMP)."</seg>
<seg id="2549">"according to CHMP guidelines, risk management systems must be submitted to date and updated simultaneously with the next PSUR (periodic Safety Update Report)."</seg>
<seg id="2550">"furthermore, an upset file should be submitted: • If new information is available, the current security guidelines, the Pharmacovigilance plan or risk minimization activities • on request of the European Pharmaceuticals Agency (EMEA)"</seg>
<seg id="2551">"12 PSURs The holder of permission for the transport will take place during the first year after the Commission decision to submit to the alli 60 mg Hartblackles PSURs every 6 months, then for two years and after all three years."</seg>
<seg id="2552">"do not use when you are under 18, • If you are pregnant or breastfeeding, • If you are sensitive to Orlistat or any other blood thinner, • If you have hypersensitive to Orlistat or any of the other constituents (illness of the liver, when you have problems with food intake (chronic malabsorption synficiency Syndrome)."</seg>
<seg id="2553">"• take three times each day with each main meals, the fat contains, one capsule with water. • You should take one day no more than three capsules. • You should take once daily, before bedtime, a multivitamintablette (with the vitamins A, D, E and K). • You should not apply more than 6 months."</seg>
<seg id="2554">"application: • If you take three times each day with each main meals a capsule with water. • You should take no more than three capsules per day. • You should take once daily, before bedtime a multivitamintablette (with the vitamins A, D, E and K). • You should not apply more than 6 months before bedtime."</seg>
<seg id="2555">Maybe you want to read this later again. • ask your doctor or pharmacist if you need further information or advice. • If you have any further information or advice. if you have not reached any weight loss before you ask a doctor or a pharmacist.</seg>
<seg id="2556">"you may need to finish the intake of alli. • If any of the listed side effects you have considerably affected or you notice unwanted side effects, which are not listed in this usage information, please inform your doctor or a pharmacist."</seg>
<seg id="2557">What do you need to consider before taking alli made? • alli must not be used • In the intake of alli made with other medicines • For intake of alli along with foods and drink • pregnancy and breastfeeding for machines 3.</seg>
<seg id="2558">How is alli made? • How can you take your weight loss? O Chokes your starting point for your calorie intake and fat intake • How long should you take? O adults from 18 years o How long should I take alli? O When you have alli made in big quantities - If you have forgotten the intake of alli 4.</seg>
<seg id="2559">What side effects are possible? • serious side effects • Very common side effects • Frequent side effects • Effect on blood tests • How can you control occupational conditional agents?</seg>
<seg id="2560">Further information • What alli contains • How to alli and content of the package • pharmaceutical entrepreneurs and manufacturers • Additional information</seg>
<seg id="2561">"alli is used for weight reduction, and is used for overweight adults from 18 years with a Body-Mass-Index (BMI) of 28 or above."</seg>
<seg id="2562">The BMI helps you determine whether you have a normal weight in relation to your body size or are overweight.</seg>
<seg id="2563">"even if these conditions do not happen at first, you should feel uncomfortable, you should nevertheless ask your doctor for checkcheckout."</seg>
<seg id="2564">"for each 2 kg of body weight, which you dieting within the framework of a diet, you can lose with the help of alli gains additional kilograms."</seg>
<seg id="2565">"please inform your doctor or a pharmacist, if you take other medicines or have recently taken, even if it is not prescription drugs."</seg>
<seg id="2566">"Ciclosporin is utilized according to organtransplants, in severe rheumatoid arthritis and certain severe skin diseases. • warfarin or other medicines that have a blood thinner effect."</seg>
<seg id="2567">Oral contraception and alli • The effect of oral inhaling funds for pregnancy prevention (pill) is under circumstances weaving or lifted if you have strong Diarrhö (diarrhea).</seg>
<seg id="2568">Please contact your doctor or pharmacist if you need: • Amiodaron to treat cardiac arrhythmia treatment. • Acarbons to treat diabetes.</seg>
<seg id="2569">"ask your doctor or pharmacist when you take alli and • If you take drugs against hypertension, as possibly the dosage must be adjusted to high cholesterol levels as possibly the dosage must be adjusted."</seg>
<seg id="2570">"as you can specify your calorie goals and fat boundaries, you can learn more information on the blue sides in section 6."</seg>
<seg id="2571">"if you don't have a meal or includes a meal no fat, take no capsule. alli can only be effective if the food fat contains."</seg>
<seg id="2572">"if you are taking the capsule in conjunction with a meal that contains too much fat, risk nutritional supplements (see Section 4)."</seg>
<seg id="2573">"to get used to your body to the new eating habits, you are already beginning before the first capsule with an calorie and fetal diet."</seg>
<seg id="2574">"nutritional supplements are effective, as you can comprehend whenever you eat, how much you eat and it will likely drop you easier to change your dietary habits."</seg>
<seg id="2575">"to achieve your target weight safely, you should set up two daily goals: one for the calories and one for fat."</seg>
<seg id="2576">"• feed yourself fetters to decrease the likelihood of nutritional agents (see Section 4). • Try to move more, before you start with the intake of the capsules."</seg>
<seg id="2577">Remember in advance your doctor if you are not used to exercise physical activity. • Stays during intake and even after ending the intake of alli physically active.</seg>
<seg id="2578">"• alli must not be taken longer than 6 months. • If you are not applying for twelve weeks application of alli made no reduction of your weight, please ask your doctor or a pharmacist for advice."</seg>
<seg id="2579">"under circumstances, you need to end the intake of alli. • At a successful weight loss it is not about having to re-establish nutrition and return to old habits."</seg>
<seg id="2580">"• If less than an hour has passed since the last meal, take taking the capsule after. • If more than an hour has passed since the last meal, do not take a capsule."</seg>
<seg id="2581">Blacks with and without hesitating resignation, sudden or multiplied Stuhldjumped and softer chair) are due to the action mechanism (see Section 1). "</seg>
<seg id="2582">"severe allergic reactions • severity allergic reactions can be seen in the following changes: severe respiratory, welded quarries, itching ashes, swelling, swelling, swelling, irritation."</seg>
<seg id="2583">"29 Very common side effects These can occur with more than 1 of 10 people, the alli, occur. • Blacks (Flatulence) with and without hesitant resetting • Which chair informing your doctor or pharmacist, if one of these side-side effects increases or you greatly affected."</seg>
<seg id="2584">"frequent side effects these can occur at 1 of 10 people, the alli (abs), • Inkontinenz (chair) • Inkontinenz (chair) • Creditches Informing your doctor or pharmacist, if any of these side effects increases or significantly affected."</seg>
<seg id="2585">"effects on blood tests It is not known how often these effects occur. • raising certain liver enzymes • effects on blood clotting in patients, the warfarin or other blood thinners (antikoagulation) medicines."</seg>
<seg id="2586">"please inform your doctor or a pharmacist, if any of the listed side effects you have considerably affected or you notice unwanted side effects which are not listed in this usage information."</seg>
<seg id="2587">The most common side effects are related to the effectiveness of the capsules and thus resulting in excess fat out of the body.</seg>
<seg id="2588">"these side effects occur usually within the first weeks after the start of treatment, as you have not yet consistently reduced the fat content in diet."</seg>
<seg id="2589">"with the following basic rules, you can learn to minimize your nutritional supplements, • Have you already several days, or better one week before the first intake of capsules with a fatty diet. • learn more about the usual fat content of your favourite food and about the size of the portions that you normally take."</seg>
<seg id="2590">"if you know exactly how much you eat, lowers the likelihood you can exceed your fat. • You share your recommended amount equal to daily meals."</seg>
<seg id="2591">"save the amount of calories and grease that you may take a meal per meal, not to take them in the form of a fat reduction or a chopped up with other programs to control it with other programs to control it with time due to adaptation of their nutrition."</seg>
<seg id="2592">• To save medicines for children inaccessible. • You are not allowed to apply more than 25 ° C. The bottle contains two white sealed vessels with Silicagel that serve to keep capsules dry.</seg>
<seg id="2593">Swallow this on no case. • You can set up your daily dose alli made in the blue container box (Shuttle) with which this package is beicumbent.</seg>
<seg id="2594">"FAMAR, 190 11 Avlona, Greece Catalent UK Packaging Limited, Sedge Close, Headway, Great Oakley, Corby, Northamptonshire NN18 8HS, United Kingdom"</seg>
<seg id="2595">Obesity affects your health and raises the risk for the emergence of different weighty diseases such as: • hypertension • Diabetes • Hercereal infections • Osteoarthritis relief you with your doctor about your risk to these disorders.</seg>
<seg id="2596">"a permanent weight loss, for example by improving the diet and more exercise, can preventable diseases and has a positive impact on your health."</seg>
<seg id="2597">"choose meals that contain a wide range of nutrients, and learn to and after, permanently eat healthy."</seg>
<seg id="2598">"energy is also measured in kilogoule, which you can also find as stating on the packaging of foods. • The recommended calorie intake are available, how many calories you should take up a maximum of day."</seg>
<seg id="2599">"notice the further down in this section tables. • The recommended fat supply in gramms is the maximum amount of fat, which you should take with each meal."</seg>
<seg id="2600">"what amount of you is suitable, see the bottom of the information that is suitable for you. • Reading of the active effect of the capsule is decisive for compliance with the recommended fats."</seg>
<seg id="2601">"if you take the same amount of fat as before, this can mean that your body cannot process this amount of fat."</seg>
<seg id="2602">"by compliance with the recommended fats, you can maximize the weight loss and at the same time reduce the probability for nutritional deficiencies. • You should try to gradually increase gradually."</seg>
<seg id="2603">"34 These reduced calorie intake should allow you to develop gradually and continuously approximately 0.5 kg per week, without to develop fruit and disappointments."</seg>
<seg id="2604">"the more active you are, the higher your recommended calorie intake. •" "low physical activity" "means that you're going to work everyday only little or even other physical activities, e.g. through 3 km walking, 30- to 45-minute garden work or 2 km running in 15 minutes."</seg>
<seg id="2605">• For a permanent weight loss it is necessary to put yourself realistic calorie and fat goals and to adhere to these also. • sensible is a nutritional service with details of calorie and fat content of your meals. • Try to move more before you start with the intake of alli.</seg>
<seg id="2606">"the alli programme for supporting the weight loss combines the capsules with a nutritional plan and a large number of additional information material that can help you to feed calorie and fetters, be physically active."</seg>
<seg id="2607">"in conjunction with a tailored program to support the weight loss program, this information can help you develop healthier lifestyle and achieve your target weight."</seg>
<seg id="2608">"Aloxi is used in chemotherapy, the strong trigger for nausea and vomiting (as cisplatin), as well as in chemotherapy, the trigger trigger for nausea and vomiting (such as Cyclophosphamide, Doxorubicin or Carboplatin)."</seg>
<seg id="2609">"the effectiveness of Aloxi can be increased through the additional gift of a corticosteroids (a drug, which can be used as antiemetikum)."</seg>
<seg id="2610">The application in patients under the age of 18 is not recommended because the effects in this age group is not enough information.</seg>
<seg id="2611">"this means that the active ingredient of a chemical substance in the body, 5-hydroxytryptamine (5HT, also known as serotonin), to the receptors in the intestine."</seg>
<seg id="2612">"Aloxi was studied in three main studies on 1 842 adults, the Chemists received strong or excessive trigger for nausea and vomiting."</seg>
<seg id="2613">"in chemotherapy, the strong trigger for nausea and vomiting are 59% of the patients treated with aloxi in 24 hours following chemotherapy (132 of 223), compared to 57% of patients with ondansetron treated patients (126 of 221)."</seg>
<seg id="2614">"in chemotherapy, the trigger trigger for nausea and vomiting are showed 81% of patients treated with aloxi, in the 24 hours following chemotherapy (153 of 189), compared to 69% of the patients (127 of 185)."</seg>
<seg id="2615">In a comparison with Dolasetron these values at 63% for Aloxi (119 of 189 patients) and 53% for Dolasetron (101 of 191 patients).</seg>
<seg id="2616">March 2005 the European Commission shared the Helsinki Birex Pharmaceuticals Ltd. approve of the transport of alxi in the entire European Union.</seg>
<seg id="2617">Aloxi is indices: the prevention of acute nausea and vomiting at strongly emetogenic chemotherapy due to cancer prevention and vomiting at unionogenic chemotherapy due to cancer prevention.</seg>
<seg id="2618">"the effectiveness of aloxi on prevention of nausea and vomiting, which is induced by a strongly emetogenic chemotherapy can be reinforced by adding a given corticosteroids."</seg>
<seg id="2619">"as Palonosetron extend the Dickdarmpassage, patients should be monitored with anamnestial obstipation or signs of subsidizing Ileus after injections."</seg>
<seg id="2620">"however, as with other 5HT3 antagonists, however, caution is advisable with drugs which extend the QT-Intervall or in patients with which Qt- interval is extended or that tend to be one of such an extender."</seg>
<seg id="2621">"except in connection with an additional chemotherapy medicine, Aloxi in days after chemotherapy is not used to prevent nausea and vomiting."</seg>
<seg id="2622">"in preclinical studies hemonosetron inhibit the tumors of the five subjunctive chemotherapy (cisplatin, Cyclophosphamide, Cytarabin, Doxorubicin and Mitomycin C)."</seg>
<seg id="2623">A clinical trial did not prove a significant pharmacopoinetic interaction between a unique intravenous dose of Palonosetron and a steady concentration oroclopramids, of a CYP2D6 inhibitors. "</seg>
<seg id="2624">"in a population based pharmacopoetic analysis, it has been shown that the simultaneous gift of CYP2D6 inhibitors (Dexamethason and Rifampicin), doxorubicin, Fluidoxetine, Chinaavir, Sershalin and Terbinafin) have no significant impact on the clearance of Palonosetron."</seg>
<seg id="2625">"experience to the use of Palonosetron in human pregnancies are not before, therefore Palonosetron should not be applied in pregnant, unless it is considered by the treating physicians than necessary."</seg>
<seg id="2626">"clinical trials were the most common in a dose of 250 microgram to follow-up side effects (a total of 633 patients) which were at least possibly with aloxi in connection, headaches (9%) and Obstipation (5%)."</seg>
<seg id="2627">"very rare cases (&lt; 1 / 10,000) of hypersensitivity and reactions at the administration (burning, hardening, discomfort and pain) were given in post-marketing experience."</seg>
<seg id="2628">"in the group with the highest dosage showed similar frequencies of unwanted events, as in the other dosing groups, there were no dose-active relationships."</seg>
<seg id="2629">"there were no dialysis studies conducted because of the large distribution volume, however, there is probably no effective therapy for an alchemist overdose."</seg>
<seg id="2630">"in two randomized double-indstudies were given a total of 1,132 patients having a moderate chemotherapy with &lt; 50 mg / m2, carboplatin (half-time 4 hours) or 100 mg Dolasetron (half-time 7.3 hours), which was given on day 1 without Dexamethason intravenously."</seg>
<seg id="2631">"in a randomized double blue study, a total of 667 patients who received a strongly emetogeneous chemotherapy with &gt; 60 mg / m2 Cyclophospheramide and Dacarbazin and 250 or 750 micrograms of Palonosetron, with patients compared to the 32 mg of Ondanzron, which were given to day 1 intravenously."</seg>
<seg id="2632">Results of the studies with moderemetogenated chemotherapy and the study with strongly emetogenated chemotherapy products are summarised in the following tables.</seg>
<seg id="2633">In clinical trials for the indication of chemotherapy induced nausea and vomiting (CINV) were the effects of Palonosetron to blood pressure, heart rate and EKG parameters, including the corresponding effects of Ondanzron and Dolasetron. "</seg>
<seg id="2634">"according to the findings, Palonosetron has the ability to block the centricular de- and repolarisation involved and to extend the duration of the shareholder potential."</seg>
<seg id="2635">"the study conducted by 221 healthy volunteers were the assessment of the EKG effects of i.v. administered Palonosetron in single-osen of 0,25 s, 0,75 and 51 mg."</seg>
<seg id="2636">Resorption After intravenous gift follows an extensive Elimination from the body with an average season half-time period about 40 hours.</seg>
<seg id="2637">The average maximum Plasmakonzentration (Cmax) and the surface under the concentration time curve (AUC0- ∞) are generally proportional to the entire dosage range of 0,3- 90 μ g / kg in healthy and cancer patients. "</seg>
<seg id="2638">"after intravenous gift of Palonosetron 0,25 mg every second day for a total of 3 doses, which stood between day 1 and day 5 (± SD) rise in Palonosetron Plasmakonzentration at 42 ± 34%."</seg>
<seg id="2639">"from pharmacokinetic simulations indicate that once again a daily giver of 0.25 mg Palonosetron had comparable to 3 consecutive days (AUC0- ∞) with the following a non-recurring administration of 0,75 mg was comparable; however, the Cmax was higher after the use of 0,75 mg higher."</seg>
<seg id="2640">Around 40% will be eliminated via the kidneys and about another 50% will be transformed into two primary metabolic parasites which have less than 1% of the antagonistic effect on 5HT3 receptor.</seg>
<seg id="2641">"in-vitro-studies on Metabolarization have shown that CYP2D6 and, in lower dimensions, the Isoenzymes CYP3A4 and CYP1A2 is involved in the Metabolism of Palonosetron."</seg>
<seg id="2642">"Elimination After a intravenous single dose of 10 microgram / kg [14C] -Palonosetron were re-found approximately 80% of the dose within 144 hours in the urine, Palonosetron made as unchangeable active ingredient, made approximately 40% of the given dose."</seg>
<seg id="2643">After a unique intravenous boltion in healthy was the overall body of 173 ± 73 ml / min and the renal clearance 53 ± 29 ml / min.</seg>
<seg id="2644">"although in patients with severe liver interrupting the terminale Eliminationshftzeit, and the average systemic exposure with Palonosetron increased, but a reduction in the dose is therefore not justified."</seg>
<seg id="2645">"in clinical trials, effects were observed only after expositions that can be seen as sufficiently above the maximum human therapeutic exposure, which indicates a low relevance for the clinical use."</seg>
<seg id="2646">10 From pre-clinical trials take evidence that Palonosetron can only be blocking in very high concentrations of icons which are involved in ventricular De- and Repolarisation.</seg>
<seg id="2647">"high doses Palonosetron (every dose unrach in about the 30times of the therapeutic exposure to humans), who were given every day over two years, led to an increased incidence of Lebertumers, endocrine neoplastics, Pancreas, adrenal erenmark) and rampes with rats, but not with mice."</seg>
<seg id="2648">"the underlying mechanisms are not completely known, but due to the high dosing and since alxi where it is for the unique application, the relevance of these results is regarded as low as humans."</seg>
<seg id="2649">The owner of this permission for the transport must be provided by the European Commission on the plans for the transport of the law in the framework of this decision approved.</seg>
<seg id="2650">"• If any of the listed side effects you have considerably affected or you notice unwanted side effects, which are not specified in this usage information, please inform your doctor."</seg>
<seg id="2651">"• Aloxi is a clear, colored injection solution to injecting in a Vene. • The substance (Palonosetron) is a group of drugs called serotonin and vomiting. • Aloxi is used to prevent nausea and vomiting that arise in connection with chemotherapy because of cancer."</seg>
<seg id="2652">"21 In use of Aloxi with other medicines please inform your doctor if you are taking other medicines / or have recently taken / applied, even if it is not prescription drugs."</seg>
<seg id="2653">"pregnant If you are pregnant or believe to be pregnant, your doctor will not give you aloxi, unless it is definitely necessary."</seg>
<seg id="2654">"before taking care of all medicines your doctor or pharmacists for advice, if you are pregnant or believe to be pregnant."</seg>
<seg id="2655">"in some very rare cases, it came to allergic reactions to aloxi or to burning or pain at the same time."</seg>
<seg id="2656">"like Aloxi looks and content of the package Aloxi injection solution is a clear, colored solution and is available in a package with 1 flow bottle of glass available, which contains 5 ml of the solution."</seg>
<seg id="2657">"Бълария сикария сикария арикария сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия сия</seg>
<seg id="2658">Latvija pharmaceutical Swiss Latvia SIA 54-5-drowns of Street Riga, LV-1011 Tel: + 37167502185 Lietuva UAB Phetyeimyniš kist. "</seg>
<seg id="2659">United Kingdom IS Pharmaceuticals Ltd Office Village Chester Business Park Chester CH4 9QZ - UK Tel: + 44 1244 625 152</seg>
<seg id="2660">"June 2006, the Committee on Humanarzs (CHMP) passed a negative value in which the failure of the approval of the treatment of hepatitis C for the treatment of hepatitis C is recommended using Alpheon 6 million IE / ml injection solution."</seg>
<seg id="2661">"this means that Alpheon is similar to a biological medicine called Roferon-A with the same arztally effective component, which is already approved in the EU (also" "reference frequency." ")."</seg>
<seg id="2662">Alpheon should be used for the treatment of adult patients with chronic (long-prolonged) hepatitis C (one by virus infection.</seg>
<seg id="2663">"for a microscopic examination the liver tissue indicates, moreover, the values of liver enzymes Alanin- Aminotransferase (ALT) increases in the blood abnormal."</seg>
<seg id="2664">It is produced by a yeast into which a gene (DNA) was introduced to the formation of the substance.</seg>
<seg id="2665">"the manufacturer of Alpheon placed data that overtake the comparison of Alpheon with roferon-A (drug structure, composition and purity of the drug, effectiveness, safety and effectiveness in hepatitis C)."</seg>
<seg id="2666">"in the study of patients with hepatitis C, the effectiveness of Alpheon was compared to the effectiveness of the reference to 455 patients."</seg>
<seg id="2667">"in the study, how many patients were measured after 12 from a total of 48 treatment weeks and 6 months after the treatment of treatment on the drug (i.e. there are no indication of the virus in the blood)."</seg>
<seg id="2668">(44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail @ emea.eu.int http: / / www.emea.eu.int http: / / www.emea.eu.int</seg>
<seg id="2669">"in addition, concerns have expressed concerns that the data on the stability of the substance and the drug is not sufficient."</seg>
<seg id="2670">"the number of patients with hepatitis C, which spoke to the treatment with Alpheon and Roferon-A, was similar in clinical trial."</seg>
<seg id="2671">"after the cessation of the treatment with Alpheon flammite the disease again in more patients than in the reference frequency; moreover, aleon had more side effects."</seg>
<seg id="2672">"apart from that, the test has been introduced in the study to investigate the question, to what extent the medication is an immune response (i.e. the body forms antibodies - specific proteins - against the drug), not sufficiently validated."</seg>
<seg id="2673">"it may be applied to the treatment of Impetigo (a with crucified skin infection) and small ininfected Lazerations (Riss- or chievils), scopes and paralyzed wounds."</seg>
<seg id="2674">"Altargo is not intended to treat infections, evidence or probably caused by methicidal resistant Staphylococcus aureus (MRSA) because Alargo against these kinds of infections may not be affected."</seg>
<seg id="2675">"Altargo can be applied in patients from the age of nine months, but patients under the age of 18 may not be considered 2% of the body surface."</seg>
<seg id="2676">"if the patient is not talking to the treatment two or three days, the doctor should study the patient again and consider alternative treatments."</seg>
<seg id="2677">"it works by blocking the bacterial reef cells (the parts of the bacterial cells, where proteins are produced) and inhibits the growth of bacteria."</seg>
<seg id="2678">"the main indeer of the effectiveness was in all five studies of the patients, whose infection was caused by the end of the treatment."</seg>
<seg id="2679">119 (85.3%) of the 139 patients under Altargo and 37 (52.1%) of the 71 patients under placebo spoke to the treatment.</seg>
<seg id="2680">"during the treatment of infected Hauges, Altargo and Cefalexin relate: if the results of both studies were raised in Hautes, spoke about 90% of the patients of both groups."</seg>
<seg id="2681">"however in these two studies, however, that Altargo was found in the treatment of abscesses (eitful cavity in the body tissues) or of infections that have been caused by MRSA, not effective enough."</seg>
<seg id="2682">The most common side effect with altargo (which was observed in 1 to 10 of 100 patients) is a maturity of the order.</seg>
<seg id="2683">"the Committee on Humanarzs (CHMP) led to the conclusion that the benefits of Altargo in the course-treatment of the following superficial rash compared to the risks: • Impetigo, • infied small inserts, scopes or paralyzed wounds."</seg>
<seg id="2684">May 2007 the European Commission shared the Glaxo Group Ltd. approve of the transport of Altargo in the entire European Union.</seg>
<seg id="2685">Patients who show no improvement within two or three days are to be examined and considered a alternative therapy (see Section 4.4).</seg>
<seg id="2686">"in the event of raising awareness or severe local irritation by the application of retapamulin salbe, the treatment is discontinued, the salbe carefully abusive and proper alternative therapy of the infection can be started."</seg>
<seg id="2687">Reapamulin should not be used to treat infections where MRSA is known as pathogen or suspected (see Section 5.1).</seg>
<seg id="2688">Clinical trials included in secondary wounds was the effectiveness of Retapamulin in patients with infections that caused by a methicillin-resistent Staphylococcus aureus (MRSA) were insufficient.</seg>
<seg id="2689">Alternative therapy is supposed to be considered when after an 2- or 3-day treatment no improvement or a deterioration of the infected passage.</seg>
<seg id="2690">The effect of simultaneous use of retapamulin and other topical means at the same skin surface is not tested and the simultaneous application of other topical medicines is not recommended.</seg>
<seg id="2691">"due to the small plasma concentration, which have been reached when people after topical application on shielced skin or infected superficial wounds, is a clinically relevant inhibition not to be expected (see Section 5.2)."</seg>
<seg id="2692">3 After simultaneous gift of 2-times 200 mg Ketoconazol increased the mean Retapamulin AUC (0-24) and Cmax according to topical application of 1% Retapamulin salbe on shielced skin of healthy adult men by 81%.</seg>
<seg id="2693">"due to the low systemic exposure to topical application in patients, dosages cannot be considered required when topical retaliamulin is used during a systemic treatment with CYP3A4 inhibitors."</seg>
<seg id="2694">Animal studies have shown a reproduction xicity to oral intake and are inadequate in terms of a statement on the birth and the soldering / postnatal development (see Section 5.3).</seg>
<seg id="2695">Reapamulin Salbe should only be applied during pregnancy when a topical antibacterial therapy is clearly indicative and the application of retapululin the gift of a systemic antibiotic.</seg>
<seg id="2696">"when deciding whether or breastfeeding continues, or the therapy with Altargo will be continued / terminated, is between the benefit of breastfeeding for infant and the benefit of the altargo therapy for the woman."</seg>
<seg id="2697">"clinical trials to 2150 patients with superficial rash, the Altargo, was the most commonly reported annexation of irritation at the administration, which concerned about 1% of the patient."</seg>
<seg id="2698">"transapamulin is a semi-synthetic derivatives of Pleuromutilin, a substance that is insulated by fermentation from Clitopilus passwerianus (formerly plurotus passwanus)."</seg>
<seg id="2699">The action mechanism of retreat by Retapamulin is based on selective inhibitors of the bacterial protein synthesis through interaction with a particular relation of the 50s sub-unit of the bacterial Ribosoms which differs from the ties of other ribosomal interacting anti-bacterial substances.</seg>
<seg id="2700">Data suggest that the Binding office ribosomales Protein L3 involved and is located in the area of the ribosomalen P-Binding office and the PeptidyltransferaseCentre.</seg>
<seg id="2701">"through Binding to this Binding site inhibit Pleuromutiline the Peptidyltransfer, blocking partly P-binding interactions and prevent the normal education active 50s ribosomal subunits."</seg>
<seg id="2702">"on the basis of local prevalence of resistance, the application of Retapamulin at least some infectious forms appear, should be pursued a consultation by experts."</seg>
<seg id="2703">"there were no differences in the In-vitro activity of Retapamulin opposite S.aureus, regardless of whether the isolates are sensitive or resistant to methicillin."</seg>
<seg id="2704">"in the case of failure to treatment at S.aureus, the presence of tribes with additional viral factors (such as PVL = Panton-Valentine Leucocidin) should be considered."</seg>
<seg id="2705">Resorption In a study with healthy adults was brought to 1% retaliamulin salbe daily under occlusion on intact and upted skin for up to 7 days.</seg>
<seg id="2706">"from 516 patients (adults and children), the 1% Retapamulin Salbe received twice daily for 5 days for the topical treatment of secondary infected persons, individual Plasmaproben were obtained."</seg>
<seg id="2707">The sampling took place on the days 3 or 4 in the adult patients in front of the medication and in children between 0-12 hours after the last application.</seg>
<seg id="2708">"however, the maximum individual system inclusion at the people after topical application of 1% of salbe to 200 cm2 deducted skin (Cmax = 22 ng / ml; AUC (0-24) = 238 ng · h / ml) 660-times lower than the retruamulin IC50 for the pGP inhibition."</seg>
<seg id="2709">Metabolism The in vitro oxidative Metabolism of Retapamulin in humanous liver-microsomen has been conveyed primarily by CYP3A4, under small participation of CYP2C8 and CYP2D6 (see Section 4.5). "</seg>
<seg id="2710">"in studies for orical toxicity of rats (50, 150 or 450 mg / kg) that were conducted over 14 days, there were signs of adaptive liver and thyromodification."</seg>
<seg id="2711">In-vitro-checking on-mutation and / or chromosomal effects in the mouse-lymphoma test or in cultures of human peripheral hemtic lymphocytes as well as in the rats-microkernel test for in-vivo-investigation-omaler effects.</seg>
<seg id="2712">"there was neither male nor female rats, signs of limited fertilisation of 50, 150 or 450 mg / kg / day, thereby causing a maximum to 5-times higher exposure was achieved as the highest estimated exposure to humans (topical application on 200 cm2) skin:"</seg>
<seg id="2713">In an embryotoxicity review to rats were used in orical dispositions of &gt; &gt; 150 mg / kg / day (according to &gt; &gt; &gt; &gt; &gt;] estimated human exposure (see above)), development stoxicity (decreased body weight) and maternal toxicity. "</seg>
<seg id="2714">"the holder of permission for the transport must ensure that an Pharmacovigilance system, which is present in the module 1.8.1 of the authorisation application (version 6.2) and operates before the product is marketed and as long as the product market is applied."</seg>
<seg id="2715">"the holder of permission for the transport system is obliged to perform detailed studies and additional pharmaceuticals plan, as described in the version 1 of the Risk Management Plan (RMP) and in the module 1.8.2 of the authorisation application, and all additional updates of the RMP, which are agreed with the CHMP."</seg>
<seg id="2716">"as described in the CHMP" Guideline on Risk Management Systems for human use "," the updated file should be submitted at the same time with the next period odic Safety Update Report. "</seg>
<seg id="2717">Irritation or other signs and symptoms present at the same point are to finish the application of Altargo and talk to your doctor.</seg>
<seg id="2718">"do not use other salts, creams or lotions on the surface that is treated with Altargo if you have not expressly ordered from your doctor."</seg>
<seg id="2719">"it must not be used in the eyes, on the mouth or on the lips, in the nose or female genital area."</seg>
<seg id="2720">"if the salbe from hiding on one of these surfaces, wash the place with water and ask your doctor about advice, if complaints occur."</seg>
<seg id="2721">"after revealing the anoint you can cover the affected area with a sterile association or a gazing band, unless your doctor has come to cover the area."</seg>
<seg id="2722">"it is offered in an aluminum tube with a plastic box, which contains 5, 10 or 15 grams of salbe, or in a aluminum bag, which contains 0,5 g salbe."</seg>
<seg id="2723">Ambirix is intended to protect hepatitis A and hepatitis B (diseases which apply the liver) in children aged between one and 15 years which are not immun against these two diseases.</seg>
<seg id="2724">Ambirix is used as part of one of two doses of existing vaccines, whereby a protection against hepatitis B may only be achieved after administration of the second dose. "</seg>
<seg id="2725">"for this reason, Ambirix must be used only when the immunisation is a low risk of hepatitis B infection and is ensured that which can be led out of two doses, existing vaccines."</seg>
<seg id="2726">"if a refresher dose is desired against hepatitis A or B, Ambirix or other hepatitis B or B vaccine can be given."</seg>
<seg id="2727">"vaccines contribute by bringing the immune system (the natural defying of the body)," as it can fight against a disease. "</seg>
<seg id="2728">"after having received the human vaccine, the immune system detects the virus and surface antigens as" "foreign" "and generates antibodies against it."</seg>
<seg id="2729">Ambirix contains the same ingredients such as that since 1996 approved vaccine Twinrix adults and since 1997 approved vaccine Twinrix children since 1997.</seg>
<seg id="2730">"the three vaccines are applied to the protection against the same diseases, however, Twinrix adults and Twinrix children are administered by three doses of existing vaccines."</seg>
<seg id="2731">"because Ambirix and Twinrix adults contain identical ingredients, some of the data used by the application of Twinrix adults, also used as proof for the application of Ambirix."</seg>
<seg id="2732">The main indeer for the effectiveness was the share of vaccinated children which had developed a month after the last injtion of a protective antibodies.</seg>
<seg id="2733">"in an additional study with 208 children, the effectiveness of the vaccine has been compared to a six-month and a 12-month distance between the two injections."</seg>
<seg id="2734">Ambirix led children between 98 and 100% of the vaccinated children a month after the last injecting to the development of protective antibodies against hepatitis A and B.</seg>
<seg id="2735">The additional study showed that the degree of protection by Ambirix was similar to a hexagonal and a 12-month distance between injections.</seg>
<seg id="2736">"the most common side effects of Ambirix (observed in more than 1 of 10 vaccine) are headaches, appetisers, pain at the injection, redness, softness (tiredness) as well as irritability."</seg>
<seg id="2737">Ambirix must be used in patients who may possibly oversensitively (allergic) to the active ingredients that are responding to the other components or neomycin (an antibiotic) not to be applied.</seg>
<seg id="2738">August 2002 announce the European Commission to the company GlaxoSmithKline Biologicals s.a. a permit for the transport of Ambirix in the whole</seg>
<seg id="2739">"the standardization plan for the Grundimmaker with Ambirix consists of two vaccines, whereby the first dose is administered at the date of choice and the second dose, between six and twelve months after the first dose."</seg>
<seg id="2740">"if a refresher, is required for hepatitis A and hepatitis B, it can be vaccinated with the corresponding monovent vaccines or with a combination."</seg>
<seg id="2741">The anti-hepatitis anti-hepatitis (anti-HBsAg) - and anti-hepatitis B-A-Virus (anti-HAV) - and anti-hepatitis A-A-Virus (anti-HAV) antibodies are in the same size as after vaccination with the respective monovalent vaccines.</seg>
<seg id="2742">"it is not entirely secured, whether immunomable individuals addressed to a Hepatitis A- vaccine would require a refresher as protection, since they are also protected with no longer-evidence antibodies possibly by the immunologic memory."</seg>
<seg id="2743">3 As with all injections should be available for the rare case of an anaphylactic reaction after the gift of the vaccine for medical treatment and monitoring always immediately available.</seg>
<seg id="2744">"if a fast protection against hepatitis B is required, the Standardium scheme is recommended, the 360 ELISA units of formalininactive Hepatitis C-A virus and 10 µg recombinant Hepatitis B."</seg>
<seg id="2745">"with Hematalysis patients and individuals with disorders of the immune system, after the pridimmagation may be achieved under circumstances no sufficient anti-HAV- and anti-hbs antibodies, so that in these cases the gift of further vaccines can be necessary."</seg>
<seg id="2746">"as an intradermal injecting or intra-muscular administration in the gluteal muscle can lead to a suboptimal implication success, these injections should be avoided."</seg>
<seg id="2747">"in case of Thrombozytopenie or bleeding disorders, Ambirix cannot inject however, since it can occur in these cases of intra-muscular gift."</seg>
<seg id="2748">If Ambirix had been administered in the form of a separate injecting together with a combined Diphtherie-, Tetanophilus Steriae type b vaccine (DTPa-IPV / Hib) or with a combined mask (DTPa-IPV / Hib) or with a combined mask on all antigens. (see Section 5.1). "</seg>
<seg id="2749">"in case of patients on immunosuppressive therapy, or with patients with immune defective people have to be assumed that possibly not sufficient immune response is achieved."</seg>
<seg id="2750">"in a clinical study that has been conducted with 3 vaccinations of this formulation in adults, the frequency of pain, redness, swelling, swelling, headaches and fever is comparable to the frequency that observed in the former Thiomersal- and preservatives vaccine."</seg>
<seg id="2751">"in clinical studies, 2029 vaccination Ambirix were administered in a total of 1027 vaccinations at the age of 1 to 15 years."</seg>
<seg id="2752">In a study with 300 participants at the age of 12 to including 15 years the tolerability of Ambirix has been compared with the 3-cans combination.</seg>
<seg id="2753">Only exceptions were the higher frequency of pain and matriity on a calculation basis per vaccination Ambirix which is not on a calculation basis per person.</seg>
<seg id="2754">"pain was observed after the gift of Ambirix at 50,7% of the probanden, compared to 39.1% for the gift of a dose of the 3-cans combination."</seg>
<seg id="2755">"after the whole vaccine of 66,4% of the promotrix reported the Ambirix had received over pain, compared to 63,8% in the promoters, which had been vaccinated with the 3-dos- combination vaccine."</seg>
<seg id="2756">"however, the frequency of intoxicity was a pro-band comparable (that is, compared to the entire vacccycle of 39.6% of the promoters, the Ambirix had, compared with a 36.2% in the promoters, which received the 3-cans combination."</seg>
<seg id="2757">"the frequency of unambiguous pain and softness was small and comparable to, that was observed after administration of the combination therapy with the 3-doses of vaccination scheme."</seg>
<seg id="2758">"in a comparative study with 1 to 11-year Impindustriingen, the occurrence of local actions and general actions in the Ambirixic group comparable to that with the 3-cans of formalininactivated Hepatitis-A-virus and 10 µg recombinant hepatitis B surface area."</seg>
<seg id="2759">"at the 6- until 11- year-old, however, after vaccination with Ambirix was reported a frequent appearance of pain (an injection point) per dose, not per trial."</seg>
<seg id="2760">The proportion of impflingen that reported over heavy side effects during the 2-doses-vaccine with Ambirix or during the 3-doses of vaccine with 360 ELISA- units of formal hepatitis A-virus and 10 µg recombinant hepatitis C.</seg>
<seg id="2761">"clinical trials, which were conducted at Imposingen at the age of 1 to 15 years, were the Seroconversionrates for Anti-HAV 99,1% a month after the first dose and 100% a month after the second, for the month 6 administered dose (d. h. in month 7)."</seg>
<seg id="2762">"the servo conversionrates for anti-hbs were 74,2% a month after the first dose and 100% a month after the second, for the month 6 administered dose (d. h. in month 7)."</seg>
<seg id="2763">"7 In a comparative study, which was conducted at 12- to including 15-year-olds, 142 two doses were Ambirix and 147 the standard combination."</seg>
<seg id="2764">"with the 289 persons whose immune ogeneity were value-value, the seroprotective rates (SP in the table below) against hepatitis B in the month 2 and 6 according to gift of the 3-dosenimpfes significantly higher than with Ambirix."</seg>
<seg id="2765">"immune response, which in a clinical trial study with 1 to 11-year-olds have been reached a month after the full vaccination series (i.e., in month 7), are listed in the following table."</seg>
<seg id="2766">In both studies the impanzinge were either a 2-doses-vaccination with Ambirix or a 3-doses-vaccine with a combination of 360 ELISA units in the virus-A-virus and 10µg recombinant hepatitis B surface.</seg>
<seg id="2767">Individuals who were at the time of pridimmaging between 12 and 15 years old could be detected the persistence of anti-HAV- and anti-hbs antibodies to be detected at least 24 months after the immunisation of Ambirix in the 0-6-month vaccine.</seg>
<seg id="2768">The observed immune reaction against both antigens were comparable to that which was found after vaccination of 3 cans with a combination of 360 ELISA units of formalininactivated hepatitis- A-virus and 10 µg recombinant hepatitis B surface in a dosage volume of 0,5 ml.</seg>
<seg id="2769">In a clinical trial at 12- up to 15-year-olds could be shown that the Persistence of anti-HAV- and anti-hbs antibodies to compare 24 months after immunisation in the 0-6- months-vaccine is comparable to that in the 0-12-month vaccine.</seg>
<seg id="2770">"if the first dose of Ambirix takes place in the second year with the refreshed Diphtherie-, Tetanus-, inactive polomyelius type b-vaccine (DTPa-IPV / Hib), or with the first dose of a combined mask vaccine used, the immune response was adequate to all antigens."</seg>
<seg id="2771">"a clinical study, which was conducted with 3 doses of the present formulation in adults, showed similar Seroprotective and seroconversionrates as for the previous formulation."</seg>
<seg id="2772">The vaccine is both before and after the resuspening can be examined as well as to the remnant foreign parables and / or physical visible changes.</seg>
<seg id="2773">"in accordance with Article 114 of Directive 2001 / 83 / EC, the state charmed by a state laboratory or one to this purpose authorized to be authorized."</seg>
<seg id="2774">14 information on the outer enveloping 1 FERTIGSPRITZE OHNE needle 1 FERTIGSPRITES OHMENT needles 10 FERTIGSPRITZEN OHNE Nadab 50 FERTIGSPRINZEN OHNE Nadels</seg>
<seg id="2775">Suspension for injecting 1 production splash with needle 10 presplash with needle 10 manufacturing splash with needles 50 manufacturing splash with needles without needles 1 dose (1 ml)</seg>
<seg id="2776">EU / 1 / 02 / 224 / 001 1 fsplash with needle EU / 1 / 02 / 224 / 003 10 Completsplash with needles EU / 1 / 02 / 224 / 005 50 manufacturing splash with no needles</seg>
<seg id="2777">"the Hepatitis A-virus is usually transmitted by viral food and beverages, but can also be transferred through other ways such as bathing in by dewatser contaminated waters."</seg>
<seg id="2778">"you can feel very tired, have a dark urine, a blue face, yellow skin and / or eyes (yellowing) and other symptoms that may possibly make a stationary treatment necessary."</seg>
<seg id="2779">"as with all vaccines, Ambirix cannot be completely protected from an infection with Hepatitis A- or hepatitis B virus, even if the whole vaccine has been completed with 2 doses."</seg>
<seg id="2780">If you are infected / your Child in front of the administration of both vaccination Ambirix is already infected with Hepatitis A- or Hepatitis B-virus (although you / your child may not feel uncomfortable or ill) a vaccine may not prevent disorder.</seg>
<seg id="2781">"a protection against other infections that cause the liver compensate or symptoms, which are similar to those after a Hepatitis A- or Hepatitis infection, cannot be conveyed."</seg>
<seg id="2782">• If you have already shown an allergic reaction to Ambirix or any component of this vaccine including Neomycin (an antibiotic).</seg>
<seg id="2783">An allergic reaction can express themselves through juckraging skin suggestions, respiratory or swelling of the face or tongue. • If you have performed an allergic reaction to an earlier vaccination against hepatitis A or hepatitis B. • If you have a serious infection with fever. "</seg>
<seg id="2784">"• If you want to have a protection against hepatitis B, i.e. within 6 months and prior to the administration of the second vaccination (i.e. the second vaccination)."</seg>
<seg id="2785">"with a possible risk of infection with hepatitis B between the first and second vaccination, the doctor will advise you / your child from an impure with Ambirix."</seg>
<seg id="2786">"instead, he will recommend you / your child 3 injections of a combined hepatitis B vaccine with a reduced salary to effective components per vaccination (360 ELISA units of a formal hepatitis A-virus and 10 micrograms of a recombinant Hepatitis B."</seg>
<seg id="2787">The second vaccination of this vaccine with reduced salary to effective components is usually administered a month after the first dose and is likely to give you a vaccine before completion of the vaccination.</seg>
<seg id="2788">Sometimes Ambirix will suffer from severe bleeding suffering because of the skin and not in the muscle stimulated. • if you are weakened in your child due to illness or treatment in your body or treatment in your body or treatment.</seg>
<seg id="2789">Ambirix can be given in these cases but the immune response of these persons on vaccination may not be sufficient so a blood test can be required to see how strong the reaction to vaccination is.</seg>
<seg id="2790">"21 Sign you to your doctor if you are taking further medicines / redeem (including those that you have received without prescription) or if you have been administered / your child have recently been vaccinated, or immunoglobulins (antibodies) have been administered / or this is planned in the near future."</seg>
<seg id="2791">"however, it may be that in this case the immune response to the vaccine is not sufficient and the person is therefore not protected against one or both hepatitis A and B viruses."</seg>
<seg id="2792">"if another vaccine has to be given at the same time with Ambirix, should be vaccinated in separate positions and as possible as possible limbs."</seg>
<seg id="2793">"if Ambirix should be administered at the same time or shortly before or after an injection of immunoglobulins, it is likely that the response to the vaccine will nevertheless be sufficient."</seg>
<seg id="2794">"usually, Ambirix Schwangeren or impending women is not administered, unless it is urgent to be vaccinated for both hepatitis A and hepatitis B."</seg>
<seg id="2795">Important information about certain other components by Ambirix Please inform your doctor if you have already shown an allergic reaction to Neomycin (antibiotic).</seg>
<seg id="2796">"if you miss the agreed appointment for the second vaccination, consult with your doctor and arrange a new date as soon as possible."</seg>
<seg id="2797">Is very common (more than 1 case per 10 decimal doses): • pain or discomfort in the singular or redness • Maternity • headaches • Appetitions</seg>
<seg id="2798">Not frequent (up to 1 case per 10 decimal doses): • swelling at the injections • Fieber (over 38 ° C) • Benziness • gastrointestinal complaints</seg>
<seg id="2799">"further side effects, the days or weeks after vaccination with comparative combination or individual ingredients for hepatitis A and hepatitis B very rarely (less than 1 case per 10,000 copies) are reported:"</seg>
<seg id="2800">"these include limited or expansive extracts, the jucks can be or blown-shaped, swelling of the eye-part and the face, startled breathing or sacks, sudden blood pressure and consciousnesses."</seg>
<seg id="2801">"flu-like complaints, including shaking frost, muscle, and joint pain constrife, misses, diseases of visual impairments, loss of sensation or musculature components, strong headaches and stiffness of neck, interruption of normal brain functions."</seg>
<seg id="2802">Impotence inflammation of inflammation or disease-esteem, appetitions, diarrhea, diarrhoea, diarrhea, diarrhoea, diarrhoea, diarrhoea, diarrhoea, diarrhea, inclination to bleeding or blood pressure (blue spots), caused by waste of blood-puzzles. "</seg>
<seg id="2803">"23 Make your doctor or pharmacist, if any of the listed side effects you have considerably impaired, or you notice unwanted side effects which are not listed in this package."</seg>
<seg id="2804">Ambirix is available in packs to 1 and 10 with or without needles and in packs to 50 without needles.</seg>
<seg id="2805">"on the basis of the data, which has been known since issuing the first permit for the transport agreement, treaties at the CHMP opinion that the benefit-risk-ratio for Ambirix remains positive."</seg>
<seg id="2806">"Ambirix had been launched in intercourse only in a member state (in the Netherlands since May 2003), the available safety data for this drug is limited due to low patient exposure."</seg>
<seg id="2807">Ammonaps can also be used in patients aged over a month with incomplete Enzymdefective or with hyperammonal-encephalopathy (brain damage as a result of high ammonium concentration) in the prehistory.</seg>
<seg id="2808">"Ammonaps is divided - split into several items to meals - swallowed, under the food mixed or over a Gastrostomiescheme (through the abdomen into the stomach of the stomach) or a nose-sun (through the nose in the stomach of the stomach)."</seg>
<seg id="2809">"it was not a comparative study, since Ammonaps not with any other treatment or placebo (a searchmedication, i.e. without an active ingredient)."</seg>
<seg id="2810">"ampmonaps can also lead to appetitive loss, a abnormative infect in blood, depression, irritability, fluid pain, nausea, stipation, rash, rash, unpleasurable body curse or weight gain."</seg>
<seg id="2811">The Committee on Humanarzs (CHMP) led to the conclusion that Ammonaps are effectively prevented from patients with disorders of the uretic cycle.</seg>
<seg id="2812">"Ammonaps was admitted under" extraordinary circumstances "because due to the rarity of the disease at the time of approval only limited information on this medicine."</seg>
<seg id="2813">The use is indices in all patients in which a complete Enzymmangel has already manifested in the re-born age (within the first 28 days of life).</seg>
<seg id="2814">"in patients with a delay (incomplete Enzymdefective, which manifests itself after the first life of life) then there is an indication of use when in the Anamnese is a hyperopulent endencephalopathy."</seg>
<seg id="2815">"for infants, for children who are not able to swallow tablets or for patients with slots, AMMONAPS is also available in granule form."</seg>
<seg id="2816">"the daily dose will be individually calculated, taking into account of the protein-tolerance and the necessary daily protein intake of the patient."</seg>
<seg id="2817">"according to recent clinical experience, the normal daily dose sodium polyyrat: • 450 - 600 mg / kg / day in children with a body weight of less than 20 kg • 9,9 - 13,0 g / m ² / day in children with a body weight over 20 kg and with grown-growing and adult."</seg>
<seg id="2818">"in patients who suffer from an earliest lack of carbamyl phosphatsynthetase or Ornithintrscarbamylase, the substitution of Citrullin or arginine in a dosage of 0.17 g / kg / day or 3,8 g / m ² / day required."</seg>
<seg id="2819">Patients with a gingiinosuccinatsynthetase deficiency must obtain arginine in a dosage of 0.7 - 0.7 g / kg / day or 8.8 - 15.4 g / m ² / day.</seg>
<seg id="2820">"AMMONAPS tablets may not be administered patients with slots, as there is a risk to the emergence of Ösophagusulzera if the tablets do not get immediately into the stomach."</seg>
<seg id="2821">"every tablet AMMONAPS contains 62 mg (2.7 mmol) sodium, according to 2.5 g (108 mmol) sodium per 20 g sodium polyyl butyrat, which is the maximum daily dose."</seg>
<seg id="2822">AMMONAPS should therefore be used in patients with constitious heart insufficiency or severe kidney insufficiency as well as with sodium and oils in clinical conditions.</seg>
<seg id="2823">"as Metabolism and excretion of sodium phenylbutyrat across the liver and the kidneys, AMMONAPS should be used in patients with liver or kidney insufficiency only with extreme caution."</seg>
<seg id="2824">The importance of these results in relation to pregnant women is not known; the use of AMMONAPS during pregnancy is therefore contrained (see 4.3).</seg>
<seg id="2825">"with subcutters gabe of phenylacetate at young rats in high dosage (190 - 474 mg / kg), it came into a slowdown of the neuronal amplifier and an increased loss of neurons."</seg>
<seg id="2826">"it also found out a delay of cerebral synapses, and a diminished number of functioning nerve damage in the brain, and therefore a disability of brain growth."</seg>
<seg id="2827">"it could not be established if Phenylacetate is retired in men into the breast milk, and for that reason is the use of AMMONAPS during breastfeeding period (see 4.3)."</seg>
<seg id="2828">In clinical trials with AMMONAPS in 56% of patients had at least one unwanted event (AE) on and at 78% of these undesirable events that they were not associated with AMMONAPS.</seg>
<seg id="2829">"frequency is defined as follows: very common (&gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; 1,000, &lt; 1 / 100)."</seg>
<seg id="2830">"a probable toxic reaction to AMMONAPS (450 mg / kg / day) has been reported by a 18 year old anorectal patient, which developed a metabolic disorder in conjunction with Laktataziebox, rhinoctopenie, periphery Neuropathy and Pancreatitis."</seg>
<seg id="2831">"an event of an overdose, with an 5-month old small child, with an accidentally single dose of 10 g (1370 mg / kg)."</seg>
<seg id="2832">These symptoms go with the accumulation of phenylacetate which showed up to 400 mg / kg / day a dose of neurotoxicity.</seg>
<seg id="2833">Phenylacetate is a metabolic connection which is contracted by acetylacetylamine glutamine that will follow the kidneys.</seg>
<seg id="2834">Rugs seen is Phenylacetylglutamine with urea (both compounds contain 2 nitrogen oxes); phenylacetylglutamine is therefore considered an alternate carrier to excretion of excess nitrogen.</seg>
<seg id="2835">5 patients with disorders of the urinary tract can be accepted that for every gramms Natriumphenylbutyrat between 0.12 and 0.15 g phenylacetylamine glutamine nitrogen.</seg>
<seg id="2836">"it is important that the diagnosis was made early and the treatment will start immediately, in order to improve the survival of the experience and the clinical results."</seg>
<seg id="2837">"the prognosis of the early-manifold form of the disease with appearance of the first symptoms in newborn age was almost always infant, and the disease led themselves to the treatment with Peritonealdialysis and essential amino acids, or with their sticking-free analogy within the first year of life."</seg>
<seg id="2838">"by Hämodialysis, the utilisation of alternate paths of nitrogen hormone (sodium hydrochloric acid), proteinduced Kost and possibly substitution of essential amino acids, it was possible to diagnose the survival rate of new salvia at postpartal (but within the first life of life) to increase diseases on 80%."</seg>
<seg id="2839">"in patients whose disease was diagnosed in the course of pregnancy and the disease is already treated before the first appearance of a hyperammonic end encephalopathy, but even in these patients it was time with many to spiritual disabilities or other neurological deficits."</seg>
<seg id="2840">"in patients with a delay in the disease (including female patients with the heterogeneous form of the Ornithintranscarcity deficiency), which were treated by a hyperopulceries butyrat and a proteinated diet, was the survival rate 98%."</seg>
<seg id="2841">Existing neurological deficits are hardly reversible in treatment and in some patients may cause further deterioration of the neurological state.</seg>
<seg id="2842">"it is known that phenylbutyrat to phenylacetate oxifies in liver and kidney enzymatic with glutamine, whereby Phenylacetylglutamine is created."</seg>
<seg id="2843">The concentrations of phenylbutyrat and its Metabolites in Plasma and Urin were determined by gift of an individual dose of 5 g sodium polyphenidation and liver cirrhosis by up to 20 g / day (not controlled studies).</seg>
<seg id="2844">The behavior of phenylbutyrat and its Metabolites were also examined in cancer victims of sodium gene butyrat (up to 2 g / m ²) or phenylacetate.</seg>
<seg id="2845">According to a oral single dose of 5 g Natriumphenylbutyrat in tablet form were established 15 minutes after taking measurable Plasmakoncentations from Phenylbutyrat.</seg>
<seg id="2846">"in the majority of patients with uretheses, or hemorrhobinopathies, after different doses of phenylbutyrat (300-650 mg / kg / day up to 20 g / day) next morning after the next fasting, no phenylacetate in plasma."</seg>
<seg id="2847">"in three of six patients with liver cirrhosis, which were repeated with sodium polyyrat (20 g / day oral in three single corpants), the medium phenylacetylkonzentrations in Plasmaspiegel in the third day five times higher than after the first gifts."</seg>
<seg id="2848">Excretion The drug is exhausted within 24 hours to roughly 80 - 100% in the form of the conjugiated product Phenylacetylglutamine via the kidneys.</seg>
<seg id="2849">"according to the results of the Micronucleus testing, Natriumphenylbutyrat with toxic and non toxicogenic effects (investigation 24 and 48 h after oral administration of a single dose of 878 to 2800 mg / kg)."</seg>
<seg id="2850">"AMMONAPS granulat is given either oral (infants and children, who can still not swallow any tablets, or patients with slots) or via a gastrostine or a nose-sun."</seg>
<seg id="2851">"according to recent clinical experience, the normal daily dose of Natriumphenylbutyrat: • 450 - 600 mg / kg / day at newborns, infants and children with a body weight of less than 20 kg • 9,9 - 13,0 g / m ² / day in children with a body weight over 20 kg and with grown-growing and adult."</seg>
<seg id="2852">"the concentration of ammonia, arginine, essential amino acids (in particular, branched amino acids), Carnitine and Serumprotocols in Plasma should be held within the normal field."</seg>
<seg id="2853">"in patients who suffer from an earliest lack of carbamyl phosphatsynthetase or Ornithintrscarbamylase, the substitution of Citrullin or arginine in a dosage of 0.17 g / kg / day or 3,8 g / m ² / day required."</seg>
<seg id="2854">AMMONAPS granulat contains 124 mg (5.4 mmol) sodium per gram of sodium phenylbutyrat which corresponds to 2.5 g (108 mmol) sodium per 20 g sodium ylphenyl butyrat resulting in the maximum daily dose.</seg>
<seg id="2855">"when Rattenfutes had exposed to Phenylacetate (active Metabolit by phenylbutyrat), it came to lesions in the pyramid cells of the brain cows."</seg>
<seg id="2856">"a probable toxic reaction to AMMONAPS (450 mg / kg / day) has been reported by a 18 year old anorectal patient, which developed a metabolic disorder in conjunction with Laktataziebox, rhinoctopenie, periphery Neuropathy and Pancreatitis."</seg>
<seg id="2857">Rugs seen is Phenylacetylglutamine with urea (both compounds contain 2 nitrogen oxes); phenylacetylglutamine is therefore considered an alternative carrier to excretion of surplus value</seg>
<seg id="2858">"on the basis of investigations on excretory of phenylacetylglutamine in patients with disorders of the uretic cycle, it can be accepted for any gramms Natriumphenylbutyrat between 0.12 and 0,15 g phenylacetylglutamine nitrogen nitrogen."</seg>
<seg id="2859">"already existing neurological deficits are hardly reversible in the treatment, and in some patients may cause further deterioration of the neurological state."</seg>
<seg id="2860">"according to a oral single dose of 5 g sodium polyyrat in granulatform, 15 minutes after taking measurable Plasmakoncentations were determined by phenylbutyrat."</seg>
<seg id="2861">"during the duration of durability, the patient can store the finished product for a period of 3 months at a temperature of no more than 25 ° C."</seg>
<seg id="2862">"with this action, the little bit of measurement will be 0.95 g, the medium measurement spoon 2,9 g and the large measuring poon 8,6 g sodium polyyrat."</seg>
<seg id="2863">"if a patient has to get the medication over a probe, AMMONAPS can also be dissolved in water (the solubility of sodium phenylbutyrat is up to 5 g in 10 ml of water)."</seg>
<seg id="2864">"in case of patients with these rare diseases are missing certain liver enzymes, so that they can rump the sticking waste products which can fake in the body after consumption of proteins in the body."</seg>
<seg id="2865">"if you are conducted with laboratory studies, you must inform the doctor that you may have AMMONAPS, since Natriumphenylbutyrat can influence the results of certain laboratory examinations."</seg>
<seg id="2866">"when taking AMMONAPS with other medicines please inform your doctor or pharmacist, if you take other medicines or have recently taken, even if it is not prescription drugs."</seg>
<seg id="2867">"during the lactation period, you must not take AMMONAPS because the drug could skip into the breast milk and harm your baby."</seg>
<seg id="2868">"in rare cases, confusions, headaches, flavoural disturbances, misconception, memory disorders and a deterioration of existing neurological conditions have been observed."</seg>
<seg id="2869">"if you notice one of these symptoms, you immediately sit down with your doctor or using the Notting of your hospital for the purpose of a corresponding treatment."</seg>
<seg id="2870">"if you have forgotten the intake of AMMONAPS, take the appropriate dose as soon as possible with the next meal."</seg>
<seg id="2871">"changes of blood (red blood cell, white blood cell, depression, irritability, depression, irritation, nausea, constipation, rash, rash, kidney dysfunctions, weight gain and anomale laboratory values."</seg>
<seg id="2872">"please inform your doctor or a pharmacist, if any of the listed side effects you have considerably affected or you notice unwanted side effects which are not listed in this usage information."</seg>
<seg id="2873">You are allowed to use AMMONAPS following the carton and containers after "use until" given expiry date no longer.</seg>
<seg id="2874">"like AMMONAPS looks and content of the AMMONAPS tablets are of white color and oval form, and they are equipped with the embossing" UCY 500 "." "</seg>
<seg id="2875">"30 If you are conducted with our laboratory studies, you must inform the doctor that you may have AMMONAPS, since Natriumphenylbutyrat can influence the results of certain laboratory examinations."</seg>
<seg id="2876">"when taking AMMONAPS with other medicines please inform your doctor or pharmacist, if you take other medicines or have recently taken, even if it is not prescription drugs."</seg>
<seg id="2877">"you should take AMMONAPS to same single individual oral oral or via a Magenfistel (hose, which is through the stomach directly into the stomach) or a nose-sun (hose, which is led by the nose into the stomach)."</seg>
<seg id="2878">"31 • can be found out of the container a hardened measurement of granulate. • Stored to remove a straight edge, for example a knife to remove granulite. • see the recommended number of kpoon granules from the container."</seg>
<seg id="2879">Angiox is applied to the treatment of adult patients with 'acute blood sugar (ACS, decreased blood sugar to the heart), for instance at instabiler Angina (a form of pain in the chest with different strength) or myocardiner (heart attack) without "" ST- Hebung "(an anomalen measuring value at the electrocardiogram or EKG)."</seg>
<seg id="2880">"Angiox is applied to the prevention of blood clauses on patients being applied to patients, a higher dose is administered and infusion can be continued up to four hours after the procedure."</seg>
<seg id="2881">This can help in patients with Angina or heart attack to maintain blood flow and increase the effectiveness of a PCI.</seg>
<seg id="2882">"approximately 14 000 patients took part in the major study on the treatment of ACS, in which the effect of Angiox has been compared with a glycopic-IIb / IIIA-Inhibitor (GPI, another medicine for preventing blood clauses) with the conventional combination treatment with Heparin (another anticoagulans) and a GPI."</seg>
<seg id="2883">"during PCI the patient has often been an stent (a short tube, used in the arteries to prevent a lock), and they also received other medicines to prevent bleeding islands such as Abciximab and aspirin."</seg>
<seg id="2884">"for the treatment of ACS was Angiox - with or without gift of GPI - in the prevention of new events (deaths, carditis or reascularization) after 30 days or a year as a whole as conventional treatment."</seg>
<seg id="2885">"patients who were subjected to a PCI was Angiox in regards to all indicators just as effective as Heparin, except for heavy blood pressure, where it was much more effective than Hepburn."</seg>
<seg id="2886">Angiox must not be applied in patients that may be hypersensitive (allergic) against bivalirudin, other Hirudine or one of the other components. "</seg>
<seg id="2887">"it must also not be used in patients who recently had a blood pressure, as well as in people with heavy blood pressure or severe kidney disease or a heart infection."</seg>
<seg id="2888">The Committee on Humanarzs (CHMP) led to the conclusion that Angiox in the treatment of ACS and during a PCI is a decent replacement for Hepburn.</seg>
<seg id="2889">September 2004 condemned the European Commission to the Company The Medicines Company UK Ltd provides permission for the transport of Angiox in the entire European Union.</seg>
<seg id="2890">For the treatment of adult patients with acute coronarsyndroms (instabile Angina / non-smoking colored (IA / NSTEMI)) during an emergency handle or if an early intervention is planned.</seg>
<seg id="2891">The recommended initialdose of Angiox in patients with ACS is a intravenous bolt of 0.1 mg / kg followed by an infusion of 0.25 mg / kg / h.</seg>
<seg id="2892">"if the patient is carried out in another episode a PCI mg / kg, an additional bolt should be increased from 0,5 mg / kg and infusion for the duration of the surgery on 1,75 mg / kg / h."</seg>
<seg id="2893">After PCI can be taken to clinical requirements again the reduced infusion dose of 0.25 mg / kg / h for 4 to 12 hours.</seg>
<seg id="2894">"immediately before the procedure, a Bolusement of 0,5 mg / kg shall be administered, followed by an infusion of 1,75 mg / kg / h for the duration of the surgery."</seg>
<seg id="2895">The recommended dosage of angiox in patients with a PCI consists of a initials of 0,75 mg / kg of body weight and a dose of intravenous infusion with a dose of 1,75 mg / kg body weight / h at least for the duration of the surgery.</seg>
<seg id="2896">The safety and effectiveness of a single bloc gift of angiox has not been studied and is not recommended even if a short PCI procedure is planned.</seg>
<seg id="2897">"this value is shortened (ACT after 5 minutes), should be shortened under 225 seconds, should be a second pin of 0.3 mg / kg / body weight."</seg>
<seg id="2898">"to reduce the appearance lower ACT values, the reconstitutive and thinner drugs should be performed quickly in front of the application and the Bolusdosis must be given intravenously."</seg>
<seg id="2899">"once the ACT amounts to more than 225 seconds, another monitoring is no longer required, provided the 1,75 mg / kg infusion dose is right administered."</seg>
<seg id="2900">"in patients with moderate kidney failure (GFR 30-59 ml / min), which are treated to a PCI (whether with Bivalirudin against ACS or not), should be used a lower infusion rate of 1,4 mg / kg / h."</seg>
<seg id="2901">"lies the ACT-value below 225 seconds, is a second Bolusdosis of 0,3 mg / kg to administered and the ACT 5 minutes after the second bolt dose."</seg>
<seg id="2902">"in patients with moderate kidney disease, which was included in the Phase III- PCI study (Replace-2) which resulted in the ACT value 5 minutes after the gift of the Bivalirudin-Bolus without dosage adjustment at an average of 366 ± 89 seconds."</seg>
<seg id="2903">3 In patients with severe kidney damage (GFR &lt; 30 ml / min) and also with dialysis patients (see under Section 4.3).</seg>
<seg id="2904">The treatment with angiox can be 30 minutes after the end of the intravenous gade of unfractionated Hepburn or 8 hours following termination of the subcutaneous gabe of low molecular entities.</seg>
<seg id="2905">• known hypersensitivity to the active ingredient or any other components or against Hirudine • active bleeding or increased blood disorders, due to a disturbance of the hemostal system and / or irreversible bargaining disorders. • severe uncontrollable hypertension disorders (GFR &lt; 30 ml / min) and with dialysis patients "</seg>
<seg id="2906">Patients are carefully monitored during treatment with regard to symptoms and signs of a blood pressure especially when Bivalirudine is administered in combination with another anticoagulant (see Section 4.5).</seg>
<seg id="2907">"even if in PCI-patients may occur at Bivalirudin most bleeding in arterial point cells, in patients who occur in an perutaneous coronary military intervention (PCI), while treating principle anywhere bleeding."</seg>
<seg id="2908">"in patients, the warfarin, and treated with Bivalirudine, should consider a monitoring of INR-Werts (International Normalised ratio), to ensure that the value of treatment with Bivalirudine is once again achieved before the treatment."</seg>
<seg id="2909">"starting from the knowledge of the action mechanism of anticoagulant (Hepburn, warfarin, Thrombolytika or Thrombolic grease inhibiting) can be assumed that these substances can increase blood risk."</seg>
<seg id="2910">"in the combination of Bivalirudin with Thrombolic aggregate numbers or anticoagulants, the clinical and biological hemostal parameters are regularly monitored in any case."</seg>
<seg id="2911">"the animal-experimental investigations are in terms of effects on pregnancy, the embryonic / fetal development, the delivery or post-natal development inadequate (see under Section 5.3)."</seg>
<seg id="2912">4612 were randomized to Bivalirudin alone; 4604 were randomized to Bivalirudin plus GPIIb / IIIA Inhibitor and 4603 were randomized to either infrtional Heparin or Enoxaparin plus GPIIb / IIIA Inhibitor.</seg>
<seg id="2913">"both in the Bivalirudin group as well as in those with Hepburn, comparative groups came to women as well as in patients over 65 years more frequently to unwanted events than in male or younger patients."</seg>
<seg id="2914">Heavy bleeding have been defined according to the ACUITY and Timi massaging for heavy bleeding such as in the footnotes of table 2.</seg>
<seg id="2915">Both light and heavy blood vessels occurred under Bivalirudin alone significantly less often than in groups with Hepburn plus GPIIb / IIIA-Inhibitor and Bivalidrudin plus GPIIb / IIIa- Inhibitor (see table 2).</seg>
<seg id="2916">"a ACUITY heavy blood pressure was defined as one of the following events: intrinsidict, intraocular blood pressure, &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; 5 g / dl with known blood point, reoperation due to a blood circulation, application of blood products to transfusion."</seg>
<seg id="2917">"further, less frequently observed blood-localisations that occurred at more than 0.1% (occasionally), were" other "score, retrospitoneal, gastroaming, ear, nose or neck."</seg>
<seg id="2918">The following information on side effects are based on the data of a clinical trial with Bivalirudin at 6000 patients who underwent a PCI.</seg>
<seg id="2919">"both in the Bivalirudin group as well as in the with Hepburn, comparative groups came to women as well as in patients over 65 years more frequently to unwanted events than in male or younger patients."</seg>
<seg id="2920">Both light and heavy blood vessels occurred under Bivalirudin significantly less often than in the comparative group under Heparin plus GPIIb / IIIA-Inhibitor.</seg>
<seg id="2921">"the following side effects that are not listed above, have been reported according to comprehensive application in practice and are arranged according to system organic classes in table 6."</seg>
<seg id="2922">"in the event of overdose, treatment with Bivalirudine can immediately break away and monitor the patient with regard to signs of blood circulation."</seg>
<seg id="2923">"Angiox contains Bivalirudin, a direct and specific thrombinders, which binds both at the catalytic centre and the anion region of Thrombin, regardless of whether Thrombin is tied in the liquid phase or at Gerinnsel."</seg>
<seg id="2924">"the bond of Bivalirudin to Thrombin, and therefore its effect, is reversible, because Thrombin turn divides the bond of Bivalirudin-Arg3-Pro4 slowly, making the function of the active center of Thrombin regenerates."</seg>
<seg id="2925">"in addition, through Bivalirudin with Serum of patients, where it had come to the heparininduced thyrofoam syndrome (HIT / HITTS) has been induced (HIT / HITTS)."</seg>
<seg id="2926">"in healthy volunteers and in patients showed Bivalirudin a dosis- and concentration of concentration, which is occupied by the extension of ACT, aPTT, PT, INR and TT."</seg>
<seg id="2927">"if you were conducted in the following form a PCI unit, an additional bolt of 0.5mg / kg Bivalirudin is given and infusion for the duration of the surgery to 1.75mg / kg / h."</seg>
<seg id="2928">In the arm A of ACUITY study was administered non-fractionated Heparin or Enoxaparin according to the relevant guidelines for the treatment of akutem KoronarsynSyndrome (ACS) in patients with instabiler Angina / non-ST-Heber (IA / NSTEMI).</seg>
<seg id="2929">Patients in arm A and B were also randomized to obtain a GPIIb / IIIA Inhibitor at the time of angiography (at the time of Randomisation) or on PCI.</seg>
<seg id="2930">"in the ACUITY study, the characteristics of high risk types, which required an angiography within 72 hours, evenly distributed over the 3 medical treatment."</seg>
<seg id="2931">"about 77% of patients had recurrent Ischia, 70% had dynamic EKG- changes or increased cardiac biomarkers, 28% had diabetes and about 99% of all patients being subjected within 72 hours of an angiography."</seg>
<seg id="2932">The primary analysis and the results from the ACUITY study for the European population (ITT) and for patients who received aspirin and Clopidogrel according to protocol (before the angiography or before PCI), are shown in tables 7 and 8. "</seg>
<seg id="2933">ACUITY Study; 30-days and 1-year risk difference for the commissable endpoint and its components for patients to have aspirin and Clopidogrel according to protocol *</seg>
<seg id="2934">Patients, the aspirin and Clopidogrel according to protocol received arm A arm B arm C UFH / Enox Bival B- A C- A Bival + GPIIb / IIIA / IIIA risk Diff. "</seg>
<seg id="2935">The frequency of bleeding in the ACUITY- as well as in the Timi scale up to a day 30 for the whole population (ITT) and for patients who received aspirin and Clopidogrel according to protocol is presented in table 9.</seg>
<seg id="2936">Patients to have the aspirin and Clopidogrel total population (ITT) according to protocol received UFH / Enox Bival / IIIA GPIIb / IIIA Inhibitor (N = 2912)% (N = 2904)%%%%%</seg>
<seg id="2937">* Clopidogrel before Angiograph or before PCI 1 A ACUITY heavy blood pressure was defined as one of the following events: intracransmitters of &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; &gt; 5 g / dl with well-known blood circulation system, reduction of hemorrhoid / dl with known blood circulation, reoperation due to a blood circulation, application of blood products to transfusion. "</seg>
<seg id="2938">"the 30-day results, based on four-one-three-fold extension of a randomized double blind study with over 6,000 patients who were subjected to a PCI-2 (Replace-2), are represented in table 10."</seg>
<seg id="2939">Clinical studies with a small number of patients supplied limited information on application of angiox in patients with HIT / HITTS.</seg>
<seg id="2940">"the pharmacokinetic properties of Bivalirudin were evaluated in patients who underwent a perutaneous coronary intervention (PCI), as well as patients with ACS."</seg>
<seg id="2941">It is expected that Bivalirudin as Peptid has a catabolism in its amino acid components with subsequent reincarments of amino acids in the body-pool.</seg>
<seg id="2942">"the primary metabolit, which results from the split of the Arg3-provisional sequence through Thrombin, is not effective due to the loss of its affinity to the catalytic centre of Thrombin."</seg>
<seg id="2943">The Elimination occurs in patients with normal kidney function after a process of first order with a temporal half-time period 25 ± 12 minutes.</seg>
<seg id="2944">"based on conventional studies for safety spharmacology, toxicity with repetitive gabe, genotoxicity or reproduction, the preclinical data cannot be distinguished with special dangers for humans."</seg>
<seg id="2945">The toxicity of animals on repetitive or continuous exposure (1 day to 4 weeks in an exposure to 10 times of the clinical Steady-state-Plasmakoncentation) are confined to excessive pharmacological effects.</seg>
<seg id="2946">"side effects as a long-term physiological strain as a response to a non-homeopathic coagulation were comparable to short-term exposure compared to those in clinical use, even with very much higher dosage, not observed."</seg>
<seg id="2947">"if the production of the ready-to-use solution 17 is not under controlled and validated aseptic conditions, this is no longer than 24 hours at 2 ° C to 8 ° C."</seg>
<seg id="2948">Angiox is a frivolted powder in single-way flow-bags made from type-1-glass to 10 ml, which is sealed with a butylum mistaken and a cap out of pressed aluminium seals. "</seg>
<seg id="2949">5 ml sterile water for injections are given into a diarrhea pox and slightly curved until all it has completely dissolved and the solution is clear.</seg>
<seg id="2950">5 ml are taken from the bottle of bottle and diluted with 5% glucose solution for injecting or with 9 mg / ml (0.9%) sodium solution for injecting in a total volume of 50 ml to obtain an end-concentration of 5mg / ml bivalirudin.</seg>
<seg id="2951">"the holder of permission for the transport is agreeing to, the studies and pharmacovigilance plan stated in version 4 of the risk management plan (RMP) and in Modul 1.8.2 of approval for the transport network, as well as any follow-changing of the RMP, which was agreed by CHMP."</seg>
<seg id="2952">"according to CHMP Guideline, the CHMP Guideline to risk management systems for human medicine should be handed over and handed over to the next period of periodic Safety Update Report (PSUR)."</seg>
<seg id="2953">• patients with breast cancer due to a coronary disease (ACS) • patients who are operated for the treatment of closures in the blood vessels (Angioplasty and / or perkutane Koronarangioplasty - PCI).</seg>
<seg id="2954">"• You are pregnant or suspected that you might be pregnant • You intend to get pregnant, you are currently breastfeeding."</seg>
<seg id="2955">"there were no studies of the impact on the traffic conditions and the ability to serve machinery, but one knows that the effects of this medication are at short notice."</seg>
<seg id="2956">"should a blood flow occur, the treatment with angiox is cancelled. • In the beginning of the injection or infusion you will inform your doctor about the possible signs of an allergic reaction."</seg>
<seg id="2957">Such reactions are rare (they occur in less than 1 of 1000 patients to patients). • A particularly careful monitoring is carried out when you provide a radiotherapy for the vessels that you receive the heart with blood (this treatment is called Beta- or Gamma-Brachytherapy). • The dose which you will receive is depend on your body weight and from the type of therapy you get.</seg>
<seg id="2958">• 0.1 mg / kg body weight as injecting followed by an infusion (dripper) with 0.25 mg / kg body weight per hour (0.1 mg / kg body weight per hour means a quarter of a milligramms of the medication by means of any kilograms per hour).</seg>
<seg id="2959">Probable if angiox is administered in combination with other gergrains or antithrows of drugs (see Section 2 "by use of Angiox with other medicines").</seg>
<seg id="2960">"these are occasional side effects (for less than 1 of 100 patients). • Thrombosis (blood clot), which could lead to serious complications such as a heart attack."</seg>
<seg id="2961">"this is a occasional side effect (for less than 1 of 100 patients). • pain, blood, and bluff, at the point of point (after PCI treatment)."</seg>
<seg id="2962">"please inform your doctor if any of the listed side effects you have considerably affected or you notice unwanted side effects, which are not listed in this usage information."</seg>
<seg id="2963">Angiox must be applied according to the label and the carton after "usable up to" given expiry date no longer.</seg>
<seg id="2964">Polska The Medicines Company UK Ltd.: + 800 843 633 26 lub + 41 61 564 1320 GS λ: + 30 210 5281700 E-mail:</seg>
<seg id="2965">"Apidra is used to treat adults, young people and children from six years with diabetes that require treatment with insulin."</seg>
<seg id="2966">Apidra is subcutaneous (among the skin) to the abdominal wall, the upper shank or the upper arm injected or as a permanent infusion with a insulin pump. "</seg>
<seg id="2967">Diabetes is a disease where the body does not produce enough insulin to the control of the Glucosespiegels (sugar) in the blood or the insulin cannot be effected.</seg>
<seg id="2968">"insulin insulin is different from the insulin insulin, and the change means that it acts faster and a shorter activity than a short-effective humaninsulin."</seg>
<seg id="2969">"Apidra was used in combination with a lengthy insulin in patients with type-1 diabetes, where the body is not to produce insulin in two studies with a total of 1 549 adults and in a study with 572 children aged between four and 17 years."</seg>
<seg id="2970">"for type-2 diabetes, in which the body in insulin is not proven effectively, Apidra was examined in a study with 878 adults."</seg>
<seg id="2971">The main indicator of the effectiveness was the change of concentration of substance glycosylized hemoglobin (HbA1c) in the blood that shows how well the blood sugar is set.</seg>
<seg id="2972">"in the first study with adults with type-1 diabetes, after six months a reduction of 0.7% (from 7,60% to 7,46%) compared to a reduction of 0.7% in insulin lisper."</seg>
<seg id="2973">"in adults with type-2 diabetes, the reduction of HbA1c concentration was reduced% after six months with Apidra in comparison to 0,30% at humanely normal insulin."</seg>
<seg id="2974">"Apidra must not be used in patients, which may be hypersensitive (allergic) against insulinglulisin or any of the other components, or in patients who have already suffered at a hypoglycaemia."</seg>
<seg id="2975">"the doses of Apidra need to be adjusted, when it is administered together with a number of other medicines that can impact on the bloodshed."</seg>
<seg id="2976">September 2004 condemned the European Commission to Sanofi-Aventis Germany GmbH as approve of the transport of Apidra in the entire European Union.</seg>
<seg id="2977">Apidra is known as subcutaneous injecting either in the area of the abdomen; the upper-thigh or damage caused by continuous infusion into the area of the abdominal shocks.</seg>
<seg id="2978">"due to decreased glconogenesis capacities and the decreased insulin insulator, the insulin need to be depressed in patients with a restriction of liver function."</seg>
<seg id="2979">"any change of the active strength, the brand (Her- unit), the insulin insulin (normal, NPH, galvanized etc.), the type of insulin (animal insulin) and / or the manufacturing method can draw a change in the insulin demand."</seg>
<seg id="2980">"3 A insufficient dosage or the breakage of a treatment, especially in patients with a insulating diabetes, can lead to a hyperglycaemia and a diabetic boetoazionale; these states are potentially vital."</seg>
<seg id="2981">"the conversion of a patient to another insulin type or insulin another manufacturer should be under stringent physician, and may make a change of dosage necessary."</seg>
<seg id="2982">The timing of a hypoglycaemia depends on the active service of the insulin insulin and can therefore change changing the treatment file.</seg>
<seg id="2983">"for the substances, which can increase blood sugar levels and increase the inclination to Hypoglycemic, angiotensin-Converting-enzymes (ACE) -Hemmer, Fluoxifyllands, alicylates, salicylates, and Sulfonamide antibiotics."</seg>
<seg id="2984">"in addition, under the effect of Sympatholytics such as Betablockers, Clonidine, Guanethidin and Reserpin the symptoms of inepinephrinism might be scraped or missing."</seg>
<seg id="2985">"animal experimental studies for reproduction stoicity showed no difference between insuiclinglulisin and humaninsulin regarding pregnancy, the embryonic / fetal development, the birth or post-natal development (see Section 5.3)."</seg>
<seg id="2986">"it is not known whether insulin breast cancers occurs in the human breast milk, but generally there occurs in neither into the breast milk, nor will it resorate after oral use."</seg>
<seg id="2987">"in the following, those of clinical trials are listed below, grouped by system organs and arranged according to decreasing frequency of their appearance (very frequently: &gt; 1 / 1,000, &lt; 1 / 1,000; very rare: &lt; 1 / 10,000); not known (frequency based on the availability of availability)."</seg>
<seg id="2988">"cold-speaking, cool and pale skin, fatigue, nervousness or tremor, fear, unusual pathological or weakness, confusion, concentrating disorders, bends, nausea, nausea and heart."</seg>
<seg id="2989">Lipodystrophy Wird failed to change the injections within the injector field, can occur in the sequence a lipodystrophy at the injections. "</seg>
<seg id="2990">Heavy Hypoglycemic with consciousnesses can be given by an intra-muscular or subcutaneous injecting from Glukagon (0.5 to 1 mg) that is given by a trained person or by intravenous gift of glucose by a doctor.</seg>
<seg id="2991">"after a gluctance, the patient should be monitored in a hospital to determine the ur- thing for the heavy hypoglycaemia and to avoid similar episodes."</seg>
<seg id="2992">Insulin insulates the blood sugar levels by the stimulation of the peripheral glucose (in particular by skeletal muscles and fat) as well as by the inhibition of glucose production in the liver.</seg>
<seg id="2993">"studies with healthy volunteers and patients with diabetes have shown that in subcutaneous Ga- be of insulinglulisin the efficiency occurs faster and the active duration is shorter than in hu- manem Normalinsulin."</seg>
<seg id="2994">"in a study with 18 male people aged 21 to 50 years with type-1-diabetes, insulin, showed insulinglulisin in the therapeutic range of 0.075 to 0,15 E / kg a perdisproportionate increase of glucoseshoptic effect, just like Humaninsulin."</seg>
<seg id="2995">Insulin insulin has twice as fast efficiency as normal humaninsulin and achieves the complete glucosescoping effect approximately 2 hours earlier than Humaninsulin.</seg>
<seg id="2996">"from the data was obvious that in an application of insulin insulin 2 minutes before the meal a comparable postprandical control is achieved as with humanized normal insulin insulin, which is 30 minutes before the meal."</seg>
<seg id="2997">"was supplied in insulinglulisin 2 minutes before the meal, a better postprandiale control was given as with humanized normal insulin, which was 2 minutes before the meal."</seg>
<seg id="2998">"will replace insulin lulisin 15 minutes after the start of the meal, a comparable glycemic control is given as for human normal-malinsulin, which is given 2 Mixed nuten before the meal (see figure 1)."</seg>
<seg id="2999">"insulin insulin at Gabe 2 minutes (GLULISIN - before) before the start of the meal in comparison to human Normalinsulin, which was given 30 minutes (NORMAL - 30 mins) before the beginning of the meal (figure 1A) and compared to human Normalinsulin, which was given 2 minutes (NORMAL - before) before a meal (figure 1B)."</seg>
<seg id="3000">Insulin insulin at Gabe 15 minutes (GLULISIN - nachher) after the start of the meal in comparison to human Nor- malinsulin, the 2 minutes (NORMAL - before) before the beginning of the meal (figure 1C). "</seg>
</doc>
</tstset>
